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ABSTRACT 
 
This thesis begins with an introduction to inflammation and the role of cell signalling 
and adhesion molecules within the body, drawing particular attention to the function 
of integrins and their ligands. Chapter 1 discusses the importance of the α4-integrin / 
paxillin interaction for α4β1-dependent cell migration and the recruitment of 
leukocytes. Herein, literature research into the identification of a racemic, non-
cytotoxic molecule that inhibits this interaction is discussed, concluding with synthetic 
approaches towards the enantiomerically pure synthesis of this compound and its 
analogues. 
 
Chapter 2 opens with the discussion of some literature approaches to the synthesis of 
the indanone framework, followed by describing some initial synthetic work that was 
performed and the particular problems encountered with these methods. The attention 
of this chapter focuses on the kinetic resolution of indanones, applying both an 
enzymatic acylation and an oxidative kinetic resolution. The chapter demonstrates 
substrate viability in the aforementioned resolution techniques.  
 
Chapter 3 begins with discussing previous work in the synthesis of the target racemic 
compound. Following this, a detailed review of appropriate synthetic transformations 
is discussed, proceeding onto work towards the transformation of the enantiomerically 
enriched indanones into their corresponding quinolinones. The approach herein 
discusses some unanticipated results during this transformation. 
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 CHAPTER 1 - INTRODUCTION 
1.1 Inflammation 
 Inflammation is a defence mechanism to the presence of injurious stimuli in the body. 
This complex biological response of vascular tissues is essential for the remedy of 
harmful stimuli, including pathogens, irritants or damaged cells.1 In its zeal to  protect 
the body, the immune response will destroy as much tissue as necessary to achieve 
this goal.2 If left unregulated, a hyperactive inflammatory response can respond to the 
traumatic effects of an accident, for instance, from burns or surgery on the body, by 
attacking and destroying healthy tissue.3  
 
Inflammation can be categorised as either acute or chronic inflammation, often 
governed by the type of cells involved in the inflammatory response.4 The initial 
response, acute inflammation, is the inaugural reaction to harmful stimuli, and is 
achieved by an increased movement of leukocytes (especially granulocytes) and 
plasma into the injured tissues.5 A cascade of biochemical events propagate and 
advance the inflammatory response, notably the local vascular system, immune system 
and various cells within the damaged tissue.6 The latter type, chronic inflammation, 
leads to a progressive change in the type of cells at the inflammatory site, characterised 
by a simultaneous healing and destruction of tissue from the inflammatory response.7 
 
Inflammation is a necessary response to tissue injury, imperative for responding to 
microbial, autoimmune, metabolic or physical insults,4 but when uncontrolled, the 
prolonged inflammation can lead to a wide array of diseases, including arthritis,8 
diabetes,9 Alzeheimers disease,10 or Parkinson’s disease, 11 and many others.12,13 
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1.1.1 The Process of Inflammation 
 
The main symptoms of such responses in the inflammatory response are often 
associated with swelling, intensified heat and redness, as a consequence of the vascular 
response at the site of injury.  
 
The swelling is the result of vicissitudes in vascular permeability, ensuing the 
exudation of fluid, white blood cells and plasma proteins. The vessels dilate and 
become ‘leaky’ resulting in the cells of the endothelium to contract,14,15 forming gaps 
between the cells through which fluid and plasma proteins can move. The increased 
vascular permeability lets plasma proteins and fluid to leave the blood vessels, known 
as exudation, with the degree of exudation being variable depending on the amount of 
proteins that leave the vessels.16 
 
The heat and redness symptoms are an effect of an increased blood flow, which in turn 
is the result of vasodilation.17 This involves the widening of the arterioles (decreasing 
vascular resistance) followed by the capillaries and venules.18 Vasodilation results 
from a relaxation of the smooth muscle layer of arterioles and the sphincter of pre-
capillaries, which opens up previously inactive capillaries resulting in a significant 
increase in blood flow in the injured area. This process of increasing the delivery of 
supplies is known as active hyperaemia.19 
 
The cellular response is predominantly involved in the activation and recruitment of 
white blood cells, (leukocytes), to the site of injury. Here, leukocytes commence to 
stick to the endothelium of the venules, known as leukocyte extravasation.11  
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The traditional three-step process of leukocyte extravasation involves; rolling, 
adhesion and transmigration, and were all identified by pathologists in the nineteenth 
century.20,21 However, with the discovery of selectins, integrins, chemokines and their 
respective ligands / receptors, the emergence of a more detailed leukocyte cascade was 
developed (Stages 1-7),22 explaining more specifically the recruitment of leukocyte 
subsets to particularly sites. An overview of this process is shown below in Figure 1, 
where particular attention for this research (Section 1.1.2) will focus on Stages 4-6. 
 
 
 
 
Figure 1 – The Leukocyte Adhesion Cascade, (reproduced from K. Ley, Nature 
Reviews Immunology, 2007)22 
 
In the initial capture stage (Stage 1), upon recognition of pathogens in tissue, (and 
subsequent activation), macrophages in the affected tissue release cytokines (IL-1, 
TNFα and chemokines), causing the endothelial cells of local blood cells to express 
cellular adhesion molecules. Circulating leukocytes are attracted to this site of injury 
due to presence of chemokines, through a process called chemotaxis,13 and are 
paramount for beginning the rolling adhesion phase of leukocyte extravasation. 
Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 Stage 7 Stage 1 
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Once captured, the rolling of the leukocyte (Stage 2) is mediated by P-selectin, E-
selectin (both expressed by inflamed endothelium cells) and L-selectin (expressed by 
most leukocytes). The interaction of these selectins with the P-selectin glycoprotein 
ligand 1 (PSGL-1),23  enables leukocytes to adhere to the inflamed endothelium, even 
under conditions of blood flow due to their exceptional high on and off-rates.24  
 
Cell surface adhesion molecules, known as integrins, have also been shown to 
participate in mediating leukocyte rolling (Stage 2 / Stage 3). In particular, 
lymphocytes have been shown to roll on immobilised vascular cell-adhesion molecule 
1 (VCAM1) by engaging their cell-surface ligand very late antigen 4 (VLA4; also 
called α4β1). The VLA4 dependent rolling is observed mostly for monocyte-like cell 
lines,25,26 including T-cell lines27 and T-cells.28  
 
Integrins however play a much more fundamental role in the leukocyte extravasation, 
(Stages 4-6), and remain an area of particular interest for this research. With the 
leukocyte in a process of slow rolling, chemokines and chemoattractants rapidly 
trigger the activation of integrins,29 starting the leukocyte arrest phase. (Stage 4) 
Integrins primarily expressed on most circulating leukocytes, are the anchors in this 
cellular adhesion process and serve in adhesion strengthening (Stage 5) and 
intracellular crawling (Stage 6).30 
 
In the final transmigration step (Stage 7), the leukocyte, immobilised on the 
endothelium, transmigrates through gaps in the endothelial cells despite the on-going 
blood flow. Transmigration of the leukocytes occurs as PECAM proteins effectively 
pull the cell through the endothelium,31 where they then undergo a migration along a 
chemotactic gradient moving towards the target area, once in the interstitial fluid.17 
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1.1.2 Role of Cell Signalling and Adhesion Molecules 
 
An area of particular interest for this project involves the region of adhesion molecules 
and co-stimulation molecules, involved in Stages 4-6 from Figure 1. The role of co-
stimulation molecules are to deliver vital signals to leukocytes, especially T-Cells (or 
T-lymphocytes), where T-cells, being most circulating lymphocytes, play a primary 
role in nearly all chronic inflammatory reactions.26 Cell adhesion molecules are 
important in mediating this leukocyte migration from the vasculature blood stream to 
sites of inflammation.32 The role of these cellular adhesion proteins, more specifically 
integrins, are explained below.  
 
Integrins – Structure and Role in Cell Signalling 
 
Cellular plasma membranes effectively create a barrier between the inside 
(intracellular) and outside (extracellular) of the cell it defines. For the cell to sense and 
respond to its environment,33 including other cells and the supportive structures that 
make up the extracellular matrix (ECM), bidirectional signalling across the plasma 
membrane has to be mediated by receptors and other structures.34 These cell surface 
receptors that mediate cell-ECM interactions are integrins.30,35,36 
 
Integrins are heterodimers, with non-covalently associated α and β subunits; 
comprising of 18 α- and 8 β- known subunits that can assemble into 24 distinct integrin 
receptors, all with different binding properties and tissue distribution.30,34 Each of 
these heterodimers consist of a large extracellular domain, allowing protein binding in 
the extracellular environment, a transmembrane domain (single membrane), and a 
short intracellular cytoplasmic tail domain.37  
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Although integrins are involved in other biological activities, including cell migration, 
patrolling38 and binding to cells of certain viruses,39 they have two main functions: 
 
 Attachment of the cell to the extracellular matrix 
 Signal transduction to the cell from the extracellular matrix 
 
Integrins function by linking the actin cytoskeleton of a cell to various external 
structures. The cytoplasmic part of each integrin binds to specific adaptor proteins, 
connecting to the actin filaments inside a cell (Figure 2).40  
 
Figure 2 – Integrin binding from the cytoskeleton to the ECM (reproduced from C. 
Connor, Essentials of Cell Biology, 2010)40 
 
It is important to note that integrin attachments to neighbouring cells can break and 
reform as the cell migrates laterally (Figure 1, Stage 6 - slow crawling), thus it is vital 
for integrins to be able to mediate these cell adhesions.41,42 Integrins usually have to 
be activated before they can mediate adhesion,36 a process is known as integrin 
activation, which controls cell adhesion, migration, and extracellular assembly.43 
Circulating leukocytes however do express abundant integrins on their surface, but 
they have low ligand binding capability; and therefore to mediate stable adhesion, they 
must undergo changes in conformation through integrin activation.44 
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Integrins exist in an equilibrium between a bent low-affinity state and an upright high-
affinity state,45 shown in Figure 3 below,46 where integrin adhesion receptors can 
rapidly increase their affinity (activation) in response to intracellular signalling, 
known as inside-out signalling.47 Integrins can additionally be activated from outside 
the cell (outside-in signalling),48 but in either case, binding of talin to β-integrin 
subunit cytoplasmic domains is a key convergence point for signals regulating integrin 
activation.49 There are a complex array of other cellular receptors that can activate 
integrins, such as chemokines,50 or α-actinin,51 but remain out the focus of this study.  
 
 
Figure 3 – Integrin structure and activation. (reproduced from A. Calderwood, 
Nature Reviews Molecular Cell Biology, 2013)45 
 
Upon activation by their ligands, a change in conformation is observed (Figure 3), 
allowing the opening of the ligand-binding pocket,37,52 which increases the intrinsic 
affinity for ligand and results in stable or persistent bonds. Clustering of integrins on 
the leukocyte surface, particularly at focal sites (focal adhesion) results in strong 
ligand affinity and avidity.53 Chemokines initiate further inside-out signalling through 
G protein-coupled receptors (GPCRs),44,54 which up-regulate α4β1 and αLβ2 integrin 
binding of leukocyte integrins to immunoglobulin superfamily members; ICAM1 and 
VCAM1, expressed by endothelial cells, 55-57 resulting in leukocyte arrest, (Stage 4). 
High affinity 
(active) 
Low affinity 
(inactive) 
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The signalling cascade initiated by GPCRs that lead to activation of integrin affinity 
however is not fully understood.44 The ligand-induced clustering of integrins and 
allosteric conformation changes contribute to the initiation of outside-in signalling 
(Figure 4).58 This outside-in signalling results in a variety of leukocyte functions, 
including spreading, motility and adhesion strengthening and stabilisation (Stage 5), 
and is required for successful leukocyte migration (Stage 6).22 
 
 
Figure 4 - Structural changes of lymphocyte function associated antigen 1 (LFA1) 
(reproduced from T. Kinashi, Nature Reviews Immunology, 2005)58 
 
 
Since the cytoplasmic domains of the integrin contains no enzymatic functions, 
activation of signalling cascades require interactions with cytoplasmic signalling 
adaptors, for example, talin, α-actinin or filamin, usually via the β-integrin chain.44 
 
The α4-integrin cytoplasmic domain is unique however, because it specifically binds 
paxillin, a signalling adaptor molecule, which further supports other protein-protein 
interactions.59,60 The role of α4-integrin-paxillin in outside signalling is relevant to 
leukocyte migration, and is discussed in more detail below.  
Affinity regulation 
Valency regulation 
Low affinity Intermediate 
affinity 
High affinity 
Clustering 
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1.1.3 The α4-Integrin / Paxillin Interaction 
 
Paxillin is a 68kDa focal adhesion-associated, phosphotyrosine-containing protein that 
has a role in several signalling pathways.61 This signal-transduction adaptor protein is 
used to regulate cell spreading and motility in the body. It contains a LIM domain that 
are zinc-binding structures resembling a double zinc-finger domain, which mediate 
protein-protein interactions.62 Paxillin specifically binds to the cytoplasmic tail of the 
α4-integrin chain, via its amino terminus,59 but research has shown this only happens 
when the serine-988 is dephosphorylated.63  
 
This dephosphorylation happens only when VLA4 (α4β1-integrins), expressed by 
leukocytes, are in a high-affinity conformation, either constitutively, where the 
integrin is constantly active through lymphoid development, or transiently, through 
recruitment to the site of inflammation by inside-out signalling from G-protein 
coupled receptors.44,64 The implications of these observations are that outside-in 
signalling is initiated through adaptor proteins associated with the β1-integrin chain in 
addition to the association with paxillin and the α4-integrin chain.44 More importantly 
for this research, the interaction between the α4-integrin and paxillin in outside-in 
signalling was found relevant to leukocyte migration.65 
 
The α4-integrin-paxillin interaction is involved in two main processes: 
 
1) α4β1 integrin dependent cell adhesion under shear flow – (cell tethering 
and cell adhesion), providing a needed connection to the actin cytoskeleton.66 
2) α4β1 dependent leukocyte migration – (leukocyte crawling), through 
temporal and spatial regulation of GTPase Rac.67  
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1) α4-Integrin / Paxillin Interaction – Cell Adhesion  
The α4β1 integrin can support tethering and rolling of leukocytes under shear flow 
conditions, a role largely associated with selectins previously mentioned.68-70 The 
interaction of paxillin with the cytoplasmic domain of the α4 integrin subunit is critical 
for supporting tethering cell adhesion under shear flow conditions as it provides an 
essential connection to the actin cytoskeleton.66 More specifically, paxillin binding to 
the skeletal tail of talin was found to be vital in linking the α4-integrin with the actin 
cytoskeleton.68 Jurkat cells (an immortalised line of human T-lymphocyte cells), 
expressing  an  α4Y991A mutation, disrupted the α4-integrin / paxillin binding, 
reduced tethering bond strength with talin in the α4-integrin adhesion complex.68  
 
Talin has already been recognised as a fundamental molecule in regulating integrin 
affinity for ligands (inside-out signalling),71 however, it was found that talin had no 
effect on α4 integrin affinity modulation. Cells expressing α4-integrin with disrupted 
paxillin binding had no defect on the α4β1 integrin affinity for its ligand VCAM1,72 
moreover, ligand induced conformational changes in α4β1 were not altered by 
knocking down talin levels.68 Thus the role of the α4-interaction is to mediate 
leukocyte tethering, through association with the cytoskeleton, strengthening 
adhesions under flow conditions.66  
 
The α4-paxillin interaction is also an important factor in establishing firm cell 
adhesion under shear stress conditions.66,68 It should be noted that this is in contrast to 
static cell adhesion, which remains unaltered by disrupting the α4-paxillin 
interaction.72 The mechanism of this cell adhesion strengthening is known to regulate 
adhesion dynamics through focal adhesion kinases (FAK), although the exact process 
of this interaction remains relatively unknown.73,74  
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2) α4-Integrin / Paxillin Interaction – Cell Migration 
 
Once a leukocyte has firmly arrested on the vascular endothelium, it will then migrate 
laterally to the junction of two or more cells where it can migrate through them, 
proceeding to the site of concern in the underlying tissue.66 α4-integrins have been 
shown to function in both of these migratory steps,75 where the α4-paxillin interaction 
has been shown as essential for α4β1 dependent leukocyte migration.76 
 
A dynamic regulation of cell adhesion allows cell migration, where new adhesions are 
formed at the leading edge of cell, and subsequently adhesions at the lateral and 
trailing edge are released, propelling the body of the cell forward (Figure 5).77,78 
Temporal and spatial regulation of the small GTPase Rac is fundamental for effective 
cell migration,67 where Rac is activated at the leading edge, promoting lamellipodia 
formation.66  
 
Figure 5 – Cell movement from new adhesions on the leading edge (reproduced 
from D. J. Tschumperlin, Physiology, 2013)77 
 
Rac activation on the other hand is inhibited at the lateral and trailing edge, thus 
preventing lamellipodia formation.79  
Cell body movement 
Adhesion 
De-Adhesion 
Lamellipodium 
New adhesion 
Old  adhesion Focal Adhesion 
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The α4-integrin subunit is dephosphorylated at ser988 at the lateral and trailing edge 
of a migrating cell, which is associated with paxillin binding, inhibiting Rac 
activation.80,81 Paxillin does this through recruiting GTPase activating protein GIT1,81 
which inhibits Arf6, another member of the GTPase family. Inhibition of Arf6 
subsequently inhibits the activation of Rac, albeit by an unknown mechanism.66 This 
causes de-adhesion, which is required for the cell to move forward. Conversely, at the 
leading edge of the migrating cell, the α4-subunit is phosphorylated, resulting in a 
disruption of the α4-paxillin interaction, and thus Rac activation will promote 
lamellipodia formation, allowing the cell to migrate directionally.79 
 
The α4-integrins can additionally function as a signalling molecule augmenting cell 
migration by other integrins.63 α4β1 integrins have been shown to stimulate αLβ2 
dependent cell migration, which requires the α4-paxillin interaction.64 Although 
paxillin does not regulate the affinity of α4β1, its association with high affinity α4β1 
contributes to the communication with the β2-integrin, driving cell migration.63,64 
 
In summary, the leukocyte movement from the blood into the peripheral tissue is a 
central feature of the immune surveillance; however, they also contribute to the 
pathogenesis of inflammatory and autoimmune diseases. The roles of the α4β1-
integrin / paxillin interaction in leukocyte trafficking can be summarised as:  
 
 Leukocyte cell adhesion, both tethered and firm cell adhesion 
 Leukocyte movement through GTPase Rac regulation 
 
These discoveries make the α4-paxillin interaction a potentially attractive therapeutic 
target in regulating leukocyte trafficking for the treatment of numerous chronic 
inflammatory and autoimmune diseases, and thus remain the focus of this research. 
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1.1.4 Current Anti-Inflammatory Drugs 
 
Although inflammation is the body’s first line of defence against injury and infection, 
it can also be regarded as a ‘double-edged sword.’ An ungoverned inflammatory 
response can result in the destruction of healthy tissue and ultimately cause further 
damage than the original problem would have produced. Anti-inflammatory 
medications can be categorized as Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs), Steroidal-Based Anti-Inflammatory Drugs, Immune Selective Anti-
Inflammatory Derivatives (ImSAIDs) with many herbs also exhibiting anti-
inflammatory properties.18 Many of these drugs target the cyclooxygenase (COX) 
enzymes, where amongst other functions; these are responsible for the production of 
gastro-protectional prostaglandins.82 Consequently, inhibition of COX, specifically 
COX-1 by drugs such as NSAIDs, can be detrimental to the body, leading to gastric 
ulcers and renal toxicity.83 
 
Given the role of the α4-integrins in the trafficking of leukocytes,84 they have proven 
attractive for a number of chronic inflammatory autoimmune diseases, including 
multiple sclerosis, rheumatoid arthritis, atherosclerosis and inflammatory bowel 
disease.85 Inhibition of α4-integrins have been shown as effective in alleviating a wide 
variety of chronic inflammatory diseases in animal models,86-89 inhibiting the 
recruitment of leukocytes to areas of inflammation.90 
 
Some examples of humanized α4-integrin targeting molecules are shown below in  
Table 1. 
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Table 1 – Selected structures of small, non-peptide inhibitors for integrins that have 
been clinically targeted91 
Name Structure Stage Indication Target 
Valategrast 
 
Terminated at 
Phase II 
Asthma α4β1 
IVL745 
 
Terminated at 
Phase II 
Asthma α4β1 
Firategrast (SB-
683699) 
 
Phase II Multiple 
Sclerosis 
α4β1 
AJM300 a 
 
 Ulcerative 
Colitis 
α4β1 
6-B345TTQ 
 
 Unknown α4-
paxillin 
interaction 
JSM6427 a 
 
Phase I Age-Related 
Macular 
Degeneration 
α5β1 
a The nature of the R-group functionality has not been disclosed.  
  
Nazilzumab, a humanized antibody against the α4-integrin cell adhesion has proven 
its therapeutic effectiveness for the treatment of autoimmune diseases such as multiple 
sclerosis,92 or inflammatory bowel disease.93,94 The mechanism of this α4-integrin 
antagonist is through inhibiting the interaction of α4-integrin with ligands such as 
VCAM1.95  
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However, given the role of α4-integrins in normal physiological functions, such as 
immune surveillance and haematopoiesis, the risk of side effects of α4-integrin 
blockage is a concern.66 At full receptor blockade, these antagonists lead to a complete 
loss of α4-integrin function, carrying the risk of serious side effects including defects 
in placentation, hematopoieses and heart development.96 Moreover, T-cell blockage 
into the central nervous system is likely accountable for the occurrence of progressive 
multifocal leukoencephalopathy, in humans treated with anti-α4-integrin antibodies.97  
 
Consequently, a more selective approach of targeting the α4-integrins to suppress 
leukocyte trafficking, whilst still enabling normal physiological trafficking may be 
therapeutically beneficial. To this aim, targeting α-integrin / paxillin interaction may 
resolve this problem.66 
 
Research has shown that mice developed bearing a Tyr991Ala mutation, specifically 
in the cytoplasmic tail of the α4-integrin chain, blocked Paxillin binding. These mice 
were viable, but showed an impaired recruitment of mononuclear leukocytes to 
inflammation in the peritoneal cavity.76 Furthermore, they showed no defect in 
haematopoiesis or immune system development. 
 
Instead of blocking the α-integrin, blocking the α4-integrin / paxillin interaction leaves 
α4-integrin mediated static adhesion intact,59,72  which suggests that interfering with 
the α4-integrin signalling is a more favourable therapeutic approach. This has been 
demonstrated with a few synthetic targets,98 one of which, being the focus of this 
research.90  
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1.2 Discovery of a Small Molecule that Inhibits the Paxillin 
- α4-Integrin Interaction 
 
Ginsberg et al, published research identifying; A Small Molecule That Inhibits the 
Interaction of Paxillin and α4 Integrin Inhibits Accumulation of Mononuclear 
Leukocytes at a Site of Inflammation.90 The paper investigates the use of small drug 
molecules to mitigate a wide range of chronic inflammatory diseases in animal models 
by inhibition of the recruitment of leukocytes to sites of inflammation. 
 
 
1.2.1 Literature Results 
 
In this paper90 the authours screened a large chemical library (~40,000 compounds) to 
identify small molecules that could hinder this α4-paxillin interaction, whereby a non-
cytotoxic inhibitor that impaired integrin α4-mediated (but not αLβ2-mediated) Jurkat 
T-cell migration was discovered. Jurkat T-cells are an immortalised line of T- 
lymphocyte cells that can be used to study T-cell signalling. These can be regarded as 
‘naïve T-cells’ whereby they can be mutated or genetically engineered for specific 
screening properties, commonly used in immunological testing.99  
 
The findings demonstrated that pharmacological blockade of the α4-integrin / paxillin 
interaction impaired α4β1-dependent migration and the recruitment of leukocytes. 
This is proof of principal for a novel anti-inflammatory strategy. 
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The compound, 6-B345TTQ, 1 shown below in Figure 6, displayed a disruption in 
the α4-integrin and paxillin interaction and therefore interfered with the α4-integrin 
signalling. It was reported to inhibit the α4-paxillin interaction in cells in vitro by 
acting as a competitive inhibitor. An isomer of this compound however, 6-B234TTQ, 
2, (Figure 6), shifting a methoxy group from position 5 to 2, showed no inhibitory 
effects on α4-mediated cell migration, cell spreading, or recruitment of leukocytes to 
an inflammatory site. Compound 6-B345TTQ, 1, inhibited α4-mediated monocyte and 
T-cell migration by 52.6 % and 56.4 % respectively, but did not specifically reduce T-
cell migration mediated by other α integrin subunits, highlighting its specificity on α4-
mediated cell migration. 
 
 
1 2 
Figure 6 – Compound 6-B345TTQ (1) and its analogue, 6-B234TTQ (2) 
 
  
Additionally, it had no effect to block the residual migration of cells bearing the 
α4(Y991A) mutation,76 supporting that the compound specifically blocks migration 
by the α4-interaction. However, further work examining the effect of this compound 
on firm adhesion under fluid shear stress remains untested, or at least unpublished. 
Compound 1 additionally showed notable specificity with respect to inhibition of 
paxillin paralogues in vitro, blocking the binding of both leupaxin and paxillin to the 
α4-integrin. By compound 1 blocking this binding, its supports its anti-migratory 
effects to be independent of which paxillin paralogues are expressed. 
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No effects were observed upon the interactions of leupaxin with focal adhesion kinase 
(FAK). FAK, or PTK2 protein tyrosine kinase 2, is a focal adhesion protein kinase 
involved in cellular adhesion and spreading processes. FAK is phosphorylated in 
response to integrin engagement, leading to the recruitment to focal adhesions.100,101 
 
Additionally, compound 1 had no effects on interactions of leupaxin with FAK or with 
Git-1, where these interactions are important in the signalling downstream of 
integrins.102 Git-1 contains an ARFGAP domain, which enables it to act as a GTPase 
activating protein.103 Compound 1 however did inhibit the interaction of paxillin with 
FAT (focal adhesion targeting) and Git-1.  
 
In thioglycollate-induced peritonitis in mice, administration of compound 1  resulted 
in significantly reduced infiltration of monocytes / macrophages after 48 hours since 
the induction of inflammation. Furthermore, neutrophils in both transgenic 
α4(Y991A) mice treated with compound 1 were unaffected. Compound 2, the control, 
had no discernable impact on the recruitment of leukocytes in vivo. 
 
The overall findings demonstrated by this paper showed that pharmacological 
blockade of the α4 integrin-paxillin interaction impairs the α4β1-dependent migration 
and the recruitment of leukocytes, presenting a novel anti-inflammatory strategy.  
 
 
Compound 1 was both patented and published as a racemate,90,104 with no other 
mention of activity on structurally similar compounds, other than the related 2,3,4-
trimethoxy-counterpart, 2. 
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This provided an opportunity to asymmetrically synthesise both enantiomers of 
compound 1, for biological testing, with the intention to identify an active enantiomer. 
Approximately 50 % of marketed drugs are chiral, with the remainder of these being 
a mixtures of enantiomers.105 The potential advantages of using single enantiomers of 
chiral drugs can reflect their dosage, efficacies, side effect profiles or even indicated 
use.106 Additionally, for progression and success in clinical trials, the single 
enantiomer or indeed racemic mixture needs to be shown as superior for the chosen 
form.107 
 
The intention of this thesis was to synthesise both enantiomers of compound 1, whilst 
also synthesising similarly related compounds for structural activity relationships in 
biological testing. A literature review was performed, assessing previous methods to 
the quinolone and quinolin-2-one structure, more specifically directing towards 4-aryl-
3,4-dihydroquinolin-2-(1H)-ones, and is shown in Section 1.1.2.  
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1.2.2 Synthesis of Quinolinones and Related Compounds 
 
The quinolone scaffold is present in many classes of biologically-active 
compounds.108 Since their discovery in the early 1960s as therapeutic agents, with the 
introduction of nalidixic acid in 1962 for the treatment of urinary tract infections,109 
quinolones have drawn a more profound attention due to their broad range of 
pharmacological properties. Quinolones are a class of bicyclic molecules, related to 
the hetereoaromatic coal tar isolate quinoline (Figure 7).  
 
 
Figure 7 – The structure of quinoline (left) and quinolin-2-one (right) 
 
The most common approach to the quinoline structure is the Skraup synthesis. 
Subsequent to the elucidation of its structure,110 the synthesis of quinoline by Skraup 
was arguably the greatest single impetus to its further study.111 Here, a mixture of 
aniline, sulphuric acid, glycerol, nitrobenzene and iron (II) sulfate are heated together 
(the last reagent used as a moderator to prevent a ‘runaway reaction’).112 Nitrobenzene 
can be replaced with an alternate oxidant such as iodine or chloranil, and is required 
to convert the 1,2-dihydroquinoline into the final product, quinoline (Scheme 1). 
 
Scheme 1 – Skraup synthesis in the formation of quinoline 
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An alternate approach is the Friedländer synthesis,113 whereby a 2-aminophenyl 
ketone is condensed with an aldehyde (or ketone) containing a methylene unit, in the 
presence of an acid or base catalyst. 
 
 
Scheme 2 – Friedländer Synthesis towards quinoline derivatives 
 
The reaction has been catalysed by toluenesulfonic acid,114 trifluoroacetic acid,115 
iodine,116 various Lewis acids,117 with several reviews being published.111,118,119 
 
The synthesis of quinolin-2-ones are remarkably similar to those of quinolines, with 
one of the very first synthesises of the quinoline class being that of quinolin-2-one, 
reported in 1852.120 This was prepared by the reductive cyclisation of 2-nitrocinnamic 
acid using ammonium sulfide.120  
 
Similar reductive cyclisations have used palladium on carbon and hydrogen gas to 
yield quinolin-2-ones (Scheme 3).121 
 
 
 
Scheme 3 – Reductive cyclisation towards quinolin-2-one derivatives121 
 
Other reagents have involved trifluoroacetic acid,122 iron with acetic acid, 123 hydrogen 
sulfide124 or zinc in near-critical water,125 typically from Bayliss-Hillman adducts. 
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A similar transformation from the corresponding amine had been reported, using a 
benzimidazole-based palladium N-heterocyclic carbene (Pd-NHC) to effectively 
catalyse the C-C cross-coupling reaction via a Heck reaction,126 (Scheme 4). 
 
Scheme 4 – Synthesis of 4-aryl substituted 2-quinolones via a Heck reaction126 
 
A small variety of 4-aryl-2-quinolones were synthesised with methoxy- and methyl 
substituents for the R functionality with reasonable yields (65-75 %). This approach 
offered a one-pot protocol towards the synthesis of the 4-aryl-2-quinolone structure 
involving a Heck coupling and cyclisation reaction. 
 
 
The synthesis of 4-substituted-3,4-dihydroquinolin-2-one structures are commonly 
synthesised from the corresponding N-cinnamoyl derivatives (Scheme 5). 
 
Scheme 5 – AlCl3-catalysed Friedel-Crafts alkylation127 
 
A variety of functional groups were tolerated in this transformation, however, poor 
yields were obtained when R2 = Ph, R1 = H (11 %). Similar improved transformations 
of N-cinnamoyl derivatives have been catalysed with zeolites,128 hydrobromic acid,129 
polyphosphoric acid,130 and trifluoromethanesulfonic acid.131 
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Jure et al.132 demonstrated a one-pot synthesis of 4-aryl-3,4-dihydroquinolin-2(1H)-
ones (Scheme 6) via the condensation of monoanilides with aromatic aldehydes, 
followed by decarboxylation and subsequent hydroarylation, catalysed by 
trifluoroacetic acid.  
 
Scheme 6 – Synthesis of 4-aryl-3,4-dihydroquinolin-2(1H)-ones via monoanilides 
with aromatic aldehydes, catalysed by trifluoroacetic acid132 
 
Alternatively, arylidene derivatives have been transformed into the corresponding 4-
aryl-3,4-dihydroquinolin-2-(1H)-ones via reflux in ethanol (Scheme 7). 
 
Scheme 7 – Reaction of 2-arylidenes with 1-aminonaphthylamines133 
 
Similar results were obtained by refluxing in an aqueous medium, catalysed by TEBA 
(benzyltriethylammonium chloride).134 Additionally this reaction was performed in 
refluxing acetic acid, yielding similar results with aromatic amines.135 
 
Stereoselective preparations of 4-aryl-3,4-dihydroquinolin-2-ones however remain 
quite limited,136 although some highly enantioselective processes towards the 
corresponding diarylmethine-precursors exist,137-139 and are discussed below. 
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Kim et al.,140 showed a (-)-sparteine-mediated dynamic thermodynamic resolution of 
2-(α-lithiobenzyl)-N-pivaloylaniline, using a temperature and concentration 
controlled epimerisation sequence. Increasing the concentration of substrate in methyl 
tert-butyl ester solvent (0.05 to 0.20) was found to offer an improved enantiomeric 
ratio (37 : 63 to 98 : 2 respectively); however the reaction example was limited to the 
substrate shown below in Scheme 8. 
 
 
Scheme 8 – (-)-Sparteine-mediated dynamic thermodynamic resolution140 
 
Taylor and co-workers141 targeted similar precursors towards the synthesis of 
enantiomerically enriched 4-aryl-3,4-dihydroquinolin-2(1H)-ones by performing an 
asymmetric reduction and intramolecular cyclisation (Scheme 9). 
 
 
Scheme 9 – Synthesis of 4-aryl-3,4-dihydroquinolin-2-ones via Heck adducts141 
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Carreira et al.136 published an enantioselective approach towards the synthesis of tert-
butyl 3,3-diarylpropanoates as useful building blocks in the preparation of 4-aryl-3,4-
dihydroquinolones (Scheme 10). 
 
Scheme 10 – Rhodium (I) catalysed conjugate addition towards 4-aryl-3,4-
dihydroquinolin-2-ones136 
 
The Rh(I)-catalysed conjugate addition of aryl boronic acids gave good 
enantioselectivities (89-93 % e.e.) and good yields (69-95 %) towards the diaryl 
derivatives. These were subsequently converted to the dihydroquinolin-2-ones by 
Pd/C and H2. 
 
These chiral diaryl-structural precursors shown above (Scheme 8 to Scheme 10) are 
present in a number of notable pharmaceuticals (for example, tolterodine142 and 
sertraline143), including some natural products.144,145  
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A number of these enantiomerically enriched targets were also synthesised from chiral 
3-arylindan-1-ones precursors. An example of this is the catalytic asymmetric 
synthesis of the muscarinic receptor (R)-tolterodine.146  
 
A chiral 3-arylindan-1-one was firstly synthesised, and upon Baeyer-Villiger reaction 
gave the corresponding coumarin (Scheme 11). Subsequent ring opening and 
additional manipulations yielded the desired (R)-tolterodine.  
 
 
Scheme 11 – Synthesis of muscarinic receptor, (R)-tolterodine146 
 
 
With chiral indan-1-ones being demonstrated as suitable precursors to structurally 
analogous 4-arylcoumarins (Scheme 11), this prompted the idea that chiral 3-
arylindan-1-ones could be useful precursors to the synthesis of enantiomerically 
enriched 4-aryl-3,4-dihydroquinolin-2(1H)-ones. Literature methods for Beckmann 
reactions from the corresponding indanone oxime were additionally available.147 As a 
result, our attention turned towards the synthesis of enantiomerically enriched indan-
1-ones and subsequent Beckmann rearrangements, and remained the focus of this 
research. 
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1.3 Research Aims 
 
The focal research paper90 has identified a small non-cytotoxic inhibitor of the α4-
integrin / paxillin interaction, promoting inhibition of leukocyte recruitment and 
migration. This compound was published as a racemate, and consequently synthesis 
and identification of the active enantiomer remained an interest (Figure 8). 
 
 
 Figure 8 – Identification of active enantiomer, (R)-1 or (S)-1 
 
Additionally, compound 2, showed a loss in activity upon changing the 3,4,5-
methoxy- positions to 2,3,4-. Consequently, investigation into the activity of the 
following structural modifications became of interest (Figure 9). 
 
Figure 9 – Structural activity – initial areas of interest 
 
Literature methods towards the synthesis of enantiomerically enriched derivatives of 
compound 1 remained limited, although enantioselective methods to structurally 
similar 3-aryl indan-1-ones were relatively abundant, and consequently our attention 
focused on this synthetic approach. 
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The following disconnection was applied for the synthesis of compound 1, shown 
below in Scheme 12. 
 
1 3 
Scheme 12 – Disconnection for compound 6-B345TTQ, 1, to the corresponding 3-
aryl-indan-1-one, 3 
 
Towards the synthesis of compound 1, the following objectives were established: 
 
1) Synthesis of enantiomerically enriched 3-aryl-indan-1-ones: To synthesise 
both enantiomers of the 3-aryl indan-1-one precursor, 3  towards the synthesis 
of compound 1. Additionally, similarly related substrates, given consideration 
to Figure 9, will also be synthesised.   
(Chapter 2) 
 
2) Beckmann rearrangement of enantiomerically enriched 3-aryl-indan-1-
ones: From the corresponding enantiomerically enriched 3-aryl indan-1-ones, 
Beckmann cyclisations will be investigated, in efforts towards the 
corresponding enantiomerically enriched 4-aryl-3,4-dihydroquinolin-2-one 
compounds, notably compound 1. 
(Chapter 3) 
 Biological testing of individual enantiomers and corresponding analogues, where 
applicable, will be outsourced in collaboration with industrial sponsors, and thus 
remains out of the focus of this research.  
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 CHAPTER 2 - SYNTHESIS OF SUBSTITUTED INDANONES 
 
2.1 Introduction 
 
The indane framework is found in a large number of important molecules.148 Chiral 3-
substituted indan-1-ones are important intermediates in the synthesis of interesting 
compounds with biological activity.149 In addition the multitude of diverse indanone 
natural products150,151 requires both selective and efficient synthetic routes.152 Many 
of these methods will be discussed in this chapter.  
 
 
2.1.1 Structure and Nomenclature of Indanones & Indenones 
 
The indanone framework, in its simplicity, consists of a benzene ring fused to a 
cyclopentanone. The nomenclature of the indanone structure is fundamentally 
contingent on the position of the cyclopentanone ring; producing indan-1-one and 
indan-2-one structures, shown below in Figure 10. 
 
 
Figure 10 – Indan-1-one (left) and indan-2-one (right) 
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2.1.2 Indanones in Use 
While a variety of indan-1-one related compounds are important bioactive molecules, 
perhaps the most renowned indan-1-one derivative is donepezil (Aricept®). Donepezil 
was discovered in 1995 as reversible acetylcholinesterase inhibitor, used as a first-line 
therapy for mitigation of Alzheimer’s disease by increasing the levels of cortical 
acetylcholine, a neurotransmitter crucial to cognitive function.153 
 
 
Figure 11 – Donepezil hydrochloride 
 
Not only is Donepezil a very potent compound with acetylcholinesterase IC50 in units 
of nM, quite interestingly, it was also patented for its ability to reduce locally 
expressed effects caused by topically applied ophthalmic pharmaceuticals. 
Subsequently, a variety of donepezil analogues, comparable in activity, have been 
produced, keeping this area of research very active in the illnesses it addresses (Figure 
12 below). 
 
 
Figure 12 – The structure of indanorine154 and indanocine155 respectively 
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Camps et al.156 synthesised a variety of cis-fused spiro(cyclopenta[a]indene-2,2′-
inden)diones, in connection with the synthesis of novel donepezil-based anti-
Alzheimer agents. These were derived from a one-pot synthesis, by treatment of 5- 
and 6- substituted indan-1-ones with various aldehydes and sodium ethoxide. 
Although no activity information was presented in the paper, it highlighted a novel 
synthesis to some interesting indan-1-one derived compounds with potential 
pharmaceutical properties. 
 
Another indan-1-one related compound, indacrinone, with a very similar structure to 
those in Figure 13, displayed antihypertensive properties and is used for patients with 
gout, as it readily decreases reabsorption of uric acid.157,158 
 
Figure 13 - Potentiators of mGluR2 receptors patented by Merck 
 
Isolated from the bracken Pteridium aquilinium, the indan-1-one moiety also 
constitutes the core of natural Pterosine compounds (Figure 14). Pterosines have been 
shown to exhibit cytotoxic and antibacterial activity at micromolar 
concentrations,159,160 with several synthesises being demonstrated.161 The importance 
of the indan-1-one pharmacophore was confirmed, as the alcohol counterparts 
displayed much lower activity.162 
  
Figure 14 – Several biologically interesting Pterosines; Pterosin A, L & H 
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The indanone moiety was further highlighted as an important pharmacaphore, with the 
development of indenone compounds used to stimulate fibroflast growth factor by 
inhibition of Dusp6 (dual specificity phosphatase 6) in micromolar concentrations (in 
vitro study). Reduction of the carbonyl group or lack of the benzylidene group resulted 
in the dramatic loss of activity.163 
 
Quite interestingly, potent and selective COX-2 inhibitors, Flusolide (and its thioether 
analogue), Figure 15, were discovered, with the potential to exert powerful anti-
inflammatory effects, while also minimising the deleterious side effects from the 
inhibition of COX-1.164-167 
 
Figure 15 – Flusolide and its thioether analogue 
 Although there are a large number of biologically important 2-substituted indan-1-one 
compounds, this discussion will focus on 3-substituted indan-1-one compounds. Such 
derivatives (Figure 16) have demonstrated anti-inflammatory activity, with in vivo 
doses of ~20 mg/kg exhibiting 70 % inhibition of edema, with the effect persisting for 
3-5 hours.168 
 
Figure 16 – Indanone acetic acid and its derivative – with anti-inflammatory activity 
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Saxena et al.169 reported 3-substituted Gallic acid-based indanone derivatives with 
very effective anticancer activity in a variety of human cancer cells lines. Furthermore, 
some of the more potent compounds displayed no toxicity to human erythrocytes even 
at high concentrations, nonetheless only being reported as a racemic mixture. 
 
Figure 17 – The structure of a gallic acid-based indanone 
 
The indanone moiety with chiral centres at the 2- and 3- position has been the core 
structural unit of a variety of other drugs and natural products, namely Pauciflora F,170 
Taiwaniaquinone B & D,171 and a Tolterodine precursor.146 One of the more prominent 
chiral indanones for this project is Indatraline; a non-selective monoamino transporter 
inhibitor, shown to block the reuptake of dopamine, norepinephrine and serotonin. 
Numerous synthetic routes have been established for this compound.172-174 
 
Figure 18 – Structure of indatraline 
 
Ultimately, indanones have found a profound use in the pharmaceutical industry; 
fortuitously for the synthesis of indanone substructures related to compound 6-
B345TTQ, a plethora of useful synthetic techniques have already been developed. 
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2.1.3 Synthesis of Indanones 
 
Developing an enantioselective synthetic route for a new drug candidate or key 
intermediate can be a resource-intensive and time-consuming process of 
pharmaceutical development.175 Consequently, preparative chiral HPLC has found a 
very useful position in some challenging synthetic situations, already demonstrating 
an effective use in the synthesis of a preclinical drug candidate.176 
 
Zwanenburg et al.177 utilised preparative chiral HPLC during the synthesis of 
pharmaceutically important indan-1-one derivatives, when the coupling of chiral 
reagents resulted in decomposition during purification. In view of synthetic problems, 
the decision to use semi-preparative chiral HPLC was supported by the rationale that 
only a small amount of sample was required at this stage for biological testing. 
 
Scheme 13 – Chiral resolution of indanone derivative; Strigolactone analogues 
 
Similar reasoning was applied for the use of preparative chiral HPLC for more 
complex spirocyclic indanone derivatives.178 Moreover, planar chromatography (PC) 
has played an important role for the real-time monitoring of chiral synthetic progress, 
owing to its simplicity, low cost and flexibility, has allowed results that can be usefully 
related to the ones achieved in columns.179 Stationary phases employed for planar 
chromatography are mainly based on cellulose derivatives.180-184 
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While the paradigm for developing and carrying out an enantioselective synthesis is 
well established, strategies for the efficient use of preparative chiral HPLC are still 
evolving. Nonetheless, it remains relatively fruitless with the separation of immensely 
varying enantiomers, where even small variations on the structure of solutes can have 
adverse effects on separation. For instance, the change of a protecting group can 
sometimes dramatically influence chromatographic resolution and productivity.185,186 
 
Whilst enantioselective methods are available for the direct synthesis of chiral 
indanones, one of the more common methods for indan-1-one synthesis encompasses 
Nazarov cyclisations. Although many examples exist, they generally focus around the 
same conditions, including the use of methanesulfonic acid,187 polyphosphoric acid 
(PPA),188 or more commonly, trifluoroacetic acid (TFA) under either thermal or 
microwave conditions.169,189-192 
 
Scheme 14 – Trifluoroacetic acid-catalysed Nazarov reaction 
 
Substituents R1 and R2, (Scheme 14) in this transformation were generally quite 
varied, although R1 being electron donating, with R2 conversely electron withdrawing 
offer the best yields. Interestingly, a more suitable HUSY zeolite catalyst allowed a 
similar transformation,193 with further examples provided in Section 2.3.2.3. Often, 
Nazarov conditions require ‘forcing conditions’ for the cyclisation,194 whilst other 
methods have proceeded via a chalcone epoxide derivative, cyclising with a Lewis 
Acid catalyst such as InCl3.195,196 
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Similar results were obtained with an analogous compound performing a Scholl 
reaction,197 (sometimes called Friedel-Crafts Arylation). More commonly used 
Friedel-Crafts acylations employed unsaturated carboxylic acids (crotonic / cinnamic 
acid) derivatives with the addition of a Lewis Acid catalyst and a substituted aromatic 
reagent.198-200 
 
 Scheme 15 – Friedel-Crafts acylation of substituted crotonic acids 
 Modest yields were obtained, although improved yields were obtained with the use of 
trifluoromethanesulfonic acid,158,201 albeit favourable substrates were again used as 
examples for this transformation. Similar transformations have been developed using 
(2-cyano-phenyl)phenylacetonitriles via spontaneous Dieckmann-type cyclisations.202 
 
The introduction of chirality in the 3-position of the indanone framework has been 
accomplished via a variety of different approaches. In 1994, Rocher and coworkers203 
used chiral auxiliaries to incorporate a substituent shown in the desired configuration  
(Scheme 16), followed by a previously encountered Friedel-Crafts acylation method 
to yield the corresponding chiral indanone. Incorporation of chiral auxiliaries has also 
been applied to muscarinic receptor antagonist Tolterodine.204 
 
 
Scheme 16 – Asymmetric cuprate addition to unsaturated carboxylate derivatives 
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Similar transformations were employed towards the synthesis of (+)-Sertraline and 
(+)-Indatraline, performing a lithiation / borylation and protodeboronation method, 
starting from a chiral homoallylic alcohol.143 The chiral alcohol was prepared from 
enzymatic resolution prior to the aforementioned method, offering excellent 
enantioselectivities (>95 % e.e.). 
 Inden-1-one precursors were additionally synthesised from the reaction of internal 
alkynes with o-iodo- or o-bromobenzaldehyde using a palladium catalyst under mild 
conditions and in moderate yields (Scheme 17).205 
 
 
Scheme 17 – Larock annulation to form substituted indan-1-ones205 
 
Closely related inden-1-one structures, used as intermediates for the synthesis of 
natural products such as C-nor-D-homosteroids,206 or Tolterodine,146 offered excellent 
templates for asymmetric transformations to the corresponding indan-1-ones (Scheme 
18). 
 
Scheme 18 – Synthesis of chiral 3-arylindan-1-one via the appropriate inden-1-one; 
 (a) PdCl2, PPh3, K2CO3, DMF, 130 °C, 1 h. (b) (S)-Me-CBS, BH3.THF, -20 °C, 2 h. 
(c) Et3N, DABCO, THF, 60 °C, 4 h 
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It was found that a more sterically demanding group such as a trimethylsilyl or tertiary 
alkyl group, favoured the 2-position of the inden-1-one. Less hindered alkynes 
unfortunately gave a mixture of regioisomers, although Larock et al. further developed 
the method, permitting different solvent/base conditions.207 
 
Further developments utilised a non-reductive Heck cyclisation, followed by an 
asymmetric hydrogenation.208 The use of (R)-MeCBS to reduce the inden-1-one, 
following work from Itsuno209 and Corey,210 afforded the inden-1-ol in excellent 
enantioselectivities (90-92 % e.e.), depending on the base employed.  
 
Scheme 19 – Enantioselective synthesis of inden-1-ol intermediate towards 
endothelin receptor antagonist SB-209670 
 
Interestingly from a mechanistic point of view, it is believed that the treatment of the 
inden-1-ol (Scheme 19) with DABCO yielded the corresponding indan-1-one via a 
1,5-H migration, shown below in Scheme 20. 
 
Scheme 20 – 1,5-H migration of inden-1-ol substituent with tertiary amine 
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The selective hydrogen rearrangement was initially attempted with a Pd(PPh3)2Cl2 / 
Et3N system, prompting a mechanistic assumption of a palladium hydride catalysed 
olefin isomerisation, however, when DABCO was used as the amine base, a slight 
increase in stereospecificity (92.2 % e.e.) was obtained, owing to a syn-facial 1,5-shift. 
This transformation is believed to happen due to geometric constraints, where it is 
believe DABCO should be incapable of undergoing palladium oxidation, thus 
negating the formation of the palladium hydride catalytic species.211 
 
Alternative methods shown by Morehead and co-workers demonstrated a rhodium-
catalysed hydroacylation towards the synthesis of 3-substituted indanones.212 This 
process offered high yields and enantiomeric excess (generally > 95 % in most cases). 
 
Scheme 21 – Hydroacylation of 2-vinyl benzaldehyde systems 
 
Similarly, Hayashi and co-workers213,214 also made use of rhodium in the synthesis of 
chiral indanones, starting from the corresponding alkynes, (Scheme 22). 
 
 
Scheme 22 – Rhodium-catalyzed asymmetric synthesis of indanones via axially 
chiral bisphosphine ligand 
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Although the aforementioned substrates employed in the 3-position were exclusively 
silicon derivatives offering high enantioselectivities (92-99 % e.e.), other methods 
below presented more pertinent substrate-cyclisations with aromatic functionality. 
 
Initial attempts at an intramolecular asymmetric cyclisation by Püschl and co-
workers215 were unsuccessful, but demonstrated an attractive method of forming 
substituted indanones from (E)-2′-bromochalcones, using high reaction temperatures 
(155 °C) or microwave conditions. Additionally, they illustrated that no reaction was 
achieved with conventional heating with –CN and –Cl in the 4-position (R1). 
 
Scheme 23 – Transformation of 2′-bromochalcones to corresponding indan-1-ones 
 
Buchwald and co-workers216 enhanced this method, demonstrating an effective 
method of transforming (E)-2′-bromochalcones into their corresponding chiral 
indanones with good yield and high enantioselectivity for some substituents. 
 
 
Scheme 24 –Enantioselective reductive Heck cyclisation  
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Optimisation of the reductive Heck reaction with PdCl2, using an (R)-3,5-Xyl-
MeOBIPHEP ligand afforded chiral indanones with good enantioselectivities (50-94 
% e.e.) and yields (42-90 %).  
 
A similar approach was performed using a rhodium-(R/S)-Monophos catalyst,217 
offering more attractive yields, (up to 95 % e.e.). 
 
Scheme 25 – Rhodium-catalysed asymmetric intramolecular 1,4-addition of pinacol-
borane chalcone derivatives 
 
This approach reported a broader range of aromatic functionality, permitting both 
electron donating and withdrawing aromatic substituents (Ar), with good 
enantioselectivities (81 – 95 % e.e.). 
 
In conclusion, the indan-1-one moiety, and indeed the inden-1-one precursor have 
further demonstrated a huge application in a variety of natural products and 
pharmaceuticals, including Fredericamycin A,218 Tolterodine,146 Sertraline,219 
Indatraline,174  and a variety of Pterosins.220 Subsequently, a plethora of synthetic 
techniques exist. By assessing particular methods more applicable to this project, it 
was important to evaluate and ‘scope’ particular reactions to their success for 
appropriate substrates. These were cemented within the aims of the project, and 
indeed, initial ‘scoping’ reactions (Section 2.2) were performed in accordance with 
this objective.   
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2.2 Initial Synthetic Reactions 
 
The objective of this chapter was the synthesis of enantiomerically enriched indan-1-
one precursors to compound 6-B345TTQ, 1, shown below in Figure 19. Additionally, 
the intention was to synthesise similarly related compounds, changing the R- and X-
groups shown below. 
 
 
Figure 19 – Synthetic precursors for the compound 6-B345TTQ, 1 (left), and related 
compounds 
 
The following section of work describes some initial synthetic routes that were 
attempted based on literature methods.  
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2.2.1 Conjugate Addition Reactions 
 
The following method included a stereoselective Michael addition of an aryl cuprate, 
applied by Rocher and coworkers.203 The method makes use of an Evans auxiliary,221 
with the appropriate disconnection described below (Figure 20). It should be noted, 
that the initial approach focused on a related compound without the bromine (X = H, 
Figure 19 shown previously). 
 
 
Figure 20 – Disconnection approach to an enantiomerically enriched propanoic acid 
 
Discussion of the Approach: 
The approach by Rocher and coworkers,203  is shown previously in Scheme 16, and 
upon forming the enantiomerically enriched 3,3-substituted propanoic acid, via chiral 
auxiliary induced enantioselective Michael addition of an aryl cuprate; the acid then 
being cyclised after conversion to the acid chloride.  
 
 
Scheme 26 – Cyclization of enantiomerically enriched acid  
 
The acid chloride was cyclised using AlCl3 from the corresponding acid chloride, 
where similarly related methods have also been employed for this transformation.  
- 54 -  
Results & Discussion 
The 3-aryl subsituted acrylic acid was synthesised via a Knoevenagel-type 
condensation reaction with malonic acid and a suitable base at reflux.222 
 
Scheme 27 – Knoevenagel condensation reaction on aromatic aldehyde 
 
The method produced compound 4 in a good yield (86 %), where the (E)-
stereochemistry was confirmed by 1H NMR, by inspection of the coupling constants 
for the vinylic protons. 
 
The chiral auxiliary was attached using a familiar n-BuLi/THF/RCOCl method,223 
producing the enantiomerically enriched product in good yield (Scheme 28). The 
method involved formation of the appropriate acid chloride, using oxalyl chloride and 
a catalytic amount of N,N,-dimethylformamide, and subsequent reaction with (R)- or 
(S)-lithiated 4-phenyl oxazolidinone. 
 
 
Scheme 28 – Attachment of Chiral Auxiliary 
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The aryl Grignard reagent was first produced successfully by standard synthetic 
conditions,224 starting from 2-bromonaphthalene, reacting with magnesium turnings 
and catalytic iodine in diethyl ether. The Grignard reagent was then introduced to a 
pre-cooled solution of copper(I)bromide dimethylsulfide complex, followed by slow 
addition to the enantiomerically enriched oxazolidinone-products mentioned 
previously, shown below in Scheme 29. 
 
Scheme 29 – Conjugate addition of 2-naphthalene 
 
The diastereoselectivity shown above was a 10 : 1 ratio for both (4R,3ʹS)-9 and 
(4S,3ʹR)-10 enantiomers, shown by inspection of the 1H NMR spectrum. The 1H NMR 
spectra were compared to that of the (4R,3ʹR), formed after cleavage of the original 
auxiliary (Scheme 30), followed by attachment of the opposite auxiliary enantiomer 
to that attached before, allowing the formation of (4R,3ʹR) and (4S,3ʹS) isomers. 
 
Scheme 30 – Cleavage of Chiral Auxiliary 
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Once the auxiliary had been removed by a combination of lithium hydroxide and 
hydrogen peroxide, an attempted cyclisation using the original conditions by Rocher 
and coworkers203 was performed. Attempting the cyclisation by first producing the 
acid chloride using cyanuric chloride, followed by an in-situ cyclisation with AlCl3 
was unsuccessful, yielding only the starting material after work-up, (Scheme 31). 
OH
O
O
O
O
O
O
O
O
(R)-12(S)-11
Cyanuric chlorideCH2Cl2
1.
AlCl32.
 
Scheme 31 – Cyclisation to enantiomerically enriched indan-1-one 
 
Attempts at heating the reaction, isolating the acid chloride prior to the cyclisation 
(rather than in-situ) and changes in solvent also gave the starting material after work-
up. Consequently, this method was not developed further. 
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2.2.2 Intramolecular Heck Cyclisation 
 Buchwald et al.216 reported a method of forming enantiomerically enriched indan-1-
one derivatives from some attractively simple 2′-bromochalcones. Consequently, the 
following disconnection approach was applied (Scheme 32). 
 
Scheme 32 – Disconnection approach to some 2′-bromochalcones derivatives 
 
Discussion of the Approach: 
Results from the Buchwald  et al. research are shown in Table 2.216 
 
Table 2 –Enantioselective Reductive-Heck Reaction of Substituted Chalcones 
reported by Buchwald et al.216 
 
Entry X Ligand Amine Ratio a:b Yield [%] a e.e. [%] b 
1 OTf (R)-BINAP MeNCy2 100:0 32 54 
2 OTf (R)-BINAP NEt3 100:0 40 53 
3 OTf (R)-BINAP ps c 100:0 65 55 
4 OTf (R)-3,5-XylMeOBIPHEP ps 100:0 88 79 
5 ONf (R)-3,5-XylMeOBIPHEP PMP d 0:100 74 80 
6 I (R)-3,5-XylMeOBIPHEP ps 100:0 25 76 
7 Br (R)-3,5-XylMeOBIPHEP ps 100:0 30 77 
a Determined by GC; b Determined by HPLC on a Chiracel OJ column; c ps = proton sponge; 
d PMP = 1,2,2,6,6-pentamethylpiperidine. 
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The ratio of a and b from transformation of the 2′-substituted chalcone can be 
governed exclusively by the amine base used, with PMP conversely yielding 
exclusively b, upon comparison to more common amines such as triethylamine or 1,8-
bis(dimethylamino)naphthalene (proton sponge), Table 2. The proton sponge (ps) 
offered a minor improvement in yield compared with triethylamine (Table 2, Entry 2 
& 3). Evaluating different phosphine ligands demonstrated a modest enantioselectivity 
using (R/S)-BINAP, with further enhancements using a (R)-3,5-XylMeOBIPHEP 
ligand for the Pd(OAc)2 catalyst. 
 
Buchwald also showed that the effect of the aromatic halide of triflate seemed to have 
negligible effect on the enantioselectivity (Table 2, Entry 4, 6 & 7), although it did 
offer a noticeable effect on the yield.216 Given the simplicity of synthesising a 2′-
bromo-substituted chalcone from commercially available 2′-bromoacetophenone, this 
approach seemed an attractive option. Some additional examples are shown in Scheme 
33, where for this project it was initially decided to proceed with BINAP as the ligand, 
owing to its more affordable assessment of the success of the reaction. 
 
 
Scheme 33 – Selected results from the Pd-catalysed reductive Heck cyclisation 216 
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Results & Discussion 
 
Synthesis of 2′-bromochalcones 
 
Commonly, chalcone synthesis involves a Claisen-Schmidt condensation, with many 
methods being discussed further in Section 2.3.2.2. The general procedure involved 
the condensation of commercially available 2′-bromoacetophenone and aromatic 
aldehyde under basic conditions, generally offering excellent yields.225 
 
 
Scheme 34 – Synthesis of substituted 2′-bromochalcones 
 
Although 2′-bromoacetophenone is commercially available, its naphthyl-counterpart 
is not. Synthesis of the 2′-bromonaphthalen-1-one, 22 proceeded from the 
commercially available β-tetralone. This was converted into 2′-bromo-1-
naphthaldehyde, 20,226,227 followed by transformation to the corresponding 2′-bromo-
1-naphthal-1-one, 22. The initial stage consisted of a Vilsmeier-Haack-Arnold 
formylation of β-tetralone, using phosphorus tribromide and N,N-dimethylformamide 
affording the β-bromovinyl aldehyde, 19, (Scheme 35).227-231 
 
 Scheme 35 – Synthesis of 2′-bromoacetonaphthalen-1-one precursor 
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The vinylic aldehyde was then aromatised into 2′-bromonaphthaldehyde, 20, via 
dehydrogenation using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), in 
excellent yields for both steps (81 %). 
 
The next step involves addition of Grignard reagent to the aldehyde to form the 
secondary alcohol, which is readily oxidised using Dess-Martin periodinane to afford 
the desired 2′-bromonaphthale-1-one (Scheme 36). 
 Scheme 36 – Synthesis of 2′-bromoacetonaphthone from its aldehyde counter-part 
 
The general formation of substituted 2′-bromochalcones proceeded with good yields 
and exclusive trans- geometry, confirmed by the coupling constants for the vinylic 
hydrogens.232 In the case of 2′-bromochalcone, Table 3, Entry 1, a small trace (~1 % 
by 1H NMR) of the cis-isomer was detected. This was subsequently converted into the 
more thermodynamically stable trans-isomer,233 by refluxing with DABCO in 
methanol.234 Additionally, elevated temperatures (45 °C) were required for the 
naphthyl-counterpart, Table 3, Entry 7 & 8. The condensation reaction showed no 
preference between an electron donating or withdrawing benzaldehyde, and the 
reaction generally boasted easy purification, through decantation/recrystallization.  
 
The results for the synthesis of the 2′-bromochalcones are shown below in Table 3. 
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Table 3 – Synthesis of substituted 2′-bromochalcones 
 
Entry R1 Groups R2 Groups Temperature. (°C) Yield (%) a Chalcone 
1  H 25 91 13 
2  4-OCH3 25 76 14 
3  3,4-OCH3 25 80 15 
4  3,4,5-OCH3 25 78 16 
5  4-CN 25 67 17 
6  4-Cl 25 59 18 
7 
 
H 45 68 23 
8  3,4,5-OCH3 45 72 24 
a Isolated yield. 
 
 
Intramolecular Heck cyclization of 2′-bromochalcones 
 
Buchwald et al.216 optimised the intramolecular heck-type cyclisation conditions 
utilising an (R)-3,5-XylMeOBIPHEP ligand with proton sponge as a base and an 
aromatic triflate. The literature found that a variation in temperature, solvent or 
palladium source did not improve the yield nor e.e.% of the product. Using a more 
hindered ligand, (R)-3,5-tert-butylMeOBIPHEP was found to have a deleterious effect 
on both yield and enantiomeric excess, supporting the hypothesis that the extent of the 
“3,5-dialkyl-meta-effect” on enantioselectivity is substrate dependent.235,236 
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The results obtained in this study for the reductive Heck cyclisation are presented 
below in Table 4. 
 
Table 4 - Intramolecular Heck-type cyclisation of substituted-2′-bromochalcones 
 
Chalcone  BINAP (R/S) Yield % a e.e. % (enantiomer) b Indanone 
 
13 R 40 50 (S) (S)-25 
 
14 S 36 43 (R) (R)-26 
 
15 S 33 40 (R) (R)-27 
 
16 S 28 19 (R) (R)-28 
 
23 S 41 10 (R) (R)-29 
 
24 S 42 (rac) 30 
aIsolate yield; b Enantiomeric excess determined by HPLC. 
 
The aforementioned results were less than satisfactory for an initial screening of 
enantioselectivity. The results showed a general decline in e.e. for both the naphthyl-
chalcone species and indeed for more electron donating substituents. Looking at the 
enantioselectivities obtained in the literature (Scheme 33),216 the naphthyl-component 
and electron donating substituents on the 3-position of the chalcone resulted in a lower 
enantioselectivity and lower yield, consistent with the results obtained above. 
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It should be noted that although cyclisation of a 4″-chloro and 4″-cyano group was 
attempted, no product was observed. These results were consistent with existing 
literature, where they only observed product using an alternative base; N,N-
dimethylcyclohexylamine.215 
 
Improved results were obtained  using the optimised (R)-3,5-XylMeOBIPHEP ligand, 
consistent with the literature.216 Firstly, the triflate was synthesised via the method 
shown below in Scheme 37.  
 
 
Scheme 37 – Synthesis of Triflyl-chalcone, 32 
 
The (S)-26 product was formed in 36 % yield and 70 % e.e. from the Heck cyclisation, 
using the optimised ligand, (Scheme 38). 
 Scheme 38 – Reductive Heck-cyclisation using the (R)-3,5-XylMeOBIPHEP ligand 
 
 
The results however, both obtained and in literature, demonstrated a lower 
enantiomeric excess for the naphthyl-chalcone species and electron donating species 
on the ‘aldehyde’ aromatic ring. Consequently, given the desired indan-1-one 
derivatives, the general encouragement to continue this work was quite low, and thus 
was not continued further.  
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2.2.3 Conclusive Remarks – Initial Synthetic Reactions 
 
In summary, the aforementioned results were relatively unattractive, based on the 
following drawbacks: 
 
Chiral Auxiliary Method: 
 Formation of a diastereomeric mixture (10 : 1), with difficult separation by 
silica column chromatography. 
 Unable to cyclise the enantiomerically enriched 3,3-substituted propanoic acid 
by current literature methods 
 
Reductive Heck Cyclisation 
 Poor substrate applicability, given naphthyl substituents adjacent to the 
carbonyl, and electron donating substituents on the aromatic ring in the 3-
position were generally unfavourable – resulting in poor enantiomeric excess 
 Limitations for the introduction of the desired bromine moiety present in 
Compound 6-B345TTQ. Given the catalyst is palladium, this functionality will 
unlikely be tolerated in the transformation.237 
 
Consequently, our attention turned towards kinetic resolution. The attractiveness of 
kinetic resolution for this project is discussed below in Section 2.3.  
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2.3 Kinetic Resolution 
The goal of asymmetric synthesis – whether performed industrially or in an academic 
setting – is to prepare stereochemically enriched molecules in the most practical and 
efficient method possible. Nonetheless, the strategy is rarely simple, as the ways in 
which practicality and efficiency are defined are a consequence of a vast number of 
factors; reagent costs, time permitted/required, number of manipulations, 
specifications for product purity, availability of equipment and potential hazards, to 
name a few. Fundamentally, there are considered to be three different approaches,238 
defined as the following: 
 
 Stereoselective synthesis (chiral reagents or catalysts) 
 Making use of the chiral pool (provided by nature) 
 Separation of enantiomers by physical or chemical means (resolution) 
 
The chiral pool is unfortunately limited with respect to the target indanones, and 
attempted asymmetric manipulations have proven difficult given the preferred 
functional groups. For this reason, resolution was chosen as a vitally important 
strategy for accessing both single enantiomers. 
 
Although in many instances, great effort has been directed towards avoiding such 
approaches as a result of perceived inelegance and inefficiency from poor atom 
economy, fortuitously for this project, both enantiomers can be achieved from one 
manipulation. In this project, both enantiomers are required, so chiral resolution is 
valuable and remains the focus of this chapter. 
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Proposal: 
 
The strategy, once in possession of a small library of racemic indan-1-ones, was to 
kinetically resolve the racemic mixture, either directly from the indan-1-one, or from 
the corresponding indan-1-ol, into the respective enantiomers. A brief over of this 
resolution is shown below in Scheme 39. 
 Scheme 39 – Kinetic resolution of racemic indan-1-ols 
 
Current methods for related kinetic resolutions of indan-1-ol derivatives are discussed 
below. Furthermore, methods to synthesise the racemic indan-1-one or indan-1-ol 
structures required for the kinetic resolution are discussed further in Section 2.3.2. 
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2.3.1 Introduction to Kinetic Resolution 
The first reported resolution was achieved as far back as 1858 by Louis Pasteur,239 
after reacting aqueous racemic ammonium tartrate with mould from Penilicilium 
glaucum. Chiral microorganisms contained in the mould were responsible for the 
selective metabolism of (R,R)-tartrate, leaving an excess of (S,S)-tartrate. Marckwald 
and McKenzie240 provided the first kinetic resolution by synthetic means, with the 
esterification of racemic mandelic acid with optically active (-)-menthol. 
 
Scheme 40 – First kinetic resolution by synthetic means; racemic mandelic acid 
 
The importance of this observation paved the way for other successful resolutions of 
other chiral acids; dawning the emergence of kinetic resolution for a useful method in 
organic chemistry.241-243 
 
Kinetic resolution is a means of differentiating two enantiomers in a racemic mixture, 
by means of a chiral catalyst or reagent (Figure 21).244 
 
 
Where;   ܵܯோ                    ௞ೃ                  ሱۛ ۛۛ ۛۛ ۛۛ ۛۛ ۛۛ ሮ ோܲ  
ܵܯௌ                    ௞ೄ                  ሱۛ ۛۛ ۛۛ ۛۛ ۛۛ ۛۛ ሮ ௌܲ  
 
Figure 21 - Kinetic resolution of a racemic mixture, SM 
ܵܯோ +   ܵܯௌ  ௖௛௜௥௔௟ ௖௔௧௔௟௬௦௧ ሱۛ ۛۛ ۛۛ ۛۛ ۛۛ ۛሮ ோܲ  +  ܵܯௌ   ௦௘௣௔௥௔௧௜௢௡ ሱۛ ۛۛ ۛۛ ۛۛ ሮ   ܵܯௌ      ோܲ 
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Under certain chiral circumstances, substrate enantiomers ܵܯோ and ܵܯௌ  react at 
different rates, ݇ோ and ݇ௌ, affording enantiomeric products, ோܲ and ௌܲ  (or indeed, one 
unreacted enantiomer of the starting material, for example ܵܯௌ, depending on the 
resolution), respectively. This principle facilitates biological or chemical kinetic 
resolutions of racemic compounds.  
 
While both enantiomers of the starting material, by definition, exist at the same Gibbs 
free energy level, as do to the enantiomeric products, P,245 the transition state energy 
can differ. Figure 22 shows an energy profile, where the reaction of the R enantiomer 
has a lower activation energy and thus would react faster than the S enantiomer. 
 
 
Figure 22 – Representative energy diagram for kinetic resolution 
 
The energy difference between the high- and low-energy transition states, is defined 
as ΔΔG‡.238 The free energy difference, ΔΔG‡, can be written in terms of the relative 
rates of reaction for each enantiomer, ݇ோ / ݇ௌ, which can also be expressed as the 
selectivity factor, (S).246 The selectivity of a kinetic resolution has been utilized for 
assessing this efficiency.247-250 
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The ideal kinetic resolution is that in which only one enantiomer reacts, for example, 
where ݇ோ ≫  ݇ௌ, then the selectivity of the kinetic resolution, being related to the rate 
constants of the reaction of the R and S enantiomers, can be expressed as the 
following:251,252 
Equation 1 
 
For simple first-order kinetics in substrate concentration, analytical solutions have 
been derived. The ݇ோ / ݇ௌ ratio of Equation 1 is correlated to the extent of substrate 
conversion, and the enantiomeric excess of the recovered substrate and product, ݁݁ௌெ 
and ݁݁௉ respectively.253 
 
Equation 2 
 
In enzyme catalysed kinetic resolution the enantioselectivity is normally expressed as 
the Enantiomeric Ratio, (E) value,254,255 which corresponds to the ratio of specificity 
constants, demonstrated in Equation 2. The E value for irreversible enzymatic 
transformations is generally calculated using Equation 3 and Equation 4.253,256-259  
 
When the conversion is lower than 50 %, Equation 3 applies: 
 Equation 3 
 
When the conversion is greater than 50 %, Equation 4 applies: 
Equation 4 
 
Where conv = conversion (%)/100; eep = e.e. of product / 100; eesm = e.e. of remaining 
starting material/100. 
ܧ =  ln[1 − ܿ݋݊ݒ(1 + ݁݁௉)]ln[1 − ܿ݋݊ݒ(1 − ݁݁௉)] 
ܧ =  ln[(1 − ܿ݋݊ݒ)(1 − ݁݁ௌெ)]ln[(1 − ܿ݋݊ݒ)(1 + ݁݁ௌெ)] 
݇ோ݇ௌ =
ln[(1 − ܿ݋݊ݒ)(1 − ݁݁ௌெ)]ln[(1 − ܿ݋݊ݒ)(1 + ݁݁ௌெ)] =  
ln[1 − ܿ݋݊ݒ(1 + ݁݁௉)]ln[1 − ܿ݋݊ݒ(1 − ݁݁௉)] 
ݏ = ݇ோ݇ௌ = ݁∆∆ீ
‡ / ோ் 
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Equation 3 and Equation 4 give reliable results for very low and very high extents of 
conversion, restricted by accuracies derived from sample manipulation. Consequently, 
the following equation is recommended as an alternative, because the only values that 
need to be measured are the optical purities (HPLC) of the substrate and product. The 
latter are deemed as relative quantities in contrast to conversion, which is an absolute 
quantity.260   
 
Equation 5 
 
 
Although the selectivity factor (s) is mathematically identical and thus synonymous to 
the E-value,249,261 in chemo-catalysis, the selectivity factor is more widely 
used.243,262,263 Product enantiomeric ratios can be regarded as moderate to good for 
selectivity factors of 15-30, while below this value they are not useful practical 
purposes, and above this range are considered excellent.238  
 
It must be noted however, that values of E > 200 cannot accurately be determined, for 
reasons due to inaccuracies emerging from the determination of the enantiomeric 
excess.264 Small variations or imprecisions by NMR, HPLC or GC, can cause a 
significant change in the numerical value of E. 
 
 
 
 
 
ܧ = ݈݊
(݁݁௉ (1 − ݁݁ௌ௠)(݁݁௉ + ݁݁ௌ௠)
݈݊ [݁݁௉(1 + ݁݁ௌ௠)](݁݁௉ +  ݁݁ௌ௠)
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Dynamic Kinetic Resolution: 
 
Dynamic kinetic resolution can occur when a starting material has the ability to 
racemise easily during a reaction. The enantiomer with the lower barrier to activation 
has the potential to form, theoretically, up to 100 % yield of enantiomerically enriched 
product, in contrast to standard kinetic resolution, which has a maximum yield of 50 
%. While a number of excellent methods are available,265 including a variety of 
suitable racemisation agents,266,267 it does depend on starting materials that can be 
racemised in the relevant reaction conditions.268 
 
Practicality of Kinetic Resolution: 
 
The following criteria present a recommendation for practical kinetic resolution:238 
 
 Inexpensive racemate and/or catalyst 
 Simple separation of racemic starting material  
 Selective catalyst and low catalyst loading  
 No appropriate direct enantioselective methods 
 
The enantiomeric purity of products, ܲ ோ and ܲ ௌ are limited by the degree of enantiomer 
discrimination in the reaction, however, when these are excellent, the kinetic 
resolution can be a worthy method to obtain ோܲ and ௌܲ.269 A range of catalysts and 
methodologies are present that satisfy the above criteria for indan-1-ols, and resolution 
techniques performed on these substrates are illustrated below.  
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2.3.2 Synthesis of 3-Aryl Indan-1-ones and Indan-1-ols 
 The strategy, once in possession of a small library of racemic indan-1-ones, was to 
kinetically resolve the racemic mixture, either directly, or from the corresponding 
indan-1-ol, into the corresponding enantiomers. 
 
The indan-1-ols can be synthesised by the reduction of indanones, which in turn, can 
be made by a Nazarov cyclisation of chalcones. This transformation tolerates a number 
of functional groups relevant to this project, (Scheme 41). 
 
  
Scheme 41 – Disconnection approach from indan-1-ol derivatives 
(See Section 2.3.2.4 and 2.3.2.3 respectively) 
 
The chalcone compounds can be synthesised by a Claisen-Schmidt condensation 
reaction of an acetophenone and an aromatic aldehyde (Scheme 42). 
 
 
 Scheme 42 – Synthesis of racemic indan-1-ones from the corresponding  
(See Section 2.3.2.2) 
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The Nazarov cyclisation reaction is accelerated by electron-donating groups in the 
aromatic ring at the 1-position of the chalcone structure.270 Consequently, for testing 
the Nazarov reaction on similarly related structures, the commercially available 3′-
methoxyacetophenone was used (Figure 24). Indan-1-ones with electron donating 
substituents have been synthesised in the literature, including two trimethoxy-indan-
1-one derivatives with potential anti-cancer activity (Figure 23).169 As these have only 
been reported as racemic compounds, it would be interesting to test whether this can 
be made asymmetrically by the methods presented below. 
 
 
Figure 23 – Examples of electron donating indanone substituents with biological 
activity 
 
Consequently, these commercially available acetophenones were used to test the 
following reactions, but would additionally provide a small catalogue of similarly 
related compounds to the desired 6-B345TTQ indan-1-one precursor. Moreover, we 
were interested in testing these analogues for biological activity. 
 
Figure 24 – Commercially available electron donating acetophenone substituents 
used in this project (3-methoxyacetophenone and 3,4,5-trimethoxyacetophenone) 
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1-Acetyl-4-halonaphthalene substituents are not commercially available. This 
disconnection for their synthesis would involve a Friedel-Crafts acylation of the 
corresponding 1-halonaphthalene (Scheme 43) 
 
Scheme 43 – Disconnection approach for the 1-acetyl-4-halonaphthalen-1-one 
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2.3.2.1 Friedel-Crafts Acylation of Halo-naphthalenes 
 
Although 4′-haloacetophenones have been synthesised via Sandmeyer-type reactions 
on 4′-amino-1′-acetophenones,271-273 from the corresponding aryl triflates274 or boronic 
acids275;  a more common and practical approach involved a Friedel-Crafts acylation 
from readily available 1-halonaphthalenes.276-281  
 
Scheme 44 – Friedel-Crafts acylation: synthesis of 1′-acetyl-4′-bromonaphthalene 
 
This method was further considered advantageous over bromination of the appropriate 
aryl ketone,282 where the 4′-isomer is a minor product amongst a variety of others.283  
 
Conditions for this Friedel-Crafts transformation remained fairly consistent over 
various literature reports, albeit the use of dichloromethane as the solvent in contrast 
to carbon disulfide281 offered a minor improvement in yield (62-91 % yield, >95 % 
selectivity). Under certain conditions, notably with AlCl3 and CCl4 as the solvent, it 
was found that 1-chloronaphthalene isomerised to the 2-isomer upon standing.284 
Although Schweitzer285 first prepared a bromoacetonaphthone by the reaction shown 
in Scheme 44 in carbon disulfide, the structure was not proven. It was not until 
Dziewonski and Sternbach286 carried out the same reaction and demonstrated that 4′-
bromo-1′-acetonaphthone was the principal product by oxidation to the corresponding 
known 4′-bromo-1′-naphthoic acid.  
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This regioselectivity is unexpected when one appreciates the inherent substituent 
effects. When the substituent at the 1-position is an electron-donating group, it will 
subsequently activate the ring to which it is attached, stabilising any substitution in an 
ortho or para position. Similarly an electron-withdrawing group will have the opposite 
effects.  
 
Based on experimental data, halogens exhibit a negative inductive effect (-I), with a 
positive mesomeric effect (+M), offering a substituent effect of modest positivity.287 
The opposite effects exhibited for halogens for -I  and +M  causes partial cancellation, 
but overall causes deactivation of the aromatic system. The meta positions experience 
more of this substituent effect (compared to para, Table 5), due to the fact that the 
mesomeric effect is greatly reduced in a meta substituent. Therefore, halogen 
substituents are ortho / para directing, but deactivate the ring. 
 
Table 5 – Hammett values derived from the dissociation constants of benzoic 
acids287-289 
Substituent σpara σmeta 
Bromo- 0.232 0.352 
Chloro- 0.227 0.373 
Fluoro- 0.062 0.337 
 
Normally, for a benzene system, a chloro-substituent is thus expected to deactivate the 
aromatic ring by a combination of –I and +M mechanism, where I > M, and thus 
overall deactivation ensues.290  
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For a 1-halo-naphthalene, one would therefore expect electrophilic aromatic 
substitution to occur in the non-substituted ring. Table 6 below shows some literature 
Friedel-Crafts acylations on 1-chloronaphthalene, demonstrating an effect of solvent 
and temperature on the ratio of isomers formed.291 
 
Table 6 – Friedel-Crafts acetylations of 1-chloronaphthalene by the Perrier 
procedurea: effect of solvents on isomeric composition291 
Solvent Temp. (°C) b 
 Isomers (%) 
2- 3- 4- 5- 6- 7- 8- 
CHCl3 20  3.6 2.4 79.8 4.4 4.8 4.4 0.56 
CH2Cl2 20  2.8 2.5 83.3 3.8 3.7 3.5 0.40 
C2H4Cl2 20  2.4 2.9 81.1 3.7 8.1 1.3 0.63 
CS2 20  3.8 4.5 83.6 3.8 2.0 1.5 0.73 
MeNO2 20  22.0 0.04 62.3 2.7 5.4 5.3 2.3 
PhNO2 4  20.3 0.76 32.5 9.5 21.3 15.5 0.053 
PhNO2 20  12.9 1.0 36.9 6.0 25.0 18.2 0.042 
a The Perrier procedure involves final addition of substrate to the pre-formed complex of acyl chloride 
and aluminium chloride in the solvent; b Duration 6h. 
 
Furthermore, the nitration of 1-chloronaphthalene was observed to give isomers; 1,4- 
(31-63 %), 1,8- (30-65 %) and 1,5- (0-20 %),292 with sulfonation which gave a mixture 
of 1,4- and 1,5-compounds.293 Similarly, sulfonation of 1-fluoronaphthalene appeared 
to give exclusively 4-substitution,294 and 1-bromonaphthalene nitrates in the 4-
position,293 highlighting the unpredictability. In contrast with reports from nitrations, 
where substantial (ca. 40 %) of 1′-chloro-8′-nitronaphthalene was reported,295 peri-
acetylation is subject to serious hindrance (C1-8 peri interaction),296 analogous to 1-
methylnaphthalene acetylations, where it was not formed at all.297 
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Results & Discussion 
The desired 4′-halo-1′-acetonaphthones were synthesised using aluminium chloride as 
a Lewis acid, acetyl chloride and the appropriate 1-halonaphthalene in 
dichloromethane. Table 7 shows the effect of temperature on the ratio of obtained 
isomers for this transformation; (1,4- vs 1,5-isomers). 
 
Table 7 - Friedel-Crafts acetylation of 1-halo-naphthalenes with aluminium chloride 
catalyst 
 
Substituent X Temperature (°C) a Ratio (a : b) b Yield (a) c  
Br 20 80 : 20 - d  
Br 0 88 : 12 - d  
Br -10 >95 : 5 62 35 
Cl -10 >95 : 5 96 34 
F -10 >95 : 5 84 33 
a Temperature controlled by a thermostat water bath containting antifreeze; b Ratio determined by 1H 
NMR; c Isolated yield after column chromatography; d Yield was not isolated for this isomeric mixture.  
 
Although other isomers were likely produced in small quantities, seemingly from the 
very small peaks present on the baseline (crude 1H NMR spectrum), they were not 
easily distinguishable nor isolatable from the crude mixture. Reducing the temperature 
showed an increased preference for substitution at the 4-position. 
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The ratio (a : b) was determined by 1H NMR spectrometry, using the integration of the 
CH3 peak at  2.73 and 2.75 ppm respectively.279 In contrast to previous literature 
reporting this isomeric mixture to be the 4-(major) and 2-(minor) products,281 
comparison of the chemical shifts to that of the 2-acylated isomer,298 found the CH3 
peak for this latter isomer to be further up-field at 2.58 ppm, suggesting it was not a 
product. The reactivity of the peri- (8-) position of 1-halonaphthalene was not 
observed at all in the Friedel-Crafts acetylation reaction conducted at -10 °C (Table 
7), and reassuringly was reported in the literature showing only small amounts in a 
variety of solvents performed at 20 °C (Table 6) on 1-chloronaphthalene.291 
 
Pure 4′-bromo-1′-acetylnaphthone was isolated as a beige solid, rather than a brown 
oil as reported.281,299 Nonetheless, the reaction gave the appropriate 4′-halo-1′-
acetonaphthones for the Claisen-Schmidt Condensation in good yields and excellent 
selectivity (>95 % acetylation in the 4-position). 
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2.3.2.2 Claisen-Schmidt Condensation towards Substituted Chalcones 
 
For the synthesis of substituted chalcones as a precursor to the desired indan -1-ones 
moiety, the following disconnection was applied, shown below in Scheme 45. 
 
Scheme 45 – Disconnection approach of substituted-chalcones 
 
 
Discussion on the Chalcone Moiety, the Synthesis and Application 
 
Chalcone derivatives were synthesised according to common literature procedures.146 
The chalcone moiety is a common substructure in a number of different natural 
products belonging to the flavonoid family.300-302 Chalcone derivatives are very 
versatile as pharmaceutically active compounds and substrates for the evaluation of 
various organic syntheses.303 With the chalcone moiety having such varied 
pharmacological activity, the attraction for medicinal chemists has therefore presented 
several strategies in the development of chalcones.  
 
First reported by Claisen304 and Schmidt305 concurrently in 1881, this reaction is 
essentially the condensation of an aromatic aldehyde with a ketone (or indeed, another 
aldehyde306), in the presence of both an acid or a base, to form an α,β-unsaturated 
ketone with high chemoselectivity.307 The reaction, identical to the Aldol 
condensation306,308, is generally known as the Claisen-Schmidt condensation,309-311 or 
Claisen-Schmidt reaction.312-314 
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This method has found a vast use in pharmaceuticals,315 and has subsequently been 
utilised in the synthesis of a 644-member library of chalcones, by a parallel synthesis 
from substituted acetophenones and benzaldehydes.308,316,317  
 
The principal synthetic route to these chalcone are classically catalysed by strong 
acids,318,319  and more likely by base, both with or without solvents.313,320-323 Various 
reagents have been introduced, using a variety of catalysts, including: solid NaOH,320 
BF3OEt2,324 InCl3,325 TMSCl/NaI,326 Cu(OTf)2,327 RuCl3,328 FeCl3,329 SmI3,330 
molecular iodine331 or SOCl2.332 Additionally, microwave irradiation methods have 
also been reported, offering significant reductions in reaction time.333 Catalysts 
include: KF-Al2O3,334 NaOH-Al2O3,335 acidic alumina335 or bis(p-
methoxyphenyl)telluroxide.336 
 
Many of these methods involve expensive, toxic or hazardous catalysts, or with long 
reaction times. Aside from these examples, some facile yet versatile methods exist for 
the preparation of substituted chalcone derivatives.146 
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Results & Discussion: 
 
Within the current study, chalcone derivatives were synthesised according to common 
literature procedures,146 (Table 8). The reaction tolerated both electron-donating and 
withdrawing substituents, although for electron withdrawing aldehyde-substituents (4-
F and 4-Cl), an alternate method was employed, using a potassium hydroxide solution 
in methanol, to avoid nucleophilic aromatic substitution.337 
 
Table 8 – Claisen-Schmidt Reactions towards substituted methoxychalcones 
 
R1 R2 R3 R4 Temp. (°C) Yield (%) a Chalcone 
OCH3 H H H 20 91 36 
OCH3 H H 4-OCH3 20 87 37 
OCH3 H H 3,4-OCH3 20 63 38 
OCH3 H H 3,4,5-OCH3 20 95 39 
OCH3 H H 2,3,4-OCH3 20 97 40 
OCH3 H H 4-F   50 b 96 41 
OCH3 H H 4-Cl   50 b 56 42 
OCH3 OCH3 OCH3 3-F, 4-OCH3   20 b 94 57 
OCH3 OCH3 OCH3 3-NO2, 4-OCH3 20 99 58 
H Br H 3,4,5-OCH3 20 86 43 
a Isolated yield; b Reaction performed with aqueous KOH (15 % m/v) instead of 
NaOCH3 to avoid nucleophilic aromatic substitution. 
 
Similarly, chalcone derivatives were synthesised from the corresponding 1′-acetyl-4′-
halonaphthylenes derivatives formed in Section 2.3.2.1, shown below in Table 9. 
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Table 9 – Claisen-Schmidt Condensation of Substituted 1-Acetylnaphthalenones 
 
Entry Ketone X Group R Groups Temperature (°C) 
Yield 
(%) a Chalcone 
1  35 Br H 20 98 48 
2  35 Br 4-OCH3 20 97 49 
3  35 Br 2,3-OCH3 20 81 50 
4  35 Br 3,4-OCH3 20 85 51 
5  35 Br 3,5-OCH3 20 75 52 
6  35 Br 2,3,4-OCH3 20 99 54 
7  35 Br 3,4,5-OCH3 20 99 53 
8  35 Br 4-F   20 b 55 55 
9  35 Br 4-Cl   20 b 82 56 
10   H H 20 92 44 
11   H 3,4,5-OCH3 20 95 45 
12  33 F 3,4,5-OCH3   20 b 81 46 
13  34 Cl 3,4,5-OCH3   20 b 84 47 
a Isolated yield; b Reaction performed with aqueous KOH (15 % m/v) instead of 
NaOCH3 to avoid nucleophilic aromatic substitution. 
 
The more thermodynamically stable trans-geometry was confirmed by 1H NMR 
spectrometry, by inspection of the coupling constants for the vinylic CHs (CH-2 and 
CH-3). Chalcones predominantly exist as the E-isomer, with the configuration of the 
Z-isomer generally being less stable, due to strong steric effects between the carbonyl 
and 3-aryl-group.233 
 
In summary, a variety of substituted chalcones have been synthesised in a simple 
manner, yielding exclusively trans-isomers. Moreover, the substrates were easily 
isolated, in most cases, by simple filtration from the reaction mixture.  
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2.3.2.3 Nazarov Reaction of Substituted Chalcones 
 
The synthesis of substituted indan-1-ones involves a Nazarov cyclisation, and a 
disconnection for this approach is shown below in Scheme 46. 
 
Scheme 46 – Disconnection approach of substituted indan-1-ones 
 
 
Discussion on the Nazarov Reaction 
 In 1903, Vorländer and co-workers found that treatment of dibenzylideneacetone with 
concentrated sulfuric acid and acetic anhydride and subsequent hydrolysis by sodium 
hydroxide yielded a cyclic ketol, the structure of which being unknown at the time 
(Scheme 47).338 
 
Scheme 47 – Cyclisation observed by Vorländer and co-workers 
 
Later in the 1940s and 1950s, Nazarov et al. revisited the topic and extensively studied 
the cyclization, particularly cyclization of the intermediate allyl vinyl ketones to the 
corresponding 2-cyclopentenones.339, 340, 341 Braude and Coles proposed a carbocation 
intermediate as a consequence of acid protonation on the sites of unsaturation,342 
however it was not until 1967 when Woodward, through deuterium labelling, 
confirmed the pericyclic cyclization occurred in a conrotatory fashion.343  
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Indan-1-ones have also been synthesised via a Nazarov reaction, catalysed by strong 
acids. Catalysts have included; polyphosphoric acid (PPA),344-347 AlCl3,270,348 
trifluoroacetic acid (TFA),169,189-191,349 trifluoromethanesulfonic acid (TFMSA),350 
cupric triflate,187 methanesulfonic acid (MSA),187  BF3.OEt2,351 sulfuric acid,352 and a 
HUSY-zeolite catalyst.193 It is believed that P2O5 is the active cyclisation agent in 
PPA.188 
 
The acid-catalysed cyclisations of naphthyl-chalcone derivatives is reported to 
proceed at either the 2- or 8-position of the naphthyl-ring, according to either 
substituent or catalyst changes.353 
 
Scheme 48 – Catalyst and substrate effect on 2- and 8-position selectivity353 
 Substituents with electron donating groups in the 4- and 7-positions were found to 
cyclise chiefly at the 8-position. It is not known if AlCl3 was responsible for the 
selectivity in this cyclisation as only ring substituted methoxy- groups were tested.346 
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Results & Discussion 
Within this study, the Nazarov reaction was performed using trifluoroacetic acid as 
the catalyst.354 An attempted improvement of the transformation was attempted (Table 
10), to minimise some observed side-products (Scheme 49), such as the 
intermolecular 2,3-dihydrochalcone product (c),201 or the retro-Claisen Schmidt 
product (d).189 The observation of these side products were in the 1H NMR spectrum 
of the crude reaction product, comparable to literature values. 
 
 
 
Scheme 49 – Observable side-products (c) and (d) 
 
 
 
The synthesis of 3-phenyl indan-1-one, 25 using trifluoroacetic acid was problematic, 
and 1H NMR analysis of the crude reaction mixture showed approximately 20 % 
acetophenone product, possibly formed by a water promoted retro-Claisen-Schmidt 
reaction. Adding phosphorus pentoxide to the reaction reduced the formation of this 
by-product.355 A combination of trifluoroacetic acid with phosphorus pentoxide 
offered the best yield of the desired 3-phenyl indan-1-one, 25 (Table 10, Entry 4), 
and consequently this method was used thereafter. 
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Table 10 – Optimisation of the Nazarov Cyclisation of trans-chalcone 
 
Entry a Catalyst / Conditions Temperature (°C) b Yield %c 
1 PPA (2 equiv.)e  136 31 
2 P2O5 (2 equiv.), in toluene 110 14 
3 TFA (2 mL/mmol) 73 32 
4 TFA : P2O5 (2 mL/mmol, 2 equiv.) 73 54 
5 TFA : AlCl3 (2 mL/mmol, 2 equiv.) 73 35 
6 Eatons Reagent (2 equiv.)f 73 - 
a Reaction based on chalcone (1.00 g, 4.8 mmol); b Temperature monitored via an 
internal thermometer; c Isolated yield; e PPA containing 2 equivalents of P2O5, based 
on 100 % PPA (72.4 % P2O5 content); f Eaton’s reagent, P2O5 : methanesulfonic acid 
(1 : 10), with P2O5 content at 2 equivalents. 
 
 
The Nazarov reaction of 3′-methoxy substituted chalcones, shown below in Table 11, 
formed both the 6-methoxy- and 4-methoxy-3-aryl-indan-1-one derivatives, 
consistent with literature reports.348,356 The ratio was determined by 1H NMR 
spectrometry, in comparison with literature examples. The desired 6-methoxy-3-aryl-
indan-1-ones were separated from the mixture by column chromatography. 
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Table 11 – Nazarov Reactions of 3′-methoxy-substituted chalcones 
 
Chalcone R Groups Ratio a : b b 3′-Methoxy Indan-1-one Yield % a  
36 H 17 : 1 84 59 
37 4-OCH3 17 : 1 41 60 
38 3,4-OCH3 17 : 1 38 61 
39 3,4,5-OCH3 - c 35 62 
40 2,3,4-OCH3 10 : 1 24 63 
41 4-F 11 : 1 87 64 
42 4-Cl 12 : 1 84 65 
a Isolated yield; b Isomer % determined by 1H NMR prior to purification; c Not 
deducible from crude 1H NMR. 
 
Electron donating substituents on the 3-aryl ring impeded the cyclisation, resulting in 
much lower yields. Conversely, increased electron density on the 1-aryl ring were 
found to greatly improve the reaction yield (Table 12), possibly by stabilising the 
positive-charge character in the intermediate.357  
 
 
 
 
 
 
- 89 -  
Table 12 – Nazarov Reactions on 3′,4′,5′-trimethoxy-substituted chalcones 
80 oC, 48 h
O OOO
(±)
R
R
O
O
O O
Trifluoroacetic Acid (2 mL/mmol)P2O5 (1.5 equiv.)
 
Chalcone R Groups Yield % a Indan-1-one 
57 3-F, 4-OCH3 72 66 
58 3-NO2, 4-OCH3 85 67 
a Isolated yield. 
  
Attempts at the Nazarov cyclisation using the optimised reaction conditions for 
substrate 43 were unsuccessful. An alternate route195 via the chalcone-epoxide, also 
proved ineffective, (Scheme 50). 
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O
O
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O
O
Br OH
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Scheme 50 – Attempted synthesis of indan-1-one compound  
(a) TFA (2 mL/mmol, P2O5 (1.5 equiv.); (b) H2O2 (30 wt%), NaOH (5M sol.); (c) 
InCl3, CH2Cl2. 
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Similar results were found for the Nazarov cyclisation of naphthyl- chalcone 
derivatives regarding the electron donating and withdrawing character of substituents. 
The cyclisation only occurred in the 2-position, consistent with the literature, rather 
than the 8-position, found with other catalytic systems.353 However, even after 
multiple attempts, the transformation of the 3,5-dimethoxy derivative, 52, to the 
corresponding naphthalen-1-one was unsuccessful. These results for the naphthyl-
derivatives are shown below in Table 13. 
 
Table 13 – Nazarov Reactions on substituted naphthyl- chalcones 
 
Chalcone X Group R Groups Yield % a Indan-1-one 
48 Br H 70 72 
49 Br 4-OCH3 30 73 
50 Br 2,3-OCH3 28 74 
51 Br 3,4-OCH3 28 75 
52 Br 3,5-OCH3 - b  
54 Br 2,3,4-OCH3 24 77 
53 Br 3,4,5-OCH3 30 76 
55 Br 4-F 72 78 
56 Br 4-Cl 76 79 
44 H H 62 68 
45 H 3,4,5-OCH3 41 69 
46 F 3,4,5-OCH3 31 70 
47 Cl 3,4,5-OCH3 33 71 
a Isolated yield, b No product isolated. 
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2.3.2.4 Selective cis-Reduction of Racemic Indan-1-ones 
 
The planned synthesis of substituted indan-1-ols would occur via reduction of the 
indanone carbonyl group, with a disconnection shown below in Scheme 51.  
 
 
 
Scheme 51 – Disconnection approach of substituted-indan-1-ols 
 
 
 Discussion on the Reductive Methods for the Indan-1-one Moiety 
 
Reduction of the racemic 3-aryl indan-1-ones (Scheme 52), with sodium borohydride 
was shown to yield only the cis-diastereoisomers.344,358 In contrast, the corresponding 
4-phenyl-1-tetralone analogues are reported to be reduced as a mixture of cis- and 
trans-diastereoisomers.358 
 
Scheme 52 – Sodium borohydride cis-reduction of some dopamine-uptake inhibitor 
precursors 
Compounds with X = H, 3-Cl, 4-Cl, 4-F or 4-OCH3 were all reported to react to give 
cis-isomers exclusively. A variety of R-groups also had little effect on the high 
stereoselectivity.358 
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A recent patent additionally demonstrated the use of sodium borohydride towards the 
synthesis of some deuterated 1-piperazino-3-phenyl-indanes for the treatment of 
schizophrenia.359 This selectivity has also been observed with some other 
pharmaceutically important compounds.360  
 
While this selectivity is well known, 3-acylamino indan-1-ones react with the trans- 
diastereoisomer as the major product, Scheme 53.361 
 
Scheme 53 – Borohydride reduction of 3-aminoindan-1-ols 
 
The moderate diastereoselectivity observed can be explained by the initial reaction 
between borohydride and the free amino group to form the corresponding boramide. 
In good agreement with previously published results,362 this would favour an 
intramolecular reduction, leading to a trans- configuration. Furthermore, both cis- and 
trans- stereochemistry was confirmed by X-ray crystallography.361 
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Results & Discussion 
 Given the high selectivity reported344 for a cis-reduction of indan-1-ones using sodium 
borohydride, this method was applied with excellent selectivity for the substituted 
indan-1-one structures. The results bearing methoxy-substituents on the indan-ring are 
shown below in Table 14. 
 
Table 14 – Selective cis-reduction of racemic 6-methoxy-3-arylindan-1-ones 
 
rac-Indan-1-one rac-Indan-1-ol 
 R1/R2 R3 Yield % a  
59 H H 98 80 
60 H 4-OCH3 77 81 
61 H 3,4-OCH3 71 82 
62 H 3,4,5-OCH3 70 83 
63 H 2,3,4-OCH3 66 84 
64 H 4-F 80 85 
65 H 4-Cl 91 86 
66 OCH3 3-F, 4-OCH3   65 b 87 
66 OCH3 3-F, 4-OCH3   55 c 87 
67 OCH3 3-NO2, 4-OCH3     51 d,e 88 
a Isolated yield. b Formed in an inseparable cis- / trans- ratio of 4 : 1; c L-Selectride 
method used,363 giving exclusively the cis-isomer;  d Formed in a separable cis- / trans- 
ratio of (4 : 1); e Isolated yield of cis-isomer. 
 
R3 substituents mostly appear to have little effect on the outcome of the cis : trans- 
ratio. The cis-isomer (80 and 86) was deduced by comparison with results obtained in 
the literature,361 with others by analogy.  
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The presence of multiple methoxy-substituents on the indanone-ring (4,5,6-methoxy) 
had a noticeable, yet minor effect on the selectivity of the cis : trans relationship, 
producing the diastereoisomers in a 4 : 1 ratio for 87 and 88. Attempts at lowering the 
temperature and performing the reduction at -78 °C had a slight improvement on this 
ratio, producing the indan-1-ol 87 in a cis-/trans- ratio of 5 : 1.  Although the 
stereoisomers could be separated by standard silica column chromatography for the 3-
nitro-4-methoxy-3-aryl indanol, 88, a more difficult situation arose trying to separate 
the similarly related 3-F, 4-OCH3 substituent, 87. Consequently, an alternative, more 
selective reductive method was applied, using the more sterically demanding L-
Selectride reducing agent.363,364 Application to substrate 87, is shown below in 
Scheme 54.  
 
Scheme 54 – Reduction of 3-(3′-fluoro-4′-methoxyphenyl)-4,5,6-trimethoxy-3,4-
dihydro-1H-inden-1-one, using L-Selectride at -78 °C 
 
Although the reaction was deemed less ‘clean’ from inspection of the 1H NMR 
spectrum of the crude reaction mixture with a comparably lower yield to that of 
sodium borohydride, the cis-isomer was formed exclusively.  
 
The sodium borohydride method however was successfully applied to all the 
naphthalen-1-one derivatives, (Table 15), with outstanding selectivity, yielding 
exclusive cis-isomers in all cases.  
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Table 15 – Selective cis-Reduction of Substituted Indan- and Naphthalen-1-ones 
 
rac-Indan-1-one rac-Indan-1-ol 
 X Groups R Groups Yield % a  
72 Br H 81 93 
73 Br 4-OCH3 91 94 
74 Br 2,3-OCH3 73 95 
75 Br 3,4-OCH3 89 96 
77 Br 2,3,4-OCH3 82 98 
76 Br 3,4,5-OCH3 88 97 
78 Br 4-F 64 99 
79 Br 4-Cl 92 100 
68 H H 87 89 
69 H 3,4,5-OCH3 61 90 
70 F 3,4,5-OCH3 57 91 
71 Cl 3,4,5-OCH3 60 92 
a Isolated yield. 
 
In summary, the sodium borohydride reduction method344 produced all the 
corresponding indan-1-ol derivatives with good yields and excellent cis-selectivity. 
For more demanding substituents, 87, the L-Selectride reagent proved effective. 
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2.4 Kinetic Resolution – Enzymatic Acylation 
 
For the kinetic resolution of racemic cis-3-aryl indan-1-ols, the following resolution 
was proposed, using an enzymatic acylation process (Scheme 55). 
 
 Scheme 55 – Proposed enzymatic kinetic resolution for substituted indan-1-ols 
 
Enzymatic routes are often more attractive than the conventional counterparts from an 
environmental and economic standpoint.365 From academic curiosity to standard 
practice, biocatalysts have proven their effectiveness, even on an industrial scale.366,367 
 
Lipases are a particularly well-established assembly of enzymes for the kinetic 
resolution of racemic alcohols, both in aqueous and non-aqueous media. Lipases can 
catalyse both hydrolysis and esterification reactions towards chiral alcohols.368-372  
 
 
   Scheme 56 – Lipase-catalysed hydrolysis & esterification 
 
As with chemo-catalysed kinetic resolution procedures,373,374 enzymatic acylation 
kinetic resolution has seen the broadest application in a synthetic context.  
Enzymatic hydrolysis 
Enzymatic esterification 
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On small scale, enol esters such as vinyl acetate, isopropenyl acetate and ethoxyvinyl 
esters are considered by far the best activated and most used acyl donors.375-377 The 
leaving group is an enol that immediately tautomerizes to the ketoform,378 thus the 
reaction essentially becomes irreversible as no nucleophile remains in the reaction. 
 
Candida Antarctica B (CAL-B) has been used as a highly enantioselective enzyme for 
a kinetic resolution to give (R)-1-aminoindan, an intermediate in the synthesis of (R)-
Rasagiline, a treatment for Parkinson’s disease, Scheme 57.379 
 
Scheme 57 – Kinetic resolution of racemic 1-aminoindan moiety 
 
CAL-B has also been used in the kinetic resolution of other 3-aminoindan-1-ol and 
indane-1,3-diamine derivatives.361 Novozym® 435, an acrylic resin immobilised 
enzyme; Candida Antarctica B (CAL-B), has shown a profound use in classical kinetic 
resolution of a variety of alcohols and their corresponding esters.265 A relevant patent 
has shown the enzymatic resolution by acylation on similarly related cis-arylindan-1-
ols, for the treatment of schizophrenia is shown below in Scheme 58.359 
 
Scheme 58 – Novozym® 435 used for the resolution of deuterated indan-1-ols359 
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This method has also been used for the enzymatic chiral resolution of cis-3-(1H-indol-
3-yl)-indan-1-ols (Scheme 59) into their corresponding enantiomers, as intermediates 
towards compounds effective for the treatment of central nervous system disorders.360 
The racemic cis-indan-1-ols were treated with irreversible acyl donors such as vinyl 
butyrate, catalysed by the immobilised lipase, Novozym® 435.  
 
Scheme 59 – Example of enzymatic kinetic resolution using Novozym® 435 360 
 
 
The immobilisation of lipase enzymes on a solid carrier leads to a number of benefits 
for biocatalysts,380 such as: 
 
- Convenient and safer handling 
- Efficient catalyst separation and recycling, providing cost-savings 
- Increased stability in organic solvents and heat 
 
The work in this project uses the immobilised CAL-B enzyme; Novozym® 435.  
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In CAL-B, the catalytic triad is made up of a Ser105, Asp187 and His224 residue, 
existing as a globular α/β type protein, with these residues located at the carboxy-
terminal edge of the parallel β-sheet. The three dimensional structure of CAL-B was 
determined by X-ray crystallography,381 and CAL-B, compared to other lipases, has a 
very limited available space in the active site pocket, resulting in its high selectivity. 
 
The mode of action was suggested to adopt a  similar mechanism of action to other 
lipases,381 with the reaction mechanism illustrated below in Scheme 60. 
 
 
 
 
Scheme 60 – Reaction mechanism of Candida Antarctica B (CAL-B) 381 
 
 
A carboxylic ester (R1CO2R3) binds in the active site, where the carbonyl carbon is 
attacked by the Ser105 nucleophile, resulting in transition state (TS1). The attack is 
promoted by His224, which accepts a proton from Ser105, acting as a general base. 
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The carbonyl oxygen, now a single bond, forms 3 hydrogen bonds within the oxyanion 
hole (two with Thr40 and one to Gln106),381,382  followed by the alcohol leaving, 
forming the acyl enzyme. In the example shown in Scheme 58 and Scheme 59, the 
leaving group is an enol that immediately tautomerizes to the ketoform, removing this 
nucleophilic presence from the reaction. 
 
Finally, the second alcohol (R3OH) attacks the carbonyl carbon of the acyl enzyme, 
going through a second transition state (TS2), forming the transacylated product, 
which is subsequently released from the reaction. The free enzyme is then regenerated. 
 
Literature has reported that in order to reach the catalytic serine, the substrate needs to 
travel inside a 10 x 4 Å wide and 12 Å long hydrophobic channel.381,383 Additionally, 
it was reported that interactions from more negative electrostatic potential functional 
groups,383 such as substituents with a halogen atom, created an unfavourable 
interaction, reducing the enantioselectivity.  
 
This binding site of CAL-B, having a deep narrow active site into which the substrate 
can bind in a hairpin manner,384 can result in very high enantioselectivities, or 
conversely result in the complete opposite effect, where no product is acylated. The 
following section describes the work performed in this study.  
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Results & Discussion 
Within the current study, the enzymatic resolution of racemic cis-indan-1-ols was 
performed by a literature procedure.359,360 The process for this resolution involved 
Novozym® 435 as the catalyst, an acyl donor and the racemic cis-alcohols formed 
from Section 2.3.2.4. This process is shown below in Scheme 61. 
 
 
Scheme 61 – General scheme for kinetic resolution to chiral indan-1-ones 
 
Although the acyl donor was initially performed with vinyl butyrate in accordance 
with the literature procedure, and indeed was successful with high enantioselectivity 
(> 99 % for the acetate, (1R,3R)-102), vinyl acetate was chosen from its increased ease 
in purification on a small scale.378 Additionally, conducting the reaction at 40 °C 
offered shorter reaction times without hampering enantioselectivity, nor denaturing 
the enzyme, as seen for other reactions using Novozym® 435.385  
 
For the enzymatic kinetic acylation of various different substituted indan-1-ols, some 
of the substrates encountered difficulties with solubility. Some of the substrates, 
notably the more sterically encumbered indan-1-ols, were completely insoluble in the 
2-isopropoxypropane, the solvent employed in the literature.360 Although some 
research has reported a negligible effect of solvent on the chemoselectivity of 
Novozym® 435,386 other research has shown the solvent choice to be crucial, in some 
cases, showing a strong preference for hydrophilic solvents.387 
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Consequently a range of solvents were tested to see the effect on enantioselectivity 
and conversion of the transformation (Table 16). 
 
Table 16 – Optimisation and viability of solvent conditions for Novozym® 435 
catalysed acylation after 18 hours 
 
a Ratio determined by 1H NMR Analysis; b Enantiomeric excess determined by HPLC 
analysis (Diacel Chiralpak IA column, 2-propanol : n-hexane = 5 : 95, 1 mL/min.; 
Acetate: 211 nm, (1R,3R)-isomer 6.37 min., (1S,3S)-isomer 6.96 min.; Alcohol: 208 
nm, (1S,3S)-isomer 24.61 min., (1R,3R)-isomer 40.77 min. 
 
The resolution was performed on racemic cis-6-methoxy-3-phenylindan-1-ol 
substrate, 80, where the solubility of the alcohol was generally good in all the 
aforementioned solvents.  
Entry Solvent Ratio a OAc : OH 
e.e. % b 
OAc  OH 
1  Acetone 11 : 89 >99   11 
2  2-Isopropoxypropane 48 : 52  >99    90 
3  Chloroform 10 : 90  >99    12 
4  Dichloromethane 38 : 62  >99    60 
5  Toluene 26 : 74  >99    34 
6  N,N-Dimethylformamide 4 : 96  >99    >2 
7  Ethyl Acetate 27 : 73  >99    36 
8  2-Propanol 13 : 87  >99    11 
9  Acetonitrile 21 : 79  >99    28 
10  Methanol 2 : 98  >99    >1 
11  Ethanol 8 : 92 >99     8 
12  Tetrahydrofuran 5 : 95 >99     4 
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Whilst the conversion varied dramatically in different solvents (and thus affecting the 
enantiomeric excess of recovered alcohol), the acetate was formed with high 
enantioselectivity (>99 %) in all solvents. Using the above data, it was found that a 
combination of dichloromethane and 2-isopropoxypropane (1 : 1) dissolved all desired 
substrates in addition to providing good conversions and enantioselectivities. 
 
In order to effectively measure the enantioselectivity of the enzymatic acylation by 
HPLC, racemic acylated indan-1-yl acetates were synthesised directly from the 
racemic indan-1-ols using acetic anhydride and pyridine (Table 17). 
 
Table 17 – Acetylation of racemic indan-1-ols using acetic anhydride 
 
Indan-1-ol Indan-1-yl Acetate 
Rac- R1/R2 R3 Yield (%) a Rac- 
80 H H 88 101 
81 H 4-OCH3 91 103 
82 H 3,4-OCH3 82 104 
83 H 3,4,5-OCH3 85 105 
84 H 2,3,4-OCH3 80  106 
85 H 4-F 90 107 
86 H 4-Cl 89 108 
87 OCH3 3-F, 4-OCH3 93   109 
88 OCH3 3-NO2, 4-OCH3 91  110 
a Isolated yield. 
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Excellent yields were obtained for the acylation of racemic indan-1-ols and retention 
times for the racemic indan-1-yl acetates (HPLC) were obtained.  
 
The enzymatic kinetic resolution was first performed on the substrates analogous to 
literature examples,359 as shown below in Table 18. 
 
Table 18 - Kinetic Resolution of Substituted Indan-1-ols using Novozym® 435  
 
Racemic  
cis-Indan-1-ol Conv. 
% a 
Acetate (1R,3R) Alcohol (1S,3S) 
R1/R2 R3  Yield % b 
e.e.
% c  
Yield 
% b 
e.e.
% c 
H H 50 101 47 >99 80 48 >99 
H 4-OCH3 50 103 46 >99 81 46 >99 
H 3,4-OCH3 47 104 42 >99 82 44 77 
H 3,4,5-OCH3 50 105 48 >99 83 47 99 
H 2,3,4-OCH3 45 106 40 >99 84 50 81 
H 4-F 49 107 47 >99 85 48 94 
H 4-Cl 50 108 47 >99 86 48 >99 
OCH3 3-F, 4-OCH3 49 109 45 >99 87 47 96 
OCH3 3-NO2, 4-OCH3 50 110 46 >99 88 48 98 
a Conversion determined by 1H NMR; b Isolated yield, as a % of racemic starting 
material; c e.e. % determined by chiral HPLC analysis (see Chapter 5 for conditions). 
 
The above method produced all of the (R)-indan-1-yl acetates in excellent 
enantioselectivities (>99 %). In most cases where conversion was roughly 50 %, the 
(S)-alcohol was also produced with high enantioselectivity (up to 99 %). 
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A clear observation is seen for alcohol substrates with a lower enantiomeric excess, 
where as expected, it is a consequence of a lower conversion. Extension of the reaction 
time afforded the desired alcohols in higher enantiomeric excess, while not proceeding 
over the 50 % conversion threshold under the conditions presented. 
 
The enzyme substrate selectivity, acylating the (R)-alcohol only, is in good agreement 
with literature observations,359,385,386 and additionally, upon oxidising the (1R,3R)-6-
methoxy-3-phenlindan-1-ol, (1R,3R)-80, to the corresponding (R)-ketone, (R)-59, 
provided consistent HPLC and optical rotation data to that of literature examples.216,388 
The same observations were found upon oxidation of the (S,S)-enantiomer, (1S,3S)-
80, confirming the observed stereochemistry.389 The (R)- and (S)-configurations of the 
remaining substrates were deduced by analogy. 
 
After successful attempts of performing kinetic resolution with 6-methoxy-3-
arylindan-1-ols, and the similarly related 4,5,6-trimethoxy-3-arylindan-1-ol 
substituents, both with varying functional groups on the aromatic ring (R3), attempts 
to perform the reaction with the naphthylen-1-ol substituent, 97 were carried out in 2-
isopropoxypropane / CH2Cl2, but remained unsuccessful (Scheme 62).  
OH
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Scheme 62 – Attempted enzymatic acylation kinetic resolution of 97 
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Numerous attempts, including variations in solvent, reaction time and temperature 
failed to produce the desired acylated naphthalen-1-ol derivative with Novozym® 435. 
The reaction yielded only the starting alcohol, upon comparison of the 1H NMR to that 
of the racemic acylated naphthalen-1-ol, 111. 
 
The resulting enantiomerically enriched (R,R)-indan-1-yl acetates were subsequently 
transformed into the corresponding (R,R)-indan-1-ols by cleavage of the carbonyl 
bond using potassium carbonate and methanol,390 as shown below in Table 19. 
 
Table 19 – Deacetylation of Enantiomerically Enriched (R,R)-Indan-1-yl Acetates 
 
Indan-1-yl Acetate Indan-1-ol 
(1R,3R)- R1 / R2 R3 Yield (%) a (1R,3R)- 
101 H H 91 80 
103 H 4-OCH3 87 81 
104 H 3,4-OCH3 85 82 
105 H 3,4,5-OCH3 91 83 
106 H 2,3,4-OCH3 89 84 
107 H 4-F 78 85 
108 H 4-Cl 81 86 
109 OCH3 3-F, 4-OCH3 74 87 
110 OCH3 3-NO2, 4-OCH3 81 88 
a Isolated yield. 
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Finally, both enantiomers of each indan-1-ol were oxidised to the desired 
enantiomerically enriched indan-1-ones. A manganese dioxide oxidation was used,391 
which allowed a comparatively easy purification process,392 (Table 20). 
 
Table 20 – MnO2 oxidation of enantiomerically enriched cis-indan-1-ols 
 
 Indan-1-ol Indan-1-one 
Entry  R1 / R2 R3 Yield (%) a  
1 (1R,3R)-80 (1S,3S)-80 H H 
82 
84 
(R)-59 
(S)-59 
2 (1R,3R)-81 (1S,3S)-81 H 4-OCH3 
81 
76 
(R)-60 
(S)-60 
3 (1R,3R)-82 (1S,1S)-82 H 3,4-OCH3 
74 
80 
(R)-61 
(S)-61 
4 (1R,3R)-83 (1S,3S)-83 H 3,4,5-OCH3 
75 
70 
(R)-62 
(S)-62 
5 (1R,3R)-84 (1S,3S)-84 H 2,3,4-OCH3 
71 
72 
(R)-63 
(S)-63 
6 (1R,3R)-85 (1S,3S)-85 H 4-F 
81 
84 
(R)-64 
(S)-64 
7 (1R,3R)-86 (1S,3S)-86 H 4-Cl 
84 
86 
(R)-65 
(S)-65 
8 (1R,3R)-87 (1S,3S)-87 OCH3 3-F, 4-OCH3 
89 
86 
(R)-66 
(S)-66 
9 (1R,3R)-88 (1S,3S)-88 OCH3 3-NO2, 4-OCH3 
90 
89 
(R)-67 
(S)-67 
a Isolated yield. 
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In summary, the enzymatic resolution of 6-methoxy- and 4,5,6-trimethoxy-3-aryl-
indan-1-ones provided a very effective and highly enantioselectivity (>99 % in most 
cases) method of achieving both enantiomers.  
  
The reported deep narrow active site,384 in addition to unfavourable interactions are 
likely resulting in the inability for Novozym® 435 to acylate the naphthylen-1-ol 
substrate.393 Nonetheless, this method did present an excellent procedure for the 
isolation of both enantiomerically enriched (R)- and (S)-indan-1-ols by enzymatic 
resolution, and subsequent indan-1-ones (see Table 19 and Table 20), through 
deacetylation/oxidation, regarding the appropriate enantiomer. 
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2.5 Kinetic Resolution – Asymmetric Transfer Hydrogenation 
 For the kinetic resolution of racemic 3-aryl substituted indan-1-ones, the following 
resolution was proposed, using an asymmetric transfer hydrogenation process shown 
below in Scheme 63. 
 
 
Scheme 63 – Proposed asymmetric hydrogen transfer kinetic resolution 
By using a chiral catalyst, it is hoped that one enantiomer would react faster than the 
other with full catalyst control. This transformation could either be stopped before 50 
% conversion, where it is desired that high asymmetric control would yield only one 
reduced isomer (alcohol). Additionally, if the catalyst exhibited high catalytic control, 
the reaction could be driven to 100 % conversion, allowing the two reduced 
diastereoisomers to be separated by standard silica column chromatography.  
 
Asymmetric Ketone Reduction  
An example of asymmetric hydrogenation is Noyori’s asymmetric hydrogenation,394 
using a ruthenium-BINAP catalyst and hydrogen gas, (Scheme 64). In this case, an 
acidic hydrogen between the two carbonyl groups is allowed to epimerise at the chiral 
centre, where in the presence of the chiral catalyst, one of the β-ketoesters 
preferentially reacts faster.395 This dynamic kinetic resolution approach with the (R)-
BINAP catalyst gave the (S)-alcohol anti-product in 93 % e.e. 
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This reaction is shown below in Scheme 64, where methanol appeared to have a major 
influence on the diastereoselectivity of the reaction. 
 
Scheme 64 – Noyori’s classic dynamic kinetic resolution of dicarbonyl systems395  
 
Zhao et al.219 reported a chiral dendrimer to resolve indan-1-ones, with application 
towards the synthesis of (+)-sertraline, (Scheme 65). 
 
Scheme 65 – Asymmetric reduction of indan-1-ones using a chiral dendrimer and 
BH3.(CH3)2S, towards the synthesis of (+)-sertraline219 
 The chiral dendrimer contained a prolinol core, and the research reported a mixture of 
cis- and trans-isomers obtained in a ratio of (1 : 1), separable by column 
chromatography. The cis-isomer had an e.e. of about 80 %, whereas the trans isomer 
had an e.e. of about 95 %. This approach is particularly useful as both indan-1-one 
enantiomers can be obtained from the racemic mixture in good enantiomeric excess. 
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Although Corey first demonstrated the use of oxazaborolidine catalysts in the 
reduction of ketones by borane, notably in the reduction of tetralone,396 Lee et al. 
further utilised this method to enantiomerically resolve indan-1-one derivatives, 
specifically towards the synthesis of (+)-indatraline, (Scheme 66).397 
 
 
Scheme 66 – Oxazaborolidine-catalysed asymmetric carbonyl reduction of an indan-
1-one derivative, (+)-indatraline397 
 
Treatment of the ketone with an (S)-(-)-2-methyl-CBS-oxazaborolidine catalyst and 
catecholborane yielded a separable mixture of (1R,3S)-trans-indanol and its 
diastereoisomer, (1R,3R), with high enantioselectivities (31 % yield, 95 % e.e. and 50 
% yield, 85 % e.e. respectively).397 
 
With extensive research available on the asymmetric reductions of prochiral ketones, 
our attention turn towards the work of Noyori398 and Wills.399 A variety of examples 
of asymmetric hydrogenation / asymmetric transfer hydrogenation on a variety of 
ketone substituents were available in the literature, offering high enantioselectivities 
(~99 % e.e.) in most examples.400 
 
Some examples applicable to this research are shown below in Scheme 67.401 
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Scheme 67 – Asymmetric transfer hydrogenation (ATH) and asymmetric pressure 
hydrogenations (APH) of particular ketone substrates401 
 
  
Based on previous work from Noyori and Wills,401 one would expect catalyst-
selectivity to afford the (R)-enantiomer (alcohol) when subjected to the (R,R)-catalyst 
(Scheme 67).  
 
The catalytic cycle in which the transformation is believed to happen is shown below 
in Scheme 68.402,403  
 
 
Scheme 68 – Proposed mechanism for the asymmetric transfer hydrogenation402 
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The strong base leads to the facile elimination of HCl to yield the 16-electron catalytic 
species ‘Ru’. The triethylammonium formate is thought to bond to the metal oxygen, 
with subsequent loss of CO2 leading to the formation of the 18-electron reactive 
intermediate ‘Ru-H’. The prochiral ketone is then reduced by the 18-electron reactive 
intermediate ‘Ru-H’ to give the corresponding enantiomerically enriched alcohol. The 
hydridic Ru-H and protic N-H in this 18-electron reactive intermediate are transferred 
to the carbonyl oxygen and carbonyl carbon respectively. 
 
The stereo-determining step in the catalytic cycle shown in Scheme 68 is generally 
imposed by a directing functional group interacting with the complex. Aryl groups, 
such as a phenyl group,398 are some of the more common direction groups for this 
process. Noyori et al.404 performed some DFT calculations on a non-tethered catalyst, 
suggesting that the CH/π attractive interactions shown below in Figure 25 stabilises 
the transition state, leading to the high enantioselectivities of the products. 
 
 
Figure 25 – Favourable CH/π attractive interactions 
 The work suggested that the CH/π attractive interaction was between the η6-arene ring 
and the aryl substituent in the prochiral ketone. The following research utilises a 
tethered-Ru catalyst based on the high enantioselectivities in the literature, to perform 
an asymmetric transfer hydrogenation kinetic resolution on a selected indan-1-one. 
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Results & Observations 
In this current study, with the aim was to isolate single enantiomers; 3-arylindan-1-ol 
and 3-arylindan-1-one via kinetic resolution, the racemic ketone starting material, 59, 
was subject to the asymmetric transfer hydrogenation (ATH) method using the 
tethered (R,R)-TSDPEN-ruthenium catalyst.401 
O
Ph Ph(±)
O
Ph
+
(R,R)-Tethered RuCatalyst, 112
OH
NEt3 : HCO2H5 : 2
O O O
59  
Scheme 69 – Asymmetric transfer hydrogenation of compound 59 
 
The catalyst was provided by the Wills group at Warwick University and the formic 
acid : triethylamine (5 : 1) solution was prepared from the method by Sterk et al.405  
 
After 12 hours, the reaction was observed to proceed to 85 % conversion with respect 
to ketone consumption. Inspection of the HPLC chromatogram showed three distinct 
product peaks were observed in addition to the residual ketone (see Figure 26 below). 
 
 
Figure 26 – Initial HPLC for the Ru-catalysed ATH of 59 after 12 hours 
Column conditions: Diacel Chiralpak IA column, 
2-propanol : hexane = 5 : 95, 1 mL/min., 207 nm. Residual ketone (Not split into enantiomers on the Diacel 
Chiralpak IA column) 
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The racemic cis-6-methoxy-3-phenylindan-1-ol compound, 80, was formed via the 
selective reduction using sodium borohydride (see Section 2.3.2.4), yielding 
exclusively the cis-alcohol. This provided both reference 1H NMR peaks and HPLC 
retention times for this isomer. Indeed, the individual cis-isomers were also 
synthesised by an enzymatic resolution method (see Section 2.3.2.4) providing 
reference HPLC retention times for each enantiomer. 
 
Overlay of the racemic cis-6-methoxy-3-phenylindan-1-ol quickly identified two of 
the HPLC peaks (Figure 27). 
 
  
 
Figure 27 - Overlay of the racemic cis-6-methoxy-3-phenylindan-1-one, 80, on the 
HPLC of the Ru-catalysed ATH of 59, (12 hours) 
 
The sample was additionally ‘spiked’ with racemic cis-alcohol, showing an increased 
intensity for the aforementioned peaks, further supporting the assignment of the 
observed peaks. 
  
(1R,3R) (1S,3S) 
Diacel Chiralpak IA column, 2-propanol : hexane = 5 : 95, 1 mL/min., 211 
nm; Rac-cis-80, (1S,3S)-isomer 22.29 min., (1R,3R)-isomer 37.44 min.). 
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With one unaccountable peak remaining, it was hypothesised that this would be 
attributed to either racemic or enantiopure trans-6-methoxy-3-phenylindan-1-ol. 
Firstly, for identification of the racemic-trans-isomer on the HPLC trace, it was 
synthesised using a Mitsunobu transformation,406 from the corresponding racemic cis-
isomer, 80, shown in Scheme 70 below. 
 
Scheme 70 – Mitsunobu reaction to afford the racemic trans-114 
 
 
Similarly, the individual trans-alcohol enantiomers were synthesised from the 
enantiomerically enriched indan-1-ols, by the same approach shown in Scheme 70. 
 
Scheme 71 – Mitsunobu reaction to give the enantiomerically enriched (1S,3R)-114 
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Ph
O O
Ph
O O
NO2
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(1S,3S)-80 (1R,3S)-113 (1R,3S)-114
74 % 80 %  
Scheme 72 – Mitsunobu reaction to give the enantiomerically enriched (1R,3S)-114  
 
Overlay of the racemic trans-indan-1-ol HPLC trace concluded that the unidentified 
peak was that of the (1R,3S)-trans-isomer. 
  
 
Figure 28 – Overlay of the racemic trans-6-methoxy-3-phenylindan-1-one HPLC on 
the Ru-catalysed ATH of 59, (12 hours) 
 
The sample was again ‘spiked,’ this time with racemic trans-alcohol, 114, confirming 
the assignments of the peaks. The racemic trans-‘spiked’ sample resulted in an 
additional peak, shown below in Figure 29.  
  
(1R,3S) (1S,3R) 
Diacel Chiralpak IA column, 2-propanol : hexane = 5 : 95, 1 mL/min., 211 
nm; Rac-trans-114, (1S,3R)-isomer 21.60 min., (1R,3S)-isomer 25.38. 
(1R,3R) (1S,3S) 
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Figure 29 – ‘Spiking’ of racemic trans-114 alcohol to the HPLC sample obtained 
after 12 hours 
 
The identified peaks for this reaction are summarised below in Figure 30: 
 
 
 
Figure 30 – Summary of identified peaks from HPLC chromatogram 
 
This transformation gave the alcohol in a poorly selective process, and additionally 
the residual ketone was found to have a 30 % e.e. after the 85 % conversion shown in 
Figure 26, (12 hours).  
   
(1R,3S) 
(1S,3S) (1R,3R) 
Appearance of peak 
from ‘spiking’ with 
racemic trans-sample 
(1R,3R) 
(1R,3S) 
(1S,3R) 
(1S,3S) Increased upon spiking 
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After 1 hour, the reaction had proceeded to 46 % conversion with a 50 % e.e. for the 
ketone, with the residual alcohols formed in a 5 : 4 : 91 ratio for the (1S,3S), (1R,3S), 
(1R,3R) isomers respectively.  
 
Taking the reaction to 65 % conversion after 2 hours gave the residual (S)-ketone in 
46 % e.e. (Diacel Chiralpak AS column, 2-propanol : hexane = 5 : 95, 1 mL/min., 219 
nm; (S)-isomer 16.23 min., (R)-isomer 25.74 min.). As both enantiomers of ketone are 
consumed in this process, albeit at different rates, the reaction is not favourable for the 
ketone component either, and thus our attention turned to a different resolution 
approach. 
 
The rationale behind the results obtained can be explained when the transition 
states of each component are considered in the reaction, Scheme 73.
 
Scheme 73 – Possible outcomes for the asymmetric transfer hydrogenation of 
racemic 6-methoxy-3-phenyl indan-1-one, 59 
 
 - Catalyst  - Substrate 
 - Catalyst  - Substrate 
 - Catalyst  - Substrate 
 - Catalyst  - Substrate 
(1S,3S)-80  
(1R,3S)-114  
(1S,3R)-114  
(1R,3R)-80  
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These preferences can be explained given the following transition states, Figure 
31. The unfavourable steric clash can be seen for the formation of the (1S,3R)-
alcohol between the 3-phenyl ring of the indan-1-one and the aromatic ring on 
the ruthenium catalyst. Additionally, favourable CH/π interactions404 can be 
seen between the indanone aromatic ring and the C-H from the ruthenium 
aromatic ring, providing a possible explanation for the ratio of isomers observed 
in this transformation. Further computational studies would be required to 
support these transition states however. 
 
 
Figure 31 – Proposed transition states - asymmetric transfer hydrogenation of 59 
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2.6 Kinetic Resolution – Oxidative Kinetic Resolution 
 
Given that the asymmetric transfer hydrogenation reaction shown in Section 1.5 has 
an outcome of four possible stereoisomers, (Scheme 73), our attention turned towards 
the reverse of this process, to perform an oxidative kinetic resolution on racemic cis-
indan-1-ols formed in Section 2.3.2.4.  
 
As the cis-geometry of the racemic indan-1-ol is controlled in the sodium borohydride 
reduction of the appropriate ketone, the approach can be advantageous upon 
comparison to the asymmetric transfer hydrogenation performed previously, such that: 
 
 Reduction – Conversion of 2 enantiomers into a possible 4 stereoisomers 
 Oxidation – Conversion of 2 enantiomers into a possible 2 stereoisomers 
 
Consequently, the following approach was applied, shown below in Scheme 74. 
 
 
Scheme 74 – Proposed chiral oxidation of racemic cis-indan-1-ols 
 
For an ideal outcome, the conversion is desired to be 50 %, with high 
enantiomeric excess of both the residual alcohol and the oxidised ketone. This 
approach is discussed in more detail below. 
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Discussion on Oxidative Kinetic Resolution  
 
One of the first approaches to kinetic resolution via alcohol oxidation was from the 
work by Ruchnovsky et al,407 reporting the oxidation of 1-phenylethanol using a chiral 
nitroxyl radical catalyst and sodium hypochlorite as the oxidising agent, (Scheme 75). 
 
Scheme 75 – Chiral nitroxy radical-catalysed oxidative kinetic resolution407 
 
Additional improvements to this method have since been realised,408 however, other 
approaches to the oxidative kinetic resolution of secondary alcohols generally employ 
transition metal catalysts.409 
 
Sigman et al.410 reported a system using (-)-sparteine as the chiral ligand, with a 
Pd(OAc)2 catalyst and O2 as the stoichiometric oxidant, shown below in Scheme 76. 
 
 
 
Scheme 76 – (-)-Sparteine used as a chiral ligand with Pd(OAc)2 and O2 as the 
stoichiometric oxidant410 
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The system was optimised using t-BuOH as a solvent to obtain modest selectivity for 
a wide range of secondary alcohols. 
 
Xia has similarly reported an oxidative kinetic resolution of benzylic alcohols using a 
manganese-salen catalyst, with iodobenzene diacetate as the stoichiometric oxidant,411 
shown below in Scheme 77.  
 
Scheme 77 – Oxidative of benzylic alcohols using a manganese-salen catalyst411 
 
It was later reported by Xia that solvent changes allowed for better selectivity in some 
substrates.412 Additionally, Toste et al. reported a vanadium catalyst using a chiral 
salicylaldimine ligand for the asymmetric oxidation of α-hydroxy esters,413,414 
(Scheme 78). 
 
Scheme 78 – Chiral salicylaldimine-vanadium catalyst used for asymmetric 
oxidation of α-hydroxy esters413,414 
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Noyori has developed highly enantioselective variants of a ruthenium catalysed kinetic 
resolution of secondary alcohols, using a ruthenium diamine catalyst, with acetone as 
the hydrogen acceptor.415 The process is essentially the reverse of that shown in 
Scheme 68, where acetone is reduced to propan-2-ol, with the appropriate alcohol 
enantiomer being oxidised into the corresponding enantiomerically-enriched ketone. 
Selected results of this transformation are shown below in Scheme 79, showing the 
enantioselectivity of the residual alcohol. 
 
  
Scheme 79 – Kinetic resolution of secondary alcohols by Ruthenium catalysed 
oxidation415 
 The resolution of racemic indan-1-ol and α-tetralol gave the (R)-enantiomers in 97-99 
% e.e. at 50-55 % conversion upon being subjected to the (S,S)-catalyst. Many of the 
given examples were also difficult to obtain in high enantiomeric purity by reduction 
of the corresponding ketone with 2-propanol.416-418 
 
Encouraged by these results, the following research was performed in accordance with 
the aforementioned method,415 and is discussed below. 
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Results and Discussion 
 
In this current study, the following oxidative kinetic resolution was performed in 
accordance with the method provided by Noyori et al.415 
 
Synthesis of the active catalyst for this reaction was performed using Noyori’s 
procedure, yielding dark purple crystals for the 16 electron species. Unfortunately, 
attempts at obtaining a crystal structure were unsuccessful, however the spectroscopic 
and observational data was consistent with the literature.415 Formation of the catalyst 
is shown below in Scheme 80. 
 
 
Scheme 80 – Synthesis of Ru Complex (1S,2S)-Ru(p-cymene)(TsDPEN), 115 
 
 
Although both the (R,R)- and (S,S)- ruthenium catalysts were synthesised, only the 
(S,S)-115 ruthenium catalyst was employed for the following oxidative kinetic 
resolutions. 
 
Firstly, the reaction was performed on the 6-methoxy-3-aryl indan-1-ol substituents, 
as shown below in Table 21. As the reactions were allowed to proceed to less than 50 
% conversion, only the ketone enantioselectivity was analysed.  
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Table 21 – Oxidative Kinetic Resolution of Substituted Racemic cis-6-methoxy-3-
arylindan-1-ols  
 
Racemic cis-Indan-1-ol Ratio  
Alcohol : Ketone 
Conversion 
(%) 
Ketone (S) 
 R- e.e.% c 
80 H 1.9 : 1 33 78 
81 4-OCH3 2.8 : 1 26 86 
82 3,4-OCH3 2.0 : 1 34 70 
85 4-F 2.6 : 1 38 99 
86 4-Cl 1.2 : 1 45 78 
a Conversion determined by 1H NMR Analysis; b Isolated yield, as a % of racemic 
starting material; c e.e. % determined by chiral HPLC analysis (see Chapter 5). 
 
The stereochemistry of each product was confirmed by analogy, where both 
enantiomers of the 6-methoxy-3-phenylindan-1-one, (R)-59 and (S)-59, were 
consistent with literature reports.216 Additionally, these results were consistent with 
those obtained from the enzymatic acylation kinetic resolution. The enzymatic 
approach for these substrates was generally considered more suitable for the above 
substrates, however, the ruthenium oxidation did provide opportunity for the kinetic 
resolution of the naphthyl- derivatives, where they were unsuccessful in the enzymatic 
acylation. 
 
Encouraged by these results, the following substituted naphthylen-1-ols were 
subjected to the oxidative kinetic resolution method. The (S,S)-catalyst, 115 was used 
with acetone as the proton acceptor; the results being shown below in Table 22. 
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Table 22 – Oxidative Kinetic Resolution of Substituted Racemic cis-Indan-1-ols  
 
Racemic  
cis-Indan-1-ol Conv. 
% a 
Ketone (S) Alcohol (1R,3R) 
 R- X-   Yield % b 
e.e.% 
c  
Yield 
% b 
e.e.% 
c 
93 H Br 35 72 32 >99  - 33  57d  - - 93 40 87 
94 4-OCH3 Br 50 73 48 96 94 48 95 
95 2,3-OCH3 Br 50 74 47 96 95 48 >99 
97 3,4,5-OCH3 Br 52 76 49 96 97 46 >99 
98 2,3,4-OCH3 Br 55 77 51 93 98 39 >99 
99 4-F Br 43 78 41 95  - 60  56d  - - 99 41 >99 
100 4-Cl Br 48 79 40 91 100 42 >99 
89 H H 49 68 46 76 89 46 80 
90 3,4,5-OCH3 H 51 69 46 91 90 45 97 
91 3,4,5-OCH3 F 52 70 47 98 91 46 >99 
92 3,4,5-OCH3 Cl 48 71 44 96 92 48 95 
a Reaction conversion determined by 1H NMR Analysis; b Isolated yield, as a % of 
racemic starting material; c e.e. % determined by chiral HPLC analysis (see Chapter 
5 for conditions); d Conversion after second oxidative kinetic resolution, after 
separation of both materials from the first resolution. 
 
 
The residual alcohol products where then oxidised using MnO2 to give the 
corresponding enantiomerically enriched indan-1-ones (Table 23 below). 
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Table 23 – Manganese Oxidation of cis-Enantiomerically Enriched Indan-1-ols 
 
Entry Alcohol (1R,3R)- R Group X Group Indanone Yield % a 
1  93 H Br (R)-72 77 
2  94 4-OCH3 Br (R)-73 81 
3  95 2,3-OCH3 Br (R)-74 81 
4  97 3,4,5-OCH3 Br (R)-76 87 
5  98 2,3,4-OCH3 Br (R)-77 69 
6  99 F Br (R)-78 80 
7  100 Cl Br (R)-79 79 
8  89 H H (R)-68 72 
9  90 3,4,5-OCH3 H (R)-69 89 
10  91 3,4,5-OCH3 F (R)-70 91 
11  92 3,4,5-OCH3 Cl (R)-71 86 
a Isolated yield. 
 
In summary, the oxidative kinetic resolution method shown in this study provides a 
novel method for the access of enantiomerically enriched indan-1-ols and indan-1-
ones, not previously accessible by other methods tried previously in this project.  
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2.7 Conclusions 
 In this chapter, we have illustrated the difficulty in synthesising specific 
enantiomerically enriched 3-arylindan-1-ones by some existing methodologies. A 
reductive Heck cyclisation method216 gave poor yields and enantioselectivity for the 
desired substrates. Additionally, a cyclisation of enantiomerically enriched 3,3-diaryl 
propanoic acids was attempted, but remained unsuccessful. 
 
We have shown an enzymatic acylation kinetic resolution for 3-aryl indan-1-ols, 
which were synthesised from the corresponding indan-1-ones. This resolution 
provided both the (R)-acylated and recovered (S)-indan-1-ols in excellent 
enantioselectivities and in near quantitative yields. Furthermore, due to the relatively 
low environmental implications associated with enzymatic catalysts, this method 
provided an ideal prospect for the scale-up of certain substrates.419  
 
Unfortunately, naphthyl-indan-1-ol derivatives were not acylated in the enzymatic 
resolution, and consequently an oxidataive kinetic resolution was performed, using an 
(S,S)-Ru catalyst, 115. This method generally gave good enantioselectivities, yielding 
the desired (R)- and (S)-76 indan-1-one precursor in 99 % e.e. 
 
A summary of the enzymatic selectivity, (E), for the enzymatic acylation kinetic 
resolution and chemo-catalyst selectivity, (S), for the ruthenium oxidative kinetic 
resolution is shown in Figure 32 below for each appropriate substrate. These have 
been calculated using Equation 3 & Equation 4 from Section 2.3.1 The (1R,3R) is 
drawn and is the faster reacting enantiomer in the enzyme acylation reaction, and the 
recovered starting material in the (S,S)-catalysed oxidation. We had wished to obtain 
S-values from the ruthenium oxidation for all substrates, but this remains future work. 
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(1R,3R)-80
 
(1R,3R)-81
 
(1R,3R)-82
 
(1R,3R)-84
 E = >100 a S = 13 b E = >100 
a S = 14 b E = >33 
a S = 8 b E = >100 
a 
 
(1R,3R)-83
 
(1R,3R)-85
 
(1R,3R)-86
 
(1R,3R)-87
 
E = >100 a E = >100 a S = >100 b E = >100 
a S = 16 b E = >100 
a  
(1R,3R)-88
 
(1R,3R)-89
 
(1R,3R)-90
 
(1R,3R)-91 
 
E = >100 a  E = No reaction S = 16 b E = No reaction S = 78 b E = No reaction S = >100 a 
(1R,3R)-92
 
(1R,3R)-97
 
(1R,3R)-98
 
(1R,3R)-95
 
E = No reaction S = >100 b E = No reaction S = >100 a E = No reaction S = 49 a E = No reaction S = >100 b 
(1R,3R)-94
 
(1R,3R)-99
 
(1R,3R)-100
 
(1R,3R)-93
 
E = No reaction S = >100 b E = No reaction S = 16 a E = No reaction S = 56 b E = No reaction S = >100 b 
 Figure 32 – Summary of catalyst selectivity factors, where E represents enzyme 
selectivity and S represents the ruthenium oxidation selectivity; a Based on recovered 
starting material (alcohol). c Based on products.  
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 CHAPTER 3 - ASYMMETRIC SYNTHESIS OF SUBSTITUTED 4-ARYLQUINOLIN-2-ONES 
3.1 Introduction 
 
This chapter discusses research towards the synthesis of enantiomerically enriched 4-
aryl-3,4-dihydroquinolin-2(1H)-ones from the corresponding 3-arylindan-1-ones 
synthesised in the previous chapter. The intention is to asymmetrically synthesise both 
enantiomers of compound 6-B345TTQ, 1, for biological testing, and to identify the 
active enantiomer. A disconnection for this approach is shown below in Scheme 81.  
 
 
 
 
Scheme 81 – Disconnection approach for the synthesis of compound 6-B345TTQ, 1 
 
 
Consequently, this chapter will focus on the Beckmann rearrangement of indan-1-one 
derivatives. This synthetic approach was chosen from literature in this field showing 
examples for similarly related structures, and is discussed below. The precursors for 
this transformation will be the naphthyl-indan-1-one compounds synthesised from the 
oxidative kinetic resolution, Table 22, Chapter 2.  
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3.1.1 Previous Synthesis of Racemic 4-Arylquinolin-2-ones 
 
 
 Previous work420 in our research group has focused on the synthesis of compounds 6-
B345TTQ, 1, as a racemate, and structurally similar analogues. The synthetic 
approach involved a two-step process, encompassing the formation and subsequent 
reaction of substituted arylidene derivatives (Scheme 82).   
 
Scheme 82 – Disconnection of compound of racemic compound, 6-B345TTQ, 1. 
 This process was important for comparison of spectroscopic data to results obtained 
within this chapter, and for comparative biological testing of racemates with their 
corresponding enantiomers. This two-step synthetic process is discussed below. 
 
Knoevenagel Condensation 
The first step involved a Knoevenagel condensation using substituted aromatic 
aldehydes with 2,2-dimethyl-1,3-dioxane-4,6-dione, Meldrum’s acid. Although this 
reaction is generally catalysed by bases such as pyridines,421,422 or by pyridine / glacial 
acetic acid in benzene with water removal,423 the applied method was based on 
previous work by Bigi et al.,424 performing a Knoevenagel condensation by heating at 
75 °C in water. Excellent yields were obtained for this transformation particularly for 
electron donating substituents.420 These results obtained in this previous work are 
discussed below (Table 24). 
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Table 24 – Knoevenagel condensation of aromatic aldehydes with Meldrum’s 
acid420 
 
Entry R Groups Yield  (%) a 
1 3,4,5-OCH3 90 2 2,3,4-OCH3 91 3 2,4,5-OCH3 88 4 2,3-OCH3 85 5 3,4-OCH3 87 6 4-OCH3 83 7 4-F   64 b 
8 4-Cl   59 b 
9 H (bis-adduct formation) 
a Isolated yield; b Bis-adducts were additionally observed, although products were 
more easily separated from the bis-product, albeit with a reduced yield. 
 
The presence of the bis-adduct formation (Scheme 83) from the reaction with 
benzaldehyde (and aldehydes with electron withdrawing substituents) was observed. 
Solvent effects appeared crucial, as performing the 1H NMR in d6-DMSO resulted in 
the bis-adduct forming an equimolar mixture of arylidene and Meldrum’s acid. 
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 Scheme 83 – Formation of a bis-adduct in the Knoevenagel condensation420 
 
Consequently a more judicious choice of solvent was required to minimise the 
formation of the bis-adduct (DMSO for example), or an excess of aldehyde. As it was 
found that generally the product precipitates out of solution, excess aldehyde was used.   
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Conjugate Addition Reaction 
 
The reaction of the arylidene products formed previously into the corresponding 4-
arylquinolin-2-ones was by a method developed by Hao et al.,425 (Scheme 84), with 
the results being shown below in Table 25. The reaction was reported as a microwave-
assisted process towards the synthesis of some spirocyclic compounds,425 but 
fortunately gave quinolin-2-ones. Scheme 84-A was found to not participate in the 
reaction. 
 Scheme 84 – Synthesis of quinolin-2(1H)-one Derivative 
 
Table 25 – Conjugate addition of aromatic amines to arylidene-derivatives420 
 
Entry R-Groups X Groups Yield  % 1 3,4,5-OCH3 H 55 2 3,4,5-OCH3 Cl 58 3 3,4,5-OCH3 Br 60 4 2,3,4-OCH3 Br 51 5 3,4-OCH3 Br 66 6 2,3-OCH3 Br 62 7 4-OCH3 Br 69 8 4-F Br 54 
9 4-Cl Br 53 
 
This previously reported work420 provided spectroscopic data for compound 6-
B345TTQ, 1, and similarly related compounds.   
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3.1.2 Beckmann Rearrangements toward Quinolin-2-ones 
 
The conversion of aldoximes and ketoximes to the corresponding amides under acidic 
conditions is known as the Beckmann rearrangement.426 It is especially useful in the 
industrial synthesis of ε-caprolactam, an important monomer for the production of 
synthetic fibres.427,428 More commonly, the Beckmann rearrangement is performed in 
strongly acidic and dehydrating media, including phosphorus pentachloride, 
concentrated sulfuric acid, or the so-called ‘Beckmann’s mixture’, containing acetic 
acid, acetic anhydride and hydrogen chloride.429  
 
 
Scheme 85 – General Beckmann rearrangement to N-substituted amides 
 
The R group anti to the leaving group on the nitrogen will migrate, (R1 in the example 
shown in Scheme 85), however if the oxime isomerises under the reaction conditions, 
a mixture of two amide products are obtained.430  
 
Formation of the oxime is generally prepared using hydroxylamine as the reactant with 
a suitable acid or base catalyst, with many examples present in the literature.431-436 A 
traditional procedure involves refluxing the ketone and hydroxylamine hydrochloride 
in pyridine,437  shown below in Scheme 86. 
 
 
Scheme 86 – Transformation of a ketone to its corresponding oxime derivative437 
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Additionally, oximes may be converted to O-substituted oximes, typically O-tosyl 
oximes, allowing milder transformations than in traditional Beckmann conditions.438 
 
Classical media for Beckmann rearrangements of unsubstituted oximes are strongly 
acidic conditions, using concentrated sulfuric acid,439 anhydrous hydrogen fluoride,440 
aluminium chloride441 or polyphosphoric acid,442 usually with good yields. Many of 
these reagents are not suitable for large-scale synthesis or sensitive substrates, 443,444 
and thus, enormous efforts445 have been dedicated to the development of milder and 
more effective versions of this reaction.  
 
Along this line, a wealth of useful reagents have been used, including; silica gel,446 
thionyl chloride,447 montmorillonite KSF,448 P2O5,449 bismuth (III) chloride,450 PCl5,451 
dichlorophosphate,452 cyanuric chloride,453,454 molydenum trioxide on silica gel,455 
HSO3Cl,456 and gallium (III) triflate.457 A variety of metallic Lewis acid catalysts have 
also been utilised, including; [RhCl(cod)]2,458 Yb(OTf)3,459 RuCl3,460 and HgCl2.461 
Several liquid-phase catalysis have also be employed such as ethyl chloroformate / 
boron trifluoride etherate,462 sulfamic acid,454 anhydrous oxalic acid,463 chlorosulfonic 
acid,453 bis(2-oxo-3-oxazolidinyl) phosphoric chloride,464 and diethyl 
chlorophosphate.465  
 
Conveniently, naphthyl groups have been shown to migrate with high selectivity 
offering excellent yields using a NH2SO3 / ZnCl2 catalyst system, (Scheme 87).466 
 
Scheme 87 – Beckmann rearrangement catalysed by NH2SO3H / ZnCl2 466 
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Similar results have been found for this transformation using cyanuric chloride,453,454 
or using triphosphazene catalyst system.467 
 
Beckmann rearrangements of indan-1-one oxime derivatives have been performed 
using a number of reagents with varying success. Substituents on the indanone ring 
have a profound effect on the ratio of isomers formed (Table 26).468 
 
Table 26 – Aluminium chloride-catalysed Beckmann rearrangement468 
 
R Groups (E) / (Z) Oxime Ratio Yield (%) 
Carbostyril Isocarbostyril 
H 97 / 3 92 8 
CH3 100 / 0 85 15 
OCH3 100 / 0 74 26 
NO2 80 / 20 27 73 
 
Lee and colleagues468 showed that in the absence of Lewis acids the rotational barrier 
of the oxime C=N bond is quite high, but in the presence of Lewis acid catalysts the 
rotational barrier is lower.438 The complex formation of AlCl3 and tosylate allows 
double bond rotation with the product distribution being determined by the relative 
stability of the oxime (E) / (Z) isomers. Torisawa et al.469 found a similar result, 
although they proposed a 1,2-pinacol rearrangement around a single C-N bond.  
 
Similar reports across a variety of publications have shown different isomer ratios 
depending on the substituents on the indan-1-one structure. Beckmann rearrangements 
of these substrates are shown with their respective ratio of isomers in Table 27.443 
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Table 27 – Beckmann rearrangements of different Indan-1-one substrates443 
 
Entry Substrate Conditions Ratio (% migration) a Ref. Carbostyril Isocarbostyril 
1 
 
PPA, 125-130 °C 100 - b 470 
2 
 
PPA, 110-130 °C, 5-10 min 90 10 
471 
3 
 
PPA, 100 °C, 75 min 100 - b 472 
4 
 
P2O5 / CH3SO3H - b 100 473 
5 
 
P2O5 / CH3SO3H - b 100 473 
6 
 
PPA, 110-130 °C, 5-10 min 34 66 
471 
7 
 
PPA, 110-130 °C, 5-10 min 19 81 
471,474-
476 
8 
 
PPA, 110-130 °C, 5-10 min 27 73 
471 
a Based on lactams only; b Limited discussion on isomeric ratio. 
 
[ The example in Table 27, Entry 1, additionally reported some fragmentation in the 
reaction, from the presence of a nitrile band in infrared spectroscopy. The structure 
however was not elucidated. Some of these publications are seemingly old too, and 
thus there is concern to the reported ratio, but nonetheless, these results provide an 
insight into influence of the substrate in the Beckmann rearrangement.147 
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Similar substrate changes were observed upon the acidic rearrangement of indanone 
oximes using PPA and Bi(OTf)3 (Scheme 88). The carbostyril core was found to be 
highly dependent of the substituent of the aromatic ring, regardless of the 
stereochemistry of the oximes.438 
 
Scheme 88 – Beckmann rearrangement of different substituted indan-1-ones 
 
Torisawa et al.147 found that performing the rearrangement with Eaton’s reagent 
(P2O5-CH3SO3H), failed to give normal Beckmann products (carbostyril or 
isocarbostyril) with methoxyindan-1-one oximes, (Scheme 89). 
 
Scheme 89 – Formation of α-sulfonyloxy- and dimeric- products with Eaton’s 
reagent 
 
Further experimentation with the tosylate derivative yielded the same products albeit 
in a slightly higher yield, with the remainder of the products being oxime or ketone. 
 
Beckmann reagents have been reported to effect selective (thus two directional) 
transformations from a single oxime isomer using polyphosphoric acid, as reported by 
Paquette et al.477 Accordingly, Torisawa et al.478, reported selective conversion into 
the corresponding isocarbostyril using TiCl4.  
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Remarkably, TiCl4 in the presence of mesyl chloride and ethylene dichloride yielded 
the carbostyril product, but replacement of MsCl with BF3CH3OH as a key additive,469 
effective conversion into the isocarbostyril was found in near quantitative yields,478 
(Scheme 90). Oxime mesylates were also found to be superior to tosylates.479 
 
 
Scheme 90 – Two directional Beckmann rearrangements 
 
 ZrCl4 was found to be sluggish in the same conditions presented towards the 
isocarbostyril compounds, (with BF3CH3OH, Scheme 90), although it was presented 
as a suitable promoter for carbostyril synthesis.469 The reaction was successful using 
ZrCl4 with BF3OEt2 as the solvent,479 however, upon discovering that residual MsCl 
in samples from oxime mesylation offered improved conversion, it was later realised 
that mesyl chloride as the solvent offered more optimised conditions, (Scheme 91). 
 
 
 Scheme 91 – Beckmann rearrangement of indan-1-one oxime mesylates in the 
presence of ZrCl4 and MsCl as a solvent469 
 
It was hypothesised that ZrCl4 offered stronger coordination, and thus less scrambling 
of the oxime mesylate in the transition state, relative to weaker acids like Eaton’s 
reagent of FeCl3, where mixtures of isomers were obtained.469   
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3.2 Results & Discussion 
In this study, the appropriate naphthyl-indan-1-ones formed from the previous chapter 
were subjected to Beckmann conditions presented in the literature by Torisawa.469 The 
method involved employing a ZrCl4 catalyst in mesyl chloride as the solvent, with the 
appropriate indan-1-one oxime mesylates.  
 
The intention was to transform the indan-1-one oxime mesylate into the corresponding 
4-aryl-3,4-dihydroquinolin-2(1H)-one shown below in Scheme 92. 
 
 
Scheme 92  – Beckmann rearrangement of 3-aryl indan-1-ones 
 
 
Given the advancements in indan-1-one Beckmann rearrangements presented by 
Torisawa,469 the aim was to synthesise 4-aryl-3,4-dihydroquinolin-2(1H)-ones as the 
major isomers, rather than the 4-aryl-3,4-dihydroquinolin-1(2H)-one. More 
specifically, the aim was to synthesise the target enantiomers of compound 6-
B345TTQ, 1 and structurally similar analogues. 
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3.2.1 Indan-1-one Oxime Formation 
 
Formation of the indan-1-one oxime derivatives was prepared by the common 
procedure, heating the appropriate ketone and hydroxylamine hydrochloride in 
pyridine for 18 hours, (Scheme 86).437 
 
The reaction was carried out on the (S)-indan-1-one compounds formed from 
oxidative kinetic resolution, Table 22, in the previous chapter, giving the 
corresponding oximes in good yields. The results are shown below in Table 28. 
 
Table 28 – 3-Arylindan-1-one oxime formation using NH2-OH.HCl in pyridine 
 
 
Entry (S)-Ketone R Groups X Groups Oxime Yield % a 
1  68 H H (S)-123 90 
2  70 3,4,5-OCH3 F (S)-122 83 
3  72 H Br (S)-116 88 
4  73 4-OCH3 Br (S)-117 83 
5  76 3,4,5-OCH3 Br (S)-119 84 
6  77 2,3,4-OCH3 Br (S)-118 79 
7  78 4-F Br (S)-120 90 
8  79 4-Cl Br (S)-121 89 
a Isolated yield. 
 
Although a crystal structure was not obtained for the oxime products, the 
stereochemistry was deduced as trans- given previous literature reports.468,469,480 
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Lee et al.468 found that cis-indan-1-one oximes were isomerised to trans even on 
mildly acidic silica, and although they could not isolate pure cis-oxime, they were able 
to isolate the more stable trans-oxime by subsequent recrystallization. The oxime 
substrates (Table 28) were recrystallized and isolated, where the 13C NMR spectrum 
indicated the presence of only a single isomer.  
 
Previously reported oximes, especially indan-1-one oximes, throughout this chapter 
were found to be predominately trans-, so it was reasonable at this point to assume the 
single oxime isomer isolated for each of the compounds in Table 28 was indeed trans.  
 
One can imagine that the relative stability of the trans-oxime isomer mesylate is 
greater than that of the cis-isomer, given the steric repulsion between the mesyl group 
and the naphthyl-ring (CAr-H), (Figure 33). 
 
 
Figure 33 – Diagram showing the trans-oxime mesylate (left) compared with the 
cis-oxime mesylate isomer (right) 
 
 
Consequently, by analogy, these compounds were deduced as the more stable trans-
isomer, given the overwhelming reported data mentioned previously in Section 3.1.2. 
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3.2.2 Beckmann Rearrangement 
 
Initial experiments involved the Beckmann rearrangement of the indanone oxime, (S)-
116, with AlCl3 (3 equiv.),468 both at room temperature and at reflux in acetonitrile. 
Additionally, changing the catalyst to phenyl dichlorophosphate (1.5 equiv.),481 at both 
ambient or reflux temperature in acetonitrile yielded the same results (Scheme 93). 
 
 Scheme 93 – Attempted Beckmann rearrangement of substrate (S)-116 
 
 
In both cases, only the starting oxime, (S)-116, was observed, with some hydrolysed 
ketone product, (S)-72, also identified in small amounts. 
 
Consequently, in this study, our attention for the Beckmann reactions were performed 
in accordance with the procedure from Torisawa et al.,469 (Scheme 91), using a 
zirconium (IV) chloride catalyst and mesyl chloride as the solvent. At least 3 
equivalents of ZrCl4 were required for optimisation in accordance with the 
literature.468 
 
The oxime mesylates were formed from the corresponding indan-1-one oxime 
derivatives shown in Table 28. These were synthesised using mesyl chloride and 
triethylamine in dichloromethane at -20 °C, (Scheme 94). 
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Scheme 94 – Formation of indan-1-one oxime mesylates 
 
The mesylates were not fully characterised, but were identified using 1H NMR 
spectroscopy, formed in near quantitative yields. They were then immediately reacted 
in the Beckmann conditions presented by Torisawa.469  
 
Initial inspection of the 1H NMR spectrum of the crude reaction mixture indicated 
there were indeed two products as anticipated, however, to our surprise, upon 
comparison of the 1H NMR spectrum to those of the racemic products formed in 
previous work (Section 3.1.1) the desired products, 4-aryl-3,4-dihydroquinolin-
2(1H)-ones, were not formed at all.  
 
Separation of the two products and subsequent analysis confirmed that the 4-aryl-3,4-
dihydroquinolin-1(2H)-one product was formed, (Table 29). This was deduced upon 
comparison of the 1H NMR spectrum with the racemic compounds formed from 
Section 3.1.1, where a relatively downfield signal was observed for the CH2 cyclic 
protons, with additional 3J coupling to NH, consistent with literature.468 
 
The other product was seemingly more challenging to identify, however, analysis of 
the mass spectrum and IR, (showing the presence of a nitrile group (2217 cm-1)), it 
was found that the product was rather unexpectedly formed as a 2-(chloro-1-
arylethyl)-1-naphthonitrile derivative. These results are shown below in Table 29. 
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Table 29 – Beckmann rearrangement of 3-arylindan-1-one mesylated oximes using 
ZrCl4 in mesyl chloride 
 
 
Oxime R Groups X Groups Ratio a (a:b) 
Product (a) Product (b) 
Product  Yield % b Product 
Yield 
% b 
(S)-123 H H 37 : 63 (S)-137 30 (S)-138 55 
(S)-122 3,4,5-OCH3 F 60 : 40 (S)-135 49 (S)-136 31 
(S)-116 H Br 48 : 52 (S)-124 45 (S)-125 45 
(S)-117 4-OCH3 Br 5 : 95 (S)-126 5 (S)-127 70 
(S)-119 3,4,5-OCH3 Br 53 : 47 (S)-129 50 (S)-130 35 
(S)-118 2,3,4-OCH3 Br 8 : 92 - - c (S)-128 66 
(S)-120 4-F Br 32 : 68 (S)-131 28 (S)-132 52 
(S)-121 4-Cl Br 39 : 61 (S)-133 33 (S)-134 56 
a Ratio determined by NMR; b Isolated yield; c Product not isolated from crude reaction 
mixture. 
 
 
To our surprise, the reaction yielded the unusual quinolin-1(2H)-one isomer and the 
Beckmann fragmentation product. The ratio of these products varied greatly on 
substituents on the aromatic ring in addition to the X-group on the naphthyl ring, with 
no seemingly obvious trends to the obtained ratio.  
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Werner and Piguet first reported Beckmann fragmentation482 in 1904,483 where certain 
oximes, particularly oximes having a quaternary centre anti to the hydroxyl leaving 
group, are likely to undergo the rearrangement to form nitriles instead of amides.484 
This process is sometimes called a secondary Beckmann rearrangement,485 Beckmann 
fission486 or abnormal Beckmann rearrangement,487 where other oximes such as 
bridged bicyclic ketoximes,488,489 or oximes with an electron donating substituent at 
the α-carbon can also undergo fragmentation.484  
 
In some cases, the fragmentation product is largely predominant, or sometimes even 
the only product observed.438 Fragmentation occurs when the α-carbon-carbon bond 
breaks rather than migrates, and becomes increasingly important when assisted by 
neighbouring groups, either through hyperconjugation or by electron donation, when 
the ability of the α-carbon atom to support a positive charge increases. Such examples 
are quaternary carbons, benzylic carbons or α-amino / hydroxy oximes.438 
 
Examples involving indanone or tetralone derivatives have previously been reported 
with polyphosphoric acid.490 Examples of α-hydroxy oximes under Beckmann 
conditions have also been shown to give fragmented products,483,491 however, 
chlorinated substituted fragmentation products remain limited.139,492 For the results 
obtained in Table 29, a plausible mechanism is shown below in Scheme 95. 
 
 
Scheme 95 – Possible mechanism towards unexpected fragmentation product 
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Literature examples appear limited for this type of reaction involving a ring opening 
from chloride, although it has been observed before as shown in Scheme 96,451 where 
the corresponding Beckmann fragmentation products were observed unexpectedly. 
 
 
 
Scheme 96 – Beckmann rearrangement of cyclopentanone oxime in BMImBF4/PCl5 
 
The cyclopentanone oxime was formed at a much lower conversion than the 
cyclohexanone oxime, where the corresponding lactam was observed.451 It has been 
reported that the ring strain was the driving force for fragmentation.493,494  
 
Previous literature results indicated that the selection of catalyst and solvent was 
crucial for the conversion of indan-1-ones into carbostyrils,478,479,495 and thus it appears 
for the results obtained in Table 29, it is likely to be subjective to the catalyst / solvent 
conditions. Future work for the synthesis of the desired 4-aryl-3,4-dihydroquinolin-
2(H)-ones are discussed in Chapter 4. 
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3.3 Conclusion 
 In this chapter, we have shown an unexpected outcome to the Beckmann 
rearrangement of naphthyl-indan-1-one oxime mesylates, formed from the 
corresponding ketones from Chapter 2. The work herein has demonstrated a 
Beckmann fragmentation reaction under the conditions presented, with a possible 
mechanism accounting for these observations, as well as a potential enantioselective 
route to aryl-isocarbostyril derivatives. Measurement of product enantioselectivities 
will require the synthesis of racemic compounds for chiral HPLC comparison. 
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 CHAPTER 4 - CONCLUSIONS 
 
Ginsberg et al.90 published research identifying a small molecule that inhibits the 
interaction of paxillin and α4-integrin, inhibiting accumulation of leukocytes to the 
site of inflammation. The identified compounds were published and patented104 as a 
racemate, shown below in Figure 34. 
 
Figure 34 - Compound 6-B345TTQ (1) and its analogue, 6-B234TTQ (2) 
 
The synthesis of indan-1-one precursors to this compound and its analogues were 
synthesised in Chapter 2. Initial methods were attempted, including a reductive heck 
cyclisation, using the procedure from Buchwald et al,216 and a conjugate addition 
reaction,203 using an Evans auxiliary and an aryl cuprate. These methods were deemed 
unsuccessful, either from poor enantioselectivity or from being unable to cyclise the 
appropriate 3,3-diarylpropionic acid, respectively. 
 
Consequently, our attention turned to kinetic resolution, where Novozym® 435 was 
used to selectively acylate various substituted (1R,3R)-3-aryl indan-1-ols with 
excellent enantioselectivities for both the acetate and the recovered alcohol starting 
material. This provided a small catalogue of indan-1-ones which were utilised further.  
 
Unfortunately the enzyme was unable to acylate the desired naphthyl-indan-1-ol 
derivatives, and thus other kinetic resolutions methods were tried. 
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Although a ruthenium asymmetric transfer hydrogenation was attempted, resulting in 
a mixture of cis- and trans- indan-1-ol isomers with poor enantiomeric excess, the 
ruthenium catalysed oxidative kinetic resolution of racemic cis-indan-1-ols selectively 
oxidised the (1S,3S)-alcohol with excellent enantioselecitivites for both the ketone and 
the recovered alcohol starting material. The process for the synthesis of this precursor, 
(and thus similarly related analogues), is illustrated below, Scheme 97. 
 
Scheme 97 – Synthetic route towards the indan-1-one precursors; (S)-76 and (R)-76 
 
(a) AlCl3, acetyl chloride; (b) NaOCH3, CH3OH; (c) TFA, P2O5; (d) NaBH4, CH2Cl2 
/ CH3OH; (e) Oxidative Kinetic resolution, (S,S)-Ru complex, 115; (f) MnO2, CH2Cl2. 
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Transformation of the ketone to the corresponding 4-aryl-3,4-dihydroquinolin-2(1H)-
one was attempted by first synthesising the corresponding oxime mesylates, followed 
by a Beckmann reaction using ZrCl4 with MsCl as the solvent. The reaction gave a 
mixture of products shown below, (Scheme 98), and unfortunately the desired 
quinolin-2-one was not formed. 
O
Br
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Scheme 98 – Beckmann results obtained from using ZrCl4 in MsCl4 
(a) MsCl, NEt3; (b) ZrCl4, MsCl 
 
The ratio of nitrile-product and isoquinolin-1-one product varied greatly on the 
substituents. Other catalyst sytems were tried, but only the starting material oxime and 
the corresponding ketone were isolated upon workup. 
 
Possible improvements on this transformation to yield the desired quinolin-2(1H)-one 
are discussed in the following section.  
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4.1 Future Work 
 
In order to transform the enantiomerically enriched indan-1-one precursors from 
Chapter 2 into the corresponding quinolin-2(1H)-ones, either alternate Beckmann 
conditions could be tested, or other methods could be attempted. 
 
An alternate synthetic approach could be to perform a Schmidt reaction. Conley496 
reported a polyphosphoric acid-catalysed Schmidt rearrangement, Scheme 99. 
 
 
Scheme 99 – Schmidt reaction on indan-1-one using PPA496 
 
This method reported the exclusive formation of the 3,4-dihydroquinolin-2(1H)-one 
(dihydrocarbostyril) under the conditions presented. The temperature appears to be 
crucial to this Schmidt reaction, where the rearrangement was found to proceed 
extremely slowly below 50 °C.  
 
However, it appears that this transformation remains very catalyst specific, as it was 
reported that using concentrated HCl instead of polyphosphoric acid gave a ratio of 
products, with the desired 3,4-dihydroquinolin-2-(1H)-one being the minor 
product.497,498 
 
Scheme 100 – Schmidt reaction of indan-1-one using conc. HCl497 
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Fortunately, it has been reported that performing the reaction in polyphosphoric acid 
(Scheme 99),496 trichloroacetic acid499 or sulphuric acid,500 instead of concentrated 
HCl, yields the desired 3,4-dihydroquinolin-2-(1H)-one as the major isomer. 
 
Synthesis of a variety of racemic 4-aryl-3,4-dihydroquinolin-2(1H)-ones via the two-
step process shown in  Section 3.1.1, provide an attractive opportunity to obtain both 
enantiomers by preparative chiral HPLC, albeit, analytical chiral HPLC testing would 
be required, where substrate separation could vary dramatically. 
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 CHAPTER 5 - EXPERIMENTAL 
 
5.1.1 General Experimental Information 
 
NMR spectra were recorded on Bruker Advance DRX 250, 300, 400, 500 and 600 and 
700 MHz spectrometers at room temperature (298 K). Chemical shifts are reported in 
parts per million (ppm), related to (CH3)4Si (TMS), for 1H and 13C spectra. 19F NMR 
spectra are referenced to an internal reference, trifluoroacetic acid, with 31P NMR 
being internally referenced to phosphoric acid. Coupling constants (J) are reported in 
Hertz (Hz) and are reported to the nearest 0.5 Hz. Multiplicities are given as multiplet 
(m), singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin.), sextet (sext.) and 
broad singlet (br. s). 1H and 13C assignments were established on the basis of COSY, 
DEPT, HMQC and HMBC correlations.  
 
All mass spectra are High Resolution Mass Spectra (HRMS) unless specified 
otherwise, and were obtained from either Dr Lijiang Song and Mr Philip Aston using 
a Bruker micro-TOF ESI spectrometer at the University of Warwick. Low Resolution 
Mass spectra (LRMS) were obtained via an Agilent 6130b ESI Quad mass 
spectrometer. Elemental analysis was peformed by Warwick Analytical Services. 
 
Melting points were determined on a Stuart Scientific melting point apparatus and are 
uncorrected. Infra-red spectra were recorded using either a Perkin Elmer Spectrum 
100 FT-IR spectrometer or an Alpha Bruker Platinum ATR single reflection diamond 
ATR module.  
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Chiral HPLC was performed on a HPLC instrument consisting of a Varian Prostar 335  
Photodiode Array Detector, a Varian Prostar Solvent Delivery Module and a Varian 
Prostar 420 Autosampler. Optical rotations were recorded on an Optical Activity Ltd. 
AA-1000 millidegree auto-ranging polarimeter (589 nm). Specific rotations are given 
in units of 10-1 deg cm2 g-1. Concentrations (c) are given in grams / Litre (g/L). 
 
Microwave reactions were performed on a Personal Chemistry (now Biotage®) Emrys 
Optimizer with Pyrex reaction vessels equipped with Teflon stir bars and Teflon 
coated reaction vessel caps. These were secured with aluminium crimp seals. 
 
Room temperature (rt) refers to ambient temperature (20-22 °C), 5 °C refers to a cold 
water bath and 0 °C refers to an ice-slush bath. Heated experiments were conducted 
using thermostatically controlled oil baths or heating blocks. Reactions involving 
moisture sensitive compounds were performed under an atmosphere of dry, oxygen-
free-nitrogen and in dry solvents. Solvent was dried prior to use using the methods 
described in Purification of Laboratory Chemicals, 6th Ed., and used accordingly.355 
The use of ‘petroleum ether’ refers to ‘petroleum ether (40-60 °C)’ unless otherwise 
stated. pH 2 buffer is an aqueous solution (0.25 M H2SO4 and 0.75 M Na2SO4). Thin 
layer chromatography (TLC) analysis was performed on aluminium sheets coated with 
0.2 mm silica gel (DC Kieselgel 60 F254, Merck). Visualisation was effected by UV 
light (254 nm) or by potassium permanganate solution followed by heating. Silica 
column chromatography was performed on 40-60 Å silica gel. 
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Single X-ray crystal structures were performed by Dr Guy J. Clarkson on an Oxford 
Diffraction Gemini XRD which was obtained with support from Advantage West 
Midlands and part funded by the European Regional Development Fund. 
 
Novozym® 435 (immobilised Candida Antartica B) was supplied by Novo Nordisk 
and has an activity of 7550 PLU/G. 
 
Naming of compounds has been performed in accordance with IUPAC guidelines.501 
(R) and (S) configurations were assigned according to the Cahn-Ingold-Prelog priority 
rules.502 The following is an example of this applied numbering system (Figure 35): 
 Figure 35 – Examples of the applied compound characterisation numbering system503,504 
(In some cases, equivalent hydrogen / carbon atoms are labelled with the lowest assignment.) 
 
NMR assignments for each compound are using the following notations: 
 
1H NMR Assignments: 
ArH-# (aromatic hydrogen), CHX-# (non-aromatic hydrogens), where # denotes the 
position of the carbon attached, according to the IUPAC guidelines. 
 13C NMR Assignments: 
CAr-# (aromatic carbon bearing no hydrogens), CArH-# (aromatic carbon bearing a 
hydrogen), CH-# (non-aromatic carbon, bearing a hydrogen), C-# (non-aromatic 
carbon, bearing no hydrogens). 
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5.1.1.1 Purification of Purchased Chemicals 
 
Palladium (II) Acetate 
The following procedure was performed in accordance with previous literature.505 
Pd(OAc)2 was dissolved in minimal refluxing benzene (0.5 g Pd(OAc)2 / 8.0 mL 
benzene). A black precipitate was removed from the refluxing solution by vacuum 
filtration. The resulting solution was cooled to room temperature and amber crystals 
began to form immediately. After 1 hour the solution was filtered to give the 
recrystallised Pd(OAc)2 as gold plates. The recrystallised Pd(OAc)2 was then stored 
under a nitrogen atmosphere.  
 
NMR 1H spectrometric data consistent in change with literature values.505 
 
Trifluoroacetic Acid 
 
The following procedure was performed in accordance with previous literature.355 To 
a stirred flask of trifluoroacetic acid (100 mL) under nitrogen was added P2O5 (~10.00 
g), and the reaction mixture was stirred overnight. Trifluoroacetic acid was then 
distilled off and stored under nitrogen.  
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5.2 Experimental for Chapter 2 
5.2.1 Conjugate Addition Reaction 
(E)-3-(3′,4′,5′-Trimethoxyphenyl)acrylic acid  
 
4 
 
 
The following procedure was performed in accordance with previous literature.222 To 
a solution of 3,4,5-trimethoxybenzaldehyde (3.14 g, 16 mmol) in pyridine (20 mL) 
was added malonic acid (2.08 g, 20 mmol) in pyridine (20 mL) and two drops of 
piperidine. The reaction mixture was refluxed for 16 hours and evaporated to remove 
pyridine. The residue was suspended in H2O (30 mL) and extracted with EtOAc (2 x 
50 mL). The solution was further washed with NaHCO3, brine, dried over MgSO4 
and the solvent was removed in vacuo. The crude solid was washed with diethyl ether 
and dried, yielding a beige solid (3.28 g, 86 %); m.p. 127-128 °C, (lit.506 127-128 °C); 
νmax/cm-1 3003 (m, COO-H, stretch), 1652 (s, C=O, stretch), 1115 (s, C-O, stretch) ; 
δH (400 MHz, d6-DMSO) 12.7-12.0 (1H, br. s, COOH), 7.52 (1H, d, J 16, CH-3), 
7.02 (2H, s, 2 x ArH-2′), 6.54 (1H, d, J 16, CH-2); δC (100 MHz, d6-DMSO) 167.8 
(C-1), 153.1 (2 x CAr-3′), 144.0 (C-3), 139.2 (CAr-4′), 129.9 (CAr-1′), 118.8 (C-2), 
105.8 (2 x CAr-2′), 60.1 (CAr-4′ OCH3), 56.0 (2 x CAr-3′ OCH3); m/z (MH+ 
C12H14O5H+ requires 239.0914) found 239.0916. 
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(E)-3-(3′,4′,5′-Trimethoxyphenyl)acryloyl chloride  
 
5 
 
 
To a solution of (E)-3-(3′,4′,5′-trimethoxyphenyl)acrylic acid, 4 (2.00 g, 8.4 mmol) 
in dry dichloromethane (30 mL), was added oxalyl chloride (0.79 g, 9.2 mmol) and 1 
drop of DMF. The solution was stirred at room temperature for 1 h and then 
evaporated to afford (E)-3-(3′,4′,5′-trimethoxyphenyl)acryloyl chloride, 5 as a dark 
yellow solid (2.13 g, 99 %); m.p. 97-98 °C; (lit.507 97-98 °C); νmax/cm-1 1744 (s, C=O, 
stretch), 1128 (s, C-O, stretch), 813 (s, C-Cl, stretch); δH (400 MHz, CHCl3) 7.76 
(1H, d, J 15.5, CH-3), 6.80 (2H, s, 2 x ArH-2′), 6.55 (1H, s, CH-2), 3.92 (3H, s, CAr-
4′ OCH3), 3.91 (6H, s, 2 x CAr-3′ OCH3); δC (100 MHz, CDCl3) 165.9 (C-1), 153.5 
(2 x CAr-3′), 150.7 (CH-3), 141.7 (CAr-4′), 128.3 (CAr-1′), 121.3 (CH-2), 106.3 (2 x 
CArH-2′), 61.0 (CAr-4′ OCH3), 56.2 (2 x CAr-3′ OCH3).  
 
(R,E)-4-phenyl-3′-(3′-(3″,4″,5″-trimethoxyphenyl)acryloyl)oxazolidin-2-
one  
 
6 
 
 
n-Butyllithium (2.5 M in hexane, 10.7 mmol) was added to a solution of (R)-(-)-4-
phenyl-2-oxazolidinone (1.57 g, 9.6 mmol)  in dry THF (30 mL) at -78 °C under 
nitrogen. The resulting mixture was stirred for 45 minutes and a solution of the 
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corresponding acyl chloride, 5, (2.50 g, 9.7 mmol) in THF (15 mL) was added at -78 
°C. The reaction mixture was stirred for an additional 30 minutes and warmed to 
ambient temperature overnight. Saturated aqueous ammonium chloride (20 mL) was 
added to the mixture and diluted with water (30 mL). After extraction with ether (3 x 
30 mL), the combined organics were dried over MgSO4, filtered and concentration in 
vacuo. The crude product was subsequently purified by column crystallography on 
silica gel (ethyl acetate : hexane 1 : 2) yielding a white solid (2.90 g, 78 %); m.p. 138-
139 °C; [હ]ࡰ૜૚ (c 0.2, CHCl3) +8.1; νmax/cm-1 3100 (m, CAr-H, stretch), 1776 (s, C=O, 
stretch), 1246 (s, C-O, stretch); δH (400 MHz, d6-DMSO) 7.74 (1H, d, J 15.5, CH-3′), 
7.63 (1H, d, J 15.5, CH-2′), 7.44-7.39 (2H, m, 2 x ArH-2″′), 7.38-7.31 (3H, m, 2 x 
ArH-3″′ & ArH-4″′), 7.00 (2H, s, 2 x ArH-2″), 5.61 (1H, dd, J 8.5, 4, CH-4), 4.82 
(1H, t, J 8.5, CHH-5), 4.23 (1H, dd, J 8.5, 4, CHH-5), 3.83 (6H, s, 2 x CAr-3″ OCH3), 
3.72 (3H, s, CAr-4″ OCH3); δC (100 MHz, d6-DMSO) 164.1 (CAr-1), 153.9 (CAr-1′), 
153.1 (2 x CAr-3′), 144.9 (CH-3′), 139.8 (CAr-4″), 139.7 (CAr), 129.8 (CAr), 128.8 
(CArH), 128.0 (CArH), 125.8 (CArH), 117.0 (CH-2′), 105.8 (2 x CArH-2″), 70.2 (CH2-
5), 60.1 (CAr-4″ OCH3), 57.2 (CH-4), 56.0 (2 x CAr-3 OCH3); m/z (MNa+ 
C21H21NO6Na+ requires 406.1261) found 406.1259. 
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(S,E)-4-phenyl-3′-(3′-(3″,4″,5″-trimethoxyphenyl)acryloyl)oxazolidin-2-
one  
 
7 
 
 
The reaction procedure was performed in accordance with the previous compound, 
using the (S)-(+)-4-phenyl-2-oxazolidinone (1.57 g, 9.6 mmol) enantiomer instead, 
yielding a white crystalline solid (2.76 g, 74 %); Spectroscopic data similar to that of 
other enantiomer; [હ]ࡰ૜૚ (c 0.2, CHCl3) -9.0. 
 
2-Naphthylmagnesium Bromide Solution  
 8 
 
 
The following procedure was performed in accordance with previous literature. 
Under nitrogen atmosphere, a three-necked, round bottom flask was fitting with a 
reflux condenser, pressure-equalized addition funnel, stirring bar and a thermometer, 
was charged with magnesium turnings, (0.43 g, 18 mmol) and two iodine crystals. 
Then 30 mL of a solution of 2-bromonaphthalene (3.55 g, 17.0 mmol) in THF (20 
mL) was added. As soon as the reaction has started, the remainder of the THF solution 
was added at such a rate that a gentle reflux was maintained. After complete addition, 
reflux was continued for 1 hour by heating with an oil bath. Finally, the reaction 
mixture was allowed to cool to room temperature prior to further use. Note: Although 
titration methods were available to determine the concentration,508,509 upon testing 
this with the aforementioned Grignard reagent, the colour change was very 
insignificant and thus difficult to observe. Consequently, a large excess of Grignard 
reagent was used in further synthesis steps. 
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(R)-3-((S)-3′-(naphthalen-2″-yl)-3′-(3″′,4″′,5″′-
trimethoxyphenyl)propanoyl)-4-phenyloxazolidin-2-one  
 
9 
 
 
The following procedure was performed using the method from previous literature.510 
To a pre-cooled (-40 °C) solution of copper(I)bromide methylsulfide complex (1.21 
g, 5.9 mmol), in THF (20 mL) was added dimethylsulfide (6 mL), followed by the 
slow addition of 2-naphthylmagnesium bromide solution, 8, (~12 mmol). The 
mixture was then allowed to warm to -20 °C and a solution of (R,E)-4-phenyl-3′-(3′-
(3″,4″,5″-trimethoxyphenyl)acryloyl)oxazolidin-2-one, 6, (1.45 g, 3.9 mmol), was 
added drop-wise over 1 hour. The reaction mixture was then stirred at -20 °C for 1 
hour, and stirred overnight at room temperature. The reaction mixture was poured 
into saturated aqueous ammonium chloride (100 mL), the mixture being extracted 
with ethyl acetate (3 x 30 mL). The combined organic fractions were washed with 
ammonium hydroxide (2 x 15 % aq. 40 mL), water (50 mL), brine (50 mL) and dried 
over sodium sulfate and concentrated in vacuo. The crude product was purified by 
silica column chromatography, eluting with ethyl acetate : hexane (1 : 1), giving a 
white solid (1.84 g, 61 %); m.p. 146-147 °C; [હ]ࡰ૜૚ (c 0.21, CHCl3) -51.9; νmax/cm-1 
3050 (w, CAr-H, stretch), 1771 (s, C=O, stretch), 1709 (s, C=O, stretch), 1124 (s, 
C=O, stretch); δH (400 MHz, CDCl3) 7.80-7.71 (3H, m, 3 x ArH), 7.66 (1H, s, ArH-
1′), 7.48-7.41 (2H, m, 2 x ArH), 7.37 (1H, dd, J 8.5, 2, ArH), 7.16 (1H, ddd, J 7.5, 4, 
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1, ArH), 7.09-7.04 (2H, m, 2 x ArH), 7.00-6.96 (2H, m, 2 x ArH), 6.54 (2H, s, 2 x 
ArH-2″′), 5.34 (1H, dd, J 8.5, 4, CH-4), 4.72 (1H, t, J 8, CH-3′), 4.60 (1H, t, J 9, 
CHH-5), 4.17 (1H, dd, J 9, 4, CHH-5), 3.86 (2H, dd, J 9, 8, CHH-2′), 3.80 (3H, s, 
CAr-4″′ OCH3), 3.79 (6H, s, 2 x CAr-3″′ OCH3); δC (100 MHz, CDCl3) 171.0 (CAr-1), 
153.8 (2 x CAr-3″′), 153.2 (CAr-1′), 140.5 (CAr), 138.7 (CAr), 138.4 (CAr), 132.5 (CAr), 
132.3 (CAr), 129.1 (CArH), 129.0 (CArH), 128.5 (CArH), 128.3 (CArH), 127.9 (CArH), 
127.6 (CArH), 126.4 (CArH), 126.1 (CArH), 125.8 (CArH), 125.7 (CArH), 125.5 (CArH), 
105.1 (2 x CArH-2″′), 69.9 (CH-5), 60.8 (CAr-4″′ OCH3), 57.7 (CH-4), 56.2 (2 x CAr-
3″′ OCH3), 47.2 (CH-3′), 40.7 (CH2-2); m/z (MNa+ C31H29NO6Na+ Requires 
534.1887) found 534.1888. 
 
 
(S)-3-((R)-3′-(naphthalen-2″-yl)-3′-(3″′,4″′,5″′-
trimethoxyphenyl)propanoyl)-4-phenyloxazolidin-2-one 
 
10 
 
 
The reaction procedure was performed in accordance with the previous compound, 
using the (S,E)-4-phenyl-3′-(3′-(3″,4″,5″-trimethoxyphenyl)acryloyl)oxazolidin-2-
one, 7 (1.45 g, 3.9 mmol) enantiomer instead, yielding a white crystalline solid (2.96 
g, 63 %); Spectroscopic data similar to that of other enantiomer; [હ]ࡰ૜૚ (c 0.20, 
CHCl3) +52.5. 
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(S)-3-(naphthalen-2′-yl)-3-(3″,4″,5″-trimethoxyphenyl)propanoic acid  
 
11 
 
 
To a solution of (R)-3-((S)-3′-(naphthalen-2″-yl)-3′-(3″′,4″′,5″′-
trimethoxyphenyl)propanoyl)-4-phenyloxazolidin-2-one, 9 (400 mg, 0.8 mmol) in a 
THF : H2O, (4 : 1, 40 mL), at 0 °C, was added hydrogen peroxide solution (30 % w/w 
in water, 0.4 mL), followed by lithium hydroxide (28 mg, 1.2 mmol), and the reaction 
was stirred at room temperature for 2 hours. Saturated aqueous sodium sulfite was 
added and the organic solvents were removed in vacuo. The  aqueous phase was 
washed with dichloromethane (2 x 30 mL), then cooled to 0 °C, acidified to pH 2 
with sulfate buffer and the product extracted with dichloromethane (5 x 20 mL). The 
combined organic layers were dried with MgSO4 and concentrated in vacuo, to give 
the title compound as a white solid (244 mg, 85 %); m.p. 183-184 °C; [હ]ࡰ૜૚ (c 0.2, 
CHCl3) +1.5; νmax/cm-1 3674 (m, COO-H, stretch), 1693 (s, C=O, stretch), 1120 (s, 
C-O, stretch); δH (400 MHz, CDCl3) 7.86-7.76 (3H, m, 3 x ArH), 7.71 (1H, s, ArH-
1′), 7.53-7.42 (2H, m, 2 x ArH), 7.35 (1H, d, J 8.5, ArH), 6.49 (2H, s, 2 x ArH-2″), 
4.65 (1H, t, J 8, CH-3), 3.82 (3H, s, CAr-4″ OCH3), 3.80 (6H, s, 2 x CAr-3″ OCH3), 
3.26-3.10 (2H, m, 2 x CHH-2); δC (100 MHz, CDCl3) 177.0 (CAr-1), 153.3 (2 x CAr-
3″), 140.4 (CAr), 138.8 (CAr), 136.7 (CAr), 133.4 (CAr), 132.3 (CAr), 128.4 (CArH), 
127.9 (CArH), 127.6 (CArH), 126.3 (CArH), 126.2 (CArH), 125.8 (CArH), 125.5 (CArH), 
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104.8 (2 x CArH-2″), 60.8 (CAr-4″ OCH3), 56.1 (2 x CAr-3″ OCH3), 46.9 (CH-3), 40.4 
(CH2-2); m/z (MNa+ C22H22O5Na+ Requires 389.1359) found 389.1358. 
 
 
(R)-3-(naphthalen-2′-yl)-3-(3″,4″,5″-trimethoxyphenyl)propanoic acid  
 
12 
 
 
The reaction procedure was performed in accordance with the previous compound, 
using (S)-3-((R)-3′-(naphthalen-2″-yl)-3′-(3″′,4″′,5″′-trimethoxyphenyl)propanoyl)-
4-phenyloxazolidin-2-one, 10 (400 mg, 0.8 mmol), yielding a white crystalline solid 
(249 mg, 87 %); Spectroscopic data similar to that of other enantiomer; [હ]ࡰ૜૚ (c 0.2, 
CHCl3) -2.5. 
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5.2.2 Asymmetric Reductive Heck Cyclisation 
 
5.2.2.1 Claisen-Schmidt Condensation Reaction for the General Formation 
of Substituted-Bromochalcones 
 
The following procedure was performed in accordance with previous literature.146 To 
a solution of 2′-bromoacetophenone (2.5 mmol) and substituted benzaldehyde (2.5 
mmol) in dry methanol (20 mL), was added sodium methoxide (3.8 mmol) in dry 
methanol (20 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 5 hours and 
warmed to room temperature overnight. If a precipitate formed, this was filtered, 
washed with methanol and dried under vacuum. If no precipitate formed, aqueous HCl 
(2 M, 20 mL) was added slowly and the mixture was evaporated to near dryness under 
reduced pressure. The residue was suspended in saturated NaHCO3 (50 mL) and 
extracted with diethyl ether (3 x 100 mL). The organic layer was washed with brine, 
dried over MgSO4 and concentrated in vacuo. If cis/trans isomers were present, the 
crude mixture was dissolved in methanol and DABCO (5 mol%) was added. The 
reaction was stirred at reflux for 2 hours, cooled and concentrated in vacuo. The 
product was re-dissolved in diethyl ether ether (50 mL), washed with NaHCO3 (50 
mL), dried over MgSO4 and concentrated in vacuo. Further purification for all 
compounds was either performed with silica column chromatography or recrystallised 
as mentioned specifically. 
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(E)-1-(2′-Bromophenyl)-3-phenylprop-2-en-1-one  
 
13 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.1, using 2′-bromoacetophenone (1.69 mL, 12.5 mmol), benzaldehyde 
(1.28 mL, 12.5 mmol) and sodium methoxide (0.75 g, 18.8 mmol). The crude product 
was subjected to DABCO/methanol isomerism as mentioned in the general 
procedure. The trans-crude product then purified by silica column chromatography, 
eluting with diethyl ether : petroleum ether (1 : 4), yielding the title compound as a 
yellow oil (0.98 g, 91 %); νmax/cm-1 3059 (w, CAr-H, stretch), 1645 (s, C=O, stretch); 
δH (400 MHz, CDCl3) 7.65 (1H, dd, J 7.5, 1, ArH-3′), 7.60 (2H, dd, J 7, 3, 2 x ArH-
2″), 7.47-7.30 (7H, m, 2 x ArH-3″, ArH-4′, ArH-5′, ArH-6′, ArH-4″, CH-3), 7.10 
(1H, d, J 16, CH-2); δC (100 MHz, CDCl3) 194.6 (C-1), 146.5 (CH-3), 141.0 (CAr-
1′), 134.3 (CAr-1″), 133.3 (CArH-3′), 131.3, 130.8, 129.1, 128.9, 128.5, 127.3 (CArH-
4′, CArH-5′, CArH-6′, 2 x CArH-2″, 2 x CArH-3″ & CArH-4″), 126.0 (CH-2), 119.4 (CAr-
2′); m/z (MNa+ C15H1179BrONa+ Requires 308.9885) found 308.9883, MNa+ 
C15H1181BrONa+ Requires 3310.9866) found 310.9864. Data consistent with those 
previously reported.216 
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(E)-1-(2′-Bromophenyl)-3-(4″-methoxyphenyl)prop-2-en-1-one  
Br
O
O
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.1, using 2′-bromoacetophenone (0.34 mL, 2.5 mmol), 4-
methoxybenzaldehyde (0.31 mL, 2.5 mmol) and sodium methoxide (0.20 g, 3.8 
mmol). The crude product was purified by silica column chromatography, eluting 
with diethyl ether : petroleum ether (1 : 4), yielding the title compound as a yellow 
solid (0.61 g, 76 %); m.p. 89-90 °C, (lit.511 88-90 °C); νmax/cm-1 3062 (w, CAr-H, 
stretch), 1591 (s, C=O, stretch), 1253 (s, C-O, stretch); δH (400 MHz, CDCl3) 7.63 
(1H, d, J 8, ArH-3′), 7.50 (2H, d, J 9, 2 x ArH-2″), 7.41-7.35 (3H, m, ArH-5′, ArH-
6′, CH-3), 7.31 (1H, ddd, J 8, 6, 3, ArH-4′), 6.96 (1H, d, J 16, CH-2), 6.91 (2H, d, J 
9, 2 x ArH-3″), 3.83 (3H, s, CAr-4″ OCH3); δC (100 MHz, CDCl3) 194.7 (C-1), 161.9 
(CAr-4″), 146.6 (CH-3), 141.3 (CAr-1′), 133.3 (CArH-3′), 131.1 (CArH-4′), 130.4 (2 x 
CArH-2″), 129.0, 127.2 (CArH-5′ & CArH-6′), 127.0 (CAr-1″), 123.9 (CH-2), 119.4 
(CAr-2′), 114.4 (2 x CArH-3″), 55.4 (CAr-4″ OCH3); m/z (MNa+ C16H1379BrO2Na+ 
requires 338.9991) found 338.9991, (MNa+ C16H1381BrO2Na+ requires 340.0004) 
found 340.0006. Data consistent with those previously reported.216 
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(E)-1-(2′-Bromophenyl)-3-(3″,4″-dimethoxyphenyl)prop-2-en-1-one  
 
15 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.1, using 2′-bromoacetophenone (0.34 mL, 2.5 mmol), 3,4-
dimethoxybenzaldehyde (0.42 g, 2.5 mmol) and sodium methoxide (0.20 g, 3.8 
mmol) and was used without further purification. The title compound was formed as 
a yellow powder  (0.70 g, 80 %); m.p. 112-113 °C; νmax/cm-1 2971 (w, CAr-H, stretch), 
1633 (s, C=O, stretch), 1125 (s, C-O, stretch); δH (400 MHz, CDCl3) 7.64 (1H, d, J 
8, ArH-3′), 7.41-7.40 (2H, m, ArH-5′, ArH-6′), 7.36-7.30 (2H, m, CH-3, ArH-4′), 
7.13 (1H, dd, J 8.5, 1.5, ArH-6″), 7.08 (1H, d, J 1.5, ArH-2″), 6.95 (1H, d, J 16, CH-
2), 6.87 (1H, d, J 1.5, ArH-5″), 3.92 (3H, s, CAr-4″ OCH3), 3.91 (3H, s, CAr-3″ OCH3); 
δC (100 MHz, CDCl3) 194.8 (C-1), 151.7 (CAr-4″), 149.3 (CAr-3″), 147.0 (CH-3), 
141.4 (CAr-1′), 133.3 (CArH-3′), 131.1 (CArH-4′), 129.0, 127.3, 127.3 (CArH-5′, CArH-
6′ & CAr-1″), 124.2 (CH-2), 123.5 (CArH-6″), 119.4 (CAr-2′), 111.1 (CArH-5″), 110.0 
(CArH-2″), 56.0 (CAr-4″ OCH3), 56.0 (CAr-3″ OCH3); m/z (MNa+ C17H1579BrO3Na+ 
requires 369.0097) found 369.0097, (MNa+ C17H1581BrO3Na+ requires 371.0076) 
found 371.0077. 
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(E)-1-(2′-Bromophenyl)-3-(3″,4″,5″-trimethoxyphenyl)prop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.1, using 2′-bromoacetophenone (3.39 mL, 25.1 mmol), 3,4,5-
trimethoxybenzaldehyde (4.93 g, 25.1 mmol) and sodium methoxide (2.04 g, 37.7 
mmol) and was used without further purification. The title compound was formed as 
a white solid (7.39 g, 78 %); m.p. 124-127 °C; νmax/cm-1 2840 (w, CAr-H, stretch), 
1638 (s, C=O, stretch), 1122 (m, C-O, stretch); δH (400 MHz, CDCl3) 7.65 (1H, d, J 
8, ArH-3′), 7.43-7.41 (2H, m, ArH-5′, ArH-6′), 7.36-7.29 (2H, m, ArH-4′, CH-3), 
6.98 (1H, d, J 16, CH-2), 6.78 (2H, s, 2 x ArH-2″), 3.88 (3H, s, CAr-4″ OCH3), 3.88 
(6H, s, 2 x CAr-3″ OCH3); δC (100 MHz, CDCl3) 194.7 (C-1), 153.5 (2 x  CAr-3″), 
146.8 (CH-3), 141.2 (CAr-1′), 140.7 (CAr-4″), 133.4 (CArH-3′), 131.3 (CArH-4′), 129.8 
(CAr-1″), 129.1, 127.3 (CArH-5′ & CArH-6′), 125.5 (CH-2), 119.4 (CAr-2′), 105.7 (2 x 
CArH-2″), 61.0 (2 x CAr-3″ OCH3), 56.2 (CAr-4″ OCH3); m/z (MNa+ C18H1779BrO4Na+ 
requires 399.0202) found 399.0206, (MNa+ C18H1781BrO4Na+ requires 401.0183) 
found 401.0187. 
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(E)-1-(2′-Bromophenyl)-3-(4″-cyanophenyl)prop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.1, using 2′-bromoacetophenone (0.34 mL, 2.5 mmol), 4-
cyanobenzaldehyde (0.33 g, 2.5 mmol) and sodium methoxide (0.20 g, 3.8 mmol) 
and was used without further purification. The title compound was formed as a yellow 
solid (0.53 g, 67 %); m.p. 130-131 °C, (lit.512 130-131 °C); νmax/cm-1 2987 (w, CAr-
H, stretch), 2226 (m, C≡N, stretch), 1702 (s, C=O, stretch); δH (400 MHz, CDCl3) 
7.70-7.64 (5H, m, 2 x ArH-2″, 2 x ArH-3″, ArH-3′), 7.47-7.41 (3H, m, ArH-5′, ArH-
6′, CH-3), 7.36 (1H, ddd, J 8.5, 6.5, 2.5, ArH-4′), 7.20 (1H, d, J 16, CH-2); δC (100 
MHz, CDCl3) 193.7 (C-1), 143.0 (CH-2). 140.6 (CAr-1′), 138.7 (CAr-1″), 133.5 (CArH-
3′), 132.7 (2 x CArH-3″), 131.9 (CArH-4′), 128.8 (2 x CArH-2″), 129.4, 128.8, 127.5, 
(CArH-5′, CArH-6′ & CH-2), 119.5 (CAr-2′), 118.3 (CAr-4″ CN), 113.9 (CAr-4″); m/z 
(MH+ C16H1079BrNOH+ requires 312.0019) found 312.0017, (MH+ C16H1081BrNOH+ 
requires 313.9999) found 313.9996. Data consistent with those previously 
reported.216 
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(E)-1-(2′-Bromophenyl)-3-(4″-chlorophenyl)prop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.1, using 2′-bromoacetophenone (0.34 mL, 2.5 mmol), 4-
chlorobenzaldehyde (0.35 g, 2.5 mmol) and sodium methoxide (0.20 g, 3.8 mmol) 
and was used without further purification. The title compound was formed as a white 
solid (0.48 g, 59 %); m.p. 102-103 °C, (lit.511 101-103 °C); νmax/cm-1 3052 (w, CAr-
H, stretch), 1640 (s, C=O, stretch); δH (400 MHz, CDCl3) 7.65 (1H, d, J 8.5, ArH-3′), 
7.49 (2H, d, J 8, 2 x ArH-2″), 7.43-7.32 (6H, m, 2 x ArH-3″, CH-3, ArH-5′, ArH-6′ 
& ArH-4′), 7.07 (1H, d, J 16, CH-2); δC (100 MHz, CDCl3) 194.3 (C-1), 144.5 (CH-
3), 141.0 (CAr-1′), 136.8 (CAr-4″), 133.5 (CArH-3′), 132.9 (CAr-1″), 131.5 (CArH-4′), 
129.7, 129.3, 129.2, 127.4 (2 x CArH-3″, 2 x CArH-2″, CArH-5′ & CArH-6′), 126.5 
(CH-2), 119.5 (CAr-2′); m/z (MH+ C15H1179Br35ClOH+ requires 320.9676) found 
320.9679, (MH+ C15H1181Br35ClOH+ requires 322.9655) found 322.9657. 
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2-Bromo-3,4-dihydronaphthalene-1-carbaldehyde  
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The aforementioned product was synthesised in accordance with previous 
literature.226 Dry DMF (0.79 mL, 10.3 mmol) was cooled to 0 °C in dry chloroform 
(30 mL) and phosphorous tribromide (0.81 mL, 8.6 mmol) was added dropwise. The 
mixture was stirred at 0 °C for 1 hour to give a pale yellow suspension. A solution of 
β-tetralone (0.45 mL, 3.4 mmol) in dry chloroform (20 mL) was added to the yellow 
suspension, and the mixture was heated at reflux for 1 hour. The reaction mixture was 
then cooled to 0 °C and made basic with saturated aqueous NaHCO3 solution. The 
resulting mixture was extracted with dichloromethane, dried with MgSO4 and 
concentrated in vacuo. The residue was then purified using flash column 
chromatography, eluting with diethyl ether : petroleum ether (1 : 4) yielded the 
product as a yellow oil which solidified upon standing (0.73 g, 90 %); m.p. 25-26 °C, 
(lit.226 26-27 °C); νmax/cm-1 2946 (w, CAr-H, stretch), 1681 (s, C=O, stretch); δH (400 
MHz, CDCl3) 10.33 (1H, s, CH-1), 7.99-7.97 (1H, m, ArH), 7.29-7.25 (2H, m, 2 x 
ArH), 7.23-7.17 (1H, m, ArH), 3.08-3.04 (2H, m, CH2-4), 2.97-2.92 (2H, m, CH2-3); 
δC (100 MHz, CDCl3) 192.6 (C-1 COH), 145.0 (C-1), 134.6, 132.7, 129.9 (C-2, 2 x 
CAr), 128.3 (CArH), 127.4 (CArH), 126.7 (CArH), 125.7 (CArH), 37.8 (CH2-3), 28.7 
(CH2-4); m/z (MNa+ C11H979BrONa+ requires 258.9723) found 258.9729, (MNa+ 
C11H981BrONa+ requires 260.9709) found 260.9703. Data consistent with those 
previously reported.226 
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2-Bromo-1-naphthaldehyde  
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The aforementioned product was synthesised in accordance with previous 
literature.226 2-Bromo-3,4-dihydro-1-naphthaldehyde, 19 (5.43 g, 22.9 mmol) and 
DDQ (5.20 g, 22.9 mmol) was heated at reflux in toluene (50 mL) for 12 hours. After 
being cooled to room temperature, the mixture was filtered through a Celite® bed and 
the filtrate was evaporated to dryness. The residue obtained was purified by silica 
column chromatography eluting with EtOAc:hexanes (1:5) yielding a beige solid 
(4.83 g, 90 %); m.p. 81-82 °C, (lit.226 80-82 °C); νmax/cm-1 3067 (w, CAr-H, stretch), 
1673 (s, C=O, stretch); δH (400 MHz, CHCl3) 10.75 (1H, s, C-1 COH), 9.09 (1H, d, 
J 8.5, ArH-5), 7.89 (1H, d, J 8.5, CH-3), 7.86 (1H, d, J 8.5, ArH-8), 7.71 (1H, d, J 
8.5, ArH-4), 7.69 (1H, ddd, J 8.5, 7, 1.5, ArH-6), 7.60 (1H, ddd, J 8, 7, 1.5, ArH-7); 
δC (100 MHz, CHCl3) 194.8 (C-1 COH), 135.4 (CArH-3), 132.9 (CArH), 131.7 (CArH 
& CAr-1), 130.7 (CArH-4), 130.5 (CAr-2), 129.7 (CArH-6), 128.4 (CArH-8), 127.2 
(CArH-7), 124.7 (CArH-5); m/z (MH+ C11H779BrOH+ requires 234.9753) found 
234.9763, (MH+ C11H781BrOH+ requires 236.9733) found 236.9742. Data consistent 
with those previously reported.226 
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1-(2′-Bromonaphthalen-1-yl)ethanol  
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The aforementioned product was synthesised in accordance with previous 
literature.513 To a solution of methylmagnesium bromide in diethyl ether (1.0 M, 8.6 
mmol) was added 2′-bromo-1-naphthaldehyde, 20 (2.00 g, 8.6 mmol) in THF (20 mL) 
dropwise at 0 °C. The reaction mixture was gradually warmed to room temperature 
and the reaction mixture was stirred for 2 hours. The mixture was then quenched with 
aqueous NH4Cl (50 mL), washed with brine (50 mL) and dried over MgSO4. The 
solution was then concentrated in vacuo, with further purification being performed 
using silica column chromatography eluting with dichloromethane : petroleum ether 
(1 : 3), affording the product as a white solid (2.09 g, 97 %); m.p. 99-100 °C; νmax/cm-
1 3284 (s, OH, stretch), 2978 (w, CAr-H, stretch); δH (400 MHz, CHCl3) 8.83 (1H, dd, 
J 7.5, 2.5, ArH-8′), 7.83-7.80 (1H, m, ArH-5′), 7.58-7.56 (2H, m, ArH-3′ & ArH-4′), 
7.55-7.48 (2H, m, ArH-6′ & ArH-7′), 5.96 (1H, q, J 6.5, CH-1), 2.46 (1H, br. s, CH-
1 OH), 1.74 (3H, d, J 6.5, CH3-2) ; δC (100 MHz, CDCl3) 138.2 (CAr-1′), 133.7 (CAr), 
130.2 (CAr), 129.4 (CArH), 128.8 (CArH), 126.2 (CArH), 125.9 (CArH), 125.8 (CArH), 
120.4 (CAr-2′), 71.8 (CH-1), 22.3 (CH3-2); m/z (MNa+ C12H1179BrONa+ requires 
272.9885) found 272.9889, (MNa+ C12H1181BrONa+ requires 274.9865) found 
274.9878. Data consistent with those previously reported.513 
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1-(2′-Bromonaphthalen-1-yl)ethanone  
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To a solution of 1-(2′-bromonaphthalen-1-yl)ethanol, 21 (1.50 g, 6.0 mmol)  in 
CH2Cl2 (30 mL) was added Dess-Martin periodinane (3.80 g, 9.0 mmol) at room 
temperature under constant stirring for 12 hours. The resulting suspension was 
filtered, washed once with H2O and concentrated in vacuo. The crude product was 
then purified using silica column chromatography eluting with petroleum ether : 
CHCl3 (4 : 1) affording the product as a colourless oil (1.43 g, 96 %); νmax/cm-1 3059 
(w, CAr-H, stretch), 1702 (s, C=O, stretch); δH (400 MHz, CDCl3) 7.84-7.82 (1H, m, 
ArH-8′), 7.71 (1H, d, J 9, ArH-4′), 7.63-7.60 (1H, m, ArH-5′), 7.56 (1H, d, J 9, ArH-
3′), 7.54-7.51 (2H, m, ArH-6′ & ArH-7′), 2.70 (3H, s, CH3-2); δC (100 MHz, CDCl3) 
204.4 (C-1), 140.1 (CAr-1′), 132.0 (CAr), 130.2 (CArH), 130.0 (CAr), 129.4 (CArH), 
128.4 (CArH), 128.0 (CArH), 126.6 (CArH), 123.9 (CArH), 114.7 (CAr-2′), 31.9 (CH3-
2); m/z (MNa+ C12H979BrONa+ requires 270.9729) found 270.9733, (MNa+ 
C12H981BrONa+ requires 272.9709) found 272.9712. 
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(E)-1-(2′-Bromonaphthalen-1-yl)-3-phenylprop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.1, using 1-(2′-bromonaphthalen-1-yl)ethanone, 22 (0.5 g, 2.0 mmol), 
benzaldehyde (0.20 mL, 2.0 mmol) and sodium methoxide (0.16 g, 3.0 mmol) at 45 
°C for 5 hours, and was used without further purification. The title compound was 
formed as a beige solid (0.46 g, 68 %); m.p. 157-158 °C; νmax/cm-1 1635 (s, C=O, 
stretch); δH (400 MHz, CDCl3) 7.90-7.87 (1H, m, ArH-8′), 7.80 (1H, d, J 9, ArH-4′), 
7.70-7.65 (2H, m, ArH-3′ & ArH-5′), 7.56-7.47 (4H, m, ArH-6′, ArH-7′, 2 x ArH-
2″), 7.41 – 7.34 (3H, m, 2 x ArH-3″, ArH-4″), 7.28 (1H, d, J 16, CH-3), 7.12 (1H, d, 
J 16, CH-2); δC (100 MHz, CDCl3) 196.9 (C-1), 147.9 (C-3), 138.0 (CAr-1′), 134.2 
(CAr-1″), 132.0 (CAr), 131.6 (CAr), 131.1 (CArH), 130.4 (CArH), 129.6 (CArH), 128.9 
(CArH), 128.6 (CArH), 128.3 (CArH), 127.8 (CArH), 127.3 (CArH), 126.7 (CArH), 124.9 
CArH), 116.8 (CAr-2′); m/z (MH+ C19H1379BrOH+ requires 337.0223) found 337.0225, 
(MH+ C19H1381BrOH+ requires 339.0203) found 339.0205. 
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(E)-1-(2′-Bromonaphthalen-1-yl)-3-(3″,4″,5″-trimethoxyphenyl)prop-2-
en-1-one  
 
24 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.1, using 1-(2′-bromonaphthalen-1-yl)ethanone, 22 (0.4 g, 1.6 mmol), 
3′,4′,5′-trimethoxybenzaldehyde (0.32 g, 1.6 mmol) and sodium methoxide (0.13 g, 
2.4 mmol) at 45 °C for 5 hours, and was further purified by silica column 
chromatography, eluting with ethyl acetate : petroleum ether (1 : 9). The title 
compound was formed as a white solid (0.49 g, 72 %); m.p. 140-141 °C; νmax/cm-1 
1633 (s, C=O, stretch), 1136, (s, C-O, stretch); δH (400 MHz, CDCl3) 7.88 (1H, d, J 
7.5, ArH-8′), 7.79 (1H, d, J 9, ArH-4′), 7.69-7.64 (2H, m, ArH-5′, ArH-3′), 7.56-7.47 
(2H, m, ArH-6′ & ArH-7′), 7.16 (1H, d, J 16, CH-3), 7.04 (1H, d, J 16, CH-2), 6.73 
(2H, s, 2 x ArH-2″), 3.87 (3H, s, CAr-4″ OCH3), 3.84 (6H, s, 2 x CAr-3″ OCH3); δC 
(100 MHz, CDCl3) 196.7 (C-1), 153.4 (2 x CAr-3″), 147.9 (CH-3), 140.8 (CAr-4″), 
138.0 (CAr-1′), 132.0, 131.5 (CAr & CAr), 130.3 (CArH-4′), 129.6 (CArH-3′), 129.5 
(CAr-1″), 128.2 (CArH-8′), 127.7 (CArH-7′), 126.6 (CArH-6′), 126.6 (CH-2), 124.9 
(CArH-5′), 116.8 (CAr-2′), 105.77 (2 x CArH-2″), 60.9 (CAr-4″ OCH3), 56.1 (2 x CAr-
3″ OCH3); m/z (MH+ C22H1979BrO4H+ requires 427.0539) found 427.0542, (MH+ 
C22H1981BrO4H+ requires 429.0520) found 429.0520. 
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5.2.2.2 Reductive Heck Cyclisations of Substituted-bromochalcones – 
Method 1 (Microwave) 
The following procedure was performed in accordance with previous literature.216 To 
a Biotage® 5 mL microwave vial charged with a magnetic stirrer was added the 
appropriate 2′-bromochalcone (1.75 mmol), palladium (II) acetate (0.1 mmol), (R/S)-
BINAP (0.2 mmol) and triethylamine (3.5 mmol). The remaining solids were 
dissolved in DMF (2 mL/mmol bromochalcone), and the solution was purged with 
nitrogen for 10 minutes. The vial was sealed with an aluminium crimp seal, and pre-
stirred for 2 minutes. The reaction mixture was then irradiated for 40 minutes at 100 
°C under microwave irradiation (300 W). The reaction mixture was cooled to room 
temperature, diluted with ethyl acetate (20 mL / mmol of bromochalcone) and filtered 
through Celite®. The reaction mixture was then washed with aqueous HCl (1.0 M, 20 
mL/mmol of bromochalcone). The organic phase was separated, washed with brine 
(40 mL), dried over MgSO4 and concentrated in vacuo. Further purification was either 
performed with silica column chromatography or recrystallized as mentioned 
specifically. 
 
5.2.2.3 Reductive Heck Cyclisations of Substituted-bromochalcones 
Method 2-(Conventional Heating) 
The following procedure was performed in accordance with previous literature.216 
Using the same quantities as Section 5.2.2.2, the mixture was purged with nitrogen 
for 10 minutes, followed by conventional heating to 100 °C for 12 hours. The 
subsequent work-up procedure was performed as mentioned above, with the crude 
material purified by column chromatography on silica gel, as mentioned specifically. 
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3-Phenyl-2,3-dihydro-1H-inden-1-one  
 
25 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.3, using (E)-1-(2′-bromophenyl)-3-phenylprop-2-en-1-one, 13 (0.50 g, 
1.8 mmol), palladium (II) acetate (0.02 g, 0.1 mmol), rac-BINAP (0.11 g, 0.2 mmol) 
and triethylamine (0.49 mL, 3.5 mmol). Further purification of the crude material was 
performed using silica chromatography eluting with hexane : ethyl acetate (5 : 1), 
yielding the title compound as a white solid (163 mg, 45 %); m.p. 35-36 °C, (lit.216 
35 °C); νmax/cm-1 2940 (w, CAr-H, stretch), 1640 (s, C=O, stretch); δH (400 MHz, 
CDCl3) 7.81 (1H, d, J 7.5, ArH-8), 7.56 (1H, t, J 7.5, ArH-7), 7.41 (1H, t, J 7.5, ArH-
7), 7.33-7.22 (4H, m, ArH-5, ArH-4′ & 2 x ArH-3′), 7.13 (2H, d, J 7, 2 x ArH-2″), 
4.57 (1H, dd, J 8, 4, CH-3), 3.22 (1H, dd, J 19, 8, CHH-2), 2.55 (1H, dd, J 19, 4, 
CHH-2); δC (100 MHz, CDCl3) 206.0 (C-1), 157.9 (CAr), 143.7 (CAr-1′), 136.7 (CAr), 
135.1 (CArH-6), 128.9 (CArH), 127.9 (CArH), 127.6 (CArH), 127.0 (CArH), 126.9 
(CArH), 123.4 (CArH-8), 46.8 (CH2-2), 44.4 (CH-3); m/z (MNa+ C15H12ONa+ requires 
231.0780) found 231.0779. Data consistent with those previously reported.216 
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(S)-3-Phenyl-2,3-dihydro-1H-inden-1-one  
 
(S)-25 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.3, using (E)-1-(2′-bromophenyl)-3-phenylprop-2-en-1-one, 13 (0.50 g, 
1.8 mmol), palladium (II) acetate (0.02 g, 0.1 mmol), (R)-BINAP (0.11 g, 0.2 mmol) 
and triethylamine (0.49 mL, 3.5 mmol). Further purification of the crude material was 
performed using silica chromatography eluting with hexane : ethyl acetate (5 : 1), 
yielding the title compound as a white solid (145 mg, 40 %, 50 % e.e.). 
Spectroscopic data similar to that of racemate; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralcel OD-H column, 2-propanol : n-hexane = 5 : 95, 1 
mL/min., 208 nm, (R) isomer 8.97 min., (S) isomer 10.45 min.). Data consistent with 
those previously reported.216 
 
3-(4′-Methoxyphenyl)-2,3-dihydro-1H-inden-1-one  
 
26 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.3, using (E)-1-(2′-bromophenyl)-3-(4″-methoxyphenyl)prop-2-en-1-
one, 14 (0.20 g, 0.6 mmol), palladium (II) acetate (7.1 mg, 0.03 mmol), rac-BINAP 
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(40 mg, 0.06 mmol) and triethylamine (0.18 mL, 1.3 mmol). Further purification of 
the crude material was performed using silica chromatography eluting with hexane : 
ethyl acetate (5 : 1), yielding the title compound as a yellow solid (55.6 mg, 37 %); 
m.p. 70-71 °C, (lit.216 75-77 °C); νmax/cm-1 2956 (w, CAr-H, stretch), 1702 (s, C=O, 
stretch); δH (400 MHz, CDCl3) 7.80 (1H, d, J 7.5, ArH-8), 7.57 (1H, t, J 7.5, ArH-6), 
7.41 (1H, t, J 7.5, ArH-7), 7.27 (1H, d, J 7, ArH-5), 7.04 (2H, J 8.5, 2 x ArH-2′), 6.85 
(2H, d, J 8.5, 2 x ArH-3′), 4.54 (1H, dd, J 8, 4, CH-3), 3.80 (3H, s, CAr-4′ OCH3), 
3.22 (1H, dd, J 19, 8, CHH-2), 2.65 (1H, dd, J 19, 4, CHH-2); δC (100 MHz, CDCl3) 
206.1 (C-1), 158.5 (CAr-4′), 158.2 (CAr), 136.6 (CAr), 135.7 (CAr), 135.0 (CArH-6), 
128.5 (2 x CArH-3′), 127.1 (CArH-7), 126.8 (CArH-5), 123.3 (CArH-8), 114.2 (2 x 
CArH-2′), 55.2 (CAr-4′ OCH3), 46.9 (CH2-2), 43.6 (CH-3); m/z (MNa+ C16H14O2Na+ 
requires 261.0886) found 261.0893. Data consistent with those previously 
reported.216 
 
(R)-3-(4′-Methoxyphenyl)-2,3-dihydro-1H-inden-1-one  
 
(R)-26 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.3, using (E)-1-(2′-bromophenyl)-3-(4″-methoxyphenyl)prop-2-en-1-
one, 14 (0.20 g, 0.6 mmol), palladium (II) acetate (7.1 mg, 0.03 mmol), (S)-BINAP 
(40 mg, 0.06 mmol) and triethylamine (0.18 mL, 1.3 mmol). Further purification of 
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the crude material was performed using silica chromatography eluting with hexane : 
ethyl acetate (5 : 1), yielding the title compound as a yellow solid (54.1 mg, 36 %, 43 
% e.e.);  
Spectroscopic data similar to that of racemate; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralcel OJ column, 2-propanol : n-hexane = 5 : 95, 1 
mL/min., 206 nm, (S) isomer 20.80 min., (R) isomer 35.02 min.). Data consistent 
with those previously reported.216 
 
3-(3′,4′-Dimethoxyphenyl)-2,3-dihydro-1H-inden-1-one  
 
27 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.3, using (E)-1-(2′-bromophenyl)-3-(3″,4″-methoxyphenyl)prop-2-en-
1-one, 15 (0.30 g, 0.9 mmol), palladium (II) acetate (9.7 mg, 0.04 mmol), (rac)-
BINAP (54 mg, 0.09 mmol) and triethylamine (0.24 mL, 1.7 mmol). Further 
purification of the crude material was performed using silica chromatography eluting 
with dichloromethane, yielding the title compound as a yellow oil (76.5 mg, 33 %); 
νmax/cm-1 3051 (w, CAr-H, stretch), 1707 (s, C=O, stretch), 1221 (s, C-O, stretch); δH 
(400 MHz, CDCl3) 7.81 (1H, d J 7.5, ArH-8), 7.58 (1H, t, J 7.5, ArH-6), 7.42 (1H, t, 
J 7.5, ArH-7), 7.29 (1H, d, J 7.5, ArH-5), 6.81 (1H, d, J 8, ArH-5′), 6.70 (1H, dd, J 
8, 2, ArH-6′), 6.60 (1H, d, J 2, ArH-2′), 4.53 (1H, dd, J 8, 4, CH-3), 3.86 (3H, s, CAr-
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4′ OCH3), 3.80 (3H, s, CAr-3′), 3.22 (1H, dd, J 19, 8, CHH-2), 2.68 (1H, dd, J 19, 4, 
CHH-2); δC (100 MHz, CDCl3) 206.1 (C-1), 158.0 (CAr), 149.3 (CAr-3′), 148.0 (CAr-
4′), 136.7 (CAr), 136.2 (CAr), 135.1 (CArH-6), 127.8 (CArH-7), 126.8 (CArH-5), 123.3 
(CArH-8), 119.8 (CArH-6′), 111.4 (CArH-5′), 110.6 (CArH-2′), 55.9 (CAr-4′ OCH3), 
55.9 (CAr-3′ OCH3) 46.9 (CH2-2), 44.1 (CH-3); m/z (MNa+ C17H16O3Na+ requires 
291.0992) found 291.0991. Data consistent with those previously reported.216 
 
(R)-3-(3′,4′-Dimethoxyphenyl)-2,3-dihydro-1H-inden-1-one  
 
(R)-27 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.3, using (E)-1-(2′-bromophenyl)-3-(3″,4″-methoxyphenyl)prop-2-en-
1-one, 15 (0.30 g, 0.9 mmol), palladium (II) acetate (9.7 mg, 0.04 mmol), (S)-BINAP 
(54 mg, 0.09 mmol) and triethylamine (0.24 mL, 1.7 mmol). Further purification of 
the crude material was performed using silica chromatography eluting with 
dichloromethane, yielding the title compound as a yellow solid (76.0 mg, 33 %, 40 
% e.e.).  
Spectroscopic data similar to that of racemate; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralcel OD-H column, 2-propanol : n-hexane = 5 : 95, 1 
mL/min., 206 nm, (S) isomer 11.91 min., (R) isomer 13.89 min.). Data consistent with 
those previously reported.216 
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3-(3′,4′,5′-Trimethoxyphenyl)-2,3-dihydro-1H-inden-1-one  
 
28 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.3, using (E)-1-(2′-bromophenyl)-3-(3″,4″,5″-methoxyphenyl)prop-2-
en-1-one, 16 (0.30 g, 0.8 mmol), palladium (II) acetate (8.9 mg, 0.04 mmol), (rac)-
BINAP (49 mg, 0.08 mmol) and triethylamine (0.22 mL, 1.6 mmol). Further 
purification of the crude material was performed using silica chromatography eluting 
with ethyl acetate : hexane (1 : 3), yielding the title compound as a yellow solid (66.4 
mg, 28 %); m.p. 110-111 °C; νmax/cm-1 2962 (w, CAr-H, stretch), 1710 (s, C=O, 
stretch), 1232 (s, C-O, stretch); δH (400 MHz, CDCl3) 7.82 (1H, d, J 7.5, ArH-8), 7.60 
(1H, t, J 7.5, ArH-6), 7.44 (1H, t, J 7.5, ArH-7), 7.33 (1H, d, J 7.5, ArH-5), 6.31 (2H, 
s, 2 x ArH-2″), 4.51 (1H, dd, J 19, 8, CH-3), 3.79 (3H, s, CAr-4′ OCH3), 3.22 (6H, s, 
2 x CAr-3′ OCH3), 3.22 (1H, dd, J 19, 8, CHH-2), 2.70 (1H, dd, J 19, 4, CHH-2); δC 
(100 MHz, CDCl3) 205.7 (C-1), 157.5 (CAr), 153.4 (2 x CAr-3′), 139.2 (CAr-4′), 136. 
8 (CAr), 136.5 (CAr), 135.0 (CArH-6), 127.8 (CArH-7), 126.7 (CArH-5), 123.2 (CArH-
8), 104.5 (2 x CArH-2′), 60.7 (CAr-4′ OCH3), 56.0 (2 x CAr-3′ OCH3), 46.6 (CH2-2), 
44.6 (CH-3); m/z (MH+ C18H18O4H+ requires 299.1278) found 299.1277. 
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(R)-3-(3′,4′,5′-Trimethoxyphenyl)-2,3-dihydro-1H-inden-1-one  
 
(R)-28 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.3, using (E)-1-(2′-bromophenyl)-3-(3″,4″,5″-methoxyphenyl)prop-2-
en-1-one, 16 (0.30 g, 0.8 mmol), palladium (II) acetate (8.9 mg, 0.04 mmol), (S)-
BINAP (49 mg, 0.08 mmol) and triethylamine (0.22 mL, 1.6 mmol). Further 
purification of the crude material was performed using silica chromatography eluting 
with ethyl acetate : hexane (1 : 3), yielding the title compound as a yellow solid (66.4 
mg, 28 %, 19 % e.e.) 
Spectroscopic data similar to that of racemate; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralcel OD-H column, 2-propanol : n-hexane = 5 : 95, 1 
mL/min., 207 nm, (R) isomer 34.30 min., (S) isomer 41.97 min.). 
 
3-Phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one  
 
29 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.3, using (E)-1-(2′-bromonaphthalen-1-yl)-3-phenylprop-2-en-1-one, 
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23 (0.20 g, 0.5 mmol), palladium (II) acetate (6.0 mg, 0.03 mmol), (rac)-BINAP (33 
mg, 0.05 mmol) and triethylamine (0.15 mL, 1.1 mmol). Further purification of the 
crude material was performed using silica chromatography eluting with ethyl acetate 
: hexane (1 : 3), yielding the title compound as a beige solid (63 mg, 46 %); m.p. 119-
120 °C, (lit.216 115 °C); νmax/cm-1 3022 (m, CAr-H, stretch), 1695 (s, C=O, stretch); 
δH (400 MHz, CDCl3) 9.24 (1H, d, J 8.5, ArH-9), 8.00 (1H, d, J 8.5, ArH-5), 7.89 
(1H, d, J 8, ArH-6), 7.72 (1H, t, J 7.5, ArH-8), 7.59 (1H, t, J 7.6, ArH-7), 7.31 (4H, 
m, ArH-4′, ArH-4 & 2 x ArH-3′), 7.15 (2H, d, J 7, 2 x ArH-2′), 4.63 (1H, dd, J 8, 3, 
CH-3), 3.35 (1H, dd, J 19, 8, CHH-2), 2.81 (1H, dd, J 19, 3.5, CHH-2); δC (100 MHz, 
CDCl3) 206.5 (C-1), 160.7 (CAr), 143.3 (CAr-1′), 136.1 (CArH-5), 132.7 (CAr), 130.6 
(CAr), 129.1 (CArH), 128.9 (CArH), 128.0 (CArH), 127.7 (CArH), 127.0 (CArH), 126.9 
(CArH-6′), 124.2 (CArH-9), 123.8 (CArH), 47.4 (CH2-2), 44.4 (CH-3), Missing one 
CAr; m/z (MH+ C19H14OH+ requires 259.1117) found 259.1117. Data consistent with 
those previously reported.216 
 
(R)-3-Phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one  
 
(R)-29 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.3, using (E)-1-(2′-bromonaphthalen-1-yl)-3-phenylprop-2-en-1-one, 
23 (0.20 g, 0.5 mmol), palladium (II) acetate (6.0 mg, 0.03 mmol), (S)-BINAP (33 
mg, 0.05 mmol) and triethylamine (0.15 mL, 1.1 mmol). Further purification of the 
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crude material was performed using silica chromatography eluting with ethyl acetate 
: hexane (1 : 3), yielding the title compound as a beige solid (56.2 mg, 41 %, 10 % 
e.e.); 
Spectroscopic data similar to that of racemate; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralcel OD-H column, 2-propanol : n-hexane = 5 : 95, 1 
mL/min., 213 nm, (S) isomer 10.12 min., (R) isomer 14.41 min.). Data consistent with 
those previously reported.216 
 
 
3-(3′,4′,5′-Trimethoxyphenyl)-2,3-dihydro-1H-cyclopenta[a]naphthalen-
1-one  
 
30 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.3, using (E)-1-(2′-bromonaphthalen-1-yl)-3-phenylprop-2-en-1-one, 
24 (0.10 g, 0.23 mmol), palladium (II) acetate (2.6 mg, 0.01 mmol), (rac)-BINAP (15 
mg, 0.02 mmol) and triethylamine (0.07 mL, 0.5 mmol). Further purification of the 
crude material was performed using silica chromatography eluting with ethyl acetate 
: hexane (1 : 3), yielding the title compound as a yellow solid (33.4 mg, 42 %); m.p. 
148-149 °C; νmax/cm-1 2929 (w, CAr-H, stretch), 1690 (s, C=O, stretch), 1220 (s, C-
O, stretch); δH (400 MHz, CDCl3) 9.23 (1H, d, J 8.5, ArH-9), 8.03 (1H, d, J 8.5, ArH-
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5), 7.91 (1H, d, J 8, ArH-6), 7.72 (1H, ddd, J 8.5, 7, 1, ArH-8), 7.60 (1H, ddd, J 8, 7, 
1, ArH-7), 7.35 (1H, d, J 8.5, ArH-4), 6.35 (2H, s, 2 x ArH-2′), 4.57 (1H, dd, J 8, 3.5, 
CH-3), 3.84 (3H, s, CAr-4′ OCH3), 3.77 (6H, s, 2 x CAr-3′ OCH3), 3.33 (1H, dd, J 19, 
8, CHH-2), 2.81 (1H, dd, J 19, 3.5, CHH-2); δC (100 MHz, CDCl3) 206.3 (C-1), 160.4 
(CAr), 153.6 (2 x CAr-3′), 139.0 (CAr-1′), 137.0 (CAr-4′), 136.2 (CArH-5), 132.8 (CAr), 
130.7 (CAr), 129.1 (CArH-8), 129.0 (CAr), 128.1 (CArH-6), 127.0 (CArH-6), 124.2 
(CArH-9), 123.8 (CArH-4), 104.7 (2 x CArH-2′), 60.8 (CAr-4′ OCH3), 56.1 (2 x CAr-3′ 
OCH3), 47.4 (CH2-2), 44.8 (CH-3); m/z (MH+ C22H20O4H+ requires 349.1434) found 
349.1426. 
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5.2.2.4 Claisen-Schmidt Condensation Reaction for the General Formation 
of Substituted-Hydroxychalcones 
The following procedure was performed in accordance with previous literature.514 To 
a solution of 2′-hydroxyacetophenone (15 mmol) and substituted aldehyde (15 mmol) 
in ethanol (40 mL) at 50 °C was added aqueous NaOH solution (50 %, 20 mL) 
dropwise to the reaction over a period of 30 minutes. The reaction mixture was further 
stirred at 50 °C for 5 hours, and then kept at room temperature overnight. The reaction 
mixture was then diluted with ice-cold H2O (50 mL) and acidified with aqueous HCl 
(2M, 20 mL), maintaining the temperature at 0 °C. The precipitates that formed were 
filtered off, dried over MgSO4 and recrystallised as mentioned specifically if required. 
If precipitates did not form, the product was extracted in dichloromethane, washed 
twice with brine and concentration in vacuo. The residue was then purified using flash 
column chromatography eluting with CH2Cl2 : petroleum ether or recrystallised as 
mentioned specifically. 
 
 
(E)-1-(2′-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one  
 
31 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.4, using 2′-hydroxyacetophenone (2.00 g, 15 mmol), 4-
methoxybenzaldehyde (1.82 mL, 15 mmol) and aquous NaOH solution (50 %, 20 
mL), with the crude product being purified by recrystallisation in ethanol yielding a 
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yellow solid (3.32 g, 89 %); m.p. 92-93 °C, (lit.216 88-90 °C); νmax/cm-1 2970 (w, CAr-
H, stretch), 1634 (s, C=O, stretch), 1272 (s, C-O, stretch); δH (400 MHz, CDCl3) 
12.94 (1H, s, COH), 7.93 – 7.89 (2H, m, CH-3, ArH-6′), 7.63 (2H, d, J 9, 2 x ArH-
2″), 7.54 (1H, d, J 15.5, CH-2), 7.49 (1H, ddd, J 8.5, 7.5, 1.5, ArH-4′), 7.02 (1H, dd, 
J 8.5, 1, ArH-3′), 6.98-6.91 (3H, m, ArH-5′, 2 x ArH-3′′), 3.87 (3H, s, COCH3); δC 
(100 MHz, CDCl3) 193.7 (C-1), 163.5 (CAr-2′), 162.0 (CAr-4′′), 145.3 (CH-3), 136.1 
(CArH-4′), 130.5 (2 x ArH-2′′), 129.5 (CArH-6′), 127.3 (CAr-1′′), 120.1 (CAr-1′), 118.7 
(CArH-5′), 118.6 (CArH-3′), 117.6 (CH-2), 114.5 (2 x CArH-3′′), 55.4 (CAr-4′′ OCH3); 
m/z (MNa+ C16H14O3Na+ requires 277.0835) found 277.0837. Data consistent with 
those previously reported.216 
 
 
(E)-2′ -(3-(4′′-methoxyphenyl)acryloyl)phenyl trifluoromethanesulfonate  
 
32 
 
 
The following method was performed in accordance with the literature.216 To a 
solution of (E)-1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one, 31 (0.50 
g, 2.0 mmol) in pyridine (5 mL) at 0 °C, was added trifluoromethanesulfonic 
anhydride (0.43 mL, 2.6 mmol), and the reaction was stirred for 12 hours at room 
temperature. The solution was then diluted with diethyl ether (50 mL), washed with 
a saturated solution of CuSO4 (50 mL) and water (50 mL). The organic phase was 
dried over MgSO4 and the solvent evaporated under reduced pressure. The crude 
material was purified by column chromatography, eluting with ethyl acetate : hexane 
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(1 : 4) to yield the title compound as a viscous yellow oil (0.64 g, 84 %); νmax/cm-1 
2937 (w, CAr-H, stretch), 1587 (s, C=O, stretch), 1202 (s, C-O, stretch); δH (400 MHz, 
CDCl3) 7.77 (1H, dd, J 7.5, 2, ArH-6′), 7.65 (1H, d, J 16, CH-3), 7.65-7.59 (1H, m, 
ArH-4′), 7.58 (2H, d, J 9, 2 x ArH-2′′), 7.52 (td, J 7.5, 1, ArH-5′), 7.41 (1H, d, J 8, 
ArH-3′), 7.10 (1H, d, J 16, CH-2), 6.95 (2H, d, J 9, 2 x ArH-2′′), 3.88 (3H, s, CAr-4′′ 
OCH3); δC (100 MHz, CDCl3) 189.7 (C-1), 162.2 (CAr-4′′), 146.8 (CH-3), 133.5 (CAr), 
132.7 (CArH), 130.7 (CArH), 130.6 (2 x CArH-3′′), 128.4 (CArH), 127.0 (CAr), 122.5 
(CArH), 120.1 (CAr), 116.9 (CAr-2′ OSO2CF3), 114.5 (2 x CArH-2′′), 55.5 (CAr-4′′ 
OCH3); m/z (MNa+ C17H13O5SF3Na+ requires 409.0328) found 409.0322. Data 
consistent with those previously reported.216 
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5.2.2.5 Asymmetric Reductive Heck Cyclisations of Substituted-
Triflylchalcones 
 
(S)-3-(4′-Methoxyphenyl)-2,3-dihydro-1H-inden-1-one  
 
(S)-26 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.2.3, using (E)-2′-(3-(4′′-methoxyphenyl)acryloyl)phenyl 
trifluoromethanesulfonate, 32, (0.20 g, 0.5 mmol), palladium (II) acetate (5.8 mg, 
0.05 mmol), (R)-3,5-XylMeOBIPHEP (52.1 mg, 0.08 mmol) and triethylamine (0.2 
mL, 1 mmol). Further purification of the crude material was performed using silica 
chromatography eluting with hexane : ethyl acetate (5 : 1), yielding the title 
compound as a yellow solid (44 mg, 36 %, 70 % e.e.);  
Spectroscopic data similar to that of racemate; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralcel OJ column, 2-propanol : n-hexane = 5 : 95, 1 
mL/min., 206 nm, (R) isomer 20.80 min., (S) isomer 35.02 min.). Data consistent with 
those previously reported.216 
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5.2.3 Synthesis of Racemic Indan-1-ones 
 
5.2.3.1 Friedel-Crafts Acylation of 1-Halo-Naphthalenes 
The following procedure was performed using the method from previous literature.278 
To a solution of acetyl chloride (53.1 mmol) and AlCl3 (62.7 mmol) in dry CH2Cl2 
(100 mL) at -10 °C was added 1-halonaphthalene (48.3 mmol) in CH2Cl2 (1 mL/ 1 
mmol) slowly over a period of 2 hours. The reaction mixture was then stirred for 18 
hours at -10 °C and at room temperature for 2 h. The reaction mixture was then cooled 
to 0 °C and H2O was added slowly until gas evolution ceased. The organics were then 
collected, washed with saturated NaHCO3 (50 mL), dried over MgSO4 and 
concentrated in vacuo. The title compounds were used without further purification. 
 
1-(4′-Fluoronaphthalen-1-yl)ethanone  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.1, using 1-fluoronaphthalene (8.85 mL, 68.4 mmol), AlCl3 (10.95 g, 
82.0 mmol) and acetyl chloride (5.37 mL, 75.3 mmol) yielding a yellow oil (10.77 g, 
84 %); νmax/cm-1 1673 (s, C=O, stretch), 1229 (s, C-F, stretch); δH (400 MHz, CDCl3) 
8.81 (1H, d, J 8.5, ArH-8′), 8.08 (1H, d, J 8, ArH-5′), 7.89 (1H, dd, J 8, 5.5, ArH-2′), 
7.59 (1H, ddd, J 8.5, 7, 1.5, ArH-7′), 7.52 (1H, ddd, J 8, 7, 1, ArH-6′), 7.07 (1H, dd, 
J 10, 8, ArH-3′), 2.65 (3H, s, CH3-2); δC (100 MHz, CDCl3) 200.2 (C-1), 161.3 (d, 
1JCF 260, CAr-4′), 132.3 (d, 3JCF  6, CAr-8a), 131.4 (d, 4JCF 4, CAr-1′), 130.1 (d, 3JCF 10, 
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CArH-2′), 129.1 (CArH-7′), 126.8 (d, 4JCF 2, CArH-6′), 126.3 (d, 4JCF 2, CArH-8′), 124.1 
(d, 2JCF 16, CAr-4a′), 120.7 (d, 3JCF 7, CArH-5′), 108.1 (d, 2JCF 21, CArH-3′), 29.7 (CH3-
2); δF (282 MHz, CDCl3) -144.6 (ddd, J 8, 5.5, 2, CArF-4′); m/z  (MNa+ C12H9FONa+ 
requires 211.0530) found 211.0531. Characterisation data consistent with that 
previously recorded.278 
 
1-(4′-Chloronaphthalen-1-yl)ethanone  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.1, using 1-chloronaphthalene (8.39 mL, 61.5 mmol), yielding a red oil  
(12.07 g, 96 %); νmax/cm-1 1673 (s, C=O, stretch), (1180 (s, C-Cl, stretch); δH (400 
MHz, CDCl3) 8.79-8.72 (1H, m, ArH-8′), 8.38-8.30 (1H, m, ArH-5′), 7.83 (1H, d, J 
8, ArH-2′), 7.65 (2H, m, ArH-6′ & ArH-7′), 7.60 (1H, d, J 8, ArH-3′), 2.73 (3H, s, 
CH3-2); δC (100 MHz, CDCl3) 201.0 (C-1), 136.9 (CAr-4′), 134.6 (CAr-1′), 131.3 
(CAr), 131.1 (CAr), 128.7 (CArH-7′), 128.2 (CArH-2′), 127.5 (CArH-6′), 126.4 (CArH-
8′), 124.8, 124.7 (CArH-3′ & CArH-5′), 30.0 (CH3-2); m/z  (MNa+ C12H935ClONa+ 
requires 227.0234) found 227.0227. Characterisation data consistent with that 
previously recorded.278 
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1-(4′-Bromonaphthalen-1-yl)ethanone  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.1, using 1-bromonaphthalene (6.76 mL, 48.3 mmol), yielding a red oil. 
The crude product was then subject to Soxhlet extraction in refluxing methanol for 
12 hours and the filtrate was concentrated in vacuo. The residual slurry was then re-
dissolved in cold methanol and filtered repeatedly until no residual black oil persisted. 
The solution was then concentrated in vacuo yielding a beige solid (7.58 g, 62 %); 
m.p. >300 °C (decomp.); νmax/cm-1 3001 (m, CAr-H, stretch), 1673 (s, C=O, stretch); 
δH (500 MHz, CDCl3) 8.73-8.70 (1H, m, ArH-8′), 8.34-8.32 (1H, m, ArH-5′), 7.84 
(1H, d, J 8, ArH-2′), 7.74 (1H, d, J 8, ArH-3′), 7.67-7.64 (2H, m ArH-6′ & ArH-7′), 
2.74 (3H, s, CH3-2); δC (125 MHz, CDCl3) 201.2 (C-1),  135.4 (CAr-4′), 132.4 (CAr), 
131.2 (CAr), 128.7 (CArH-6′), 128.7 (CArH-2′), 128.3 (CArH-3′), 127.8 (CArH-5′), 
127.6 (CArH-7′), 126.4 (CArH-8′), 30.1 (CH3-2); m/z (MNa+ C12H979BrONa+ requires 
270.9729) found 270.9734, (MNa+ C12H981BrONa+ requires 272.9709) found 
272.9715. Characterisation data consistent with that previously recorded.278 
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5.2.3.2 Claisen-Schmidt Condensation Reaction for the General Formation 
of Substituted-Chalcones  
The following procedure was performed in accordance with previous literature.146 To 
a solution of substituted acetophenone (67 mmol) and substituted benzaldehyde (67 
mmol) in dry methanol (30 mL), was added sodium methoxide (99 mmol) in dry 
methanol (20 mL) at 0 °C. The resulting mixture was stirred at room temperature for 
2.5 hours unless otherwise stated. If a precipitate formed, this was filtered, washed 
with methanol and dried under vacuum. If no precipitate formed, aqueous HCl (2 M, 
20 mL) was added slowly and the mixture was evaporated to near dryness under 
reduced pressure. The residue was suspended in saturated NaHCO3 (50 mL) and 
extracted with diethyl ether (3 x 100 mL). The organic layer was washed with brine, 
dried over MgSO4 and concentrated in vacuo. Further purification was either 
performed with silica column chromatography or recrystallised as mentioned 
specifically.  
 
(E)-1-(3′-Methoxyphenyl)-3-phenylprop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 3′-methoxyacetophenone (9.14 mL, 67 mmol), benzaldehyde 
(6.76 mL, 67 mmol) and sodium methoxide (5.40 g, 99 mmol) and was used without 
further purification. The title compound was formed as a viscous yellow oil (14.4 g, 
91 %); νmax/cm-1 3001 (m, CAr-H, stretch), 1661 (s, C=O, stretch), 1252 (s, C-O, 
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stretch); δH (400 MHz, CDCl3) 7.71 (1H, d, J 16, CH-3), 7.50-7.47 (3H, m, 3 x ArH), 
7.44 (1H, dd, J 2.5, 1.5, ArH), 7.39 (1H, d, J 16, CH-2), 7.28-7.24 (4H, m, 4 x ArH), 
6.99 (1H, ddd, J 8, 2.5, 1, ArH), 3.71 (3H, s, CAr-3′ OCH3); δC (100 MHz, CDCl3) 
190.2 (C-1), 159.8 (CAr-6), 144.8 (C-3), 139.5 (CAr), 134.8 (CAr), 130.5 (CArH), 129.5 
(CArH), 128.9 (CArH), 128.4 (CArH), 122.0 (CH-2), 121.0 (CArH), 119.3 (CArH), 112.8 
(CArH), 55.4 (CAr-3′ OCH3); m/z (MNa+ C16H14O2Na+ requires 261.0879) found 
261.0886. 
 
 
(E)-1-(3′-Methoxyphenyl)-3-(4″-methoxyphenyl)prop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 3′-methoxyacetophenone (9.14 mL, 67 mmol), 4-
methoxybenzaldehyde (8.15 mL, 67 mmol) and sodium methoxide (5.39 g, 99 mmol) 
and was used without further purification. The title compound was formed as a yellow 
solid (15.5 g, 87 %); m.p. 50-51 °C, (lit.515 45-47 °C); νmax/cm-1 2833 (m, CAr-H, 
stretch), 1653 (s, C=O, stretch), 1247 (s, C-O, stretch); δH (400 MHz, CDCl3) 7.77 
(1H, d, J 15.5, CH-3), 7.59-7.51 (4H, m, 2 x ArH & 2 x ArH-2″), 7.40-7.34 (2H, m, 
CH-2 & ArH), 7.09 (1H, dd, J 8, 2.5, ArH-4′), 6.90 (2H, d, J 9, 2 x ArH-3″), 3.84 
(3H, s, CAr-3′ OCH3), 3.81 (3H, s, CAr-4″ OCH3); δC (100 MHz, CDCl3) 190.0 (C-1), 
161.5 (CAr-4″), 159.7 (CAr-3′), 144.5 (CH-3), 139.7 (CAr-1′), 130.1 (CArH), 129.4 
(CArH), 127.4 (CAr-1″), 120.8 (CArH), 119.6 (CH-2), 118.8 (CArH-4″), 114.3 (2 x 
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CArH-3″), 112.7 (CArH), 55.3 (CAr-3′ OCH3), 55.2 (CAr-4″ OCH3); m/z (MH+ 
C17H16O3H+ requires 269.1172) found 269.1173. 
 
 
(E)-1-(3′-Methoxyphenyl)-3-(3″,4″-dimethoxyphenyl)prop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 3′-methoxyacetophenone (9.14 mL, 67 mmol), 3,4-
dimethoxybenzaldehyde (11.07 g, 67 mmol) and sodium methoxide (5.39 g, 99 
mmol) and was used without further purification. The title compound was formed as 
a yellow solid (12.57 g, 63 %); m.p. 63-64 °C, (lit.516 66-68 °C, (ethanol)); νmax/cm-1 
2831 (m, CAr-H, stretch), 1649 (s, C=O, stretch), 1255 (s, C-O, stretch); δH (400 MHz, 
CDCl3) 7.72 (1H, d, J 15.5, CH-3), 7.55 (1H, d, J 7.5, ArH-6′), 7.51-7.48 (1H, m, 
ArH-2′), 7.35 (1H, t, J 8, ArH-5′), 7.33 (1H, d, J 15.5, CH-2), 7.17 (1H, dd, J 8.5, 2, 
ArH-6″), 7.12 (1H, d, J 8.5, ArH-2″), 7.06 (1H, dd, J 8, 2.5, ArH-4′), 6.84 (1H, d, J 
8.5, ArH-5″), 3.89 (3H, s, CAr-3″ OCH3), 3.87 (3H, s, CAr-4″ OCH3), 3.82 (3H, s, CAr-
3′ OCH3); δC (100 MHz, CDCl3) 189.9 (C-1), 159.6 (CAr-3′), 151.3 (CAr-4″), 149.0 
(CAr-3″), 144.8 (CH-3), 139.7 (CAr-1′), 129.3 (CArH-5′), 127.6 (CAr-1″), 123.0 (CArH-
6″), 120.7 (CArH-6′), 119.8 (CH-2), 118.7 (CArH-4′), 112.8 (CArH-2′), 110.9 (CArH-
5′), 109.9 (CArH-2″), 55.8 (CAr-3″ OCH3 & CAr-4″ OCH3), 55.2 (CAr-3′ OCH3); m/z 
(MH+ C18H18O4H+ requires 299.1278) found 299.1283. 
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(E)-1-(3′-Methoxyphenyl)-3-(3″,4″,5″-trimethoxyphenyl)prop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 3′-methoxyacetophenone (4.57 mL, 33 mmol), 3,4,5-
trimethoxybenzaldehyde (6.53 g, 33 mmol) and sodium methoxide (2.70 g, 50 mmol) 
and was used without further purification. The title compound was formed as a 
viscous yellow oil (3.01 g, 95 %); νmax/cm-1 2938 (m, CAr-H, stretch), 1648 (s, C=O, 
stretch), 1121 (s, C-O, stretch); δH (400 MHz, CDCl3) 7.72 (1H, d, J 15.5, CH-3), 
7.59 (1H, d, J 7.5, ArH-6′), 7.53 (1H, m, ArH-2′), 7.41 (1H, t, J 8, ArH-5′), 7.38 (1H, 
d, J 15.5, CH-2), 7.13 (1H, dd, J 8, 2.5, ArH-4′), 6.86 (2H, s, 2 x ArH-2″), 3.92 (6H, 
s, 2 x CAr-3″ OCH3), 3.90 (3H, s, CAr-4″ OCH3), 3.88 (3H, s, CAr-3′ OCH3); δC (100 
MHz, CDCl3) 190.1 (C-1), 159.8 (CAr-3′), 153.4 (CAr-4″), 144.9 (CH-3), 140.4 (2 x 
CAr-3″), 139.6 (CAr-1″), 130.3 (CAr-1′), 129.5 (CAr-5′), 121.4 (CH-2), 120.9 (CArH-
6′), 118.9 (CArH-4′), 113.0 (CArH-2′), 105.6 (2 x CArH-2″), 60.9, 56.2, 55.4 (CAr-3′ 
OCH3, CAr-4″ OCH3 & 2 x CAr-3″ OCH3); m/z (MH+ C19H20O5H+ requires 329.1384) 
found 329.1376. 
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(E)-1-(3′-Methoxyphenyl)-3-(2″,3″,4″-trimethoxyphenyl)prop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 3′-methoxyacetophenone (9.14 mL, 67 mmol), 2,3,4-
trimethoxybenzaldehyde (12.79 g, 67 mmol) and sodium methoxide (5.39 g, 99 
mmol) and was used without further purification. The title compound was formed as 
a viscous yellow oil (21.16 g, 97 %); νmax/cm-1 2939 (m, CAr-H, stretch), 1648 (s, 
C=O, stretch), 1256 (s, C-O, stretch); δH (400 MHz, CDCl3) 8.00 (1H, d, J 16, CH-
3), 7.58 (1H, d, J 7.5, ArH-6′), 7.52 (1H, d, J 16, CH-2), 7.54-7.52 (1H, m, ArH-2′), 
7.41-7.35 (2H, m, ArH-5′ & ArH-6″), 7.10 (1H, ddd, J 8, 2.5, 0.5, ArH-4′), 6.70 (1H, 
d, J 9, ArH-5″), 3.89 (3H, s, CAr-2″ OCH3), 3.88 (3H, s, CAr-3″ OCH3), 3.86 (3H, s, 
CAr-4″ OCH3), 3.86 (3H, s, CAr-3′ OCH3); δC (100 MHz, CDCl3) 190.5 (C-1), 159.8 
(CAr-3′), 155.7 (CAr-3″), 153.7 (CAr-2″), 142.4 (CAr-4″), 140.0 (CH-3), 139.9 (CAr), 
129.4 (CArH-5′), 123.8 (CArH-6″), 121.9 (CAr-1″), 121.3 (CH-2), 120.9 (CArH-6′), 
118.9 (CArH-4′), 112.8 (CArH-2′), 107.6 (CArH-5″), 61.3 (CAr-2″ OCH3), 60.8 (CAr-4″ 
OCH3), 56.0 (CAr-3″ OCH3), 55.3 (CAr-3′ OCH3); m/z (MNa+ C19H20O5Na+ requires 
351.1203) found 351.1210. 
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(E)-1-(3′-Methoxyphenyl)-3-(4″-fluorophenyl)prop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 3′-methoxyacetophenone (9.14 mL, 67 mmol), 4-
fluorobenzaldehyde (7.14 mL, 67 mmol) and potassium hydroxide solution (3 M, 3 
mL) instead of sodium methoxide. The reaction was performed in methanol (40 mL) 
and was used without further purification. The title compound was formed as a white 
solid (16.31 g, 96 %); m.p. 67-68 °C; νmax/cm-1 2839 (m, CAr-H, stretch), 1649 (s, 
C=O, stretch), 1229 (s, C-F, stretch); δH (400 MHz, CDCl3) 7.76 (1H, d, J 15.5, CH-
3), 7.65-7.60 (2H, m, 2 x ArH-2″), 7.60-7.57 (1H, m, ArH-6′), 7.53 (1H, dd, J 2.5, 
1.5, ArH-2′), 7.43 (1H, d, J 15.5, CH-2), 7.42-7.38 (1H, m, ArH-5′), 7.14-7.07 (3H, 
m, ArH-4′ & 2 x ArH-3″), 3.87 (3H, s, CAr-3′ OCH3; δC (100 MHz, CDCl3) 190.0 (C-
1), 164.0 (d, 1JCF 252, CAr-4″), 159.9 (CAr-3′), 143.5 (CH-3), 139.4 (CAr-1′), 131.1 (d, 
4JCF 3.5, CAr-1″), 131.1 (d, 3JCF 8.5, 2 x CArH-2″), 129.5 (CArH-5′), 121.7 (CH-2), 
121.0 (CArH-6′), 119.3 (CArH-4′), 116.1 (d, 2JCF 22, 2 x CArH-3″), 112.8 (CArH-2′), 
55.4 (CAr-3′ OCH3); δF (282 MHz, CDCl3) -109.5 - -106.7 (m, CF-4″) m/z (MNa+ 
C16H13FO2Na+ requires 279.0792) found 279.0791. 
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(E)-1-(3′-Methoxyphenyl)-3-(4″-chlorophenyl)prop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 3′-methoxyacetophenone (6.50 mL, 47 mmol), 4-
chlorobenzaldehyde (6.65 g, 47 mmol) and potassium hydroxide solution (3 M, 3 
mL) instead of sodium methoxide. The reaction was performed in methanol (40 mL) 
and was used without further purification. The title compound was formed as a white 
solid (7.20 g, 56 %); m.p. 85-86 °C, (lit.517 83 °C); νmax/cm-1 2836 (m, CAr-H, stretch), 
1655 (s, C=O, stretch), 1253 (s, C-O, stretch); δH (400 MHz, CDCl3) 7.76 (1H, d, J 
16, CH-3), 7.63-7.52 (4H, m, ArH-6′, ArH-2′ & 2 x ArH-2″), 7.48 (1H, d, J 16, CH-
2), 7.44-7.36 (3H, m, ArH-5′ & 2 x ArH-3″), 7.19-7.12 (1H, m, ArH-4′), 3.89 (3H, s, 
CAr-3′ OCH3); δC (100 MHz, CDCl3) 189.9 (C-1), 159.9 (CAr-3′), 143.3 (CH-3), 139.4 
(CAr-1′), 136.4 (CAr-4″), 133.4 (CAr-1″), 129.6 (2 x CArH-2″), 129.2 (2 x CArH-3″), 
122.5 (CH-2), 121.0 (CArH), 119.4 (CArH-4′), 112.9 (CArH-2′), 55.5 (CAr-3′ OCH3); 
m/z (MNa+ C16H1335ClO2Na+ requires 295.0496) found 295.0489. 
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(E)-1-(4′-Bromophenyl)-3-(3″,4″,5″-trimethoxyphenyl)prop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 4′-bromoacetophenone (10.00 g, 50 mmol), 3,4,5-
trimethoxybenzaldehyde (9.86 g, 50 mmol) and sodium methoxide (4.07 g, 75 mmol) 
and was used without further purification. The title compound was formed as a pale 
yellow solid (16.29 g, 86 %); m.p. 132-133 °C, (lit.518 102 °C); νmax/cm-1 2942 (m, 
CAr-H, stretch), 1605 (s, C=O, stretch), 1177 (s, C-O, stretch); δH (400 MHz, CDCl3) 
7.86 (2H, d, J 8.5, 2 x ArH-2′), 7.70 (1H, d, J 15.5, CH-3), 7.63 (2H, d, J 8.5, 2 x 
ArH-3′), 7.33 (1H, d, J 15.5, CH-2), 6.85 (2H, s, 2 x ArH-2″), 3.91 (6H, s, 2 x CAr-3″ 
OCH3), 3.89 (3H, s, CAr-4″ OCH3); δC (100 MHz, CDCl3) 189.4 (C-1), 153.4 (2 x 
CAr-3″), 145.6 (CH-3), 140.6 (CAr-4″), 136.9 (CAr-1′), 131.9 (2 x CArH-3′), 130.1 
(CAr-1″), 130.0 (2 x CArH-2′), 127.8 (CAr-4′), 120.8 (CH-2), 105.7 (2 x CArH-2″), 61.0 
(CAr-4″ OCH3), 56.2 (2 x CAr-3″ OCH3); m/z (MH+ C18H1779BrO4H+ requires 
377.0383) found 377.0385, (MH+ C18H1781BrO4H+ requires 379.0365) found 
379.0366. 
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(E)-1-(Naphthalen-1′-yl)-3-phenylprop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 1-acetylnaphthalene (4.46 mL, 30 mmol), benzaldehyde (3.12 
mL, 30 mmol) and sodium methoxide (2.38 g, 44 mmol) and was used without further 
purification. The title compound was formed as a yellow oil (7.16 g, 94 %); νmax/cm-
1 3009 (m, CAr-H, stretch), 1641 (s, C=O, stretch), 1279 (s, C-O, stretch); δH (400 
MHz, CDCl3) 8.45 (1H, d, J 8, ArH-8′) 7.99 (1H, d, J 8, ArH), 7.92 (1H, d, J 7.5, 
ArH), 7.80 (1H, d, J 7, ArH), 7.67 (1H, d, J 16, CH-3), 7.65-7.51 (6H, m, 6 x ArH), 
7.39 (2H, dd, J 5, 1.5, 2 x ArH), 7.35 (1H, d, J 16, CH-2); δC (100 MHz, CDCl3) 
195.2 (C-1), 145.6 (CH-3), 136.7 (CAr), 134.3 (CAr), 133.6 (CAr), 131.4 (CArH), 130.4 
(CArH), 130.2 (CAr), 128.7 (CArH), 128.2 (CArH), 127.2 (CArH), 127.0 (CArH), 126.7 
(CArH), 126.2 (CArH), 125.4 (CArH), 124.3 (CArH), (missing 1 x CArH); m/z (MNa+ 
C19H14ONa+ requires 281.0937) found 281.0932. 
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(E)-1-(Naphthalen-1′-yl)-3-(3″,4″,5″-trimethoxyphenyl)prop-2-en-1-one  
 
45 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 1-acetylnaphthalene (4.46 mL, 30 mmol), 3,4,5-
trimethoxybenzaldehyde (5.77 g, 30 mmol) and sodium methoxide (2.38 g, 44 mmol) 
and was used without further purification. The title compound was formed as a yellow 
oil (4.40 g, 95 %); νmax/cm-1 3010 (m, CAr-H, stretch), 1659 (s, C=O, stretch), 1251 
(s, C-O, stretch); δH (400 MHz, CDCl3) 8.29 (1H, d, J 9, ArH), 7.98 (1H, d, J 8, ArH), 
7.90 (1H, m, ArH), 7.75 (1H, d, J 7, ArH), 7.59-7.52 (3H, m, 3 x ArH), 7.49 (1H, d, 
J 16, CH-3), 7.20 (1H, d, J 16, CH-2), 6.79 (2H, s, ArH-2″), 3.89 (3H, s, CAr-4″ 
OCH3), 3.86 (6H, s, 2 x CAr-3″ OCH3); δC (100 MHz, CDCl3) 195.7 (C-1), 153.3 (2 
x CAr-3″), 146.1 (C-3), 140.3 (CAr-4″), 137.0 (CAr), 133.7 (CAr), 131.3 (CArH), 130.3 
(CAr), 129.9 (CAr), 128.3 (CArH), 127.3 (CArH), 126.8 (CArH), 126.4 (CArH), 126.4 
(CArH), 125.5 (CArH), 124.4 (CArH), 105.5 (2 x CAr-2″), 60.9 (CAr-4″ OCH3), 56.0 (2 
x CAr-3″ OCH3); m/z (MNa+ C22H20O4Na+ requires 371.1254) found 371.1248. 
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(E)-1-(4′-Fluoronaphthalen-1′-yl)-3-(3″,4″,5″-trimethoxyphenyl)prop-2-
en-1-one  
 
46 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 1-acetyl-4-fluoronapthalene, 33 (10.00 g, 53 mmol), 3,4,5-
trimethoxybenzaldehyde (10.43 g, 53 mmol) and potassium hydroxide solution (3 M, 
3 mL) instead of sodium methoxide. The reaction was performed in methanol (40 
mL) and was used without further purification. The title compound was formed as a 
yellow solid (15.78 g, 81 %); m.p. 96-97 °C; νmax/cm-1 2941 (s, CAr-H, stretch), 1650 
(s, C=O, stretch), 1121 (s, C-F, stretch); δH (400 MHz, CDCl3) 8.41-8.38 (1H, m, 
ArH-8′), 8.21-8.18 (1H, m, ArH-5′), 7.77 (1H, dd, J 8, 5.5, ArH-2′), 7.67-7.59 (2H, 
m, ArH-6′ & ArH-7′), 7.51 (1H, d, J 16, CH-3), 7.20 (1H, dd, J 10.5, 7.5, ArH-3′), 
7.19 (1H, d, J 16, CH-2), 6.80 (2H, s, 2 x ArH-2″), 3.90 (3H, s, CAr-4″ OCH3), 3.89 
(6H, s, 2 x CAr-3″ OCH3); δC (100 MHz, CDCl3) 194.4 (C-1), 160.4 (d, 1JCF 258, CAr-
4′), 153.5 (2 x CAr-3″), 146.1 (CH-2), 140.5 (CAr-4″), 133.1 (d, 4JCF 4, CAr), 132.3 (d, 
4JCF 5, CAr), 129.9 (CAr-1″), 128.5 (CArH-2′), 127.9 (d, 4JCF 9.5, CArH-6′), 126.8 
(CArH-7′), 126.0 (CH-2), 125.6 (CArH-8′), 123.9 (d, 2JCF 16, CAr-4a′), 120.7 (d, 3JCF 
6, CArH-5′), 108.2 (d, 2JCF 21, CArH-3′), 105.6 (2 x CArH-2″), 60.9 (CAr-4″ OCH3), 
56.1 (2 x CAr-3″ OCH3); δF (282 MHz, CDCl3) -117.1 (ddd, J 7, 5.5, 2, CArF-4′); m/z 
(MH+ C22H19FONa+ requires 389.1160) found 389.1157. 
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(E)-1-(4′-Chloronaphthalen-1′-yl)-3-(3″,4″,5″-trimethoxyphenyl)prop-2-
en-1-one  
 
47 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 1-acetyl-4-chloronaphthalene, 34 (9.00 g, 44 mmol), 3,4,5-
trimethoxybenzaldehyde (8.62 g, 44 mmol) and potassium hydroxide solution (3 M, 
3 mL) instead of sodium methoxide. The reaction was performed in methanol (40 
mL) and was used without further purification. The title compound was formed as a 
yellow solid (14.06 g, 84 %); m.p. 125-126 °C; νmax/cm-1 2937 (m, CAr-H, stretch), 
1650 (s, C=O, stretch), 1123, (s, C-O, stretch), 1095 (s, C-Cl, stretch); δH (400 MHz, 
CDCl3) 8.33 (1H, d, J 8.5, ArH-8′), 8.28 (1H, d, J 8.5, ArH-5′), 7.70-7.58 (4H, m, 
ArH-2′, ArH-3′, ArH-6′ & ArH-7′), 7.45 (1H, d, J 16, CH-3), 7.14 (1H, d, J 16, CH-
2), 6.78 (2H, s, 2 x ArH-2″), 3.89 (3H, s, CAr-4″ OCH3), 3.87 (6H, s, 2 x CAr-3″ 
OCH3); δC (100 MHz, CDCl3) 195.1 (C-1), 153.5 (2 x CAr-3″), 146.7 (CH-3), 140.7 
(CAr-4″), 136.3 (CAr), 135.2 (CAr), 131.6 (CAr), 131.0 (CAr), 129.8 (CAr), 128.1 (CArH), 
127.6 (CArH), 126.5 (CArH), 126.4 (CArH), 126.0 (CArH), 125.0 (CArH), 124.8 (CArH), 
105.7 (2 x CArH-2″), 61.0 (CAr-4″ OCH3), 56.1 (2 x CAr-3″ OCH3); m/z (MNa+ 
C22H19ClO4Na+ requires 405.0864) found 405.0865.  
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(E)-1-(4′-Bromonaphthalen-1′-yl)-3-phenylprop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 1-acetyl-4-bromo-naphthalene, 35 (10.00 g, 40 mmol), 
benzaldehyde (4.08 mL, 40 mmol) and sodium methoxide (3.25 g, 60 mmol) and was 
used without further purification. The title compound was formed as an orange oil 
(13.21 g, 98 %); νmax/cm-1 1650 (s, C=O, stretch), 1069 (s, C-Br, stretch); δH (400 
MHz, CDCl3) 8.38-8.32 (2H, m, 2 x ArH), 7.88-7.85 (1H, d, J 7.5, ArH), 7.69-7.56 
(6H, m, CH-3 & 5 x ArH), 7.44-7.40 (3H, m, 3 x ArH), 7.29 (1H, d, J 16, CH-2); δC 
(100 MHz, CDCl3) 194.9 (C-1), 146.3 (CH-3), 136.9 (CAr), 134.2 (CAr), 132.1 (CAr), 
131.4 (CAr), 130.8 (CArH), 128.9 (2 x CArH), 128.7 (CArH), 128.4 (2 x CArH), 128.0 
(CArH), 127.8 (CArH), 127.5 (CArH), 126.9 (CArH), 126.8 (CArH), 126.0 (CArH), 
(missing 1 x CAr); m/z (MH+ C19H1379BrOH+ requires 337.0223) found 337.0223, 
(MH+ C19H1381BrOH+ requires 339.0203) found 339.0203. 
 
(E)-1-(4′-Bromonaphthalen-1′-yl)-3-(4″-methoxyphenyl)prop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 1-acetyl-4-bromo-naphthalene, 35 (10.00 g, 40 mmol), 4-
methoxybenzaldehyde (4.88 mL, 40 mmol) and sodium methoxide (3.25 g, 60 mmol) 
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and was used without further purification. The title compound was formed as a yellow 
solid (14.23 g, 97 %); m.p. 105-106 °C, (lit.519 123-124 °C); νmax/cm-1 2938 (w, CAr-
H, stretch), 1649 (s, C=O, stretch), 1172 (s, C-O, stretch); δH (400 MHz, CDCl3) 8.34 
(1H, d, J 8.5, ArH-8′), 8.26 (1H, d, J 8.5, ArH-5′), 7.85 (1H, d, J 7.5, ArH-3′), 7.78-
7.82 (2H, m, ArH-6′ & ArH-7′), 7.56-7.48 (4H, m, CH-3, ArH-2′ & 2 x ArH-2″), 7.12 
(1H, d, J 16, CH-2), 6.91 (2H, d, J 8.5, 2 x ArH-3″), 3.83 (3H, s, CAr-4″ OCH3); δC 
(100 MHz, CDCl3) 195.3 (C-1), 161.9 (CAr-4″), 146.6 (CH-3), 137.4 (CAr-1′), 132.2 
(CAr-4′), 131.6 (CAr-1″), 130.3 (2 x CArH-2″), 128.8 (CArH-3′), 128.0 (CArH), 127.8 
(CArH), 127.5 (CArH-8′), 127.0 (CAr-1″) 126.6 (CArH-2′), 126.1 (CArH-5′), 124.8 (CH-
2), 114.5 (2 x CArH-3″), 55.4 (CAr-4″ OCH3), (missing 1 x CAr); m/z (MH+ 
C20H1579BrO2H+ requires 367.0328) found 367.0331, (MH+ C20H1581BrO2H+ requires 
369.0309) found 369.0310. 
 
(E)-1-(4′-Bromonaphthalen-1′-yl)-3-(2″,3″-dimethoxyphenyl)prop-2-en-
1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 1-acetyl-4-bromo-naphthalene, 35 (10.00 g, 40 mmol), 2,3-
dimethoxybenzaldehyde (6.67 g, 40 mmol) and sodium methoxide (3.25 g, 60 mmol) 
and was used without further purification. The title compound was formed as an off-
white solid (12.91 g, 81 %); m.p. 106-107 °C; νmax/cm-1 2942 (w, CAr-H, stretch), 
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1655 (s, C=O, stretch), 1270 (s, C-O, stretch); δH (500 MHz, CDCl3) 8.38-8.30 (2H, 
m, ArH-8′ & ArH-5′), 7.92 (1H, d, J 16, CH-3), 7.86 (1H, d, J 7.5, ArH-3′), 7.68-7.58 
(3H, m, ArH-6′, ArH-7′ & ArH-2′), 7.31 (1H, d, J 16, CH-2), 7.23 (1H, dd, J 8, 1, 
ArH-6′′), 7.08 (1H, t, J 8, ArH-5′′), 6.97 (1H, dd, J 8, 1, ArH-4′′), 3.88 (3H, s, CAr 
OCH3), 3.79 (3H, s, CAr OCH3); δC (125 MHz, CDCl3) 195.2 (C-1), 153.1 (CAr), 148.9 
(CAr), 141.2 (C-3), 137.1 (CAr), 132.3 (CAr), 131.7 (CAr), 128.8 (CArH), 128.6 (CAr), 
128.1 (CArH), 128.1 (CArH), 127.8 (CArH), 127.6 (CArH), 127.1 (CArH), 126.7 (CAr), 
126.2 (CArH), 124.3 (CArH-3′′), 119.4 (CArH-6′′), 114.5 (CArH-4′′), 61.3 (CAr OCH3), 
55.9 (CAr OCH3); m/z (MNa+ C21H1779BrO3Na+ requires 419.0253) found 419.0254, 
(MNa+ C21H1781BrO3Na+ requires 421.0233) found 421.0237. 
 
(E)-1-(4′-Bromonaphthalen-1′-yl)-3-(3″,4″-dimethoxyphenyl)prop-2-en-
1-one  
 
51 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 1-acetyl-4-bromo-naphthalene, 35 (10.00 g, 40 mmol), 3,4-
dimethoxybenzaldehyde (6.67 g, 40 mmol) and sodium methoxide (3.25 g, 60 mmol) 
and was used without further purification. The title compound was formed as a pale 
yellow solid (13.56 g, 85 %); m.p. 134-135 °C; νmax/cm-1 2995 (w, CAr-H, stretch), 
1619 (s, C=O, stretch), 1135 (s, C-O, stretch); δH (400 MHz, CDCl3) 8.33 (1H, d, J 
8, ArH-8′), 8.24 (1H, d, J 8.5, ArH-5′), 7.84 (1H, d, J 7.5, CH-3′), 7.68-7.56 (3H, m, 
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ArH-6′, ArH-7′ & ArH-2′), 7.48 (1H, d, J 16, CH-3), 7.14-7.05 (3H, CH-2, ArH-2′′ 
& ArH-6′′), 6.85 (1H, d, J 8.5, ArH-5′′), 3.90 (3H, s, CAr OCH3), 3.90 (3H, s, CAr 
OCH3; δC (100 MHz, CDCl3) 195.4 (C-1), 151.8 (CAr), 149.3 (CAr), 146.9 (CH-3), 
137.4 (CAr), 132.3 (CAr), 131.7 (CAr), 128.8 (CArH), 128.1 (CArH), 127.9 (CArH), 
127.6 (CArH), 127.3 (CAr), 126.7 (CArH), 126.2 (CArH), 125.1 (CArH), 123.5 (CH-2), 
111.1 (CArH-5′′), 110.0 (CArH-5′′), 56.0 (CAr OCH3), 55.9 (CAr OCH3), (missing 1 x 
CAr); m/z (MNa+ C21H1779BrO3Na+ requires 419.0253) found 419.0255, (MNa+ 
C21H1781BrO3Na+ requires 421.0235) found 421.0237. 
 
(E)-1-(4′-Bromonaphthalen-1′-yl)-3-(3″,5″-dimethoxyphenyl)prop-2-en-
1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 1-acetyl-4-bromo-naphthalene, 35 (10.00 g, 40 mmol), 3,5-
dimethoxybenzaldehyde (6.67 g, 40 mmol) and sodium methoxide (3.25 g, 60 mmol) 
and was used without further purification. The title compound was formed as a 
viscous yellow oil (11.96 g, 75 %); νmax/cm-1 2935 (w, CAr-H, stretch), 1649 (s, C=O, 
stretch), 1153 (s, C-O, stretch); δH (400 MHz, CDCl3) 8.73 (1H, d, J 8.5, ArH-8′), 
8.30 (1H, d, J 8.5, ArH-5′), 7.89 (1H, d, J 7.5, ArH-3′), 7.72-7.55 (3H, m, ArH-6′, 
ArH-7′ & ArH-2′), 7.50 (1H, d, J 16, CH-3), 7.30 (1H, d, J 16, CH-2), 6.72 (2H, s, 2 
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x ArH-2′′), 6.55 (1H, s, ArH-4′′), 3.83 (6H, s, 2 x CAr-3′′ OCH3); δC (100 MHz, 
CDCl3) 195.2 (C-1), 161.1 (2 x CAr-3′′), 146.6 (CH-3), 136.9 (CAr), 136.2 (CAr), 132.3 
(CAR), 131.6 (CAr), 128.8 (CArH), 128.2 (CArH), 127.9 (CArH), 127.7 (CArH), 127.5 
(CArH), 126.9 (CArH), 126.7 (CAr), 126.1 (CArH), 106.4 (2 x CArH-2′′), 103.3 (CArH-
4′′), 55.5 (CAr-3′′ OCH3); m/z (MNa+ C21H1779BrO3Na+ requires 419.0253) found 
419.0254, (MNa+ C21H1781BrO3 requires 421.0234) found 421.0233. 
 
(E)-1-(4′-Bromonaphthalen-1′-yl)-3-(3″,4″,5″-trimethoxyphenyl)prop-2-
en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 1-acetyl-4-bromonaphthalene, 35 (10.00 g, 40 mmol), 3,4,5-
trimethoxybenzaldehyde (7.88 g, 40 mmol) and sodium methoxide (3.25 g, 60 mmol), 
stirred at 50 °C for 2 hours, cooled to room temperature, filtered, and used without 
further purification. The title compound was formed as a yellow solid (17.04 g, 99 
%); m.p. 121-122 °C; νmax/cm-1 2937 (m, CAr-H, stretch), 1648 (s, C=O, stretch), 1126 
(s, C-O, stretch), 1003 (s, CAr-Br, stretch); δH (400 MHz, CDCl3) 8.35 (1H, d, J 8.5, 
ArH-8′), 8.25 (1H, d, J 8.5, ArH-5′), 7.85 (1H, d, J 8.5, ArH-3′), 7.67-7.58 (2H, m, 
ArH-6′ & ArH-7′), 7.54 (1H, d, J 7.5, ArH-2′), 7.44 (1H, d, J 16, CH-3), 7.14 (1H, d, 
J 16, CH-2), 6.78 (2H, s, 2 x ArH-2″), 3.89 (3H, s, CAr-4″ OCH3), 3.87 (6H, s, 2 x 
- 239 -  
CAr-3″ OCH3); δC (100 MHz, CDCl3) 195.2 (C-1), 153.4, 153.4 (CAr-4″ & 2 x CAr-
3″), 146.8 (CH-3), 140.7 (CAr-1″), 137.1 (CAr-4′), 132.2 (CAr), 131.6 (CAr), 129.7 
(CAr-1′), 128.7 (CAr-2′), 128.1, 127.9 (CAr-6′ & CAr-7′), 127.6 (CAr-8′), 126.7 (CArH), 
126.3 (CArH), 126.0 (CArH), 105.7 (2 x CAr 2″), 60.9 (CAr-4″ OCH3), 56.1 (2 x CAr 3″ 
OCH3); m/z (MH+ C22H1979BrO4H+ requires 427.0539) found 427.0548, (MH+ 
C22H1981BrO4H+ requires 429.0520) found 429.0534. 
 
(E)-1-(4′-Bromonaphthalen-1′-yl)-3-(2″,3″,4″-trimethoxyphenyl)prop-2-
en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 1-acetyl-4-bromonaphthalene, 35 (10.00 g, 40 mmol), 2,3,4-
dimethoxybenzaldehyde (7.87 g, 40 mmol) and sodium methoxide (3.25 g, 60 mmol) 
and was used without further purification. The title compound was formed as a yellow 
solid (16.94 g, 99 %); m.p. 103-104 °C; νmax/cm-1 2950 (s, CAr-H, stretch), 1649 (s, 
C=O, stretch), 1091 (s, C-O, stretch); δH (400 MHz, CDCl3) 8.33 (1H, d, J 8, ArH-
8′), 8.29 (1H, d, J 8.5, ArH-5′), 7.85 (1H, d, J 7.5, ArH-3′), 7.79 (1H, d, J 16, CH-3), 
7.67-7.58 (2H, m, ArH-6′ & ArH-7′), 7.54 (1H, d, J 7.5, ArH-2′), 7.32 (1H, d, J 9, 
ArH-6″), 7.22 (1H, d, J 16, CH-2), 6.69 (1H, d, J 9, ArH-5″), 3.88 (3H, s, CAr-3″ 
OCH3), 3.84 (3H, CAr-4″ OCH3), 3.83 (3H, s, CAr-2″ OCH3); δC (100 MHz, CDCl3) 
195.6 (C-1), 156.1 (CAr-3″), 153.6 (CAr-2″), 142.2 (CAr-4″), 141.9 (CH-3), 137.4 (CAr-
1′), 132.1 (CAr), 131.6 (CAr), 128.7 (CArH-3′), 127.8 (CArH), 127.7 (CArH), 127.5 
- 240 -  
(CArH), 126.7 (CArH-2′), 126.2 (CAr), 126.1, 125.9 (CArH-5′ & CH-2), 123.7 CArH-
2″), 121.3 (CAr-1″), 107.6 (CArH-5″), 61.4 (CAr-2″ OCH3), 60.8 (CAr-4″ OCH3), 56.0 
(CAr-3″ OCH3); m/z (MNa+ C22H1979BrO4Na+ requires 449.0359) found 449.0361, 
(MNa+ C22H1981BrO4Na+ requires 451.0340) found 451.0343. 
 
(E)-1-(4′-Bromonaphthalen-1′-yl)-3-(4″-fluorophenyl)prop-2-en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 1-acetyl-4-bromonaphthalene, 35 (10.00 g, 40 mmol), 4-
fluorobenzaldehyde (4.31 mL, 40 mmol) and potassium hydroxide solution (3 M, 3 
mL) instead of sodium methoxide. The reaction was performed in methanol (40 mL) 
and was used without further purification. The title compound was formed as a off-
white solid (7.95 g, 55 %); m.p. 76-77 °C; νmax/cm-1 2974 (w, CAr-H, stretch), 1660 
(s, C=O, stretch), 1223 (s, C-F, stretch); δH (400 MHz, CDCl3) 8.39-8.27 (2H, m, 
ArH-8′ & ArH-5′), 7.84 (1H, d, J 8, ArH-3′), 7.75 (1H, d, J 8, ArH-2′), 7.71-7.52 (6H, 
m, 2 x ArH-2′′, CH-3, ArH-6′ & ArH-7′), 7.20 (1H, d, J 16, CH-2), 7.14-7.11 (2H, 
m, ArH-3′′); δC (100 MHz, CDCl3) 194.9 (C-1), 164.3 (d, 1JCF 252, CAr-4′′), 145.1 
(CH-3), 136.9 (CAr), 135.4 (CAr), 132.3 (CAr), 131.6 (CAr), 131.2 (CAr), 130.5 (d, 3JCF 
8.5, 2 x CArH-2′′), 128.3 (CArH), 182.2 (CArH), 127.7 (CArH), 127.6 (CArH),  126.9 
(CArH), 126.4 (CArH), 126.1 (CH-2), 116.3 (d, 2JCF 22, 2 x CArH-3′′) m/z (MNa+ 
C19H1279BrFONa+ requires 376.9948) found 376.9950, (MNa+ C19H1281BrFONa+ 
requires 378.9929) found 378.9931. 
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(E)-1-(4′-Bromonaphthalen-1′-yl)-3-(4″-chlorophenyl)prop-2-en-1-one  
 
56 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 1-acetyl-4-bromonaphthalene, 35 (10.00 g, 40 mmol), 4-
chlorobenzaldehyde (5.64 g, 40 mmol) and potassium hydroxide solution (3 M, 3 
mL) instead of sodium methoxide. The reaction was performed in methanol (40 mL) 
and was used without further purification. The title compound was formed as a yellow 
solid (12.25 g, 82 %); m.p. 125-126 °C, (lit.519 100-101 °C); νmax/cm-1 1657 (s, C=O, 
stretch), 1087 (s, C-Br, stretch), 987 (s, C-Cl, stretch); δH (400 MHz, CDCl3) 8.36 
(1H, d, J 8.5, ArH-8′), 8.32 (1H, d, J 8.5, ArH-5′), 7.87 (1H, d, J 7.5, ArH-3′), 7.69 
(2H, m, ArH-6′ & ArH-7′), 7.59 (1H, d, J 7.5, ArH-2′), 7.55 (1H, d, J 16, CH-3), 7.50 
(2H, d, J 8.5, 2 x ArH-2′′), 7.38 (2H, d, J 8.5, 2 x ArH-3′′), 7.24 (1H, d, J 16, CH-2); 
δC (100 MHz, CDCl3) 194.7 (C-1), 144.9 (CH-3), 136.9 (CAr), 136.8 (CAr), 132.9 
(CAr), 132.3 (CAr), 131.6 (CAr), 129 (2 x CArH), 129.3 (2 x CArH), 128.8 (CArH), 128.3 
(CArH), 127.9 (CArH), 127.7 (CArH), 127.3 (CArH), 127.1 (CArH), 126.9 (CAr), 126.1 
(CArH); m/z (MH+ C19H1279BrClOH+ requires 370.9833) found 370.9835, (MH+ 
C19H1281BrClOH+ requires 372.9812) found 372.9808. 
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(E)-1-(3″-Fluoro-4″-methoxyphenyl-1-(3′,4′,5′-trimethoxyphenyl)prop-2-
en-1-one  
 
57 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 3,4,5-trimethoxyacetophenone (6.81 g, 32 mmol), 3-fluoro-4-
methoxybenzaldehyde (5.00 g, 32 mmol) and potassium hydroxide solution (3 M, 3 
mL) instead of sodium methoxide. The reaction was performed in methanol (40 mL) 
and was used without further purification. The title compound was formed as a yellow 
solid (10.58 g, 94 %); m.p. 108-109 °C, (lit.520 103-105 °C); νmax/cm-1 1650 (s, C=O, 
stretch), 1127 (s, C-F, stretch); δH (400 MHz, CDCl3); 7.71 (1H, d, J 15.5, CH-3), 
7.41 (1H, dd, J 12, 2, ArH-2″), 7.33 (1H, d, J 15.5, CH-2), 7.33 (1H, m, ArH-6″), 
7.25 (2H, s, 2 x ArH-2′), 6.97 (1H, t, J 8.5, ArH-5″), 3.93 (6H, s, 2 x CAr-3′ OCH3), 
3.92 (3H, s, CAr OCH3), 3.92 (3H, s, CAr OCH3); δC (100 MHz, CDCl3) 188.8 (C-1), 
153.1 (2 x CAr-3′), 152.4 (d, 1JCF 247, CAr-3″), 149.7 (d, 2JCF 11, CAr-4″), 143.3 (d, 
4JCF 2, CH-3), 142.4 (CAr-4′), 133.4 (CAr-1′), 128.1 (d, 3JCF 6.5, CAr-1″), 126.2 (CArH-
6″), 120.5 (CH-2), 114.6 (d, 2JCF 18.5, CArH-2″), 113.1 (CArH-5″), 106.0 (2 x CArH-
2′), 60.9 (CAr-4″ OCH3), 56.3 (2 x CAr-3′ OCH3), 56.2 (CAr-4′ OCH3); δF (282 MHz, 
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CDCl3) -134.8 (dd, J 12, 8.5, CF-3″); m/z (MNa+ C19H19FO5Na+ requires 369.1109) 
found 369.1104. 
 
 
(E)-1-(4″-Methoxy-3″-nitrophenyl)-1-(3′,4′,5′-trimethoxyphenyl)prop-2-
en-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.2, using 3,4,5-trimethoxyacetophenone (6.24 g, 30 mmol), 4-methoxy-
3-nitrobenzaldehyde (5.38 g, 30 mmol) and sodium methoxide (2.24 g, 45 mmol) and 
was used without further purification. The title compound was formed as a yellow 
solid (10.99 g, 99 %); m.p. 142-143 °C, (lit.521 143-145 °C); νmax/cm-1 1650 (s, C=O, 
stretch), 1126 (s, C-O, stretch); δH (400 MHz, CDCl3) 8.24 (1H, d, J 2, ArH-2″), 7.86 
(1H, dd, J 9, 2.5, ArH-5″), 7.82 (1H, d, J 16, CH-3), 7.52 (1H, d, J 16, CH-2), 7.35 
(2H, s, 2 x ArH-2′), 7.22 (1H, d, J 9, ArH-5″), 4.09 (3H, s, CAr-4″ OCH3), 4.03 (6H, 
s, 2 x CAr-3′ OCH3), 4.02 (3H, s, CAr-4′ OCH3); δC (100 MHz, CDCl3) 188.4 (C-1), 
154.1 (CAr-4″), 153.2 (2 x CAr-3′), 142.7 (CAr-4′), 141.6 (CH-3), 139.9 (CAr-3″), 134.5 
(CArH-6″), 133.1 (CAr-1′), 127.6 (CAr-1″), 124.7 (CArH-2″), 121.9 (CH-2), 113.8 
(CArH-5″), 106.1 (2 x CArH-2′), 60.9 (CAr-4′ OCH3), 56.7 (CAr-4″ OCH3), 56.3 (2 x 
CAr-3′ OCH3); m/z (MH+ C19H19NO7H+ requires 374.1234) found 374.1234. 
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5.2.3.3 Nazarov-type Reactions for the General Formation of Substituted 
Indanones  
The following procedure was performed in accordance with previous literature.354 
Substituted chalcone (8.4 mmol) and phosphorus pentoxide (12.6 mmol) in 
trifluoroacetic acid (20 mL, ~2 mL/mmol) was refluxed for 48 hours under N2. To the 
resulting viscous brown mixture was added H2O (50 mL) slowly under constant 
stirring, and the product was extracted into CH2Cl2 (40 mL). The organic layer was 
washed with 2M NaOH (40 mL) twice, saturated NaHCO3 (40 mL) twice, dried over 
MgSO4 and concentrated in vacuo. The brown residue was then purified by silica 
column chromatography as mentioned specifically. 
 
6-Methoxy-3-phenyl-2,3-dihydro-1H-inden-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(3′-methoxyphenyl)-3-phenylprop-2-en-1-one, 36, (1.50 
g, 6.3 mmol), trifluoroacetic acid (15 mL ~2 mL/mmol) and phosphorus pentoxide 
(2.68 g, 9.5 mmol). The crude product by purified by silica column chromatography, 
eluting with dichloromethane : petroleum ether (1 : 2), yielding orange needles (1.26 
g, 84 %); m.p. 69-70 °C, (lit.354 69-70 °C); νmax/cm-1 2954 (m, CAr-H, stretch), 1698 
(s, C=O, stretch), 1279 (s, C-O, stretch); δH (400 MHz, CDCl3) 7.33-7.29 (2H, m, 2 
x ArH), 7.26-7.23 (2H, m, 2 x ArH), 7.17-7.16 (2H, m, 2 x ArH), 7.13-7.11 (2H, m, 
2 x ArH), 4.52 (1H, dd, J 8, 5.5, CH-3), 3.86 (3H, s, CAr-6 OCH3), 3.26 (1H, dd, J 
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19.5, 8, CHH-2), 2.70 (1H, dd, J 19.5, 3.5, CHH-2); δC (100 MHz, CDCl3) 206.0 (C-
1), 159.7 (CAr-6), 150.8 (CAr), 143.9 (CAr), 137.9 (CAr), 128.8 (CArH), 127.6 (CArH), 
127.5 (CArH), 126.9 (CArH), 124.5 (CArH), 104.3 (CArH), 55.6 (CAr-6 OCH3), 47.5 
(C-2), 43.7 (C-3); m/z (MNa+ C16H14O2Na+ requires 261.0886) found 261.0892. 
 
 
6-Methoxy-3-(4′-methoxyphenyl)-2,3-dihydro-1H-inden-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(3′-methoxyphenyl)-3-(4″-methoxyphenyl)prop-2-en-1-
one, 37, (10.00 g, 37.3 mmol), trifluoroacetic acid (75 mL, ~2 mL/mmol) and 
phosphorus pentoxide (15.9 g, 56.0 mmol). The crude product was purified by silica 
column chromatography, eluting with dichloromethane, yielding an orange oil (4.07 
g, 41 %); νmax/cm-1 2835 (w, CAr-H, stretch), 1734 (s, C=O, stretch), 1239 (s, C-O, 
stretch); δH (500 MHz, CDCl3) 7.23-7.21 (1H, m, ArH-7), 7.16-7.15 (2H, m, ArH-4 
& ArH-5), 7.03 (2H, d, J 8.5, 2 x ArH-2′), 6.84 (2H, d, J 8.5, 2 x ArH-3′), 4.47 (1H, 
dd, J 7.5, 3.5, CH-3), 3.86 (3H, s, CAr OCH3), 3.79 (3H, s, CAr OCH3)m 3.23 (1H, dd, 
J 19, 8, CHH-2), 2.65 (1H, dd, J 19, 3.5, CHH-2); δC (125 MHz, CDCl3) 206.1 (C-
1), 159.7 (CAr), 158.5 (CAr), 151.1 (CAr), 137.9 (CAr), 136.0 (CAr), 128.5 (2 x CArH-
2′), 127.6 (CArH), 124.5 (CArH), 114.2 (2 x CArH-3′), 104.3 (CArH-7), 55.6 (CAr 
OCH3), 55.3 (CAr OCH3), 47.7 (CH2-2), 43.0 (CH-3); m/z (MNa+ C17H16O3Na+ 
requires 291.0992) found 291.0991. 
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3-(3′,4′-Dimethoxyphenyl)-6-methoxy-2,3-dihydro-1H-inden-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(3′-methoxyphenyl)-3-(3″,4″-dimethoxyphenyl)prop-2-
en-1-one, 38, (10.00 g, 33.5 mmol), trifluoroacetic acid (70 mL, ~2 mL/mmol) and 
phosphorus pentoxide (14.30 g, 50.3 mmol). The crude product was purified by silica 
column chromatography, eluting with dichloromethane, yielding a yellow solid (3.75 
g, 38 %); m.p. 84-85 °C, (lit. 84-85 °C); νmax/cm-1 2936 (w, CAr-H, stretch), 1705 (s, 
C=O, stretch), 1250 (s, C-O, stretch); δH (400 MHz, CDCl3) 7.30-7.23 (2H, m, 2 x 
ArH), 7.21-7.18 (2H, m, 2 x ArH), 6.82 (1H, d, J 8, ArH), 6.71 (1H, d, J 8, ArH), 
6.60 (1H, d, J 9, ArH), 4.53-4.45 (1H, m, CH-3), 3.88 (6H, s, CAr-4′ OCH3 & CAr-6 
OCH3), 3.82 (3H, s, CAr-3′ OCH3), 3.26 (1H, dd, J 19.5, 8, CHH-2), 2.70 (1H, dd, J 
19.5, CHH-2); δC (100 MHz, CDCl3) 199.4 (C-1), 159.7 (CAr), 151.0 (CAr), 137.9 
(CAr), 136.4 (CAr), 129.8 (CAr), 127.6 (CArH), 124.6 (CArH), 119.7 (CArH), 111.3 
(CArH), 110.4 (CArH), 104.3 (CArH), 55.9 (CAr OCH3), 55.9 CAr OCH3), 55.9 CAr 
OCH3), 55.7 CAr OCH3), 47.7 (CH2-2), 43.5 (CH-3), (missing 1 x CAr); m/z MNa+ 
C18H18O4Na+ requires 321.1097) found 321.1090. 
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6-Methoxy-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-inden-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(3′-methoxyphenyl)-3-(3″,4″,5″-
trimethoxyphenyl)prop-2-en-1-one, 39, (10.00 g, 30.4 mmol), trifluoroacetic acid (60 
mL, ~2 mL/mmol) and phosphorus pentoxide (12.95 g, 45.7 mmol). The crude 
product was purified by silica column chromatography, eluting with dichloromethane 
: petroleum ether (80 : 20), yielding a yellow oil (3.48 g, 35 %); νmax/cm-1 2965 (w, 
CAr-H, stretch), 1680 (s, C=O, stretch), 1202 (s, C-O, stretch); δH (400 MHz, CDCl3) 
7.30-7.24 (4H, m, 4 x ArH), 6.32 (2H, s, 2 x ArH-2′), 4.49-4.45 (1H, m, CH-3), 3.89 
(3H, s, CAr-6 OCH3), 3.85 (3H, s, CAr-4′ OCH3), 3.81 (6H, s, 2 x CAr-3′ OCH3), 3.26 
(1H, dd, J 19.5, 8, CHH-2), 2.71 (1H, dd, J 19.5, 2, CHH-2); δC (100 MHz, CDCl3) 
193.3 (C-1), 159.8 (CAr), 153.5 (CAr), 150.5 (CAr), 139.6 (CAr), 138.0 (CAr), 127.7 
(CArH), 124.6 (CArH), 104.4 (2 x CArH-2′), 56.1 (2 x CAr-3′ OCH3), 55.7 (CAr-4′ 
OCH3), 47.5 (CH2-2), 44.2 (CH-3), (missing 1 x CAr); m/z (MH+ C19H20O5H+ requires 
329.1384) found 329.1374. 
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6-Methoxy-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-inden-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(3′-methoxyphenyl)-3-(2″,3″,4″-
trimethoxyphenyl)prop-2-en-1-one, 40, (10.00 g, 30.4 mmol), trifluoroacetic acid (60 
mL, ~2 mL/mmol) and phosphorus pentoxide (12.95 g, 45.7 mmol). The crude 
product was purified by silica column chromatography, eluting with 
dichloromethane, yielding a yellow oil (2.37 g, 24 %); νmax/cm-1 2937 (w, CAr-H, 
stretch), 1705 (s, C=O, stretch), 1270 (s, C-O, stretch); δH (400 MHz, CDCl3) 7.27-
7.15 (3H, m, 3 x ArH), 6.70 (1H, d, J 8.5, ArH-6′), 6.59 (1H, d, J 8.5, ArH-5′), 4.72-
4.67 (1H, m, CH-3), 3.86 (6H, m, 2 x CAr OCH3), 3.86 (3H, s, CAr OCH3), 3.65 (3H, 
s, CAr OCH3), 3.21 (1H, dd, J 19, 8, CHH-2), 2.73 (1H, dd, J 19, 3, CHH-2); δC (100 
MHz, CDCl3) 206.6 (C-1), 154.6 (CAr), 151.1 (CAr), 142.4 (CAr), 138.1 (CAr), 129.5 
(CAr), 127.3 (CArH), 124.1 (CArH), 122.7 (CArH), 107.0 (CAr), 104.4 (CArH), 60.7 (CAr 
OCH3), 56.0 (CAr OCH3), 55.7 (CAr OCH3), 46.6 CH2-2), 38.8 (CH-3), (missing 1 x 
CAr); m/z (MNa+ C19H20O5Na+ requires 351.1203) found 351.1199. 
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3-(4′-Fluorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(3′-methoxyphenyl)-3-(4″-fluorophenyl)prop-2-en-1-
one, 41, (10.00 g, 58.5 mmol), trifluoroacetic acid (120 mL, ~2 mL/mmol) and 
phosphorus pentoxide (24.9 g, 87.8 mmol). The crude product was purified by silica 
column chromatography, eluting with dichloromethane, yielding a white solid (8.67 
g, 87 %); m.p. 92-93 °C, (lit.522 88-91 °C); νmax/cm-1 2098 (w, CAr-H, stretch), 1702 
(s, C=O, stretch), 1218 (s, C-O, stretch); δH (500 MHz, CDCl3) 7.23 (1H, d, J 2.5, 
ArH-7), 7.17 (1H, dd, J 8.5, 2.5, ArH-5), 7.14 (1H, d, J 8.5, ArH-4), 7.07 (2H, dd, J 
8.5, 5.5, 2 x ArH-2′), 6.99 (2H, t, J 8.5, 2 x ArH-3′), 4.51 (1H, dd, J 8, 3.5, CH-3), 
3.86 (3H, s, CAr-4″ OCH3), 3.25 (1H, dd, J 19, 8, CHH-2), 2.63 (1H, dd, J 19, 3.5, 
CHH-2); δC (125 MHz, CDCl3) 205.6 (C-1), 161.7 (d, 1JCF 245, CAr-4″), 159.8 (CAr-
6), 150.5 (CAr), 139.6 (d, 4JCF 3, CAr-1′), 138.0 (CAr), 129.0 (d, 3JCF 8, 2 x CArH-2′), 
127.5 (CArH-4), 124.6 (CArH-5), 115.7 (d, 2JCF 21.5, 2 x CAr-3′), 104.4 (CArH-7), 55.6 
(CAr-6 OCH3), 47.6 (CH2-2), 43.0 (CH3); δF (282 MHz, CDCl3) -115.9 (m, CArF-4′); 
m/z (MNa+ C16H13FO2Na+ requires 279.0792) found 279.0793. 
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3-(4′-Chlorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(3′-methoxyphenyl)-3-(4″-chlorophenyl)prop-2-en-1-
one, 42, (7.00 g, 25.7 mmol), trifluoroacetic acid (50 mL, ~2 mL/mmol) and 
phosphorus pentoxide (10.92 g, 38.5 mmol). The crude product was purified by silica 
column chromatography, eluting with dichloromethane, yielding a white solid (5.91 
g, 84 %); m.p. 125-126 °C, (lit.217 118 °C); νmax/cm-1 2953 (w, CAr-H, stretch), 1705 
(s, C=O, stretch), 1279 (s, C-O, stretch); δH (500 MHz, CDCl3) 7.26 (2H, d, J 8.5, 2 
x ArH-3″), 7.22 (1H, d, J 2.5, ArH-7), 7.17 (1H, dd, J 8.5, 2.5, ArH-5), 1H (1H, d, J 
8.5, ArH-4), 7.05 (2H, d, J 8.5, 2 x ArH-2″), 4.49 (1H, dd, J 8, 3.5, CH-3), 3.85 (3H, 
s, CAr-6 OCH3), 3.24 (1H, dd, J 19, 8, CHH-2), 2.62 (1H, dd, J 19, 3.5, CHH-2); δC 
(125 MHz, CDCl3) 205.3 (C-1), 159.8 (CAr-6), 150.1 (CAr), 142.4 (CAr), 137.9 (CAr), 
132.6 (CAr), 128.9 (2 x CArH-2″), 128.8 (2 x CArH-3″), 127.4 (CArH-4), 124.5 (CArH-
5), 104.4 (CArH-7), 55.5 (CAr-6 OCH3), 47.3 (CH2-2), 43.0 CH-3); m/z (MNa+ 
C16H1335ClO2Na+ requires 295.0496) found 295.0502. 
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3-(3′-Fluoro-4′-methoxyphenyl)-4,5,6-trimethoxy-3,4-dihydro-1H-inden-
1-one  
 
66 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(3″-fluoro-4″-methoxyphenyl-1-(3′,4′,5′-
trimethoxyphenyl)prop-2-en-1-one, 57, (10.00 g, 28.9 mmol), trifluoroacetic acid (60 
mL, ~2 mL/mmol) and phosphorus pentoxide (12.27 g, 43.3 mmol). The crude 
product was purified by silica column chromatography, eluting with 
dichloromethane, yielding a off-white solid (7.23 g, 72 %); m.p. 116-117 °C; νmax/cm-
1 2937 (w, CAr-H, stretch), 1705 (s, C=O, stretch), 1242 (s, C-O, stretch); δH (500 
MHz, CDCl3) 7.07 (1H, s, ArH-7), 6.87 (1H, t, J 8.5, ArH-6′), 6.83-6.79 (2H, m, 
ArH-5′ & ArH-2′), 4.51 (1H, dd, J 8, 2.5, CH-3), 3.91 (3H, s, CAr OCH3), 3.90 (3H, 
s, CAr OCH3), 3.85 (3H, s, CAr-4′ OCH3), 3.43 (3H, s, CAr OCH3), 3.16 (CHH-2), 2.54 
(CHH-2); δC (125 MHz, CDCl3) 204.9 (C-1), 155.0 (CAr), 152.3 (d, 1JCF 246, CAr-3′), 
150.3 (CAr), 148.7 (CAr), 146.2 (d, 2JCF 11, CAr-4′), 143.9 (CAr), 137.4 (d, 3JCF 5.5, 
CAr-1′), 132.1 (CAr), 122.7 (d, 3JCF 3.5, CArH-5′), 114.9 (d, 2JCF 18.5, CArH-2′), 113.4 
(d, 4JCF 1.5, CArH-6′), 100.3 (CArH-7), 60.9 (CAr OCH3), 60.1 (CAr OCH3), 56.3 (CAr 
OCH3), 56.2 (CAr OCH3), 47.0 (CH2-2), 40.7 (CH-3); δF (282 MHz, CDCl3) -134.8 
(dd, J 12, 8, CArF-3′) m/z (MNa+ C19H19FO5Na+ requires 369.1109) found 369.1112. 
 
 
- 252 -  
3-(3′-Nitro-4′-methoxyphenyl)-4,5,6-trimethoxy-3,4-dihydro-1H-inden-1-
one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(4″-Methoxy-3″-nitrophenyl)-1-(3′,4′,5′-
trimethoxyphenyl)prop-2-en-1-one, 58 (12.00 g, 32.1 mmol), trifluoroacetic acid (64 
mL, ~2 mL/mmol) and phosphorus pentoxide (13.69 g, 48.2 mmol). The crude 
product was purified by silica column chromatography, eluting with 
dichloromethane, yielding a white solid (10.20 g, 85 %); m.p. 140-141 °C; νmax/cm-1 
2988 (w, CAr-H, stretch), 1697 (s, C=O, stretch), 1128 (s, C-O, stretch); δH (400 MHz, 
CDCl3) 7.60 (1H, d, J 2, ArH-2′), 7.24 (1H, dd, J 8.5, 2, ArH-6′), 7.04 (1H, s, ArH-
7), 7.00 (1H, d, J 8.5, ArH-5′), 4.56 (1H, dd, J 8, 2.5, CH-3), 3.90 (3H, s, CAr-4′ 
OCH3), 3.89 (3H, s, CAr-7 OCH3), 3.87 (3H, s, CAr-6 OCH3), 3.48 (3H, s, CAr-7 
OCH3), 3.17 (1H, dd, J 19, 8, CHH-2), 2.51 (1H, dd, J 19, 2.5, CHH-2); δC (100 MHz, 
CDCl3) 204.1 (C-1), 155.3 (CAr), 155.3 (CAr), 151.6 (CAr), 150.1 (CAr), 148.6 (CAr), 
142.9 (CAr), 139.4 (CAr), 136.7 (CAr), 132.7 (CArH-2′), 124.3 (CArH-6′), 113.8 (CArH-
5′), 100.4 (CArH-7), 60.9 (CAr-6 OCH3), 60.2 (CAr-5 OCH3), 56.6 (CAr-7 OCH3), 56.2 
(CAr-4′ OCH3), 46.6 (CH2-2), 40.3 (CH-3); m/z (MNa+ C19H19NO7Na+ requires 
396.1054) found 396.1055. 
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3-Phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(naphthalen-1′-yl)-3-phenylprop-2-en-1-one, 44, (7.00 
g, 27.1 mmol), trifluoroacetic acid (55 mL, ~2mL/mmol) and phosphorus pentoxide 
(11.54 g, 40.7 mmol). The crude product was purified by silica column 
chromatography, eluting with ethyl acetate : petroleum ether (1 : 9), yielding a white 
solid (4.34 g, 62 %); m.p. 119-120 °C, (lit.216 115 °C); νmax/cm-1 3022 (m, CAr-H, 
stretch), 1695 (s, C=O, stretch); δH (400 MHz, CDCl3) 9.24 (1H, d, J 8.5, ArH-9), 
8.00 (1H, d, J 8.5, ArH-5), 7.89 (1H, d, J 8, ArH-6), 7.72 (1H, t, J 7.5, ArH-8), 7.59 
(1H, t, J 7.6, ArH-7), 7.31 (4H, m, ArH-4′, ArH-4 & 2 x ArH-3′), 7.15 (2H, d, J 7, 2 
x ArH-2′), 4.63 (1H, dd, J 8, 3, CH-3), 3.35 (1H, dd, J 19, 8, CHH-2), 2.81 (1H, dd, 
J 19, 3.5, CHH-2); δC (100 MHz, CDCl3) 206.5 (C-1), 160.7 (CAr), 143.3 (CAr-1′), 
136.1 (CArH-5), 132.7 (CAr), 130.6 (CAr), 129.1 (CArH), 128.9 (CArH), 128.0 (CArH), 
127.7 (CArH), 127.0 (CArH), 126.9 (CArH-6′), 124.2 (CArH-9), 123.8 (CArH), 47.4 (C-
2), 44.4 (C-3), Missing one CAr; m/z (MH+ C19H14OH+ requires 259.1117) found 
259.1117. 
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3-(3′,4′,5′-Trimethoxyphenyl)-2,3-dihydro-1H-cyclopenta[a]naphthalen-
1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(naphthalen-1′-yl)-3-(3″,4″,5″-trimethoxyphenyl)prop-
2-en-1-one, 45, (9.50 g, 27.3 mmol), trifluoroacetic acid (55 mL, ~2mL/mmol) and 
phosphorus pentoxide (11.61 g, 40.9 mmol). The crude product was purified by silica 
column chromatography, eluting with ethyl acetate : petroleum ether (1 : 9), yielding 
a yellow solid (4.18 g, 44 %); m.p. 148-149 °C; νmax/cm-1 2939 (w, CAr-H, stretch), 
1690 (s, C=O, stretch), 1240 (s, C-O, stretch); δH (400 MHz, CDCl3) 9.23 (1H, d, J 
8.5, ArH-9), 8.03 (1H, d, J 8.5, ArH-5), 7.91 (1H, d, J 8, ArH-6), 7.72 (1H, ddd, J 
8.5, 7, 1, ArH-8), 7.60 (1H, ddd, J 8, 7, 1, ArH-7), 7.35 (1H, d, J 8.5, ArH-4), 6.35 
(2H, s, 2 x ArH-2′), 4.57 (1H, dd, J 8, 3.5, CH-3), 3.84 (3H, s, CAr-4′ OCH3), 3.77 
(6H, s, 2 x CAr-3′ OCH3), 3.33 (1H, dd, J 19, 8, CHH-2), 2.81 (1H, dd, J 19, 3.5, 
CHH-2); δC (100 MHz, CDCl3) 206.3 (C-1), 160.4 (CAr), 153.6 (2 x CAr-3′), 139.0 
(CAr-1′), 137.0 (CAr-4′), 136.2 (CArH-5), 132.8 (CAr), 130.7 (CAr), 129.1 (CArH-8), 
129.0 (CAr), 128.1 (CArH-6), 127.0 (CArH-6), 124.2 (CArH-9), 123.8 (CArH-4), 104.7 
(2 x CArH-2′), 60.8 (CAr-4′ OCH3), 56.1 (2 x CAr-3′ OCH3), 47.4 (CH-2), 44.8 (CH-
3); m/z (MH+ C22H20O4H+ requires 349.1434) found 349.1426. 
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5-Fluoro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(4′-fluoronaphthalen-1′-yl)-3-(3″,4″,5″-
trimethoxyphenyl)prop-2-en-1-one, 46, (12.00 g, 32.8 mmol), trifluoroacetic acid (70 
mL, ~2 mL/mmol) and phosphorus pentoxide (13.95 g, 49.1 mmol). The crude 
product was purified by silica column chromatography, eluting with ethyl acetate : 
petroleum ether (1 : 4), yielding a yellow solid (3.72 g, 31 %); m.p. 190-191 °C; 
νmax/cm-1 2959 (w, CAr-H, stretch), 1687 (s, C=O, stretch), 1244 (s, C-O, stretch), 
1116 (s, C-F, stretch); δH (400 MHz, CDCl3) 9.22 (1H, d, J 8.5, ArH-9), 8.13 (1H, d, 
J 8.5, ArH-6), 7.70 (1H, t, J 7.5, ArH-8), 7.65 (1H, t, J 7.5, ArH-7), 6.98 (1H, d, J 10, 
ArH-4), 6.34 (2H, s, 2 x ArH-2′), 4.53 (1H, dd, J 7.5, 3, CH-3), 3.84 (3H, s, CAr-4′ 
OCH3), 3.78 (6H, s, CAr-3′ OCH3), 3.32 (1H, dd, J 19, 7.5, CHH-2), 2.81 (1H, dd, J 
19, CHH-2); δC (100 MHz, CDCl3) 204.8 (C-1), 163.6 (d, 2JCF 264.5, CAr-5), 161.9 
(d, 3JCF 10.5, CAr-3a), 153.6 (2 x CAr-3′), 138.3 (CAr-1′), 137.1 (CAr-4′), 130.4 (d, 3JCF 
7, CAr-9a), 130.2 (CArH-8), 127.3 (d, 5JCF 1, CArH-7), 127.2 (d, 4JCF 3, CAr-9b), 124.3 
(d, 4JCF 2.5, CArH-9), 123.3 (d, 2JCF 17, CAr-5a), 121.2 (d, 3JCF 6, CArH-6), 107.5 (d, 
2JCF 21, CArH-4), 104.6 (2 x CArH-2′), 60.8 (CAr-4′ OCH3), 56.1 (2 x CAr-3′ OCH3), 
47.2 (CH-2), 45.0 (CH-3); δF (282 MHz, CDCl3) -109.1 (d, J 10, CArF-5); m/z (MNa+ 
C22H19FO4Na+ requires 389.1160) found 389.1161. 
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5-Chloro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(4′-chloronaphthalen-1′-yl)-3-(3″,4″,5″-
trimethoxyphenyl)prop-2-en-1-one, 47, (13.00 g, 34.0 mmol), trifluoroacetic acid (70 
mL, ~2 mL/mmol) and phosphorus pentoxide (14.46 g, 50.9 mmol). The crude 
product was purified by silica column chromatography, eluting with ethyl acetate : 
petroleum ether (1 : 4), yielding a yellow solid (4.29 g, 33 %); m.p. 185-186 °C; 
νmax/cm-1 2937 (w, CAr-H, stretch), 1690 (s, C=O, stretch), 1229 (s, C-O, stretch); δH 
(500 MHz, CDCl3) 9.27 (1H, d, J 8, ArH-9), 8.34 (1H, d, J 8.5, ArH6), 7.78 (1H, ddd, 
J 8.5, 7, 1, ArH-7), 7.71 (1H, ddd, J 8.5, 7, 1, ArH-8), 7.45 (1H, s, ArH-4), 6.34 (2H, 
s, 2 x ArH-2′), 4.53 (1H, dd, 7.5, 3.5, CH-3), 3.85 (3H, s, CAr-4′ OCH3), 3.79 (6H, s, 
2 x CAr-3′ OCH3), 3.33 (1H, dd, 19, 7.5, CHH-2), 2.82 (1H, dd, J 19, 3.5, CHH-2); 
δC (125 MHz, CDCl3) 205.4 (C-1), 160.0 (CAr), 153.7 (2 x CAr-3′), 140.5 (CAr), 138.2 
(CAr-4′), 130.2 (CAr), 130.0 (CArH-7), 129.8 (CAr), 129.5 (CAr), 127.9 (CArH-8), 124.9 
(CArH), 124.6 (CArH), 124.2 (CArH-4), 104.7 (2 x CArH-2″), 60.8 (CAr-4′ OCH3), 56.2 
(2 x CAr-3′ OCH3), 47.3 (CH2-2), 44.7 (CH-3); m/z (MNa+ C22H1935ClO4Na+ requires 
405.0864) found 405.0869. 
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5-Bromo-3-phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(4′-bromonaphthalen-1′-yl)-3-phenylprop-2-en-1-one, 
48, (11.00 g, 32.6 mmol), trifluoroacetic acid (65 mL, ~2 mL/mmol) and phosphorus 
pentoxide (13.89 g, 48.9 mmol). The crude product was purified by silica column 
chromatography, eluting with ethyl acetate : petroleum ether (1 : 4), yielding a yellow 
solid (7.71 g, 70 %); m.p. 140-145 °C; νmax/cm-1 3022 (w, CAr-H, stretch), 1694 (s, 
C=O, stretch), 1181 (s, C-O, stretch); δH (500 MHz, CDCl3) 9.26 (1H, d, J 8.5, ArH-
9), 8.31 (1H, d, J 8.5, ArH-6), 7.76 (1H, ddd, J 8.5, 7, 1, ArH-8), 7.69 (1H, ddd, J 
8.5, 7,1, ArH-7), 7.63 (1H, s, ArH-4), 7.34 (2H, t, J 7.5, 2 x ArH-3′), 7.30-7.27 (1H, 
m, ArH-4′), 7.15 (2H, d, J 7, 2 x ArH-2′), 4.61 (1H, dd, J 7.5, 3.5, CH-3), 3.33 (1H, 
dd, J 19, 8, CHH-2), 2.81 (1H, dd, J 19, 3.5, CHH-2); δC (125 MHz, CDCl3) 205.6 
(C-1), 160.3 (CAr), 142.6 (CAr), 132.1 (CAr), 131.2 (CAr), 130.2 (CAr), 129.9 (CArH-
8), 129.7 (CAr), 129.1 (CArH), 128.2 (CArH), 128.1 (CArH), 127.7 (CArH), 127.5 
(CArH), 127.3 (CArH), 124.6 (CArH-9), 47.4 (CH2-2), 44.2 (CH-3); m/z (MNa+ 
C19H1379BrONa+ requires 359.0042) found 359.0044, (MNa+ C19H1381BrONa+ 
requires 361.0023) found 361.0027. 
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5-Bromo-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]naphthalen-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(4′-bromonaphthalen-1′-yl)-3-(4″-methoxyphenyl)prop-
2-en-1-one, 49 (8.00 g, 21.8 mmol), trifluoroacetic acid (45 mL, ~2 mL/mmol) and 
phosphorus pentoxide (9.28 g, 32.6 mmol). The crude product was purified by silica 
column chromatography, eluting with ethyl acetate : petroleum ether (1 : 3), yielding 
a yellow solid (2.36 g, 30 %); m.p. 143-144 °C; νmax/cm-1 2934 (w, CAr-H, stretch), 
1687 (s, C=O, stretch), 1277 (s, C-O, stretch); δH (500 MHz, CDCl3) 9.25 (1H, d, J 
8, ArH-9), 8.29 (1H, d, J 8.5, ArH-6), 7.75 (1H, ddd, J 8.5, 7, 1, ArH-8), 7.67 (1H, 
ddd, J 8.5, 7, 1, ArH-7), 7.62 (1H, s, ArH-4), 7.06 (2H, d, J 8.5, 2 x ArH-2′), 6.87 
(2H, d, J 8.5, 2 x ArH-3′), 4.55 (1H, dd, J 7.5, 3.4, CH-3), 3.80 (3H, s, CAr-4′ OCH3), 
3.30 (1H, dd, J 19, 8, CHH-2), 2.76 (1H, dd, J 19, 3.5, CHH-2); δC (125 MHz, CDCl3) 
205.8 (C-1), 160.6 (CAr-4′), 158.8 (CAr), 134.6 (CAr), 132.0 (CAr), 131.2 (CAr), 130.1 
(CAr), 129.9 (CArH), 129.7 (CAr), 128.8 (2 x CArH-2′), 128.2 (CArH), 128.1 (CArH), 
127.6 (CArH), 124.6 (CArH), 114.5 (2 x CArH-3′), 55.3 (CAr-4′ OCH3), 47.6 (CH2-2), 
43.5 (CH-3); m/z (MH+ C20H1579BrO2H+ requires 367.0328) found 367.0332, (MH+ 
C20H1581BrO2H+ requires 369.0310) found 369.0313. 
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5-Bromo-3-(2′,3′-dimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(4′-Bromonaphthalen-1′-yl)-3-(2″,3″-
dimethoxyphenyl)prop-2-en-1-one, 50 (16.00 g, 40.3 mmol), trifluoroacetic acid (81 
mL, ~2 mL/mmol) and phosphorus pentoxide (17.15 g, 60.4 mmol). The crude 
product by purified by silica column chromatography, eluting with dichloromethane 
: petroleum ether (2 : 1), yielding a beige solid (4.48 g, 28 %); m.p. 174-175 °C; 
νmax/cm-1 2929 (w, CAr-H, stretch), 1697 (s, C=O, stretch), 1279 (s, C-O, stretch); δH 
(400 MHz, CDCl3) 9.28 (1H, d, J 8.5, ArH-9), 8.32 (1H, d, J 8.5, ArH-6), 7.77 (1H, 
t, J 7.5, ArH-8), 7.72-7.66 (2H, m, ArH-7 & ArH-4), 7.00 (1H, t, J 8, ArH-5′), 6.87 
(1H, d, J 8, ArH-4′), 6.56 (1H, d, J 7.5, ArH-6′), 4.98 (1H, d, J 6, CH-3), 3.90 (3H, s, 
CAr-3′ OCH3), 3.72 (3H, s, CAr-2′ OCH3), 3.31 (1H, dd, J 19, 8, CHH-2), 2.84 (1H, 
d, J 19, CHH-2); δC (100 MHz, CDCl3) 206.0 (C-1), 160.6 (CAr), 153.0 (CAr-3′), 147.2 
(CAr-2′), 136.0 (CAr), 131.8 (CAr), 131.2 (CAr), 130.3 (CAr), 129.8 (CAr), 129.8 (CArH), 
128.1 (CArH), 128.0 (CArH), 127.5 (CArH), 124.5 (CArH-9), 124.5 (CArH-5′), 120.3 
(CArH-6′), 111.4 (CArH-4′), 60.8 (CAr-2′ OCH3), 55.8 (CAr-3′ OCH3), 46.5 (CH2-2), 
38.5 (CH-3); m/z (MNa+ C21H1779BrO3Na+ requires 419.0253) found 419.0248, 
(MNa+ C21H1781BrO3Na+ requires 421.0235) found 421.0232. 
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5-Bromo-3-(3′,4′-dimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(4′-Bromonaphthalen-1′-yl)-3-(3″,4″-
dimethoxyphenyl)prop-2-en-1-one, 51 (12.70 g, 32.0 mmol), trifluoroacetic acid (64 
mL, ~2 mL/mmol) and phosphorus pentoxide (13.61 g, 48 mmol). The crude product 
by purified by silica column chromatography, eluting with dichloromethane : 
petroleum ether (2 : 1), yielding a beige solid (3.56 g, 28 %); m.p. 185-186 °C; 
νmax/cm-1 2934 (w, CAr-H, stretch), 1692 (s, C=O, stretch), 1236 (s, C-O, stretch); δH 
(500 MHz, CDCl3) 9.25 (1H, d, J 8, ArH-9), 8.31 (1H, d, J 8.5, ArH-6), 7.75 (1H, 
ddd, J 8, 7, 1, ArH-8), 7.68 (1H, ddd, J 8.5, 7, 1, ArH-7), 7.64 (1H, s, ArH-4), 6.83 
(1H, d, J 8, ArH-4′), 6.72 (1H, dd, J 8, 2, ArH-6′), 6.60 (1H, d, J 2, ArH-2′), 4.55 
(1H, dd, J 7.5, 3.5, CH-3), 3.87 (3H, s, CAr-4′ OCH3), 3.80 (3H, s, CAr-3′ OCH3), 3.32 
(1H, dd, J 19, 8, CHH-2), 2.79 (1H, dd, J 19, 3.5, CHH-2); δC (125 MHz, CDCl3) 
205.7 (C-1), 160.5 (CAr), 149.5 (CAr), 148.3 (CAr), 135.0 (CAr), 132.1 (CAr), 131.3 
(CAr), 130.1 (CAr), 130.0 (CArH), 129.7 (CAr), 128.2 (CArH), 128.1 (CArH), 127.6 
(CArH), 124.6 (CArH-9), 120.0 (CArH-6′), 111.5 (CArH-4′), 110.6 (CArH-2′), 56.0 (CAr-
3′ OCH3 & CAr-4′ OCH3), 47.5 (CH2-2), 43.9 (CH-3); m/z (MNa+ C21H1779BrO3Na+ 
requires 419.0253) found 419.0256, (MNa+ C21H1781BrO3Na+ requires 421.0235) 
found 421.0251. 
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5-Bromo-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]napthalen-1-one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(4′-bromonaphthalen-1′-yl)-3-(3″,4″,5″-
trimethoxyphenyl)prop-2-en-1-one, 53 (10.00 g, 23.4 mmol), trifluoroacetic acid (47 
mL, ~2 mL/mmol) and phosphorus pentoxide (9.97 g, 35.1 mmol). The crude product 
by purified by silica column chromatography, eluting with ethyl acetate : petroleum 
ether (1 : 4), yielding a yellow solid (3.00 g, 30 %); m.p. 207-208 °C; νmax/cm-1 2936 
(m, CAr-H, stretch), 1686 (s, C=O, stretch), 1108 (s, C-O, stretch), 1001 (s, CAr-Br, 
stretch); δH (400 MHz, CDCl3) 9.26 (1H, d, J 8, ArH-9), 8.32 (1H, d, J 8.5, ArH-6), 
7.77 (1H, m, ArH-8), 7.70 (1H, m, ArH-7), 6.34 (2H, s, 2 x ArH-2″), 4.53 (1H, dd, J 
7.5, 3.5, CH-3), 3.85 (3H, s, CAr-4′ OCH3), 3.79 (6H, s, 2 x CAr-3′ OCH3), 3.31 (1H, 
dd, J 19, 7.5, CHH), 2.81 (1H, dd, J 19, 3.5, CHH); δC (100 MHz, CDCl3) 205.5 (CAr-
1), 160.0 (CAr), 153.7 (2 x CAr-3′), 138.2 (CAr), 138.2 (CAr), 132.1 (CAr), 131.3 (CAr), 
130.2 (CAr), 129.9 (CArH), 129.7 (CAr), 128.2 (CArH), 128.0 (CArH), 127.6 (CArH-6′), 
124.6 (CArH-9), 104.7 (2 x CArH-2′), 60.8 (CAr-4′ OCH3), 56.2 (2 x CAr-3′ OCH3), 
47.3 (CH2-2), 44.6 (CH-3); (MH+ C22H1979BrO4H+ requires 427.0539) found 
427.0534, (MH+ C22H1981BrO4H+ requires 429.0520) found 429.0519. 
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5-Bromo-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
O
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(4′-Bromonaphthalen-1′-yl)-3-(2″,3″,4″-
trimethoxyphenyl)prop-2-en-1-one, 54 (11.50 g, 26.9 mmol), trifluoroacetic acid (54 
mL, ~2 mL/mmol) and phosphorus pentoxide (11.46, 40.4 mmol). The crude product 
by purified by silica column chromatography, eluting with ethyl acetate : petroleum 
ether (1 : 4), yielding an orange oil (2.76 g, 24 %); νmax/cm-1 2934 (w, CAr-H, stretch), 
1696  (s, C=O, stretch), 1233 (s, C-O, stretch); δH (400 MHz, CDCl3) 9.25 (1H, d, J 
8.5, ArH-9), 8.30 (1H, d, J 8.5, ArH-6), 7.74 (1H, ddd, J 8.5, 7, 1.5, ArH-8), 7.69-
7.64 (2H, m, ArH-7 & ArH-4), 6.65 (1H, d, J 8.5, ArH-6′), 6.59 (1H, d, J 8.5, ArH-
5′), 4.81 (1H, dd, J 7.5, 3, CH-3), 3.88 (3H, s, CAr-4′ OCH3), 3.84 (3H, s, CAr-3′ 
OCH3), 3.68 (3H, s, CAr-2′ OCH3), 3.26 (1H, dd, J 19, 8, CHH-2), 2.79 (1H, dd, J 19, 
3, CHH-2); δC (100 MHz, CDCl3) 206.1 (C-1), 160.6 (CAr), 153.2 (CAr-3′), 152.0 
(CAr-2′), 142.5 (CAr-4′), 131.7 (CAr), 131.1 (CAr), 130.3 (CAr), 129.8 (CAr), 129.8 
(CArH), 128.2 (CAr), 128.1 (CArH), 130.0 (CArH), 127.5 (CArH), 124.5 (CArH-9′), 
122.9 (CArH-6′), 107.4 (CArH-5′), 60.9 (CAr OCH3), 60.8 CAr OCH3), 56.0 (CAr-3′ 
OCH3), 46.7 (CH2-2), 38.9 (CH-3); m/z (MH+ C22H1979BrO4H+ requires 427.0539) 
found 427.0539, (MH+ C22H1981BrO4H+ requires 429.0522) found 429.0520. 
 
 
- 263 -  
5-Bromo-3-(4-fluorophenyl)-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-
one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(4′-Bromonaphthalen-1′-yl)-3-(4″-fluorophenyl)prop-2-
en-1-one, 55 (7.00 g, 19.7 mmol), trifluoroacetic acid (39 mL, ~2 mL/mmol) and 
phosphorus pentoxide (8.39 g, 29.6 mmol.). The crude product by purified by silica 
column chromatography, eluting with dichloromethane : petroleum ether (1 : 2), 
yielding a yellow solid (5.04 g, 72 %); m.p. 145-146 °C; νmax/cm-1 3059 (w, CAr-H, 
stretch), 1689 (s, C=O, stretch); δH (500 MHz, CDCl3) 9.24 (1H, d, J 8.5, ArH-9), 
8.30 (1H, d, J 8.5, ArH-5), 7.78-7.73 (1H, m, ArH-8), 7.71-7.67 (1H, m, ArH-7), 7.60 
(1H, s, ArH-4), 7.14-7.08 (2H, m, 2 x ArH-2′), 7.02 (2H, t, J 8.5, 2 x ArH-3′), 4.60 
(1H, dd, J 8, 3.5, CH-3), 3.32 (1H, dd, J 19, 8, CHH-2), 2.75 (1H, dd, J 19, 3.5, CHH-
2); δC (125 MHz, CDCl3) 205.3 (C-1), 162.0 (d, 1JCF 246, CArF-4′), 160.0 (CAr), 138.4 
(d, 4JCF 3 CAr-1′), 132.2 (CAr), 131.3 (CAr), 130.2 (CAr), 130.1 (CArH), 129.7 (CAr), 
129.3 (d, 3JCF 8, 2 x CArH-2′), 128.3 (CArH), 130.0 (CArH), 127.6 (CArH), 124.6 
(CArH), 116.0 (d, 2JCF 21.5, 2 x CArH-3′), 47.5 (CH2-2), 43.5 (CH-3); δF (282 MHz, 
CDCl3) -115.1 (m, CArF-4′); m/z (MH+ C19H1279BrFOH+ requires 355.0128) found 
355.0133, (MH+ C19H1281BrFOH+ requires 357.0110) found 357.0018. 
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5-Bromo-3-(4′-chlorophenyl)-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-
one  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.3, using (E)-1-(4′-Bromonaphthalen-1′-yl)-3-(4″-chlorophenyl)prop-2-
en-1-one, 56 (12.00 g, 32.3 mmol), trifluoroacetic acid (65 mL, ~2 mL/mmol) and 
phosphorus pentoxide (13.75, 48.4 mmol). The crude product by purified by silica 
column chromatography, eluting with dichloromethane : petroleum ether (1 : 2), 
yielding a yellow solid (9.12 g, 76 %); m.p. 148-149 °C; νmax/cm-1 3026 (w, CAr-H, 
stretch), 1687 (s, C=O, stretch), 1158 (s, C-O, stretch); δH (400 MHz, CDCl3) 9.21 
(1H, d, J 8, ArH-9), 8.29 (1H, d, J 8.5, ArH-6), 7.74 (1H, t, J 7.5, ArH-8), 7.67 (1H, 
t, J 7.5, ArH-7), 7.58 (1H, s, ArH-4), 7.29 (2H, d, J 8.5, 2 x ArH-3′), 7.06 (2H, d, J 
8.5, 2 x ArH-2′), 4.57 (1H, dd, J 8, 3.5, CH-3), 3.31 (1H, dd, J 19, 8, CHH-2), 2.72 
(1H, dd, J 19, 3.5, CHH-2); δC (100 MHz, CDCl3) 205.2 (C-1), 159.7 (CAr), 141.2 
(CAr-1′), 133.2 (CAr), 132.4 (CAr), 131.4 (CAr), 130.2 (CAr), 130.1 (CArH), 129.6 (CAr), 
129.3 (2 x CArH-2″), 129.1 (2 x CArH-3″), 128.3 (CArH), 127.9 (CArH), 127.6 (CArH), 
124.6 (CArH-9), 47.3 (CH2-2), 43.6 (CH-3); m/z (MNa+ C19H1279Br35ClONa+ requires 
392.9652) found 392.9653, (MNa+ C19H1281Br35ClONa+ requires 394.9631) found 
394.9634. 
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5.2.3.4 Selective cis-reduction using Sodium Borohydride 
The following procedure was performed in accordance with previous literature.344 To 
the substituted indan-1-one (8.4 mmol) in methanol : dichloromethane (1 : 1, 20 mL), 
was added NaBH4 (8.8 mmol) portionwise at 0 °C under constant stirring. The 
resulting reaction mixture was stirred at room temperature for 2 hours, and the solvent 
was removed in vacuo. The reaction mixture was then dissolved in diethyl ether (50 
mL) and washed with water (40 mL), brine (40 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was then purified by flash column 
chromatography or as mentioned specifically.  
 
5.2.3.5 Selective cis-reduction using L-Selectride 
The following procedure was performed in accordance with previous literature.364 To 
a solution of lithium tri-sec-butylborane solution (L-Selectride®) in THF (1.0 M, 15.0 
mL, 15.0 mmol) at -78 °C was added 3-substituted inden-1H-one in THF (2.0 M, 4.00 
g, 11.5 mmol) slowly and the mixture was stirred for 3 hours. The reaction mixture 
was then warmed up gradually to room temperature, and saturated aqueous NH4Cl was 
added. After extraction with CH2Cl2, the combined organic layers were washed with 
brine (20 mL), water (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. 
The residue was purified by silica column chromatography as mentioned specifically. 
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(1RS,3RS)-6-Methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol  
 
80 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 6-methoxy-3-phenyl-2,3-dihydro-1H-inden-1-one, 59 (5.60 g, 
23.5 mmol) and sodium borohydride (0.93 g, 24.7 mmol). The product was used 
without further purification, yielding an off-white solid (5.53 g, 98 %); m.p. 103-104 
°C; νmax/cm-1 3434 (br., O-H, stretch), 3025 (m, CAr-H, stretch), 1278 (s, C-O, 
stretch); δH (400 MHz, CDCl3) 7.36-7.33 (2H, m, 2 x ArH-3′), 7.28-7.24 (3H, m, 
ArH-4′ & 2 x ArH-2′), 7.04 (1H, d, J 2.5, ArH-7), 6.87 (1H, d, J 8.5, ArH-4), 6.82 
(1H, dd, J 2.5, 8.5, ArH-5), 5.27 (1H, t, J 7.5, CH-1), 4.14 (1H, t, J 8.5, CH-3), 3.85 
(3H, s, CAr-6 OCH3), 3.04 (1H, dt, J 13, 7, CHH-2), 2.01 (1H, br. s, C-1 OH), 1.93 
(1H, ddd, J 13, 9, 7.5, CHH-2); δC (100 MHz, CDCl3) 159.4 (CAr-6), 146.6 (CAr), 
144.5 (CAr-1′), 137.6 (CAr), 128.5, 128.1, 126.5 (CArH-4′, 2 x CArH-2′ & 2 x CArH-
3′), 125.8 (CArH-4), 115.2 (CArH-5), 108.0 (CArH-7), 75.1 (CH-1), 55.5 (CAr-6 
OCH3), 47.7 (CH2-2), 47.5 (CH-3); m/z (MNa+ C16H16O2Na+ requires 263.1043) 
found 263.1038. 
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(1RS,3RS)-6-Methoxy-3-(4′-methoxyphenyl)-2,3-dihydro-1H-inden-1-ol  
O OH
(±)
O  
81 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 6-methoxy-3-(4′-methoxyphenyl)-2,3-dihydro-1H-inden-1-
one, 60 (3.00 g, 11.2 mmol), and sodium borohydide (0.44 g, 11.7 mmol). The crude 
product was purified by silica column chromatography, eluting with ethyl acetate : 
dichloromethane (1 : 9), yielding a off-white solid (2.33 g, 77 %); m.p. 119-120 °C; 
νmax/cm-1 3428 (br., O-H, stretch), 2951 (w, CAr-H, stretch), 1239 (s, C-O, stretch); 
δH (400 MHz, CDCl3) 7.14 (2H, d, J 8.5, 2 x ArH-2′), 7.01 (1H, m, ArH-7), 6.86 (2H, 
d, J 8, 2 x ArH-3′), 6.84-6.77 (2H, m, ArH-4 & ArH-5), 5.23 (1H, t, J 7.5, CH-1), 
4.09 (1H, t, J 8.5, CH-3), 3.83 (3H, s, CAr-6 OCH3), 3.80 (3H, s, CAr-4′ OCH3), 3.06-
2.95 (1H, m, CHH-2), 1.96 (1H, br. s, C-1 OH) 1.89 (1H, dt, J 12.5, 8.5, CHH-2); δC 
(100 MHz, CDCl3) 159.3 (CAr-6), 158.2 (CAr-4′), 146.5 (CAr), 137.9 (CAr), 136.6 
(CAr), 129.1 (2 x CArH-2′), 125.8 (CArH-4), 115.1 (CArH-5), 113.9 (2 x CArH-3′), 107.9 
(CArH-7), 75.0 (CH-1), 55.5, 55.3 (CAr-5 OCH3 & CAr-4′ OCH3), 47.9 (CH2-2), 46.7 
(CH-3); m/z (MNa+ C17H18O3Na+ requires 293.1448) found 293.1157. 
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(1RS,3RS)-3-(3′,4′-Dimethoxyphenyl)-6-methoxy-2,3-dihydro-1H-inden-1-
ol  
 
82 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 3-(3′,4′-dimethoxyphenyl)-6-methoxy-2,3-dihydro-1H-inden-
1-one, 61 (3.25 g, 10.9 mmol) and sodium borohydride (0.43 g, 11.4 mmol). The 
crude product was purified by silica column chromatography, eluting with ethyl 
acetate : dichloromethane (1 : 9), yielding a off-white solid (2.32 g, 71 %); m.p. 95-
96 °C; νmax/cm-1 3250 (br., O-H, stretch), 2998 (CAr-H, stretch), 1233 (s, C-O, 
stretch); δH (400 MHz, CDCl3) 7.02-6.98 (1H, m, ArH-7), 6.88-6.81 (1H, m, ArH), 
6.81-6.72 (3H, m, ArH), 5.22 (1H, t, J 7.5, CH-1), 4.07 (1H, t, J 8, CH-3), 3.86 (3H, 
s, CAr OCH3), 3.80 (3H, s, CAr-6 OCH3), 3.80 (3H, s, CAr OCH3), 2.98 (1H, dt, J 13, 
7, CHH-2), 2.25 (1H, br. s, C-1 OH) 1.91 (1H, dd, J 12.5, 8.5, CHH-2); δC (100 MHz, 
CDCl3) 159.2 (CAr-6), 148.9 (CAr), 147.5 (CAr), 146.5 (CAr), 137.6 (CAr), 137.0 (CAr), 
125.9 (CArH), 120.1 (CArH), 115.0 (CArH), 111.0 (CArH), 107.9 (CArH-7), 74.7 (CH-
1), 55.8 (CAr OCH3), 55.7 (CAr OCH3), 55.4 (CAr OCH3), 47.6 (CH2-2), 47.1 (CH-3), 
(missing 1 x CAr); m/z MNa+ C18H20O4Na+ requires 323.1254) found 323.1253. 
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(1RS,3RS)-6-Methoxy-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
inden-1-ol  
 
83 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 6-methoxy-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
inden-1-one, 62 (4.00 g, 12.2 mmol) and sodium borohydride (0.48 g, 12.8 mmol). 
The crude product was purified by silica column chromatography, eluting with ethyl 
acetate : dichloromethane (1 : 9), yielding a yellow oil (2.82 g, 70 %); νmax/cm-1 3473 
(br., O-H, stretch), 2936 (w, CAr-H, stretch), 1118 (s, C-O, stretch); δH (500 MHz, 
CDCl3) 7.01 (1H, d, J 2, ArH-7), 6.91 (1H, d, J 8.5, ArH-4), 6.81 (1H, dd, J 8.5, 2.5, 
ArH-5), 6.44 (2H, s, ArH-2′), 5.23 (1H, t, J 7.5, CH-1), 4.09-4.03 (1H, m, CH-3), 
3.84 (3H, s, CAr-4′ OCH3), 3.83 (3H, s, CAr-6 OCH3), 3.81 (6H, s, 2 x CAr-3′ OCH3), 
3.01 (1H, dt, J 13, 7, CHH-2), 1.93 (1H, ddd, J 13, 9, 8, CHH-2), missing CAr-1 OH); 
δC (125 MHz, CDCl3) 159.5 (CAr-6), 153.3 (2 x CAr-3′), 146.5 (CAr), 140.2 (CAr), 
137.3 (CAr-4′), 125.8 (CArH-4), 122.6 (CAr), 115.2 (CArH-5), 108.0 (CArH-7), 105.0 
(2 x CArH-2′), 74.8 (CH-1), 60.8 (CAr OCH3), 56.1 (CAr OCH3), 55.5 (CAr OCH3), 
47.9 (CH-3), 47.6 (CH2-2); m/z (MNa+ C19H22O5Na+ requires 353.1359) found 
353.1369. 
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(1RS,3RS)-6-Methoxy-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-
inden-1-ol  
 
84 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 6-methoxy-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-
inden-1-one, 63 (2.37 g, 7.2 mmol) and sodium borohydride (0.29 g, 7.6 mmol). The 
crude product was purified by silica column chromatography, eluting with ethyl 
acetate : dichloromethane (1 : 9), yielding a yellow oil (1.57 g, 66 %); νmax/cm-1 3399 
(br., O-H, stretch), 2935 (w, CAr-H, stretch), 1191 (s, C-O, stretch); δH (400 MHz, 
CDCl3) 7.06-7.02 (1H, m, ArH-7), 6.94-6.87 (1H, m, ArH-4), 6.83-6.77 (2H, m, ArH-
5 and ArH-6′), 6.62 (1H, d, J 8.5, ArH-5′), 5.21 (1H, t, J 6, CH-1), 4.37 (1H, t, J 7.5, 
CH-3), 3.87 (3H, s, CAr OCH3), 3.84 (3H, s, CAr OCH3), 3.83 (3H, CAr OCH3), 3.58 
(3H, s, CAr OCH3), 3.10-3.00 (1H, m, CHH-2), 2.62 (1H, br. s, C-1 OH), 1.97-1.85 
(1H, m, CHH-2); δC (100 MHz, CDCl3) 159.3 (CAr), 152.4 (CAr), 146.6 (CAr), 138.0 
(CAr), 131.2 (CAr), 125.5 (CArH-4), 125.5 (CAr), 123.3 (CArH), 115.4 (CArH), 108.4 
(CArH-7), 107.4 (CArH-5′), 75.4 (CH-1), 60.8 (CAr OCH3), 60.7 (CAr OCH3), 55.9 (CAr 
OCH3), 55.4 (CAr OCH3), 46.0 (CH2-2), 42.3 (CH-3), (missing 1 x CAr); m/z (MNa+ 
C19H22O5Na+ requires 353.1359) found 353.1356. 
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(1RS,3RS)-3-(4′-Fluorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-ol  
 
85 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 3-(4′-fluorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-one, 
64 (8.67 g, 33.8 mmol) and sodium borohydride (1.34 g, 35.5 mmol). The crude 
product was purified by silica column chromatography, eluting with ethyl acetate : 
dichloromethane (1 : 9), yielding a white solid (6.99 g, 80 %); m.p. 89-90 °C; νmax/cm-
1 3232 (br., O-H, stretch), 3038 (w, CAr-H, stretch), 1220 (s, C-O, stretch); δH (400 
MHz, CDCl3) 7.21-7.15 (2H, m, 2 x ArH-2′), 7.03-6.96 (3H, m, 2 x ArH-3′ & ArH-
7), 6.84-6.78 (2H, m, ArH-4 & ArH-5), 5.28-5.17 (1H, m, CH-1), 4.18-4.06 (1H, m, 
CH-3), 3.83 (3H, s, CAr-6 OCH3), 3.01 (1H, dt, J 13, 7, CHH-2), 1.99 (1H, br. s, C-1 
OH) 1.88 (1H, ddd, J 13, 9, 7.5, CHH-2); δC (100 MHz, CDCl3) 161.6 (d, 1JCF 245, 
CAr-4′), 159.5 (CAr-6), 146.6 (CAr), 140 (d, 4JCF 3, CAr-1′), 137.4 (CAr), 129.5 (d, 3JCF 
8, 2 x CArH-2′), 125.7 (CArH-4), 115.3 (d, 2JCF 21, 2 x CArH-3′), 115.2 (CArH-5), 108.1 
(CArH-7), 75.0 (CH-1), 55.5 (CAr-6 OCH3), 47.7 (CH2-2), 46.8 (CH-3); δF (376 MHz, 
CDCl3) -116.7 (m, CArF-4′); m/z (MNa+ C16H15FO2Na+ requires 281.0948) found 
281.0946. 
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(1RS,3RS)-3-(4′-Chlorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-ol  
 
86 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 3-(4′-chlorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-one 
(3.69, 13.5 mmol), 65 and sodium borohydride (0.54 g, 14.2 mmol). The crude 
product was purified by silica column chromatography, eluting with ethyl acetate : 
dichloromethane (1 : 9), yielding a off white-solid (3.38 g, 91 %); m.p. 101-102 °C; 
νmax/cm-1 3248 (br., O-H, stretch), 2934 (w, CAr-H, stretch), 1201 (s, C-O, stretch); 
δH (400 MHz, CDCl3) 7.29-7.22 (2H, m, 2 x ArH-3′), 7.17-7.11 (2H, m, 2 x ArH-2′), 
7.01-6.98 (1H, m, ArH-7), 6.81-6.77 (2H, m, ArH-4, ArH-5), 5.22 (CH-1), 4.14-4.06 
(1H, m, CH-3), 3.81 (3H, s, CAr-6 OCH3), 2.99 (1H, dt, J 13, 7, CHH-2), 2.14 (1H, 
br. s, C-1 OH), 1.87 (1H, ddd, J 13, 9, 7.5, CHH-2); δC (100 MHz, CDCl3) 159.5 
(CAr-6), 146.6 (CAr), 143.1 (CAr), 137.1 (CAr), 132.2 (CAr), 129.5 (2 x CArH-2′), 128.6 
(2 x CArH-3′), 125.7 (CArH-4), 115.2 (CArH-5), 108.2 (CArH-7), 74.9 (CH-1), 55.5 
(CAr-6 OCH3), 47.5 (CH2-2), 46.9 (CH-3); m/z (MNa+ C16H15ClO2Na+ requires 
297.0653) found 297.0651. 
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(1RS,3RS)-3-(3′-Fluoro-4′-methoxyphenyl)-4,5,6-trimethoxy-2,3-dihydro-
1H-inden-1-ol  
 
87 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.5, using 3-(3′-fluoro-4′-methoxyphenyl)-4,5,6-trimethoxy-3,4-
dihydro-1H-inden-1-one, 66 (4.00 g, 11.5 mmol) and L-Selectride (1.0 M, 15 mL, 
15.0 mmol). The crude product was purified by silica column chromatography, 
eluting with ethyl acetate : dichloromethane (1 : 9), yielding a viscous yellow oil (2.21 
g, 55 %); νmax/cm-1 3419 (br., O-H, stretch), 2936 (w, CAr-H, stretch), 1112 (s, C-O, 
stretch); δH (400 MHz, CDCl3) 6.99 (1H, dd, J 12.5, 2, ArH-2′), 6.94 (1H, dd, J 8.5, 
1.5, ArH-6′), 6.89 (1H, t, J 8.5, ArH-5′), 6.80 (1H, s, ArH-7), 5.17 (1H, dd, J 11, 6, 
CH-1), 4.25 (1H, dd, J 8.5, 5.5, CH-3), 3.90 (3H, s, CAr-6 OCH3), 3.86 (3H, CAr-4′ 
OCH3), 3.81 (3H, s, CAr-5 OCH3), 3.44 (3H, s, CAr-4 OCH3), 3.00-2.92 (1H, m, CHH-
2), 1.84 (1H, ddd, J 14, 5.5, 4.5, CHH-2), 1.84 (1H, d, J 4.5, C-1 OH); δC (100 MHz, 
CDCl3) 154.4 (CAr-6), 152.3 (d, 1JCF 245 CAr-3′), 150.1 (CAr-4), 145.8 (d, 2JCF 11, 
CAr-4′), 142.7 (CAr-5), 140.4 (CAr), 139.3 (d, 2JCF 6, CAr-1′), 130.1 (CAr), 123.0 (d, 
3JCF 3, CArH-5′), 115.4 (d, 2JCF 18, CArH-2′), 113.2 (d, 4JCF 2, CArH-6′), 102.6 (CArH-
7), 75.8 (CH-1), 60.8 (CAr-5′ OCH3), 60.0 (CAr-4 OCH3), 56.3, 56.1 (CAr-4′ OCH3 & 
CAr-6 OCH3), 46.1 (CH-3), 46.0 (CH2-2); δF (376 MHz, CDCl3) -135.4 (m, CArF-3′); 
m/z (MNa+ C19H21FO5Na+ requires 371.1265) found 371.1266. 
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(1RS,3RS)-3-(4′-Methoxy-3′-nitrophenyl)-4,5,6-trimethoxy-2,3-dihydro-
1H-inden-1-ol  
 
88 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 3-(3′-nitro-4′-methoxyphenyl)-4,5,6-trimethoxy-3,4-dihydro-
1H-inden-1-one, 67 (3.12 g, 8.4 mmol) and sodium borohydride (0.33 g, 8.8 mmol). 
The crude product was purified by silica column chromatography, eluting with ethyl 
acetate : dichloromethane (5 : 95), yielding a yellow oil (1.60 g, 51 %); νmax/cm-1 
3420 (br., O-H, stretch), 2970 (w, CAr-H, stretch), 1112 (s, C-O, stretch); δH (400 
MHz, CDCl3) 7.78 (1H, d, J 2.5, ArH-2′), (1H, dd, J 8.5, 2.5, ArH-6′), 7.00 (1H, d, J 
8.5, ArH-5′), 6.79 (1H, s, ArH-7), 5.23-5.13 (1H, m, CH-1), 4.29 (1H, dd, J 8.5, 5.5, 
CH-3), 3.92 (3H, s, CAr-4′ OCH3), 3.88 (3H, s, CAr-6 OCH3), 3.80 (3H, s, CAr-5 
OCH3), 3.46 (3H, s, CAr-4 OCH3), 2.95 (1H, ddd, J 14, 8.5, 7, CHH-2), 2.20 (1H, br. 
s, C-1 OH), 1.93-1.85 (1H, m, CHH-2); δC (100 MHz, CDCl3) 154.6 (CAr-6), 151.2 
(CAr-4′), 149.8 (CAr-4), 142.5 (CAr-5), 140.4 (CAr), 139.2 (CAr), 138.4 (CAr), 133.4 
(CArH-6′), 129.3 (CAr), 124.8 (CArH-2′), 113.3 (CArH-5′), 102.7 (CArH-7), 75.4 (CH-
1), 60.7 (CAr-5 OCH3), 60.0 (CAr-4 OCH3), 56.5 (CAr-4′ OCH3), 56.1 (CAr-6 OCH3), 
45.7 (CH2-2), 45.7 (CH-3); m/z (MNa+ C19H21NO7Na+ requires 398.1210) found 
398.1210. 
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(1RS,3RS)-3-Phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-ol  
 
89 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 3-phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one, 68 
(3.50 g, 13.5 mmol) and sodium borohydride (0.54 g, 14.2 mmol). The crude product 
was purified by recrystallisation in methanol, yielding a white solid (3.07 g, 87 %); 
m.p. 137 °C, (lit. 138 °C); νmax/cm-1 3274 (br., O-H, stretch), 3054 (m, CAr-H, stretch); 
δH (400 MHz, CDCl3) 8.38 (1H, d, J 8, ArH-9), 7.91 (1H, d, J 8, ArH-6), 7.80 (1H, 
d, J 8.5, ArH-5), 7.64-7.57 (1H, m, ArH-8), 7.52 (1H, dd, J 13.5, 6.5, ArH-7), 7.38-
7.32 (3H, m, ArH-4′ & 2 x ArH-3′), 7.29 (2H, d, J 7.5, 2 x ArH-2′), 7.17 (1H, d, J 
8.5, ArH-4), 5.88-5.79 (1H, d, J 5, CH-1), 4.42 (1H, dd, J 8.5, 6, CH-3), 3.24 (1H, 
ddd, J 16, 8.5, 7.5, CHH-2), 2.19-2.08 (2H, m, CHH-2 & C-1 OH); δC (100 MHz, 
CDCl3) 145.3 (CAr-1′), 143.4 (CAr), 139.2 (CAr), 133.3 (CAr), 130.1 (CAr), 129.7 
(CArH-5), 128.5 (CArH), 128.1 (CArH), 126.6 (CArH), 126.5 (CArH), 125.5 (CArH-7), 
124.2 (CArH-9), 123.4 (CArH-4), 75.4 (CH-1), 49.4 (CH-3), 45.9 (CH2-2); m/z (MNa+ 
C19H16ONa+ requires 283.1093) found 283.1093. 
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(1RS,3RS)-3-(3′,4′,5′-Trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
 
90 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one, 69 (2.00 g, 5.7 mmol) and sodium borohydride (0.22 
g, 6.0 mmol). The crude product was purified by silica column chromatography, 
eluting with diethyl ether : petroleum ether (1 : 4), yielding a orange solid (1.23 g, 61 
%); m.p. 125-126 °C; νmax/cm-1 3513 (br. s, OH, stretch), 2923 (w, CAr-H, stretch), 
1294 (s, C-O, stretch); δH (400 MHz, CDCl3) 8.35 (1H, d, J 8, ArH-9), 7.87 (1H, d, J 
8, ArH-6), 7.76 (1H, d, J 8.5, ArH-5), 7.56-7.44 (2H, m, ArH-8 & ArH-7), 7.17 (1H, 
d, J 8.5, ArH-4), 6.53 (2H, s, 2 x ArH-2″), 5.77 (1H, t, J 6, CH-1), 4.26 (1H, t, J 7.5, 
CH-3), 3.86 (3H, s, CAr-4′ OCH3), 3.76 (6H, s, 2 x CAr-3′ OCH3), 3.16 (1H, dt, J 13.5, 
8, CHH-2), 2.77 (1H, br. s, C-1 OH), 2.13 (1H, dt, J 13.5, 6, CHH-2); δC (100 MHz, 
CDCl3) 153.1 (2 x CAr-3′), 143.1 (CAr), 140.9 (CAr), 139.0 (CAr-4′), 136.3 (CAr), 133.1 
(CAr), 130.0 (CAr), 129.4 (CArH-5), 128.3 (CArH-6), 126.3 (CArH-8), 125.3 (CArH-7), 
124.0 (CArH-9), 123.1 (CArH-4), 105.0 (2 x CArH-2′), 74.9 (CH-1), 60.6 (CAr-4′ 
OCH3), 55.8 (2 x CAr-3′ OCH3), 49.6 (CH-3), 45.7 (CH2-2); m/z (MNa+ C22H20O4Na+ 
requires 373.1410) found 373.1413. 
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(1RS,3RS)-5-Fluoro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]naphthalen-1-ol  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 5-fluoro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one, 70 (1.73 g, 4.7 mmol) and sodium borohydride (0.19 
g, 5.0 mmol). The crude product was purified by recrystallisation in methanol, 
yielding a yellow solid (1.02 g, 57 %); m.p. 170-171 °C; νmax/cm-1 3438 (br. s, OH, 
stretch), 1252 (s, C-O, stretch), 1123 (s, C-F, stretch); δH (500 MHz, CDCl3) 8.33 
(1H, d, J 8.5, ArH-9), 8.11 (1H, d, J 8.5, ArH-6), 7.62 (1H, t, J 7.5, ArH-8), 7.55 (1H, 
t, J 7.5, ArH-7), 6.83 (1H, d, J 10.5, ArH-4), 6.49 (2H, s, 2 x ArH-2′), 5.77 (1H, dd, 
J 11, 5.5, CH-1), 4.27 (1H, dd, J 8, 7, CH-3), 3.85 (3H, s, CAr-4′ OCH3), 3.79 (6H, s, 
2 x CAr-3′ OCH3), 3.19 (1H, ddd, J 14, 8.5, 7.5, CHH-2), 2.18 (1H, d, J 6.5, C-1 OH), 
2.16-2.10 (1H, m, CHH-2); δC (125 MHz, CDCl3) 159.8 (d, 1JCF 253, CAr-5), 153.4 
(2 x CAr-3′), 143.7 (d, JCF 8, CAr), 140.3 (CAr), 136.6 (CAr-4′), 131.1 (d, 3JCF 5, CAr), 
127.6 (CArH-8), 125.8 (CArH-7), 124.1 (d, 4JCF 2, CArH-9), 123.5 (d, 2JCF 17, CAr-5a), 
121.4 (d, 3JCF 6, CArH-6), 106.7 (d, 2JCF 21, CArH-4), 105.0 (2 x CArH-2′), 74.8 (CH-
1), 60.8 (CAr-4′ OCH3), 56.1 (2 x CAr-3′ OCH3), 50.1 (d, 4JCF 1, CH-3), 46.0 (CH2-2), 
(missing 1 x CAr); δF (376 MHz, CDCl3) -117.3 (m, CArF-5); m/z (MNa+ 
C22H21FO4Na+ requires 391.1316) found 391.1322. 
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(1RS,3RS)-5-Chloro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 5-chloro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one, 71 (1.17 g, 3.1 mmol) and sodium borohydride (0.12 
g, 3.2 mmol). The crude product was purified by recrystallisation in methanol, 
yielding a white solid (0.71 g, 60 %); m.p. 183-184 °C; νmax/cm-1 3392 (br. s, OH, 
stretch), 1231 (s, C-O, stretch), 1123 (s, C-Cl, stretch); δH (500 MHz, CDCl3) 8.37 
(1H, dd, J 6.5, 2.5, ArH-9), 8.31 (1H, dd, J 7, 2.5, ArH-6), 7.65-7.58 (2H, m, ArH-7 
& ArH-8), 7.27 (1H, s, ArH-4), 6.49 (2H, s, ArH-2′), 5.80 (1H, t, 7, CH-1), 4.27 (1H, 
dd, 8.5, 6.5, CH-3), 3.85 (3H, s, CAr-4′ OCH3), 3.80 (6H, s, 2 x CAr-3′ OCH3), 3.19 
(1H, ddd, J 14, 8.5, 7.5, CHH-2), 2.22-2.10 (2H, m, CHH-2 & C-1 OH); δC (125 
MHz, CDCl3) 153.4 (2 x CAr-3′), 143.5 (CAr), 138.3 (CAr), 136.7 (CAr-4′), 133.3 (CAr), 
131.0 (CAr), 130.4 (CAr), 127.4, 126.6 (CArH-7 & CArH-8), 125.2 (CArH-6), 124.6 
(CArH-9), 123.6 (CArH-4), 105.0 (2 x CArH-2′), 74.9 (CH-1), 60.8 (CAr-4′ OCH3), 56.1 
(2 x CAr-3′ OCH3), 49.8 (CH-3), 45.8 (CH2-2), (missing 1 x CAr); m/z (MNa+ 
C22H21ClO4Na+ requires 407.1021) found 407.1021. 
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(1RS,3RS)-5-Bromo-3-phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-
ol  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 5-bromo-3-phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-
1-one, 72 (1.20, 3.6 mmol) and sodium borohydride (0.14 g, 3.7 mmol). The crude 
product was purified by recrystallisation in methanol, yielding a white solid (0.96 g, 
81 %); m.p. 202-203 °C; νmax/cm-1 3373 (br. s, OH, stretch), 1033 (s, C-Br, stretch); 
δH (500 MHz, CDCl3) 8.38-8.35 (1H, m, ArH-9), 8.30-8.26 (1H, m, ArH-6), 7.65-
7.57 (2H, m, ArH-7 & ArH-8), 7.45 (1H, s, ArH-4), 7.36-7.31 (2H, m, 2 x ArH-3′), 
7.26 (3H, m, 2 x ArH-2′ & ArH-4′), 5.79 (1H, dd, J 7, 5, CH-1), 4.38 (1H, dd, J 8.5, 
6, CH-3), 3.23 (1H, ddd, J 14, 8.5, 7.5, CHH-2), 2.16-2.14 (1H, m, CHH-2), 1.97 
(1H, br. s, C-1 OH); δC (125 MHz, CDCl3) 144.5 (CAr), 144.0 (CAr), 139.2 (CAr), 
131.6 (CAr), 131.1 (CAr), 128.8 (CArH), 128.0 (CArH), 127.9 (CArH), 127.4 (CArH), 
126.9 (CArH), 126.8 (CArH), 124.7 (CArH), 124.4 (CArH-9), 75.2 (CH-1), 49.4 (CH-
3), 45.9 (CH2-2), (missing 1 x CAr); m/z (MNa+ C19H1579BrONa+ requires 361.0198) 
found 361.0200, (MNa+ C19H1581BrONa+ requires 363.0180) found 363.0182. 
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(1RS,3RS)-5-Bromo-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 5-bromo-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]naphthalen-1-one, 73 (0.65 g, 1.8 mmol) and sodium borohydride (70 
mg, 1.9 mmol). The crude product was purified by recrystallisation in methanol, 
yielding an off-white solid (0.59 g, 91 %); m.p. 169-170 °C; νmax/cm-1 3434 (br. s, 
OH, stretch), 1292 (s, C-O, stretch), 1036 (s, C-Br, stretch); δH (500 MHz, CDCl3) 
8.39-8.34 (1H, m, ArH-9), 8.30-8.26 (1H, m, ArH-6), 7.64-7.57 (2H, m, ArH-7 & 
ArH-8), 7.44 (1H, s, ArH-4), 7.17 (2H, d, J 8.5, 2 x ArH-2′), 6.87 (2H, d, J 8.5, 2 x 
ArH-3′), 5.76 (1H, dd, J 12, 7, CH-1), 4.33 (1H, dd, J 8.5, 6.5, CH-3), 3.81 (3H, s, 
CAr-4′ OCH3), 3.20 (1H, ddd, J 14, 8.5, 7.5, CHH-2), 2.09 (1H, ddd, J 14, 6, 5, CHH-
2), 1.98 (1H, d, J 7, C-1 OH); δC (125 MHz, CDCl3) 158.4 (CAr-4′), 144.4 (CAr), 139.1 
(CAr), 136.6 (CAr), 131.5 (CAr), 131.2 (CAr), 129.0 (2 x CArH-2′), 127.9 (CArH-6), 
127.5 (CArH-4), 127.4, 126.9 (CArH-7 & CArH-8), 124.7 (CArH-9), 124.3 (CAr), 114.2 
(2 x CArH-3′), 75.1 (CH-1), 55.3 (CAr-4′ OCH3), 48.5 (CH-3), 46.1 (CH2-2); m/z 
(MNa+ C20H1779BrO2Na+ requires 391.0304) found 391.0306, (MNa+ 
C20H1781BrO2Na+ requires 393.0286) found 393.0287. 
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(1RS,3RS)-5-Bromo-3-(2′,3′-dimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 5-bromo-3-(2′,3′-dimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one, 74 (1.97 g, 5.0 mmol) and sodium borohydride (0.20 
g, 5.2 mmol). The crude product was purified by recrystallisation with methanol, 
yielding a off-white solid (1.45 g, 73 %); m.p. 145-146 °C; νmax/cm-1 3384 (br. s, OH, 
stretch), 2939 (w, CAr-H, stretch), 1017 (m, C-Br, stretch); δH (400 MHz, CDCl3) 8.33 
(1H, d, J 7.5, ArH-9), 8.26 (1H, d, J 8, ArH-6), 7.67-7.55 (2H, m, ArH-7 & ArH-8), 
7.50 (1H, s, ArH-4), 7.04 (1H, t, J 8, ArH-5′), 6.87 (1H, d, J 8, ArH-6′), 6.79 (1H, d, 
J 7.5, ArH-4′), 5.78-5.67 (1H, m, CH-1), 4.58-4.53 (1H, m, CH-3), 3.86 (3H, s, CAr-
2′ OCH3), 3.31-3.28 (4H, m, CAr-3′ OCH3 & CHH-2), 3.11-3.09 (1H, m, C-1 OH), 
2.13 (1H, d, J 14.5, CHH-2); δC (100 MHz, CDCl3) 153.1 (CAr-2′), 144.0 (CAr-3′), 
138.5 (CAr), 131.4 (CAr), 131.3 (CAr), 127.8 (CArH), 127.5 (CArH), 127.3 (CArH), 
126.8 (CArH-9), 125.0 (CArH-4′), 124.4 (CArH-6′), 124.0 (CAr), 121.7 (CArH-4′), 75.1 
(CH-1), 60.3 (CAr-3′ OCH3), 55.7 (CAr-2′ OCH3), 45.6 (CH-3), 44.3 (CH2-2), 
(missing 2 x CAr); m/z (MNa+ C21H1979BrO3Na+ requires 421.0410) found 421.0413, 
(MNa+ C21H1981BrO3Na+ requires 423.0392) found 423.0395. 
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(1RS,3RS)-5-Bromo-3-(3′,4′-dimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 5-bromo-3-(3′,4′-dimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one, 75 (100 mg, 0.3 mmol) and sodium borohydride 
(10.0 mg, 0.3 mmol). The crude product was purified by recrystallisation with 
methanol, yielding an off-white solid (89 mg, 89 %); m.p. 169-170 °C; νmax/cm-1 3421 
(br. s, OH, stretch), 2955 (w, CAr-H, stretch), 1233 (s, C-O, stretch); δH (400 MHz, 
CDCl3) 8.40-8.22 (2H, m, ArH-9 & ArH-6), 7.68-7.52 (2H, m, ArH-8 & ArH-7), 7.46 
(1H, s, ArH-4), 6.86-6.72 (3H, m, ArH-2′, ArH-5′ & ArH-6′), 5.78 (1H, m, CH-1), 
4.32 (1H, m, CH-3), 3.88 (3H, s, CAr OCH3), 3.82 (3H, s, CAr OCH3), 3.30 (1H, m, 
CHH-2), 2.13 (1H, m, CHH-2), 2.04 (1H, d, J 7, C-1 OH)  ; δC (100 MHz, CDCl3) 
147.9 (CAr), 144.3 (CAr), 139.1 (CAr), 137.1 (CAr), 131.6 (CAr), 131.2 (CAr), 128.0 
(CArH-9), 127.5 (CAr-H), 126.9 (CArH), 124.7 (CArH), 120.1 (CArH), 111.3 (CArH), 
111.2 (CAr), 75.1 (CH-1), 55.9 (CAr OCH3), 49.1 (CAr OCH3), 46.0 (CH2-2), (missing 
1 x CAr & 1 x CH); m/z (MNa+ C21H1979BrO3Na+ requires 421.0410) found 421.0407, 
(MNa+ C21H1981BrO3Na+ requires 423.0392) found 423.0392. 
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(1RS,3RS)-5-Bromo-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphtalen-1-ol  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 5-bromo-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]napthalen-1-one, 76 (1.00 g, 2.3 mmol) and sodium borohydride (93 
mg, 2.5 mmol). The crude product was purified by recrystallisation in methanol, 
yielding a yellow solid (0.88 g, 88 %); m.p. 207-208 °C; νmax/cm-1 2936 (m, CAr-H, 
stretch), 1686 (s, C=O, stretch), 1108 (s, C-O, stretch), 1001 (s, CAr-Br, stretch); δH 
(500 MHz, CDCl3) 8.41-8.33 (1H, m, ArH-9), 8.30-8.27 (1H, m, ArH-6), 7.64-7.58 
(2H, m, ArH-7 & ArH-8), 7.48 (1H, s, ArH-4), 6.49 (2H, s, 2 x ArH-2′), 5.80-5.75 
(1H, m, CH-1), 4.28 (1H, dd, J 8.5, 6.5, CH-3), 3.86 (3H, s, CAr-4′ OCH3), 3.80 (6H, 
2 x CAr-3′ OCH3), 3.19 (1H, ddd, J 14, 8.5, 7.5, CHH-2), 2.14 (1H, ddd, J 14, 6.5, 5, 
CHH-2), 2.18 (1H, C-1 OH); δC (125 MHz, CDCl3) 153.4 (2 x CAr-3′), 143.9 (CAr), 
140.1 (CAr), 139.1 (CAr), 136.7 (CAr-4′), 131.5 (CAr), 131.1 (CAr), 127.9 (CArH-6), 
127.5 (CArH), 127.4 (CArH), 126.9 (CArH), 124.6 (CArH-9), 124.3 (CAr), 105.0 (2 x 
CArH-2′), 74.9 (CH-1), 60.8 (CAr-4′ OCH3), 56.1 (2 x CAr-3′ OCH3), 49.7 (CH-3), 
45.8 (CH2-2); (MH+ C22H1979BrO4H+ requires 427.0539) found 427.0534, (MH+ 
C22H1981BrO4H+ requires 429.0520) found 429.0519. 
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(1RS,3RS)-5-Bromo-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 5-bromo-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one, 77 (0.92 g, 2.2 mmol) and sodium borohydride (86 
mg, 2.3 mmol). The crude product was purified by silica column chromatography, 
eluting with dichloromethane, yielding a orange oil (0.87 g, 82 %); νmax/cm-1 3404 
(br. s, OH, stretch), 2937 (w, CAr-H, stretch), 1148 (s, C-O, stretch); δH (500 MHz, 
CDCl3) 8.32 (1H, dd, J 7.5, 1.5, ArH-9), 8.26 (1H, dd, J 7.5, 1, ArH-6), 7.65-7.56 
(2H, m, ArH-7 & ArH-8), 7.49 (1H, s, ArH-4), 6.82 (1H, d, J 8.5, ArH-6′), 6.63 (1H, 
d, J 8.5, ArH-5′), 5.76-5.67 (1H, m, CH-1), 4.50 (1H, dd, J 9.5, 4.5, CH-3), 3.86 (3H, 
s, CAr-4′ OCH3), 3.85 (3H, s, CAr-3′ OCH3), 3.40 (3H, s, CAr-2′ OCH3), 3.23 (1H, ddd, 
J 14.5, 9.5, 8, CHH-2), 2.98 (1H, d, J 9, C-1 OH), 2.09 (1H, ddd, J 14.5, 4, 3, CHH-
2); δC (100 MHz, CDCl3) 152.9 (CAr), 151.6 (CAr-2′), 144.1 (CAr), 142.6 (CAr), 139.6 
(CAr), 131.4 (CAr), 131.3 (CAr), 130.8 (CAr), 127.7 (CArH-6), 127.4, 127.2 (CArH-7 & 
CArH-8), 126.8 (CArH-9), 125.0 (CArH-6′), 124.0 (CAr), 123.7 (CAr), 107.4 (CArH-5′), 
75.0 (CH-1), 60.7 (CAr OCH3), 60.6 (CAr-2′ OCH3), 56.0 (CAr OCH3), 45.2 (CH-3), 
44.4 (CH2-2); m/z (MNa+ C22H2179BrO4Na+ requires 451.0515) found 451.0516, 
(MNa+ C22H2181BrO4Na+ requires 453.0498) found 453.0528. 
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(1RS,3RS)-5-Bromo-3-(4′-fluorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 5-bromo-3-(4-fluorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one, 78 (1.00 g, 2.8 mmol) and sodium borohydride (0.11 
g, 3.0 mmol). The crude product was purified by recrystallisation in methanol, 
yielding an off-white solid (0.95 g, 64 %); m.p. 201-202 °C; νmax/cm-1 3454 (br, s, 
OH, stretch), 1505 (s, C-O, stretch), 1075 (s, C-Br, stretch); δH (500 MHz, CDCl3) 
8.37-8.33 (1H, m, ArH-9), 8.31-8.26 (1H, m, ArH-6), 7.65-7.59 (2H, m, ArH-7 & 
ArH-8), 7.42 (1H, s, ArH-4), 7.22 (2H, dd, J 8.5, 5.5, 2 x ArH-2′), 7.02 (2H, t, J 8.5, 
2 x ArH-3′), 5.79 (1H, dd, J 11.5, 7, CH-1), 4.40 (1H, dd, J 8.5, 6, CH-3), 3.21 (1H, 
ddd, J 14, 8.5, 7.5, CHH-2), 2.09 (1H, ddd, J 14, 6, 4.5, CHH-2), 2.00 (1H, d, J 7, C-
1 OH); δC (125 MHz, CDCl3) 161.8 (d, 1JCF 245, CAr-4′), 143.9 (CAr), 140.3 (d, 4JCF 
3, CAr-1′), 139.1 (CAr), 131.6 (CAr), 131.0 (CAr), 129.5 (d, 3JCF 8, 2 x CArH-2′), 128.0 
(CArH), 127.6 (CArH), 127.3 (CArH), 127.0 (CArH), 124.7 (CArH-9), 124.5 (CAr), 115.6 
(d, 2JCF 21, 2 x CArH-3′); δF (376 MHz, CDCl3) -116.2 (m, CArF-4′); m/z (MNa+ 
C19H1479BrFONa+ requires 379.0104) found 379.0104, (MNa+ C19H1481BrFONa+ 
requires 381.0086) found 381.0086 
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(1RS,3RS)-5-Bromo-3-(4′-chlorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.3.4, using 5-bromo-3-(4′-chlorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one, 79 (1.20 g, 3.2 mmol) and sodium borohydride (0.13 
g, 3.39 mmol). The crude product was purified by recrystallisation in methanol, 
yielding a beige solid (1.11 g, 92 %); m.p. 207-208 °C; νmax/cm-1 3455 (br. s, OH, 
stretch), 1074 (m, C-Br, stretch); δH (500 MHz, CDCl3) 8.39-8.35 (1H, m, ArH-9), 
8.30-8.26 (1H, m, ArH-6), 7.66-7.57 (2H, m, ArH-7 & ArH-8), 7.45 (1H, s, ArH-4), 
7.37-7.32 (2H, m, 2 x ArH-2′), 7.29-7.24 (2H, m, 2 x ArH-3′), 5.79 (1H, dd, J 7, 5, 
CH-1), 4.39 (1H, dd, J 8.5, 6, CH-3), 3.23 (1H, ddd, J 14, 8.5, 7.5, CHH-2), 2.14 (1H, 
ddd, J 14, 6, 4.5, CHH-2), 1.97 (1H, br. s, C-1 OH); δC (125 MHz, CDCl3) 144.5 
(CAr), 144.0 (CAr), 139.3 (CAr), 131.6 (CAr), 131.1 (CAr), 128.8 (CArH), 128.0 (CArH), 
127.9 (CArH), 127.4 (CArH), 126.9 (CArH), 126.8 (CArH), 124.7 (CArH-9), 124.4 (CAr), 
75.1 (CH-1), 49.4 (CH-3), 45.9 (CH2-2), (missing 1 x CAr); m/z (MNa+ 
C19H1479BrClONa+ requires 394.9809) found 394.9812, (MNa+ C19H1481BrClONa+ 
requires 396.9788) found 396.9787. 
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5.2.4 Kinetic Resolution – Enzymatic Acylation 
5.2.4.1 Acetylation of Racemic 3-Substituted Inden-1-ols 
The following procedure was performed in accordance with previous literature.523 To 
a solution of 3-substituted inden-1-ol (2.1 mmol) in dichloromethane (40 mL) at 0 °C 
was added pyridine (2.7 mmol) followed by the drop-wise addition of acetic anhydride 
(2.7 mmol) over 10 minutes. The resulting solution was then warmed to room 
temperature and stirred for 16 hours overnight. The reaction mixture was washed three 
times with aqueous HCl solution (1M, 40 mL), brine (40 mL), dried over MgSO4 and 
concentrated in vacuo. The product was then purified as mentioned specifically. 
 
(1′RS,3′RS)-6′-Methoxy-3′-phenyl-2′,3′-dihydro-1′H-inden-1′-yl acetate  
O O
(±)
O
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.1, using (1RS,3RS)-6-methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol, 
80 (0.50 g, 2.1 mmol), acetic anhydride (0.26 mL, 2.7 mmol) and pyridine (0.22 mL, 
2.7 mmol). Further purification was performed using silica column chromatography 
eluting with dichloromethane : petroleum ether (1 : 2), yielding an off-white solid 
(0.52 g, 88 %); m.p. 81-82 °C; νmax/cm-1 3026 (w, CAr-H, stretch), 1721 (s, C=O, 
stretch), 1233 (s, C-O, stretch); δH (400 MHz, CDCl3) 7.34 (2H, t, J  7, 2 x ArH-2″), 
7.30-7.23 (3H, m, 2 x ArH-3″, ArH-4″), 76.96 (1H, d, J 2.5, ArH-7′), 6.93 (1H, d, J 
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8.5, ArH-4′), 6.87 (1H, dd, J 8.5, 2.5, ArH-5′), 6.25 (1H, t, J 7, CH-1′), 4.26 (1H, t, J 
8, CH-3′), 3.85 (3H, s, CAr-6′ OCH3), 3.14 (1H, dt, J 13.5, 7.5, CHH-2′), 2.16 (3H, s, 
CH3-2), 2.12-2.05 (1H, m, CHH-2′); δC (100 MHz, CDCl3) 171.1 (C-1), 159.4 (CAr-
6′), 144.8 (CAr), 142.6 (CAr), 138.5 (CAr), 128.5 (2 x CArH-2″), 128.1, 126.6 (2 x CArH-
3″ & CArH-4″), 126.0 (CArH-4′), 116.0 (CArH-5′), 108.9 (CArH-4′), 76.9 (CH-1′), 55.5 
(CAr-6′ OCH3), 48.0 (CH-3′), 43.3 (CH2-2′), 21.3 (CH3-2); m/z (MNa+ C18H18O3 
requires 305.1148) found 305.1151. 
 
(1′RS,3′RS)-6′-Methoxy-3′-phenyl-2′,3′-dihydro-1′H-inden-1′-yl butyrate  
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The following procedure was performed in accordance with previous literature.524 To 
a solution of butyric acid (4.6 mmol), DMAP (0.4 mmol), DCC (9.2 mmol) in CH2Cl2 
(30 mL), was added (1SR,3SR)-6-methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol, 80 
(4.2 mmol) and the reaction was stirred at room temperature overnight. The reaction 
mixture was then filtered and concentrated in vacuo. The crude product was purified 
by silica column chromatography eluting with ethyl acetate: petroleum ether (1 : 9), 
yielding a pale yellow oil (1.12 g, 86 %); νmax/cm-1 2962 (m, C-H, stretch), 1728 (s, 
C=O, stretch), 1171 (s, C-O, stretch); δH (400 MHz, CDCl3) 7.31 (2H, t, J 7.5,  2 x 
ArH-3″), 7.25-7.21 (3H, m, ArH-4″ & 2 x ArH-2″), 6.91-6.88 (2H, m, ArH-4′ & ArH-
7′), 6.83 (1H, dd, J 8.5, 2.5, ArH-5′), 6.23 (1H, t, J 7, CH-1′), 4.23 (1H, t, J 8, CH-
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3′), 3.81 (3H, s, CAr-6′ OCH3), 3.10 (1H, dt, J 13.5, 8, CHH-2′), 2.36 (2H, m, CH2-
2), 2.04 (1H, ddd, J 14, 7.5, 6.5, CHH-2′), 1.69 (2H, m, CH2-3), 0.96 (3H, t, CH3-4); 
δC (100 MHz, CDCl3) 173.7 (C-1), 159.3 (CAr-6′), 144.8 (CAr-1″), 142.7 (CAr), 138.4 
(CAr), 128.4 (2 x CArH-3″), 128.0, 126.5 (CArH-4″ & 2 x CArH-2″), 125.9 (CArH-4′), 
115.8 (CArH-5′), 108.8 (CArH-7′), 76.5 (CH-1′), 55.4 (CAr-6′ OCH3), 47.9 (CH-3′), 
43.3 (CH2-2′), 36.4 (CH2-2), 18.5 (CH2-3), 13.6 (CH3-4); m/z (MNa+ C20H22O3Na+ 
requires 333.1461) found 333.1467. 
 
 
(1′RS,3′RS)-6′-Methoxy-3′-(4″-methoxyphenyl)-2′,3′-dihydro-1′H-inden-
1′-yl acetate  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.1, using (1RS,3RS)-6-Methoxy-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
inden-1-ol, 81 (100 mg, 0.4 mmol), acetic anhydride (0.05 mL, 0.5 mmol) and 
pyridine (0.04 mL, 0.5 mmol). Further purification was performed using silica 
column chromatography eluting with dichloromethane : petroleum ether (1 : 1), 
yielding a an off-white solid (105 mg, 91 %); m.p. 88-89 °C; νmax/cm-1 2916 (w, CAr-
H, stretch), 1720 (s, C=O, stretch), 1239 (s, C-O, stretch); δH (400 MHz, CDCl3) 8.41 
(2H, d, J 8.5, 2 x ArH-2″), 6.94-6.81 (5H, m, 2 x ArH-3″, ArH-4′, ArH-5′, ArH-7′), 
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6.20 (1H, t, J 6.5, CH-1′), 4.18 (1H, t, J 8, CH-3′), 3.82 (3H, s, CAr-6′ OCH3), 3.80 
(3H, s, CAr-4″ OCH3), 3.08 (1H, dt, J 15, 7.5, CHH-2′), 2.14 (3H, s, CH3-2), 2.05-
2.00 (1H, m, CHH-2′); δC (100 MHz, CDCl3) 171.1 (C-1), 159.2 (CAr-6″), 158.2 (CAr-
4″), 142.4 (CAr), 138.7 (CAr), 136.8 (CAr), 129.0 (2 x CArH-2′), 125.9 (CArH), 115.9 
(CArH), 113.9 (CArH), 108.7 (CArH), 76.7 (CH-1′), 55.5 (CAr OCH3), 55.1 (CAr 
OCH3), 47.1 (CH-3′), 43.4 (CH2-2′), 21.3 (CH-3′); m/z (MNa+ C19H20O4Na+ requires 
335.1254) found 335.1250. 
 
 
 
(1′RS,3′RS)-3′-(3″,4″-Dimethoxyphenyl)-6′-methoxy-2′,3′-dihydro-1′H-
inden-1′-yl acetate  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.1, using (1RS,3RS)-3-(3′,4′-dimethoxyphenyl)-6-methoxy-2,3-
dihydro-1H-inden-1-ol, 82 (100 mg, 0.3 mmol), acetic anhydride (0.04 mL, 0.4 
mmol) and pyridine (0.35 mL, 0.4 mmol). Further purification was performed using 
silica column chromatography eluting with dichloromethane : petroleum ether (1 : 1), 
yielding a off-white solid (90 mg, 82 %); m.p. 95-96 °C; νmax/cm-1 2960 (w, CAr-H, 
stretch), 1719 (s, C=O, stretch), 1246 (s, C-O, stretch); δH (400 MHz, CDCl3) 6.95-
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6.88 (2H, m, ArH-4′ & ArH-6″), 6.86-6.70 (4H, m, ArH-5″, ArH-5′, ArH-7′, ArH-
2″), 6.20 (1H, t, J 6.5, CH-1′), 4.12 (1H, t, J 7.5, CH-3′), 3.86 (3H, s, CAr OCH3), 3.08 
(6H, m, CAr OCH3 & CAr OCH3), 3.15-3.01 (1H, m, CHH-2′), 2.13 (3H, s, CH3-2), 
2.06-1.98 (1H, m, CHH-2′); δC (100 MHz, CDCl3) 170.9 (C-1), 159.2 (CAr), 148.9 
(CAr), 147.5 (CAr), 142.3 (CAr), 137.2 (CAr), 125.8 (CArH), 120.0 (CArH), 115.8 
(CArH), 110.9 (CArH), 110.8 (CArH), 108.7 (CAr), 76.7 (CH-1′), 55.7 (CAr OCH3), 55.7 
(CAr OCH3), 55.3 (CAr OCH3), 47.5 (CH-3′), 43.2 (CH-2′), 21.2 (CH3-2); m/z MNa+ 
C20H22O5Na+ requires 365.1359) found 365.1362. 
 
 
(1′RS,3′RS)-6′-Methoxy-3′-(3″,4″,5″-trimethoxyphenyl)-2′,3′-dihydro-1′H-
inden-1′-yl aceate  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.1, using (1RS,3RS)-5-bromo-3-(3′,4′,5′-trimethoxyphenyl)-2,3-
dihydro-1H-cyclopenta[a]naphtalen-1-ol, 83 (100 mg, 0.3 mmol), acetic anhydride 
(0.04 mL, 0.4 mmol) and pyridine (0.03 mL, 0.4 mmol). Further purification being 
performed using silica column chromatography eluting with dichloromethane : 
petroleum ether (1 : 1), yielding a yellow oil (96 mg, 85 %); νmax/cm-1 2937 (w, CAr-
H, stretch), 1731 (s, C=O, stretch), 1228 (s, C-O, stretch); δH (400 MHz, CDCl3) 6.98-
- 292 -  
6.91 (2H, m, ArH-4′ & ArH-7′), 6.85 (1H, d, J 8.5, ArH-5′), 6.43 (2H, s, 2 x ArH-
2″), 6.21 (1H, t, CH-1′), 4.15 (1H, t, J 8, CH-3′), 3.84 (3H, s, CAr-6′ OCH3), 3.82-3.80 
(9H, s, 2 x CAr-3″ OCH3 & CAr-4″ OCH3), 3.15-3.03 (1H, m, CHH-2′), 2.14 (3H, s,  
CH3-2), 2.08-1.98 (1H, m, CHH-2); δC (100 MHz, CDCl3) 171.0 (C-1), 159.4 (CAr-
6′ OCH3), 153.2 (CAr), 142.5 (CAr), 140.4 (CAr), 138.1 (CAr), 126.0 (CArH-4′), 116.0 
(CArH-5′), 108.8 (CArH-7′), 104.8 (2 x CArH-2″), 76.7 (CH-1′), 60.8 (CAr-6′ OCH3), 
56.0 (CAr OCH3), 55.5 (CAr OCH3), 48.3 (CH-3′), 43.2 (CH2-2′), 21.3 (CH3-2); m/z 
(MNa+ C21H24O6Na+ requires 395.1465) found 395.1465. 
 
 
(1′RS,3′RS)-6′-Methoxy-3′-(2″,3″,4″-trimethoxyphenyl)-2′,3′-dihydro-1′H-
inden-1′-yl acetate  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.1, using (1RS,3RS)-5-bromo-3-(2′,3′,4′-trimethoxyphenyl)-2,3-
dihydro-1H-cyclopenta[a]naphthalen-1-ol, 84 (100 mg, 0.3 mmol), acetic anhydride 
(0.04 mL, 0.4 mmol) and pyridine (0.03 mL, 0.4 mmol). Further purification was 
performed using silica column chromatography eluting with dichloromethane : 
petroleum ether (1 : 1), yielding a orange oil (90 mg, 80 %); νmax/cm-1 2938 (w, CAr-
H, stretch), 1728 (s, C=O, stretch), 1231 (s, C-O, stretch); δH (400 MHz, CDCl3) 6.94-
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6.82 (3H, m, ArH-7′, ArH-4′ & ArH-5′), 6.71 (1H, d, J 8.5, ArH-6′′), 6.60 (1H, d, J 
8.5, ArH-5′′), 6.20 (1H, t, J 6.5, CH-1′), 4.58 (1H, t, J 7.5, CH-3′), 3.91 (3H, s, CAr 
OCH3), 3.88 (3H, s, CAr OCH3), 3.84 (3H, s, CAr OCH3), 3.82 (3H, s, CAr OCH3), 
3.13-3.03 (1H, m, CHH-2′), 2.12 (3H, s, CH3-2), 2.01-1.92 (1H, m, CHH-2′); δC (100 
MHz, CDCl3) 171.1 (C-1), 159.2 (CAr), 152.2 (CAr), 142.6 (CAr), 138.5 (CAr), 138.3 
(CAr), 130.8 (CAr), 125.9 (CArH-7′), 122.8 (CArH-6′′), 115.9 (CArH), 108.8 (CArH), 
107.5 (CArH-5′′), 61.4 (CAr OCH3), 60.8 (CAr OCH3), 55.9 (CAr OCH3), 55.5 (CAr 
OCH3), 42.8 (CH2-2′), 21.4 (CH3-2); m/z (MNa+ C21H24O6Na+ requires 395.1465) 
found 395.1465. 
 
 
(1′RS,3′RS)-3′-(4″-Fluorophenyl)-6′-methoxy-2′,3′-dihydro-1′H-inden-1′-yl 
acetate  
 
107 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.1, using (1RS,3RS)-3-(4′-fluorophenyl)-6-methoxy-2,3-dihydro-1H-
inden-1-ol, 85 (100 mg, 0.4 mmol), acetic anhydride (0.05 mL, 0.5 mmol) and 
pyridine (0.04 mL, 0.05 mmol). Further purification was performed using silica 
column chromatography eluting with dichloromethane : petroleum ether (1 : 1), 
yielding an off-white solid (0.10 g, 90 %); m.p. 123-124 °C; νmax/cm-1 2835 (w, CAr-
H, stretch), 1724 (s, C=O, stretch), 1234 (s, C-O, stretch); δH (400 MHz, CDCl3) 7.16 
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(2H, t, J 8.5, 2 x ArH-2′′), 6.99 (2H, t, 2 x ArH-3′′), 6.92 (1H, s, ArH-7′), 6.91-6.81 
(2H, m, ArH-4′ & ArH-5′), 6.20 (1H, t, J 6.5, CH-1′), 4.22 (1H, t, J 7.5, CH-3′), 3.82 
(3H, s, CAr-6′ OCH3), 3.15-3.05 (1H, m, CHH-2′), 2.13 (3H, s, CH3-2), 2.04-1.94 (1H, 
CHH-2′); δC (100 MHz, CDCl3) 171.0 (C-1), 162.9 (m, C-4′′), 159.4 (CAr-6′), 142.5 
(CAr), 140.5 (CAr), 138.2 (CAr), 129.5 (d, 3JCF 8, 2 x CArH-3′′), 125.9 (CArH-7′), 116.1 
(CArH), 115.3 (d, 2JCF 21, 2 x CArH-2′′), 108.9 (CArH), 55.5 (CAr-6′ OCH3), 47.3 (CH2-
2′), 43.3 (CH-3′), 21.3 (CH3-2); δF (376 MHz, CDCl3) -116.7 (m, CArF-4′′) m/z 
(MNa+ C18H17FO3Na+ requires 323.1054) found 323.1060. 
 
 
 
(1′RS,3′RS)-3′-(4″-Chlorophenyl)-6′-methoxy-2′,3′-dihydro-1′H-inden-1′-yl 
acetate  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.1, using (1RS,3RS)-3-(4′-chlorophenyl)-6-methoxy-2,3-dihydro-1H-
inden-1-ol, 86 (100 mg, 0.4 mmol), acetic anhydride (0.04 mL, 5 mmol) and pyridine 
(0.04 mL, 5 mmol). Further purification was performed using silica column 
chromatography eluting with dichloromethane : petroleum ether (1 : 1), yielding an 
off-white solid (0.10 g, 89 %); m.p. 122-123 °C; νmax/cm-1 2835 (w, CAr-H, stretch), 
1721 (s, C=O, stretch), 1233 (s, C-O, stretch); δH (500 MHz, CDCl3) 7.29 (2H, d, J 
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8.5, 2 x ArH-3″), 7.16 (2H, d, J 8.5, 2 x ArH-2″), 6.95 (1H, d, J 2, ArH-7′), 6.89 (1H, 
d, J 8.5, ArH-4′), 6.86 (1H, dd, J 8.5, 2, ArH-5′), 6.22 (1H, t, J 6.5, CH-1′), 4.23 (1H, 
t, J 7.5, CH-3′), 3.84 (3H, CAr-6′ OCH3), 3.11 (1H, ddd, J 13.5, 8, 7.5, CHH-2′), 2.13 
(3H, s, CH3-2), 2.02 (1H, ddd, J 13.5, 7.5, 6, CHH-2′); δC (125 MHz, CDCl3) 171.0 
(C-1), 159.5 (CAr-6′), 143.4 (CAr), 142.6 (CAr), 137.9 (CAr), 132.1 (CAr), 129.4 (2 x 
CArH-3″), 128.6 (2 x CArH-2″), 125.8 (CArH-7′), 116.1 (CArH-5′), 109.0 (CArH-7′), 
76.7 (CH-1′), 55.5 (CAr-6′ OCH3), 47.3 (CH-3′), 43.1 (CH-2′), 21.2 (CH3-2); m/z 
(MNa+ C18H1735Cl requires 339.0758) found 339.0748. 
 
(1′RS,3′RS)-3′-(3″-Fluoro-4″-methoxyphenyl)-4′,5′,6′-trimethoxy-2′,3′-
dihydro-1′H-inden-1′-yl acetate  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.1, using (1RS,3RS)-3-(3′-fluoro-4′-methoxyphenyl)-4,5,6-trimethoxy-
2,3-dihydro-1H-inden-1-ol, 87 (100 mg, 0.03 mmol), acetic anhydride (0.04 mL, 0.4 
mmol) and pyridine (0.03 mL, 0.04 mmol). Further purification was performed using 
silica column chromatography eluting with dichloromethane, yielding an orange solid 
(0.10 g, 93 %); m.p. 78-79 °C; νmax/cm-1 2943 (w, CAr-H, stretch), 1720 (s, C=O, 
stretch), 1262 (s, C=O, stretch); δH (500 MHz, CDCl3) 6.98-6.94 (2H, m, ArH-5″ & 
ArH-6″), 6.89-6.83 (1H, m, ArH-2″), 6.78 (1H, s, ArH-7′), 6.13 (1H, dd, J 7.5, 2.5, 
CH-1′), 4.33 (1H, CH-3′), 3.87 (3H, s, CAr-6′ OCH3), 3.85 (3H, s, CAr-4″ OCH3), 3.81 
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(3H, s, CAr-5′ OCH3), 3.44 (3H, s, CAr-4′ OCH3), 3.12-3.08 (1H, m, CHH-2′), 2.08 
(3H, s, CH3-2), 2.00 (1H, dt, 14.5, 3, CHH-2′); δC (125 MHz, CDCl3) 170.9 (C-1), 
154.3 (CAr-6′), 152.2 (d, 1JCF 245, CAr-3″), 149.8 (CAr-4′), 145.8 (d, 2JCF 11, CAr-4″), 
143.2 (CAr-5′), 139.0 (d, 3JCF 5.5, CAr-1″), 136.3 (CAr), 132.1 (CAr), 123.2 (d, 3JCF 3.5 
CArH-5″), 115.4 (d, 2JCF 18.5, CArH-2″), 112.9 (d, 4JCF 1.5, CArH-6″), 103.7 (CArH-
7′), 77.7 (CH-1′), 60.7 (CAr-4″ OCH3), 60.1 (CAr-4′ OCH3), 56.2 (CAr OCH3), 56.1 
(CAr OCH3), 46.3 (CH-3′), 41.9 (CH2-2′), 21.3 (CH3-2); δF (282 MHz, CDCl3) -135.5 
(m, CArF-3″); m/z (MNa+ C21H23FO6Na+ requires 413.1371) found 413.1367. 
 
 
(1′RS,3′RS)-3′-(4″-Methoxy-3″-nitrophenyl)-4′,5′,6′-trimethoxy-2′,3′-
dihydro-1′H-inden-1′-yl acetate  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.1, using (1RS,3RS)-3-(4′-Methoxy-3′-nitrophenyl)-4,5,6-trimethoxy-
2,3-dihydro-1H-inden-1-ol, 88 (100 mg, 0.3 mmol), acetic anhydride (0.04 mL, 0.4 
mmol) and pyridine (0.03 mL, 0.04 mmol). Further purification being performed 
using flash column chromatography eluting with dichloromethane, yielding an 
orange oil (0.10 g, 91 %); νmax/cm-1 2939 (w, CAr-H, stretch), 1731 (s, C=O, stretch), 
1527 (s, CAr-NO2, stretch), 1231 (s, C-O, stretch); δH (400 MHz, CDCl3) 7.82 (1H, s, 
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ArH-2′′), 7.52-7.43 (1H, m, ArH-6′′), 7.00 (1H, d, J 8, ArH-5′′), 6.81 (1H, s, ArH-7′), 
6.16 (1H, d, J 7, CH-1′), 4.40 (1H, dd, J 5.5, 2.5, CH-3′), 3.94 (3H, s, CAr-5′ OCH3), 
3.88 (3H, s, CAr-4′ OCH3), 3.81 (3H, s, CAr-4′′ OCH3), 3.51 (3H, s, CAr-6′ OCH3), 
3.05-2.95 (1H, m, CHH-2′), 2.11 (3H, s, CH3-2), 2.04 (1H, dd, J 14, 2, CHH-2′); δC 
(100 MHz, CDCl3) 171.0 (C-1), 154.7 (CAr), 151.4 (CAr), 149.7 (CAr), 143.2 (CAr), 
138.2 (CAr), 136.3 (CAr), 133.7 (CArH-6″), 131.5 (CAr), 125.0 (CArH-2″), 113.1 (CArH-
5″), 104.1 (CArH-7′), 77.6 (CH-1′), 60.7 (CAr-4″ OCH3), 60.2 (CAr-6′ OCH3), 56.5 
(CAr-5′ OCH3), 56.2 (CAr-4′ OCH3), 46.0 (CH-3′), 41.5 (CH2-2′), 21.4 (CH2-2); m/z 
(MNa+ C21H23NO8Na+ requires 440.1316) found 440.1307. 
 
(1′RS,3′RS)-5′-Bromo-3′-(3″,4″,5″-trimethoxyphenyl)-2′,3′-dihydro-1′H-
cyclopenta[a]naphtalen-1′-yl acetate  
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The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.1, using (1RS,3RS)-5-Bromo-3-(3′,4′,5′-trimethoxyphenyl)-2,3-
dihydro-1H-cyclopenta[a]naphtalen-1-ol, 107 (5.00 g, 14.2 mmol), acetic anhydride 
(1.5 mL, 20 mmol) and pyridine (3.45 mL, 40 mmol). Further purification being 
performed using flash column chromatography eluting with dichloromethane : 
petroleum ether (1 : 2), yielding a beige solid (5.31 g, 79 %); m.p. 109-110 °C; 
νmax/cm-1 2994 (w, CAr-H, stretch), 1722 (s, C=O, stretch), 1232 (s, C-O, stretch); δH 
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(400 MHz, CDCl3) 8.33-8.27 (1H, m, ArH-9′), 7.93-7.88 (1H, m, ArH-5′), 7.64-7.59 
(2H, m, ArH-4′ & ArH-5′), 7.54 (1H, s, ArH-4′), 6.81-6.73 (1H, m, CH-1′), 6.46 (2H, 
s, 2 x ArH-2′′), 4.38 (1H, dd, J 9, 4, CH-3′), 3.85 (3H, s, CAr-4′′ OCH3), 3.80 (6H, s, 
2 x CAr-3′′ OCH3), 3.34-3.23 (1H, m, CHH-2′), 2.21-2.09 (4H, m, CH3-2 & CHH-2′); 
δC (100 MHz, CDCl3) 170.5 (C-1), 153.4 (CAr), 145.7 (CAr), 140.1 (CAr), 135.2 (CAr), 
131.5 (CAr), 130.8 (CAr), 128.1 (CArH-9′), 127.8 (CArH), 127.4 (CArH), 127.1 (CArH), 
125.3 (CAr), 124.3 (CArH-5′), 105.0 (2 x CArH-2′′), 76.3 (CH-1′), 60.8 (CAr-4′′ OCH3), 
56.0 (2 x CAr-3′′ OCH3) 50.4 (CH-3′), 42.2 (CH2-2′), 21.3 (CH3-2) (missing 1 x CAr); 
(MNa+ C24H2379BrO5Na+ requires 493.0621) found 493.0630, (MNa+ 
C24H2381BrO5Na+ requires 495.0604) found 495.0618 
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5.2.4.2 Kinetic Resolution: Novozym® 435 Acylations 
The following procedure was performed in accordance with previous literature.359 To 
a solution of (1RS,3RS)-3-substituted-2,3-dihydro-1H-inden-1-ol (10.4 mmol) in 2-
isopropoxypropane : dichloromethane (40 mL, 1 : 1) was added vinyl acetate (42 
mmol) and Novozym-435 (70 mg/mmol). The reaction mixture was then stirred at an 
optimised 40 °C for 48 hours. The solids were filtered off and the filtrate was 
concentrated in vacuo. The product counterparts were separated by silica column 
chromatography eluting with dichloromethane : petroleum ether as mentioned 
specifically. 
 
 
 
(1S,3S)-6-Methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol  
 
(1S,3S)-80  
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-6-Methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol 
(0.50 g, 2.1 mmol) 80, vinyl acetate (0.77 mL, 8.3 mmol)  and Novozym® 435 (145 
mg, 70 mg/mmol) to give compound (1R,3R)-101 and (1S,3S)-80 in a ratio of 50 : 50. 
The title compound was isolated by silica column chromatography, eluting with 
dichloromethane : petroleum ether (3 : 1), to yield an off-white solid (0.24 g, 48 %), 
as a % of racemic starting material, in >99 % e.e.; spectroscopic data similar to that 
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of racemate; [હ]ࡰ૜૙ (c 0.1, CH3OH) +25.0; enantiomeric excess determined by HPLC 
analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 5 : 95 , 1 mL/min., 208 
nm, (S)-isomer 24.61 min., (R)-isomer 40.77 min.). 
  
(1′R,3′R)-6′-methoxy-3′-phenyl-2′,3′-dihydro-1′H-inden-1′-yl acetate  
 
(1R,3R)-101 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-6-Methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol 
(0.50 g, 2.1 mmol) 80, vinyl acetate (0.77 mL, 8.3 mmol)  and Novozym® 435 (145 
mg, 70 mg/mmol) to give compound (1R,3R)-101 and (1S,3S)-80 in a ratio of 50 : 50. 
The title compound was isolated by silica column chromatography, eluting with 
dichloromethane : petroleum ether (3 : 1), to yield an off-white solid (0.28 g, 47 %), 
as a % of racemic starting material, in >99 % e.e.; spectroscopic data similar to that 
of racemate; [હ]ࡰ૜૙ (c 0.1, CHCl3) +12.0; enantiomeric excess determined by HPLC 
analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 mL/min., 
211 nm, (R)-isomer 6.37 min., (S)-isomer 6.96 min.). 
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(1′R,3′R)-6′-methoxy-3′-phenyl-2′,3′-dihydro-1′H-inden-1′-yl butyrate  
 
(1R,3R)-102 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-6-Methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol 
(0.50 g, 2.1 mmol) 80, vinyl acetate (0.77 mL, 8.3 mmol)  and Novozym® 435 (145 
mg, 70 mg/mmol) to give compound (1R,3R)-102 and (1S,3S)-80 in a ratio of 50 : 50. 
The title compound was isolated by silica column chromatography, eluting with 
dichloromethane : petroleum ether (3 : 1), to yield a yellow oil (0.32 g, 49 %), as a % 
of racemic starting material, in 99 % e.e.; spectroscopic data similar to that of 
racemate; [હ]ࡰ૜૙ (c 0.1, CHCl3) +51.0; enantiomeric excess determined by HPLC 
analysis (Diacel Chiralcel OD-H column, 2-propanol : hexane = 5 : 95 , 1 mL/min., 
208 nm, (R)-isomer 5.81 min., (S)-isomer 6.88 min.). 
 
(1S,3S)-6-Methoxy-3-(4′-methoxyphenyl)-2,3-dihydro-1H-inden-1-ol  
 
(1S,3S)-81 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-6-Methoxy-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
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inden-1-ol (150 mg, 0.5 mmol) 81, vinyl acetate (2.0 mL, 2.2 mmol)  and Novozym® 
435 (39 mg, 70 mg/mmol) to give compound (1R,3R)-103 and (1S,3S)-81 in a ratio 
of 50 : 50. The title compound was isolated by silica column chromatography, eluting 
with dichloromethane : petroleum ether (3 : 1), to yield an off-white solid (69 mg, 46 
%), as a % of racemic starting material, in >99 % e.e.; spectroscopic data similar to 
that of racemate; [હ]ࡰ૜૙ (c 0.2, CHCl3) +7.0; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 
mL/min., 228 nm, (S)-isomer 14.41 min., (R)-isomer 28.52 min.). 
 
(1′R,3′R)-6′-Methoxy-3′-(4″-methoxyphenyl)-2′,3′-dihydro-1′H-inden-1′-yl 
acetate  
 
(1R,3R)-103 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-6-Methoxy-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
inden-1-ol (150 mg, 0.5 mmol) 81, vinyl acetate (2.0 mL, 2.2 mmol)  and Novozym® 
435 (39 mg, 70 mg/mmol) to give compound (1′R,3′R)-103 and (1S,3S)-81 in a ratio 
of 50 : 50. The title compound was isolated by silica column chromatography, eluting 
with dichloromethane : petroleum ether (3 : 1), to yield an off-white solid (80 mg, 46 
%), as a % of racemic starting material, in >99 % e.e.; spectroscopic data similar to 
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that of racemate; [હ]ࡰ૜૙ (c 0.1, CHCl3) +6.5; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralpak AD-H column, 2-propanol : hexane = 5 : 95 , 0.5 
mL/min., 229 nm, (R)-isomer 20.83 min., (S)-isomer 22.49 min.). 
 
(1S,3S)-3-(3′,4′-Dimethoxyphenyl)-6-methoxy-2,3-dihydro-1H-inden-1-ol  
 
(1S,3S)-82 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-3-(3′,4′-Dimethoxyphenyl)-6-methoxy-2,3-
dihydro-1H-inden-1-ol (0.90 g, 3.0 mmol) 82, vinyl acetate (1.10 mL, 12 mmol)  and 
Novozym® 435 (210 mg, 70 mg/mmol) to give compound (1R,3R)-104 and (1S,3S)-
82 in a ratio of 47 : 53. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield an 
off-white solid (0.39 g, 44 %), as a % of racemic starting material, in 77 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૜૙ (c 0.1, CHCl3) +12.5; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak IA column, 2-
propanol : hexane = 10 : 90 , 1 mL/min., 209 nm, (R)-isomer 22.40 min., (S)-isomer 
27.28 min.). 
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(1′R,3′R)-3′-(3″,4″-Dimethoxyphenyl)-6′-methoxy-2′,3′-dihydro-1′H-
inden-1′-yl acetate  
 
(1R,3R)-104 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-3-(3′,4′-Dimethoxyphenyl)-6-methoxy-2,3-
dihydro-1H-inden-1-ol (0.90 g, 3.0 mmol) 82, vinyl acetate (1.10 mL, 12 mmol)  and 
Novozym® 435 (210 mg, 70 mg/mmol) to give compound (1R,3R)-104 and (1S,3S)-
82 in a ratio of 47 : 53. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield a 
off-white solid (0.43 g, 42 %), as a % of racemic starting material, in >99 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૜૙ (c 0.2, CHCl3) +1.3; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak IA column, 2-
propanol : hexane = 5 : 95 , 0.5 mL/min., 210 nm, (S)-isomer 32.85 min., (R)-isomer 
35.15 min.). 
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(1S,3S)-6-Methoxy-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-inden-1-
ol  
 
(1S,3S)-83 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-6-Methoxy-3-(3′,4′,5′-trimethoxyphenyl)-2,3-
dihydro-1H-inden-1-ol (2.75 g, 8.3 mmol) 83, vinyl acetate (3.1 mL, 33.3 mmol)  and 
Novozym® 435 (0.58 g, 70 mg/mmol) to give compound (1R,3R)-105 and (1S,3S)-83 
in a ratio of 50 : 50. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane to yield a yellow oil (1.30 g, 47 %), 
as a % of racemic starting material, in 99 % e.e.; spectroscopic data similar to that of 
racemate; [હ]ࡰ૜૙ (c 0.1, CHCl3) +44.0; enantiomeric excess determined by HPLC 
analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 mL/min., 
214 nm, (R)-isomer 25.70 min., (S)-isomer 33.65 min.). 
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(1′R,3′R)-6′-Methoxy-3′-(3″,4″,5″-trimethoxyphenyl)-2′,3′-dihydro-1′H-
inden-1′-yl aceate  
 
(1R,3R)-105 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-6-Methoxy-3-(3′,4′,5′-trimethoxyphenyl)-2,3-
dihydro-1H-inden-1-ol (2.75 g, 8.3 mmol) 83, vinyl acetate (3.1 mL, 33.3 mmol)  and 
Novozym® 435 (0.58 g, 70 mg/mmol) to give compound (1R,3R)-105 and (1S,3S)-83 
in a ratio of 50 : 50. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane to yield a yellow oil (1.48 g, 48 %), 
as a % of racemic starting material, in >99 % e.e.; spectroscopic data similar to that 
of racemate; [હ]ࡰ૜૙ (c 0.1, CHCl3) +3.5; enantiomeric excess determined by HPLC 
analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 mL/min., 
214 nm, (S)-isomer 12.29 min., (R)-isomer 14.77 min.). 
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(1S,3S)-6-Methoxy-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-inden-1-
ol  
 
(1S,3S)-84 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-6-Methoxy-3-(2′,3′,4′-trimethoxyphenyl)-2,3-
dihydro-1H-inden-1-ol (0.90 g, 2.7 mmol) 84, vinyl acetate (1.0 mL, 10.9 mmol)  and 
Novozym® 435 (189 mg, 70 mg/mmol) to give compound (1R,3R)-106 and (1S,3S)-
84 in a ratio of 45 : 55. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane to yield a yellow oil (0.45 g, 50 %), 
as a % of racemic starting material, in 81 % e.e.; spectroscopic data similar to that of 
racemate; [હ]ࡰ૜૙ (c 0.1, CHCl3) +58.0; enantiomeric excess determined by HPLC 
analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 mL/min., 
215 nm, (S)-isomer 16.81 min., (R)-isomer 37.62 min.). 
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(1′R,3′R)-6′-Methoxy-3′-(2″,3″,4″-trimethoxyphenyl)-2′,3′-dihydro-1′H-
inden-1′-yl acetate  
 
(1R,3R)-106 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-6-Methoxy-3-(2′,3′,4′-trimethoxyphenyl)-2,3-
dihydro-1H-inden-1-ol (0.90 g, 2.7 mmol) 84, vinyl acetate (1.0 mL, 10.9 mmol)  and 
Novozym® 435 (189 mg, 70 mg/mmol) to give compound (1R,3R)-106 and (1S,3S)-
84 in a ratio of 45 : 55. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane to yield an orange oil (0.41 g, 40 %), 
as a % of racemic starting material, in >99 % e.e.; spectroscopic data similar to that 
of racemate; [હ]ࡰ૜૙ (c 0.2, CHCl3) +17.8; enantiomeric excess determined by HPLC 
analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 mL/min., 
214 nm, (R)-isomer 6.28 min., (S)-isomer 7.13 min.). 
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(1S,3S)-3-(4′-Fluorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-ol  
 
(1S,3S)-85 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-3-(4′-Fluorophenyl)-6-methoxy-2,3-dihydro-1H-
inden-1-ol (3.00 g, 11.6 mmol) 85, vinyl acetate (4.29 mL, 46.5 mmol)  and 
Novozym® 435 (0.81 g, 70 mg/mmol) to give compound (1R,3R)-107 and (1S,3S)-85 
in a ratio of 49 : 51. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield a 
white solid (1.44 g, 48 %), as a % of racemic starting material, in 94 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૜૙ (c 0.1, CHCl3) +45.5; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak IA column, 2-
propanol : hexane = 10 : 90 , 1 mL/min., 278 nm, (S)-isomer 11.27 min., (R)-isomer 
18.47 min.). 
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(1′R,3′R)-3′-(4″-Fluorophenyl)-6′-methoxy-2′,3′-dihydro-1′H-inden-1′-yl 
acetate  
 
(1R,3R)-107 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-3-(4′-Fluorophenyl)-6-methoxy-2,3-dihydro-1H-
inden-1-ol (3.00 g, 11.6 mmol) 85, vinyl acetate (4.29 mL, 46.5 mmol)  and 
Novozym® 435 (0.81 g, 70 mg/mmol) to give compound (1R,3R)-107 and (1S,3S)-85 
in a ratio of 49 : 51. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield an 
off-white solid (1.64 g, 47 %), as a % of racemic starting material, in >99 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૜૙ (c 0.1, CHCl3) +11.5; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak AD-H column, 
2-propanol : hexane = 5 : 95 , 0.5 mL/min., 228 nm, (R)-isomer 14.99 min., (S)-isomer 
16.23 min.). 
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(1S,3S)-3-(4′-Chlorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-ol  
 
(1S,3S)-86 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-3-(4′-Chlorophenyl)-6-methoxy-2,3-dihydro-1H-
inden-1-ol (1.35 g, 4.9 mmol) 86, vinyl acetate (1.81 g, 20 mmol)  and Novozym® 
435 (343 mg, 70 mg/mmol) to give compound (1R,3R)-108 and (1S,3S)-86 in a ratio 
of 50 : 50. The title compound was isolated by silica column chromatography, eluting 
with dichloromethane : petroleum ether (3 : 1), to yield a white solid (0.65 g, 48 %), 
as a % of racemic starting material, in >99 % e.e.; spectroscopic data similar to that 
of racemate; [હ]ࡰ૜૙ (c 0.1, CHCl3) +34.0; enantiomeric excess determined by HPLC 
analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 mL/min., 
220 nm, (S)-isomer 12.35 min., (R)-isomer 22.24 min.). 
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(1′R,3′R)-3′-(4″-Chlorophenyl)-6′-methoxy-2′,3′-dihydro-1′H-inden-1′-yl 
acetate  
 
(1R,3R)-108 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-3-(4′-Chlorophenyl)-6-methoxy-2,3-dihydro-1H-
inden-1-ol (1.35 g, 4.9 mmol) 86, vinyl acetate (1.81 g, 20 mmol)  and Novozym® 
435 (343 mg, 70 mg/mmol) to give compound (1R,3R)-108 and (1S,3S)-86 in a ratio 
of 50 : 50. The title compound was isolated by silica column chromatography, eluting 
with dichloromethane : petroleum ether (3 : 1), to yield an off-white solid (0.73 g g, 
47 %), as a % of racemic starting material, in >99 % e.e.; spectroscopic data similar 
to that of racemate; [હ]ࡰ૜૙ (c 0.1, CHCl3) +11.5; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralpak AD-H column, 2-propanol : hexane = 5 : 95 , 0.5 
mL/min., 231 nm, (S)-isomer 14.36 min., (R)-isomer 15.97 min.). 
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(1S,3S)-3-(3′-Fluoro-4′-methoxyphenyl)-4,5,6-trimethoxy-2,3-dihydro-1H-
inden-1-ol  
 
(1S,3S)-87 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-3-(3′-Fluoro-4′-methoxyphenyl)-4,5,6-trimethoxy-
2,3-dihydro-1H-inden-1-ol (1.25 g, 3.6 mmol) 87, vinyl acetate (1.3 mL, 14.4 mmol)  
and Novozym® 435 (252 mg, 70 mg/mmol) to give compound (1R,3R)-109 and 
(1S,3S)-87 in a ratio of 49 : 51. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane to yield a yellow oil (0.59 g, 47 %), 
as a % of racemic starting material, in 96 % e.e.; spectroscopic data similar to that of 
racemate; [હ]ࡰ૜૙ (c 0.2, CHCl3) +21.8; enantiomeric excess determined by HPLC 
analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 mL/min., 
224 nm, (S)-isomer 14.35 min., (R)-isomer 16.72 min.). 
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(1′R,3′R)-3′-(3″-Fluoro-4″-methoxyphenyl)-4′,5′,6′-trimethoxy-2′,3′-
dihydro-1′H-inden-1′-yl acetate  
 
(1R,3R)-109 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-3-(3′-Fluoro-4′-methoxyphenyl)-4,5,6-trimethoxy-
2,3-dihydro-1H-inden-1-ol (1.25 g, 3.6 mmol) 87, vinyl acetate (1.3 mL, 14.4 mmol)  
and Novozym® 435 (252 mg, 70 mg/mmol) to give compound (1R,3R)-109 and 
(1S,3S)-87 in a ratio of 49 : 51. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane to yield an orange solid (0.63 g, 45 
%), as a % of racemic starting material, in >99 % e.e.; spectroscopic data similar to 
that of racemate; [હ]ࡰ૜૙ (c 0.2, CHCl3) +7.8; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 5 : 95 , 0.5 
mL/min., 219 nm, (S)-isomer 19.05 min., (R)-isomer 21.71 min.). 
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(1S,3S)-3-(4′-Methoxy-3′-nitrophenyl)-4,5,6-trimethoxy--2,3-dihydro-1H-
inden-1-ol  
 
(1S,3S)-88 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-3-(4′-Methoxy-3′-nitrophenyl)-4,5,6-trimethoxy-
2,3-dihydro-1H-inden-1-ol (0.52 g, 1.4 mmol) 88, vinyl acetate (0.5 mL, 5.5 mmol)  
and Novozym® 435 (108 mg, 70 mg/mmol) to give compound (1R,3R)-110 and 
(1S,3S)-88 in a ratio of 50 : 50. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane to yield a yellow oil (0.25 g, 48 %), 
as a % of racemic starting material, in 98 % e.e.; spectroscopic data similar to that of 
racemate; [હ]ࡰ૜૙ (c 0.1, CHCl3) +61.0; enantiomeric excess determined by HPLC 
analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 mL/min., 
221 nm, (R)-isomer 27.02 min., (S)-isomer 36.84 min.). 
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(1′R,3′R)-3′-(4″-Methoxy-3″-nitrophenyl)-4′,5′,6′-trimethoxy-2′,3′-
dihydro-1′H-inden-1′-yl acetate  
 
(1R,3R)-110 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.2, using (1RS,3RS)-3-(4′-Methoxy-3′-nitrophenyl)-4,5,6-trimethoxy-
2,3-dihydro-1H-inden-1-ol (0.52 g, 1.4 mmol) 88, vinyl acetate (0.5 mL, 5.5 mmol)  
and Novozym® 435 (108 mg, 70 mg/mmol) to give compound (1R,3R)-110 and 
(1S,3S)-88 in a ratio of 50 : 50. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane to yield a orange oil (0.24 g, 46 %), 
as a % of racemic starting material, in >99 % e.e.; spectroscopic data similar to that 
of racemate; [હ]ࡰ૜૙ (c 0.1, CHCl3) +10.5; enantiomeric excess determined by HPLC 
analysis (Diacel Chiralpak AD-H column, 2-propanol : hexane = 5 : 95 , 1 mL/min., 
221 nm, (S)-isomer 30.23 min., (R)-isomer 34.04 min.). 
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5.2.4.3 Deacetylation of Chirally Substituted (R,R Inden-1-yl Acetates 
The following procedure was performed in accordance with previous literature.390 To 
a substituted (1R,3R)-3′-substituted inden-1-yl acetate (1.5 mmol) in methanol (20 
mL) was added K2CO3 (4.5 mmol) and the reaction was stirred at room temperature 
for 2 hours. The reaction mixture was concentrated in vacuo, diluted with H2O (40 
mL), and extracted with EtOAc (2 x 50 mL). The solution was then dried over MgSO4 
and concentrated in vacuo. The product was generally used without further 
purification, unless purified further as mentioned specifically. 
 
 
(1R,3R)-6-Methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol  
 
(1R,3R)-80 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.3, using (1′R,3′R)-6′-methoxy-3′-phenyl-2′,3′-dihydro-1′H-inden-1′-yl 
acetate, (1R,3R)-101 (7.50 g, 26.6 mmol) and potassium carbonate (11.0 g, 79.7 
mmol), yielding a white solid (5.80 g, 91 %); spectroscopic data similar to that of 
racemate; [હ]ࡰ૜૙ (c 0.10, CH3OH) -18.5. 
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(1R,3R)-6-Methoxy-3-(4′-methoxyphenyl)-2,3-dihydro-1H-inden-1-ol  
O OH
O  
(1R,3R)-81 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.3, using (1′R,3′R)-6′-Methoxy-3′-(4″-methoxyphenyl)-2′,3′-dihydro-
1′H-inden-1′-yl acetate, (1R,3R)-103 (0.20 g, 0.6 mmol) and potassium carbonate 
(0.24 g, 1.8 mmol), yielding an off-white solid (133 mg, 87 %); spectroscopic data 
similar to that of racemate; [હ]ࡰ૜૙ (c 0.10, CHCl3) -132.5. 
 
 
 
(1R,3R)-3-(3′,4′-Dimethoxyphenyl)-6-methoxy-2,3-dihydro-1H-inden-1-ol  
 
(1R,3R)-82 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.3, using (1′R,3′R)-3′-(3″,4″-Dimethoxyphenyl)-6′-methoxy-2′,3′-
dihydro-1′H-inden-1′-yl acetate, (1R,3R)-104 (0.28 g, 0.8 mmol) and potassium 
carbonate (0.34 g, 2.5 mmol), yielding a off-white solid (208 mg, 85 %); 
spectroscopic data similar to that of racemate; [હ]ࡰ૜૙ (c 0.10, CHCl3) -16.0. 
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(1R,3R)-6-Methoxy-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-inden-1-
ol  
 
(1R,3R)-83 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.3, using (1′R,3′R)-6′-Methoxy-3′-(3″,4″,5″-trimethoxyphenyl)-2′,3′-
dihydro-1′H-inden-1′-yl aceate, (1R,3R)-105 (0.69 g, 1.9 mmol) and potassium 
carbonate (0.77 g, 5.6 mmol), yielding a yellow oil (0.56 g, 91 %); spectroscopic data 
similar to that of racemate; [હ]ࡰ૜૙ (c 0.10, CHCl3) -50.0. 
 
(1R,3R)-6-Methoxy-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-inden-1-
ol  
 
(1R,3R)-84 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.3, using (1′R,3′R)-6′-Methoxy-3′-(2″,3″,4″-trimethoxyphenyl)-2′,3′-
dihydro-1′H-inden-1′-yl acetate, (1R,3R)-106 (0.28 g, 0.8 mmol) and potassium 
carbonate (0.31 g, 2.3 mmol), yielding a yellow oil (0.22 g, 89 %); spectroscopic data 
similar to that of racemate; [હ]ࡰ૜૙ (c 0.10, CHCl3) -72.0. 
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(1R,3R)-3-(4′-Fluorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-ol  
 
(1R,3R)-85 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.3, using (1′R,3′R)-3′-(4″-Fluorophenyl)-6′-methoxy-2′,3′-dihydro-1′H-
inden-1′-yl acetate, (1R,3R)-107 (1.25 g, 4.2 mmol) and potassium carbonate (1.72 g, 
12.5 mmol), yielding a white solid (0.84 g, 78 %); spectroscopic data similar to that 
of racemate; [હ]ࡰ૜૙ (c 0.10, CHCl3) -51.0. 
 
(1R,3R)-3-(4′-Chlorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-ol  
 
(1R,3R)-86 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.3, using (1′R,3′R)-3′-(4″-Chlorophenyl)-6′-methoxy-2′,3′-dihydro-1′H-
inden-1′-yl acetate, (1R,3R)-108 (0.59 g, 1.9 mmol) and potassium carbonate (0.77 g, 
5.6 mmol), yielding a white solid (0.41 g, 81 %); spectroscopic data similar to that of 
racemate; [હ]ࡰ૜૙ (c 0.10, CHCl3) -36.5. 
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(1R,3R)-3-(3′-Fluoro-4′-methoxyphenyl)-4,5,6-trimethoxy-2,3-dihydro-
1H-inden-1-ol  
 
(1R,3R)-87 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.3, using (1′R,3′R)-3′-(3″-Fluoro-4″-methoxyphenyl)-4′,5′,6′-
trimethoxy-2′,3′-dihydro-1′H-inden-1′-yl acetate, (1R,3R)-109 (0.33 g, 0.8 mmol) 
and potassium carbonate (0.35 g, 2.5 mmol), yielding a yellow oil (0.22 g, 74 %); 
spectroscopic data similar to that of racemate; [હ]ࡰ૜૙ (c 0.10, CHCl3) -44.5. 
 
(1R,3R)-3-(4′-Methoxy-3′-nitrophenyl)-4,5,6-trimethoxy-2,3-dihydro-1H-
inden-1-ol  
 
(1R,3R)-88 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.3, using (1′R,3′R)-3′-(4″-Methoxy-3″-nitrophenyl)-4′,5′,6′-trimethoxy-
2′,3′-dihydro-1′H-inden-1′-yl acetate, (1R,3R)-110 (0.23 g, 0.5 mmol) and potassium 
carbonate (0.22 g, 1.6 mmol), yielding a yellow oil (0.17 g, 81 %); spectroscopic data 
similar to that of racemate; [હ]ࡰ૜૙ (c 0.10, CHCl3) -63.5. 
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5.2.4.4 Oxidation of Chiral Aryl Indan-1-ols 
The following procedure was performed in accordance with previous literature.525 To 
a solution of enantiomerically enriched 3-substituted 2,3-dihydro-1H-inden-1-ol (8.3 
mmol) in dichloromethane (40 mL) was added manganese (IV) oxide (0.125 mol) at 
room temperature. The mixture was stirred for 18 hours, filtered through Celite® and 
concentrated in vacuo. The product was then purified as mentioned specifically in each 
example. 
 
(R)-6-Methoxy-3-phenyl-2,3-dihydro-1H-inden-1-one  
 
(R)-59 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1R,3R)-6-Methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol, 
(1R,3R)-80 (100 mg, 0.4 mmol) and manganese dioxide (~0.50 g), yielding an orange 
solid (81 mg, 82 %); spectroscopic data similar to that of racemate; [હ]ࡰ૛ૡ (c 0.6, 
CHCl3) -51.7). 
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(S)-6-Methoxy-3-phenyl-2,3-dihydro-1H-inden-1-one  
 
(S)-59 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1S,3S)-6-Methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol, 
(1S,3S)-80 (100 mg, 0.4 mmol) and manganese dioxide (~0.50 g), yielding an orange 
solid (83 mg, 84 %); spectroscopic data similar to that of racemate; [હ]ࡰ૛ૡ (c 0.6, 
CHCl3) +55.4, (lit.216 [હ]ࡰ૛ૡ (c 0.6, CHCl3) +43.3) 
 
(R)-6-Methoxy-3-(4′-methoxyphenyl)-2,3-dihydro-1H-inden-1-one  
 
(R)-60 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1R,3R)-6-Methoxy-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
inden-1-ol, (1R,3R)-81 (100 mg, 0.4 mmol ) and manganese dioxide (~0.50 g), 
yielding an orange oil (80 mg, 81 %); spectroscopic data similar to that of racemate; 
[હ]ࡰ૛ૡ (c 0.2, CHCl3) -51.5). 
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(S)-6-Methoxy-3-(4′-methoxyphenyl)-2,3-dihydro-1H-inden-1-one  
 
(S)-60 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1S,3S)-6-Methoxy-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
inden-1-ol, (1S,3S)-81 (100 mg, 0.4 mmol) and manganese dioxide (~0.50 g), 
yielding an orange oil (75 mg, 76 %); spectroscopic data similar to that of racemate; 
[હ]ࡰ૛ૡ (c 0.1, CHCl3) +102.5). 
 
 
(R)-3-(3′,4′-Dimethoxyphenyl)-6-methoxy-2,3-dihydro-1H-inden-1-one  
 
(R)-61 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1R,3R)-3-(3′,4′-Dimethoxyphenyl)-6-methoxy-2,3-dihydro-
1H-inden-1-ol, (1R,3R)-82 (100 mg, 0.3 mmol) and manganese dioxide (~0.50 g), 
yielding a yellow solid (73 mg, 74 %); spectroscopic data similar to that of racemate; 
[હ]ࡰ૛ૡ (c -0.2, CHCl3) -62.5). 
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(S)-3-(3′,4′-Dimethoxyphenyl)-6-methoxy-2,3-dihydro-1H-inden-1-one  
 
(S)-61 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1S,3S)-3-(3′,4′-Dimethoxyphenyl)-6-methoxy-2,3-dihydro-
1H-inden-1-ol, (1S,3S)-82 (100 mg, 0.3 mmol) and manganese dioxide (~0.50 g), 
yielding a yellow solid (79 mg, 80 %); spectroscopic data similar to that of racemate; 
[હ]ࡰ૛ૡ (c 0.1, CHCl3) +98). 
 
 
(R)-6-Methoxy-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-inden-1-one  
 
(R)-62 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1R,3R)-6-Methoxy-3-(3′,4′,5′-trimethoxyphenyl)-2,3-
dihydro-1H-inden-1-ol, (1R,3R)-83 (100 mg, 0.3 mmol) and manganese dioxide 
(~0.50 g), yielding a yellow oil (75 mg, 75 %); spectroscopic data similar to that of 
racemate; [હ]ࡰ૛ૡ (c 0.2, CHCl3) -53.3). 
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(S)-6-Methoxy-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-inden-1-one  
 
(S)-62 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1S,3S)-6-Methoxy-3-(3′,4′,5′-trimethoxyphenyl)-2,3-
dihydro-1H-inden-1-ol, (1R,3R)-83 (100 mg, 0.3 mmol) and manganese dioxide 
(~0.50 g), yielding a yellow oil (70 mg, 70 %); spectroscopic data similar to that of 
racemate; [હ]ࡰ૛ૡ (c 0.1, CHCl3) +106.5). 
 
(R)-6-Methoxy-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-inden-1-one  
 
(R)-63 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1R,3R)-6-Methoxy-3-(2′,3′,4′-trimethoxyphenyl)-2,3-
dihydro-1H-inden-1-ol, (1R,3R)-84 (100 mg, 0.3 mmol) and manganese dioxide 
(~0.50 g), yielding a yellow oil (70 mg, 71 %); spectroscopic data similar to that of 
racemate; [હ]ࡰ૛ૡ (c 0.2, CHCl3) -62.8). 
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(S)-6-Methoxy-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-inden-1-one  
 
(S)-63 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1S,3S)-6-Methoxy-3-(2′,3′,4′-trimethoxyphenyl)-2,3-
dihydro-1H-inden-1-ol, (1S,3S)-84 (100 mg, 0.3 mmol) and manganese dioxide 
(~0.50 g), yielding a yellow oil (71 mg, 72 %); spectroscopic data similar to that of 
racemate; [હ]ࡰ૛ૡ (c 0.2, CHCl3) +52.5). 
 
(R)-3-(4′-Fluorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-one  
 
(R)-64 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1R,3R)-3-(4′-Fluorophenyl)-6-methoxy-2,3-dihydro-1H-
inden-1-ol, (1R,3R)-85 (100 mg, 0.04 mmol) and manganese dioxide (~0.50 g), 
yielding a white solid (80 mg, 81 %); spectroscopic data similar to that of racemate; 
[હ]ࡰ૛ૡ (c 0.2, CHCl3) -76.0). 
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(S)-3-(4′-Fluorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-one  
 
(S)-64 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1S,3S)-3-(4′-Fluorophenyl)-6-methoxy-2,3-dihydro-1H-
inden-1-ol, (1S,3S)-85 (100 mg, 0.4 mmol) and manganese dioxide (~0.50 g), 
yielding a white solid (83 mg, 84 %); spectroscopic data similar to that of racemate; 
[હ]ࡰ૛ૡ (c 0.2, CHCl3) +72.8). 
 
(R)-3-(4′-Chlorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-one 
 
(R)-65 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1R,3R)-3-(4′-Chlorophenyl)-6-methoxy-2,3-dihydro-1H-
inden-1-ol, (1R,3R)-86 (100 mg, 0.4 mmol) and manganese dioxide (~0.50 g), 
yielding a white solid (83 mg, 84 %); spectroscopic data similar to that of racemate; 
[હ]ࡰ૛ૡ (c 0.2, CHCl3) -61.0). 
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(S)-3-(4′-Chlorophenyl)-6-methoxy-2,3-dihydro-1H-inden-1-one  
 
(S)-65 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1S,3S)-3-(4′-Chlorophenyl)-6-methoxy-2,3-dihydro-1H-
inden-1-ol, (1S,3S)-86 (100 mg, 0.4 mmol) and manganese dioxide (~0.50 g), 
yielding a white solid (85 mg, 86 %); spectroscopic data similar to that of racemate; 
[હ]ࡰ૛ૡ (c 0.1, CHCl3) +121.5), (lit.217 [હ]ࡰ૛૞ (c 0.5, CHCl3) +52) 
 
 
(R)-3-(3′-Fluoro-4′-methoxyphenyl)-4,5,6-trimethoxy-3,4-dihydro-1H-
inden-1-one  
 
(R)-66 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1R,3R)-3-(3′-Fluoro-4′-methoxyphenyl)-4,5,6-trimethoxy-
2,3-dihydro-1H-inden-1-ol, (1R,3R)-87 (100 mg, 0.3 mmol) and manganese dioxide 
(~0.50 g), yielding a off-white solid (90 mg, 89 %); spectroscopic data similar to that 
of racemate; [હ]ࡰ૛ૡ (c 0.2, CHCl3) -59.0). 
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(S)-3-(3′-Fluoro-4′-methoxyphenyl)-4,5,6-trimethoxy-3,4-dihydro-1H-
inden-1-one  
 
(S)-66 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1S,3S)-3-(3′-Fluoro-4′-methoxyphenyl)-4,5,6-trimethoxy-
2,3-dihydro-1H-inden-1-ol, (1S,3S)-87 (100 mg, 0.3 mmol) and manganese dioxide 
(~0.50 g), yielding an off-white solid (86 mg, 86 %); spectroscopic data similar to 
that of racemate; [હ]ࡰ૛ૡ (c 0.2, CHCl3) +58.0).  
 
(R)-3-(3′-Nitro-4′-methoxyphenyl)-4,5,6-trimethoxy-3,4-dihydro-1H-
inden-1-one  
 
(R)-67 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1R,3R)-3-(4′-Methoxy-3′-nitrophenyl)-4,5,6-trimethoxy-2,3-
dihydro-1H-inden-1-ol, (1R,3R)-88 (100 mg, 0.3 mmol) and manganese dioxide 
(~0.50 g), yielding a white solid (90 mg, 90 %); spectroscopic data similar to that of 
racemate; [હ]ࡰ૛ૡ (c 0.2, CHCl3) -66.5). 
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(S)-3-(3′-Nitro-4′-methoxyphenyl)-4,5,6-trimethoxy-3,4-dihydro-1H-
inden-1-one  
 
(S)-67 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.4.4, using (1S,3S)-3-(4′-Methoxy-3′-nitrophenyl)-4,5,6-trimethoxy--2,3-
dihydro-1H-inden-1-ol, (1S,3S)-88 (100 mg, 0.3 mmol) and manganese dioxide 
(~0.50 g), yielding a white solid (89 mg, 89 %); spectroscopic data similar to that of 
racemate; [હ]ࡰ૛ૡ (c 0.1, CHCl3) +133.5). 
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5.2.5 Kinetic Resolution – Asymmetric Transfer Hydrogenation 
 
 
112 
 
The (R,R)-TsDPEN-tethered Ru-Cl catalyst, 112, was supplied by Martin Wills at 
the University of Warwick. 
 
 
 
5.2.5.1 Asymmetric Hydrogen Transfer 
The following procedure was performed in accordance with previous literature.399 
(R,R)-TsDPEN-tethered Ru-Cl catalyst, 112 (15. 6 mg, 0.03 mmol) was stirred in 
formic acid/triethylamine (5:2) azeotrope (5.0 mL) at 28 °C under nitrogen for 30 
minutes. To this solution was added racemic cis-6-methoxy-3-phenylindan-1-one, 59, 
(1.20 g,  5.0 mmol) and the solution was stirred for 12  hours under nitrogen. The 
reaction was concentrated in vacuo and the crude reaction mixture was analysed by 
both 1H NMR and HPLC. 
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5.2.5.2 Epimerisation of cis-Inden-1-ol alcohol via a Mitsunobu Reaction 
and Ester Hydrolysis 
 
(1RS,3SR)-6′-methoxy-3′-phenyl-2′,3′-dihydro-1′H-inden-1′-yl 4-
nitrobenzoate  
 
113 
 
 
The following procedure was performed in accordance with previous literature.406 To 
a solution of (1SR,3SR)-6-methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol, 80 (0.80 g, 
3.3 mmol) in THF (30 mL) under nitrogen, was added 4-nitrobenzoic acid (2.20 g, 
13.3 mmol) and triphenylphosphine  (3.49 g, 13.3 mmol) under constant stirring. The 
reaction mixture was cooled to 0 °C and diisopropyl azodicarboxylate (2.62 mL, 13.3 
mmol) was added dropwise at rate such that the reaction temperature was maintained 
below 10 °C. Once the reagent had been added the reaction mixture was stirred 
overnight at room temperature. Excess solvent and volatile components were then 
removed under reduced pressure. The resulting syrup was dissolved in ethyl acetate, 
washed twice with NaOH (2M, 30 mL), dried over MgSO4 and concentrated in vacuo. 
The reaction mixture was then suspended in diethyl ether and any white precipitate 
was filtered off. The remaining filtrate was then purified by flash column 
chromatography eluting with diethyl ether : petroleum ether (1:2), yielding a pale 
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yellow powder (1.00 g, 78 %); m.p. 151-152 °C; νmax/cm-1 2980 (m, CAr-H, stretch), 
1707 (s, C=O, stretch), 1521, 1249 (s, NO2, stretch), 1102 (s, C-O, stretch); δH (400 
MHz, CDCl3) 8.28 (2H, d, J 9, 2 x ArH-3), 8.22 (2H, d, J 9, 2 x ArH-2), 7.34 (2H, t, 
J 7.5, 2 x ArH-3″), 7.28-7.24 (1H, m, ArH-4″), 7.19-7.17 (2H, m, 2 x ArH-2″), 7.12 
(1H, d, J 2.5, ArH-7′), 6.96 (1H, d, J 8.5, ArH-4′), 6.90 (1H, dd, J 8.5, 2.5, ArH-5′), 
6.60 (1H, dd, J 6.5, 2, CH-1′), 4.65 (1H, t, J 7.6, CH-3′), 3.82 (3H, s, CAr-6′ OCH3), 
2.80 (1H, ddd, J 14.5, 7.5, 2, CHH-2′), 2.56 (1H, ddd, J 14.5, 8, 7, CHH-2′); δC (100 
MHz, CDCl3) 164.6 (C-1), 159.3 (CAr-6′), 150.5 (CAr-4), 144.2 (CAr-1″), 141.8 (CAr), 
140.3 (CAr), 135.8 (CAr-1), 130.8 (2 x CAr-2), 128.7 & 127.9 (CAr-4″ & 2 x CAr-3″), 
126.7 (2 x CAr-2″), 126.0 (CAr-4′), 123.5 (2 x CAr-3), 116.6 (CAr-5′), 110.5 (CAr-7′), 
79.2 (C-1′), 55.5 (CAr-6′ OCH3), 48.5 (C-3′), 43.7 (C-2′); m/z (MNa+ C23H19NO5Na+ 
requires 412.1155) found 412.1159. 
 
(1R,3S)-6′-methoxy-3′-phenyl-2′,3′-dihydro-1′H-inden-1′-yl 4-
nitrobenzoate  
 
(1R,3S)-113 
 
 
The following procedure was performed in accordance with previous literature,406 
using the same method for compound 113. (1S,3S)-6-methoxy-3-phenyl-2,3-dihydro-
1H-inden-1-ol, (1S,3S)-80 (2.00 g, 8.3 mmol), 4-nitrobenzoic acid (5.56 g, 30 mmol) 
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triphenylphosphine (8.73 g, 30 mmol) and diisopropyl azodicarboxylate (6.55 mL, 
30 mmol) were used. The title compound was formed as a pale yellow powder (2.39 
g, 74 %); spectroscopic data similar to that of racemate. [હ]ࡰ૛ૡ (c 0.1, CHCl3) +51.5. 
 
 
(1S,3R)-6′-methoxy-3′-phenyl-2′,3′-dihydro-1′H-inden-1′-yl 4-
nitrobenzoate  
 
(1S,3S)-113 
 
 
The following procedure was performed in accordance with previous literature,406 
using the same method for compound 113. (1R,3R)-6-methoxy-3-phenyl-2,3-
dihydro-1H-inden-1-ol, (1R,3R)-80 (350 mg, 1.5 mmol), 4-nitrobenzoic acid (0.97 g, 
5.8 mmol), triphenylphosphine (1.53 g, 5.8 mmol) and diisopropyl azodicarboxylate 
(1.15 mL, 5.6 mmol) were used. The title compound was formed as a pale yellow 
powder (414 mg, 71 %); spectroscopic data similar to that of racemate. [હ]ࡰ૛ૡ (c 0.1, 
CHCl3) -40.0. 
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(1RS,3SR)-6-methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol  
 
114 
 
 
To a solution of (1RS,3SR)-6′-methoxy-3′-phenyl-2′,3′-dihydro-1′H-inden-1′-yl 4-
nitrobenzoate, 113 (100 mg, 0.26 mmol) in methanol (20 mL) was added potassium 
carbonate (0.11 g, 0.77 mmol) portion-wise at room temperature. The reaction 
mixture was stirred at room temperature for 3 hours. The resulting mixture was then 
concentrated in vacuo. The crude product was dissolved in diethyl ether (40 mL) and 
washed with water (30 mL), brine (30 mL), dried over MgSO4 and concentrated in 
vacuo. The residue was then purified by flash column chromatography eluting with 
ethyl acetate : petroleum ether (1 : 9), yielding a white solid (50 mg, 88 %); m.p. 124-
125 °C; νmax/cm-1 3371 (br., O-H, stretch), 2919 (m, CAr-H, stretch), 1270 (s, C-O, 
stretch); δH (400 MHz, CDCl3) 7.33-7.17 (3H, m, ArH-4′ & 2 x ArH-3′), 7.14-7.10 
(2H, m, 2 x ArH-2′), 7.01 (1H, d, J 2.5, ArH-7), 6.95 (1H, d, J 8.5, ArH-4), 6.84 (1H, 
dd, J 8.5, 2.5, ArH-5), 5.35 (1H, dd, J 6.5, 3.5, CH-1), 4.56 (1H, t, J 7, CH-3), 3.83 
(3H, s, CAr-6 OCH3), 2.55 (1H, ddd, J 13.5, 8, 3.5, CHH-2), 2.41 (1H, dt, J 13.5, 6.5, 
CHH-2), 1.73 (1H, br. s, C-1 OH); δC (100 MHz, CDCl3) 159.3 (CAr-6), 146.2 (CAr), 
145.0 (CAr-1′), 138.6 (CAr), 128.5, 127.7, 126.3 (CArH), 126.2 (CArH-4), 115.6 (CArH-
5), 108.8 (CArH-7), 75.4 (CH-1), 55.4 (CAr-6 OCH3), 48.0 (CH-3), 46.8 (CH2-2); m/z 
(MNa+ C16H16O2Na+ requires 263.1043) found 263.1048 
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(1R,3S)-6-methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol  
 
(1R,3S)-114 
 
 
The method was the same used for compound 114, using (1S,3R)-6′-methoxy-3′-
phenyl-2′,3′-dihydro-1′H-inden-1′-yl 4-nitrobenzoate, (1R,3S)-113 (140 mg, 0.4 
mmol) and potassium carbonate (0.15 g, 1.1 mmol) The residue was then purified by 
flash column chromatography eluting with ethyl acetate : petroleum ether (1 : 9), 
yielding a white solid (72 mg, 84 %); spectroscopic data similar to that of racemate. 
[હ]ࡰ૛ૠ (c 0.2, CHCl3) -14.0. enantiomeric excess determined by HPLC analysis 
(Diacel Chiralpak IA column, 2-propanol : hexane = 5 : 95 , 1 mL/min., 211 nm, 
(1S,3R)-isomer 21.60 min., (1R,3S)-isomer 25.38 min.). 
 
(1S,3R)-6-methoxy-3-phenyl-2,3-dihydro-1H-inden-1-ol  
 
(1S,3R)-114 
 
 
The method was the same used for compound 114, using (1S,3R)-6′-methoxy-3′-
phenyl-2′,3′-dihydro-1′H-inden-1′-yl 4-nitrobenzoate, (1S,3R)-113 (50 mg, 0.1 
mmol) and potassium carbonate (0.05 g, 0.4 mmol) The residue was then purified by 
flash column chromatography eluting with ethyl acetate:petroleum ether (1:9), 
- 338 -  
yielding a white solid (24.7 mg, 80 %); spectroscopic data similar to that of racemate. 
[હ]ࡰ૛ૠ (c 0.2, CHCl3) +13.3. enantiomeric excess determined by HPLC analysis 
(Diacel Chiralpak IA column, 2-propanol : hexane = 5 : 95 , 1 mL/min., 211 nm, 
(1S,3R)-isomer 21.60 min., (1R,3S)-isomer 25.38 min.). 
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5.2.6 Kinetic Resolution – Oxidative Kinetic Resolution  
 
Preparation of Ruthenium Complex: (1S,2S)-Ru(p-cymene)(TsDPEN)  
 
115 
 
 
The following procedure was performed in accordance with previous literature.526 To 
a mixture of [RuCl2(η6-p-cymene)]2 (20 mg, 0.03 mmol), (1S,2S)-(+)-TsDPEN (24 
mg, 0.07 mmol) in dry dichloromethane (2 mL) was added potassium hydroxide (26 
mg, 0.46 mmol). The reaction mixture was stirred at room temperature for 5 minutes, 
and then water (2 mL) was added to the reaction mixture changing the solution from 
orange to a deep purple. The purple organic layer was washed with 5 mL of water, 
dried with calcium hydride and concentrated in vacuo, yielding a deep purple 
complex (14.5 mg, 72 %); m.p. 79-80 °C (decomp.), (lit.527 80 °C (decomp.)); 
spectroscopic and observational data consistent with literature.526,527 
 
5.2.6.1 Asymmetric Ruthenium Oxidation 
To a mixture of substituted racemic cis-indan-1-ol (2.0 mmol) in dry acetone (20 mL), 
was added (1S,2S)-Ru(p-cymene)(TsDPEN), and the solution was stirred for 24-48 
hours under nitrogen, monitored by 1H NMR and HPLC. The reaction was 
concentrated in vacuo at the desired conversion (~50 %), and the products were 
separated by silica column chromatography as mentioned specifically for each 
compound. 
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(1R,3R)-3-Phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-ol 
 
(1R,3R)-89 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-3-phenyl-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, 89 (0.75 g, 2.9 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (9 mg, 0.01 mmol), to give compound (1R,3R)-89  and (S)-
68 in a ratio of 51 : 49. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield a 
white solid (0.35 g, 46 %), as a % of racemic starting material, in 80 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૛ૡ (c 0.1, CHCl3) -178.5; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak IA column, 2-
propanol : hexane = 5 : 95 , 1 mL/min., 229 nm, (S)-isomer 19.96 min., (R)-isomer 
27.96 min.). 
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(1R,3R)-5-Fluoro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]naphthalen-1-ol  
 
(1R,3R)-91 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-fluoro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-
dihydro-1H-cyclophenta[a]naphthalen-1-ol, 91 (0.90 g, 2.4 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (8 mg, 0.01 mmol), to give compound (1R,3R)-91 and (S)-
70 in a ratio of 48 : 52. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield a 
yellow solid (0.41 g, 46 %), as a % of racemic starting material, in >99 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૛ૡ (c 0.1, CHCl3) -173.5; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak AD-H column, 
2-propanol : hexane = 10 : 90 , 1 mL/min., 230 nm, (S)-isomer 26.84 min., (R)-isomer 
30.32 min.). 
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(1R,3R)-5-Chloro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
 
(1R,3R)-92 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-chloro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-
dihydro-1H-cyclopenta[a]naphthalen-1-ol, 92 (0.65 g, 1.7 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (5 mg, 8 µmol), to give compound (1R,3R)-92 and (S)-71 in 
a ratio of 52 : 48. The title compound was isolated by silica column chromatography, 
eluting with dichloromethane : petroleum ether (3 : 1), to yield a white solid (0.31 g, 
48 %), as a % of racemic starting material, in 95 % e.e.; spectroscopic data similar to 
that of racemate; [હ]ࡰ૛ૡ (c 0.1, CHCl3) -154.0; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 
mL/min., 231 nm, (R)-isomer 27.20 min., (S)-isomer 28.93 min.). 
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(1R,3R)-3-(3′,4′,5′-Trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
 
(1R,3R)-90 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, 90 (0.20 g, 0.6 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (2 mg, 3 µmol), to give compound (1R,3R)-90 and (S)-69 in 
a ratio of 49 : 51. The title compound was isolated by silica column chromatography, 
eluting with dichloromethane : petroleum ether (3 : 1), to yield a beige solid (90 mg, 
45 %), as a % of racemic starting material, in 97 % e.e.; spectroscopic data similar to 
that of racemate; [હ]ࡰ૛ૡ (c 0.1, CHCl3) -182.5; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralcel OD-H column, 2-propanol : hexane = 10 : 90 , 1 
mL/min., 228 nm, (R)-isomer 23.33 min., (S)-isomer 28.32 min.). 
 
(1R,3R)-5-Bromo-3-phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-ol  
OH
Br
 
(1R,3R)-93 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-phenyl-2,3-dihydro-1H-
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cyclopenta[a]naphthalen-1-ol, 93 (0.69 g, 2.0 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (6 mg, 0.01 mmol), to give compound (1R,3R)-93 and (S)-
72. The reaction was first taken to 35 % conversion and separated, followed by further 
resolution to 57 % conversion. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield a 
white solid (0.28 g, 41 %), as a % of racemic starting material, in 87 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૛ૡ (c 0.1, CHCl3) -70.0; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak IA column, 2-
propanol : hexane = 10 : 90 , 1 mL/min., 234 nm, (R)-isomer 8.52 min., (S)-isomer 
9.84 min.). 
 
 
(1R,3R)-5-Bromo-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
 
(1R,3R)-94 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, 94 (0.36 g, 0.1 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (3 mg, 5 µmol), to give compound (1R,3R)-94 and (S)-73 in 
a ratio of 50 : 50. The title compound was isolated by silica column chromatography, 
eluting with dichloromethane : petroleum ether (3 : 1), to yield an off-white solid 
- 345 -  
(0.17 g, 48 %), as a % of racemic starting material, in 65 % e.e.; spectroscopic data 
similar to that of racemate; [હ]ࡰ૛ૡ (c 0.1, CHCl3) -121.0; enantiomeric excess 
determined by HPLC analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 
10 : 90 , 1 mL/min., 231 nm, (R)-isomer 12.11 min., (S)-isomer 14.85 min.). 
 
 
(1R,3R)-5-Bromo-3-(2′,3′-dimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol                                                 
 
(1R,3R)-95 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-(2′,3′-dimethoxyphenyl)-2,3-dihydro-
1H-cyclopenta[a]naphthalen-1-ol, 95 (1.00 g, 2.5 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (8 mg, 0.01 mmol), to give compound (1R,3R)-95  and (S)-
74 in a ratio of 50 : 50. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield an 
off white solid (0.48 g, 48 %), as a % of racemic starting material, in >99 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૛ૡ(c 0.1, CHCl3) -124.0; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak IA column, 2-
propanol : hexane = 10 : 90 , 1 mL/min., 232 nm, (R)-isomer 10.16 min., (S)-isomer 
12.32 min.). 
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(1R,3R)-5-Bromo-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
 
(1R,3R)-97 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-(3′,4′,5′-trimethoxyphenyl)-2,3-
dihydro-1H-cyclopenta[a]naphtalen-1-ol, 97 (0.60 g, 1.4 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (4 mg, 7 µmol), to give compound (1R,3R)-97and (S)-76 in 
a ratio of 48 : 52. The title compound was isolated by silica column chromatography, 
eluting with dichloromethane : petroleum ether (3 : 1), to yield a yellow solid (0.28 
g, 46 %), as a % of racemic starting material, in >99 % e.e.; spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૡ (c 0.1, CHCl3) -104.0; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 
mL/min., 231 nm, (R)-isomer 30.80 min., (S)-isomer 34.60 min.). 
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(1R,3R)-5-Bromo-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
 
(1R,3R)-98 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-(2′,3′,4′-trimethoxyphenyl)-2,3-
dihydro-1H-cyclopenta[a]naphthalen-1-ol, 98 (0.46 g, 1.1 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (3 mg, 5 µmol), to give compound (1R,3R)-98 and (S)-77 in 
a ratio of 45 : 55. The title compound was isolated by silica column chromatography, 
eluting with dichloromethane : petroleum ether (3 : 1), to yield an orange oil (0.18 g, 
39 %), as a % of racemic starting material, in >99 % e.e.; spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૡ (c 0.1, CHCl3) -99.5; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 
mL/min., 231 nm, (S)-isomer 9.80 min., (R)-isomer 12.07 min.). 
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(1R,3R)-5-Bromo-3-(4′-fluorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
 
(1R,3R)-99 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-(4′-fluorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, 99 (0.40 g, 1.1 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (3 mg, 6 µmol), to give compound (1R,3R)-99 and (S)-78. 
The reaction was first taken to 43 % conversion and separated, followed by further 
resolution to 56 % conversion. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield a 
yellow solid (0.16 g, 41 %), as a % of racemic starting material, in >99 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૛ૡ (c 0.1, CHCl3) -102.5; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak IA column, 2-
propanol : hexane = 10 : 90 , 1 mL/min., 234 nm, (R)-isomer 9.75 min., (S)-isomer 
11.23 min.). 
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(1R,3R)-5-Bromo-3-(4′-chlorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol  
 
100 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-(4′-chlorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, 100 (0.50 g, 1.3 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (4 mg, 7 µmol), to give compound (1R,3R)-100 and (S)-79 
in a ratio of 52 : 48. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield a 
yellow solid (0.21 g, 42 %), as a % of racemic starting material, in >99 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૛ૡ (c 0.1, CHCl3) -131.0; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak IA column, 2-
propanol : hexane = 10 : 90 , 1 mL/min., 235 nm, (R)-isomer 10.17 min., (S)-isomer 
11.75 min.). 
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(S)-3-Phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one  
 
(S)-68 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-3-phenyl-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, 89 (0.75 g, 2.9 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (9 mg, 0.01 mmol), to give compound (1R,3R)-89 and (S)-
68 in a ratio of 51 : 49. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield a 
orange solid (0.36 g, 49 %), as a % of racemic starting material, in 76 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) +286.5; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralcel OD-H column, 
2-propanol : hexane = 5 : 95 , 1 mL/min., 218 nm, (S)-isomer 10.99 min., (R)-isomer 
16.97 min.). 
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(S)-5-Fluoro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]naphthalen-1-one  
 
(S)-70 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-fluoro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-
dihydro-1H-cyclophenta[a]naphthalen-1-ol, 91 (0.90 g, 2.4 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (8 mg, 0.01 mmol), to give compound (1R,3R)-91 and (S)-
70 in a ratio of 48 : 52. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield a 
yellow solid (0.42 g, 47 %), as a % of racemic starting material, in 98 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) +232.5; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak IA column, 2-
propanol : hexane = 5 : 95 , 1 mL/min., 236 nm, (S)-isomer 26.77 min., (R)-isomer 
36.88 min.). 
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(S)-5-Chloro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one 
 
(S)-71 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-chloro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-
dihydro-1H-cyclopenta[a]naphthalen-1-ol, 92 (0.65 g, 1.7 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (5 mg, 8 µmol), to give compound (1R,3R)-92 and (S)-71 in 
a ratio of 52 : 48. The title compound was isolated by silica column chromatography, 
eluting with dichloromethane : petroleum ether (3 : 1), to yield a yellow solid (0.31 
g, 48 %), as a % of racemic starting material, in 96 % e.e.; spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) +146.5; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 5 : 95 , 1 
mL/min., 243 nm, (S)-isomer 26.09 min., (R)-isomer 36.09 min.). 
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(S)-3-(3′,4′,5′-Trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
 
(S)-69 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, 90 (0.20 g, 0.6 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (2 mg, 3 µmol), to give compound (1R,3R)-90 and (S)-69 in 
a ratio of 49 : 51. The title compound was isolated by silica column chromatography, 
eluting with dichloromethane : petroleum ether (3 : 1), to yield a yellow solid (72 mg, 
49 %), as a % of racemic starting material, in 91 % e.e.; spectroscopic data similar to 
that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) +165.0; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 
mL/min., 214 nm, (S)-isomer 17.93 min., (R)-isomer 20.55 min.). 
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(S)-5-Bromo-3-phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one  
 
(S)-72 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-phenyl-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, 93 (0.69 g, 2.0 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (6 mg, 0.01 mmol), to give compound (1R,3R)-93 and (S)-
72. The reaction was first taken to 35 % conversion and separated, followed by further 
resolution to 57 % conversion. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield a 
yellow solid (0.22 g, 32 %), as a % of racemic starting material, in >99 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) +114.5; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralcel OD-H column, 
2-propanol : hexane = 5 : 95 , 1 mL/min., 242 nm, (S)-isomer 8.48 min., (R)-isomer 
13.03 min.). 
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(S)-5-Bromo-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]naphthalen-1-one  
 
(S)-73 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, 94 (0.36 g, 0.1 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (3 mg, 5 µmol), to give compound (1R,3R)-94 and (S)-73 in 
a ratio of 50 : 50. The title compound was isolated by silica column chromatography, 
eluting with dichloromethane : petroleum ether (3 : 1), to yield a yellow solid (0.17 
g, 48 %), as a % of racemic starting material, in 96 % e.e.; spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) +91.0; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralpak AD-H column, 2-propanol : hexane = 10 : 90 , 1 
mL/min., 242 nm, (R)-isomer 11.24 min., (S)-isomer 12.39 min.). 
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(S)-5-Bromo-3-(2′,3′-dimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
 
(S)-74 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-(2′,3′-dimethoxyphenyl)-2,3-dihydro-
1H-cyclopenta[a]naphthalen-1-ol, 95 (1.00 g, 2.5 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (8 mg, 0.01 mmol), to give compound (1R,3R)-95 and (S)-
74 in a ratio of 50 : 50. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield a 
beige solid (0.47 g, 47 %), as a % of racemic starting material, in 96 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) +103.0; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak AD-H column, 
2-propanol : hexane = 5 : 95 , 1 mL/min., 240 nm, (S)-isomer 11.51 min., (R)-isomer 
13.37 min.). 
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(S)-5-Bromo-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]napthalen-1-one  
 
(S)-76 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-(3′,4′,5′-trimethoxyphenyl)-2,3-
dihydro-1H-cyclopenta[a]naphtalen-1-ol, 97 (0.60 g, 1.4 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (4 mg, 7 µmol), to give compound (1R,3R)-97 and (S)-76 in 
a ratio of 48 : 52. The title compound was isolated by silica column chromatography, 
eluting with dichloromethane : petroleum ether (3 : 1), to yield a yellow solid (0.29 
g, 49 %), as a % of racemic starting material, in 96 % e.e.; spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) +109.5; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 10 : 90 , 1 
mL/min., 243 nm, (S)-isomer 14.19 min., (R)-isomer 17.68 min.). 
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(S)-5-Bromo-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
 
(S)-77 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-(2′,3′,4′-trimethoxyphenyl)-2,3-
dihydro-1H-cyclopenta[a]naphthalen-1-ol, 98 (0.46 g, 1.1 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (3 mg, 5 µmol), to give compound (1R,3R)-98 and (S)-77 in 
a ratio of 45 : 55. The title compound was isolated by silica column chromatography, 
eluting with dichloromethane : petroleum ether (3 : 1), to yield a orange oil (0.23 g, 
51 %), as a % of racemic starting material, in 93 % e.e.; spectroscopic data similar to 
that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) +138.0; enantiomeric excess determined by 
HPLC analysis (Diacel Chiralpak IA column, 2-propanol : hexane = 5 : 95 , 1 
mL/min., 241 nm, (R)-isomer 10.72 min., (S)-isomer 12.51 min.). 
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(S)-5-Bromo-3-(4-fluorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
 
(S)-78 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-(4′-fluorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, 99 (0.40 g, 1.1 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (3 mg, 6 µmol), to give compound (1R,3R)-99 and (S)-78. 
The reaction was first taken to 43 % conversion and separated, followed by further 
resolution to 56 % conversion. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield a 
yellow solid (0.13 g, 35 %), as a % of racemic starting material, in 88 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) +97.5; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak IA column, 2-
propanol : hexane = 5 : 95 , 1 mL/min., 242 nm, (R)-isomer 8.44 min., (S)-isomer 
9.25 min.). 
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(S)-5-Bromo-3-(4′-chlorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
 
(S)-79 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.1, using (1RS,3RS)-5-bromo-3-(4′-chlorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, 100 (0.50 g, 1.3 mmol) and (1S,2S)-Ru(p-
cymene)(TsDPEN), 115 (4 mg, 7 µmol), to give compound (1R,3R)-100 and (S)-79 
in a ratio of 52 : 48. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : petroleum ether (3 : 1), to yield a 
yellow solid (0.20 g, 40 %), as a % of racemic starting material, in 91 % e.e.; 
spectroscopic data similar to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) +88.0; 
enantiomeric excess determined by HPLC analysis (Diacel Chiralpak IA column, 2-
propanol : hexane = 5 : 95 , 1 mL/min., 242 nm, (R)-isomer 8.52 min., (S)-isomer 
9.17 min.). 
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5.2.6.2 Oxidation of Chiral Aryl Indan-1-ols 
The following procedure was performed in accordance with previous literature.525 To 
a solution of enantiomerically enriched 3-substituted 2,3-dihydro-1H-inden-1-ol (8.3 
mmol) in dichloromethane (40 mL) was added manganese (IV) oxide (0.125 mol) at 
room temperature. The mixture was stirred for 18 hours, filtered through Celite® and 
concentrated in vacuo. The product was then used without further purification, unless 
mentioned specifically in each example. 
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(R)-3-Phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one  
 
(R)-68 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.2, using (1R,3R)-3-Phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-
1-ol, (1R,3R)-89 (200 mg, 0.8 mmol) and manganese dioxide (~1.00 g), yielding a 
orange solid (144 mg, 72 %); spectroscopic data similar to that of racemate; [હ]ࡰ૛ૢ (c 
0.1, CHCl3) -301.5. 
 
(R)-5-Fluoro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]naphthalen-1-one  
 
(R)-70 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.2, using (1R,3R)-5-Fluoro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-
1H-cyclophenta[a]naphthalen-1-ol, (1R,3R)-91 (200 mg, 0.5 mmol) and manganese 
dioxide (~1.00 g), yielding a yellow solid (182 mg, 91 %); spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) -234.5. 
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(R)-5-Chloro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]naphthalen-1-one  
 
(R)-71 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.2, using (1R,3R)-5-Chloro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-
1H-cyclopenta[a]naphthalen-1-ol, (1R,3R)-92 (200 mg, 0.5 mmol) and manganese 
dioxide (~1.00 g), yielding a yellow solid (172 mg, 86 %); spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) -145.0. 
 
(R)-3-(3′,4′,5′-Trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
 
(R)-69 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.2, using (1R,3R)-3-(3′,4′,5′-Trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, (1R,3R)-90 (200 mg, 0.6 mmol) and manganese 
dioxide (~1.00 g), yielding a yellow solid (178 mg, 89 %); spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) -176.5. 
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(R)-5-Bromo-3-phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one  
 
(R)-72 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.2, using (1R,3R)-5-Bromo-3-phenyl-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, (1R,3R)-93 (200 mg, 0.6 mmol) and manganese 
dioxide (~1.00 g), yielding a yellow solid (154  mg, 77 %); spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) -100.5. 
 
(R)-5-Bromo-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]naphthalen-1-one  
 
(R)-73 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.2, using (1R,3R)-5-Bromo-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, (1R,3R)-94 (200 mg, 0.5 mmol) and manganese 
dioxide (~1.00 g), yielding a yellow solid (162 mg, 81 %); spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) -90.5. 
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(R)-5-Bromo-3-(2′,3′-dimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
 
(R)-74 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.2, using (1R,3R)-5-Bromo-3-(2′,3′-dimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, (1R,3R)-95 (200 mg, 0.5 mmol) and manganese 
dioxide (~1.00 g), yielding a beige solid (162 mg, 81 %); spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) -106.0. 
 
(R)-5-Bromo-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]napthalen-1-one  
 
(R)-76 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.2, using (1R,3R)-5-Bromo-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-
1H-cyclopenta[a]naphthalen-1-ol, (1R,3R)-97 (200 mg, 0.5 mmol) and manganese 
dioxide (~1.00 g), yielding a yellow solid (174 mg, 87 %); spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) -112.5. 
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(R)-5-Bromo-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
 
(R)-77 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.2, using (1R,3R)-5-Bromo-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-
1H-cyclopenta[a]naphthalen-1-ol, (1R,3R)-98 (200 mg, 0.5 mmol) and manganese 
dioxide (~1.00 g), yielding an orange oil (138 mg, 69 %); spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) -147.0. 
 
(R)-5-Bromo-3-(4-fluorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one 
 
(R)-78 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.2, using (1R,3R)-5-Bromo-3-(4′-fluorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, (1R,3R)-99 (200 mg, 0.6 mmol) and manganese 
dioxide (~1.00 g), yielding a yellow solid (160 mg, 80 %); spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) -109.5. 
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(R)-5-Bromo-3-(4′-chlorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one  
 
(R)-79 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.2.6.2, using (1R,3R)-5-Bromo-3-(4′-chlorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-ol, (1R,3R)-100 (200 mg, 0.5 mmol) and manganese 
dioxide (~1.00 g), yielding a yellow solid (158 mg, 79 %); Spectroscopic data similar 
to that of racemate; [હ]ࡰ૛ૢ (c 0.1, CHCl3) -95.5. 
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5.3 Experimental for Chapter 3 
 
The general procedure for this section can be found in Section 5.1.1. 
 
 
5.3.1 Formation of Indan-1-one Oximes 
The following procedure was performed in accordance with previous literature.437 To 
a solution of the appropriate indan-1-one (0.5 mmol), in pyridine (10 mL) was added 
hydroxylamine hydrochloride (1.0 mmol), and the reaction was stirred at 80 °C for 12 
hours. The reaction was cooled to room temperature, and 1M HCl (20 mL) was added. 
The product was extracted with dichloromethane (2 x 15 mL), and the combined 
organic layer was washed with 1M HCl (4 x 20 mL), water (20 mL), dried over 
Na2SO4, and concentrated in vacuo. The product, if solid, was then recrystallized in 
methanol, or used without futher purification if not. 
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(S,E)-5-Bromo-3-phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one 
Oxime 
 
(S)-116 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.1, using (S)-5-Bromo-3-phenyl-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one, (S)-72, (0.20 g, 0.6 mmol) and hydroxylamine 
hydrochloride (82 mg, 1.2 mmol) and the product was used without further 
purification. The title compound was formed as an off-white solid (184 mg, 88 %); 
[હ]ࡰ૛ૡ (c 0.1, CHCl3) +162.5;  m.p. 148-149 °C; νmax/cm-1 3412 (s, O-H, stretch), 1506 
(m, C=N, stretch); δH (500 MHz, CDCl3) 9.07 (1H, dd, J 8, 1, ArH-9), 8.30 (1H, dd, 
J 8.5, 1, ArH-6), 7.68 (1H, ddd, J 8.5, 7, 1.5, ArH-8), 7.64 (1H, ddd, J 8, 7, 1.5, ArH-
7), 7.51 (1H, s, ArH-4), 7.32 (2H, t, J 7, 2 x ArH-3′), 7.27-7.24 (2H, m, ArH-4′ & C-
1 NOH), 7.16-7.13 (1H, m, 2 x ArH-2′), 4.56 (1H, dd, J 8.5, 4, CH-3), 3.69 (1H, dd, 
J 19, 9, CHH-2), 3.08 (1H, dd, J 19, 4, CHH-2); δC (125 MHz, CDCl3) 164.9 (C-1), 
151.7 (CAr), 143.9 (CAr-1′), 131.5 (CAr), 130.5 (CAr), 129.5 (CAr), 129.0 (CArH), 128.6 
(CArH), 127.8 (CArH), 127.8 (CArH), 127.8 (CArH), 127.5 (CArH), 127.1 (CArH), 126.7 
(CArH), 126.7 (CAr), 47.3 (CH-3), 37.0 (CH2-2); m/z (MH+ C19H1479BrNOH+ requires 
352.0332) found 352.0333, (MH+ C19H1481BrNOH+ requires 354.0313) found 
354.0314. 
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(S,E)-5-Bromo-3-(4′-methoxyphenyl-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one Oxime 
 
(S)-117 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.1, using (S)-5-Bromo-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]naphthalen-1-one, (S)-73, (0.20 g, 0.5 mmol) and hydroxylamine 
hydrochloride (76 mg, 1.1 mmol) and the product was used without further 
purification. The title compound was formed as an off-white solid (173 mg, 83 %); 
m.p. 171-172 °C; [હ]ࡰ૛ૡ (c 0.1, CHCl3) +183.5; νmax/cm-1 3439 (m, O-H, stretch), 2935 
(w, CAr-H, stretch), 1587 (s, C=N, stretch), 1280 (s, C-O, stretch); δH (500 MHz, 
CDCl3) 9.09 (1H, d, J 8, ArH-9), 8.32 (1H, d, J 9, ArH-6), 7.72-7.68 (1H, m, ArH-
8), 7.68-7.64 (1H, m, ArH-7), 7.52 (1H, s, ArH-4), 7.26 (1H, s, C-1 NOH), 7.09 (2H, 
d, J 9, 2 x ArH-3′), 6.88 (2H, d, J 9, 2 x ArH-2′), 4.54 (1H, dd, J 8.5, 4, CH-3), 3.82 
(3H, s, CAr-4′ OCH3), 3.69 (1H, dd, J 19, 8.5, CHH-2), 3.05 (1H, dd, J 19, 4, CHH-
2); δC (125 MHz, CDCl3) 165.0 (C-1), 158.6 (CAr-4′), 152.0 (CAr), 136.0 (CAr), 131.5 
(CAr), 130.3 (CAr), 129.5 (CAr), 128.8 (2 x CArH-3″), 128.6 (CArH), 127.8 (CArH), 
127.8 (CArH), 127.4 (CArH), 126.7 (CArH), 126.6 (CAr), 114.3 (2 x CArH-2″), 55.3 
(CAr-4′ OCH3), 46.5 (CH-3), 37.2 (CH2-2); m/z (MH+ C20H1679BrNO2 requires 
382.0437) found 382.0438, (MH+ C20H1681BrNO2 requires 384.0419) found 
384.0418. 
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(S,E)-5-Bromo-3-(2′,3′,4′-trimethoxyphenyl-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one Oxime 
 
(S)-118 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.1, using (S)-5-Bromo-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one, (S)-77, (0.20 g, 0.5 mmol) and hydroxylamine 
hydrochloride (65 mg, 0.9 mmol) and the product was used without further 
purification. The title compound was formed as a pale yellow solid (164 mg, 79 %); 
[હ]ࡰ૛ૡ (c 0.1, CHCl3) +117; m.p. 111-112 °C; νmax/cm-1 3422 (m, O-H, stretch), 2935 
(m, CAr-H, stretch), 1494 (s, C=N, stretch), 1290 (s, C-O, stretch); δH (500 MHz, 
CDCl3) 9.11-9.08 (1H, m, ArH-9), 8.34-8.30 (1H, m, ArH-6), 7.70 (1H, ddd, J 8.5, 
7, 1.5, ArH-8), 7.65 (1H, ddd, J 8, 7, 1.5, ArH-7), 7.57 (1H, s, ArH-4), 7.22 (1H, s, 
C-1 NOH), 6.63-6.59 (2H, m, ArH-5″ & ArH-6″), 4.84 (1H, dd, J 8.5, 3.5, CH-3), 
3.92 (1H, s, CAr-2′ OCH3), 3.86 (CAr-3′ OCH3), 3.79 (CAr-4′ OCH3), 3.65 (1H, dd, J 
18.5, 8.5, CHH-2), 3.05 (1H, dd, J 18.5, 4, CHH-2); δC (125 MHz, CDCl3) 165.4 (C-
1), 152.8 (CAr), 152.0 (CAr), 151.9 (CAr), 142.3 (CAr), 131.4 (CAr), 130.6 (CAr), 129.7 
(CAr), 128.5 (CArH), 127.8 (CArH), 127.8 (CArH), 127.3 (CArH), 126.6 (CArH), 126.4 
(CAr), 122.8 (CArH), 107 4 (CArH), 61.1 (CAr-4′ OCH3), 60.8 (CAr-2′ OCH3), 56.0 
(CAr-3′ OCH3), 41.3 (CH-3), 36.5 (CH2-2); m/z (MNa+ C22H2079BrNO4 requires 
464.0468) found 464.0462, (MNa+ C22H2081BrNO4 requires 466.0450) found 
466.0444. 
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(S,E)-5-Bromo-3-(3′,4′,5′-trimethoxyphenyl-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one Oxime 
 
(S)-119 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.1, using (S)-5-Bromo-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]napthalen-1-one, (S)-76, (0.20 g, 0.5 mmol) and hydroxylamine 
hydrochloride (65 mg, 0.9 mmol) and the product was used without further 
purification. The title compound was formed as an off-white solid (174 mg, 84 %); 
[હ]ࡰ૛ૡ (c 0.02, CHCl3) +267.5;  m.p. 176-177 °C; νmax/cm-1 3381 (m, O-H, stretch), 
1589 (s, C=N, stretch), 1276 (s, C-O, stretch); δH (500 MHz, CDCl3) 9.10 (1H, dd, J 
8, 1, ArH-9), 8.34 (1H, dd, J 8, 1, ArH-6), 7.71 (1H, ddd, J 8.5, 6, 1.5, ArH-8), 7.68 
(1H, ddd, J 8, 7, 1.5, ArH-7), 7.57 (1H, s, ArH-4), 7.32 (1H, s, C-1 NOH), 6.36 (2H, 
s, 2 x ArH-2′), 4.51 (1H, dd, J 8.5, 4, CH-3), 3.87 (3H, s, CAr-4′ OCH3), 3.82 (6H, s, 
2 x CAr-3′ OCH3), 3.72 (1H, dd, J 19, 8.5, CHH-2), 3.08 (1H, dd, J 19, 4, CHH-2); δC 
(125 MHz, CDCl3) 164.8 (C-1), 153.6 (2 x CAr-3′), 151.4 (CAr), 139.5 (CAr-4′), 137.0 
(CAr), 131.6 (CAr), 130.4 (CAr), 139.5 (CAr), 128.7 (CArH), 127.9 (CArH), 127.8 
(CArH), 127.6 (CArH), 126.7 (CArH), 126.7 (CAr), 104.7 (2 x CAr-2′), 60.9 (CAr-4′ 
OCH3), 56.2 (2 x CAr-3′ OCH3), 47.7 (CH-3), 37.0 (CH2-2); m/z (MH+ 
C22H2079BrNO4H+ requires 442.0648) found 442.0651, (MH+ C22H2081BrNO4H+ 
requires 444.0631) found 444.0634 
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(S,E)-5-Bromo-3-(4′-fluorophenyl-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one Oxime 
 
(S)-120 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.1, using (S)-5-Bromo-3-(4-fluorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one, (S)-78, (0.20 g, 0.6 mmol) and hydroxylamine 
hydrochloride (78 mg, 1.1 mmol) and the product was used without further 
purification. The title compound was formed as an off-white solid (188 mg, 90 %); 
[હ]ࡰ૛ૡ (c 0.1, CHCl3) +148; m.p. 150-151 °C; νmax/cm-1 3413 (s, O-H, stretch), 1506 
(s, C=N, stretch); δH (500 MHz, CDCl3) 9.09 (1H, dd, J 8, 1.5, ArH-9), 8.32 (1H, dd, 
J 8.5, 1, ArH-6), 7.71 (1H, ddd, J 8.5, 7, 1.5, ArH-8), 7.67 (1H, ddd, J 8, 7, 1.5, ArH-
7), 7.50 (1H, s, ArH-4), 7.31 (1H, s, C-1 NOH), 7.13 (2H, dd, J 8.5, 5.5, 2 x ArH-2′), 
7.03 (2H, t, J 8.5, 2 x ArH-3′), 4.58 (1H, dd, J 8.5, 4, CH-3), 3.71 (1H, dd, J 19, 8.5, 
CHH-2), 3.05 (1H, dd, J 19, 4, CHH-2); δC (125 MHz, CDCl3) 164.6 (C-1), 161.9 (d, 
1JCF 245, CArF-4′), 151.4 (CAr), 139.7 (CAr), 131.5 (CAr), 130.5 (CAr), 129.5 (CAr), 
129.3 (d, 3J 8, 2 x CAr-2′), 128.7 (CArH), 127.8 (CArH), 127.7 (CArH), 127.6 (CArH), 
126.8 (CAr), 126.7 (CArH), 115.8 (d, 2JCF 21, 2 x CAr-3′), 46.5 (CH-3), 37.1 (CH2-2);  
m/z (MH+ C19H1379BrFNOH+ requires 370.0237) found 370.0236, (MH+ 
C19H1381BrFNOH+ requires 372.0219) found 372.0217. 
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(S,E)-5-Bromo-3-(4′-chlorophenyl-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one Oxime 
 
(S)-121 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.1, using (S)-5-Bromo-3-(4′-chlorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one, (S)-79, (0.20 g, 0.5 mmol) and hydroxylamine 
hydrochloride (75 mg, 1.1 mmol) and the product was used without further 
purification. The title compound was formed as an off-white solid (185 mg, 89 %); 
[હ]ࡰ૛ૡ (c 0.1, CHCl3) +212; m.p. 146-147 °C; νmax/cm-1 3406 (m, O-H, stretch), 1561 
(m, C=N, stretch); δH (500 MHz, CDCl3) 9.08 (1H, dd, J 8, 1, ArH-9), 8.32 (1H, dd, 
J 8, 1.5, ArH-6), 7.72-7.67 (2H, m, ArH-7 & ArH-8), 7.52-7.47 (2H, m, C-1 NOH & 
ArH-4), 7.31 (2H, d, J 8.5, 2 x ArH-3′), 7.10 (2H, d, J 8.5, 2 x ArH-2′), 4.55 (1H, dd, 
J 8.5, 4, CH-3), 3.70 (1H, dd, J 19, 8.5, CHH-2), 3.05 (1H, dd, J 19, 4, CHH-2); δC 
(125 MHz, CDCl3) 164.5 (CAr-1), 151.1 (CAr), 142.5 (CAr), 132.9 (CAr), 131.6 (CAr), 
130.5 (CAr), 129.5 (CAr), 129.1 (CArH), 128.8 (CArH), 12.7 9 (CArH), 127.6 (CArH), 
127.6 (CArH), 126.8 (CAr), 126.7 (CArH), 46.6 (CH-3), 37.0 (CH2-2), (Missing one 
CAr); m/z (MH+ C19H1379Br35ClNOH+ requires 385.9942) found 385.9946, (MH+ 
C19H1381Br35ClNOH+ requires 387.9921) found 387.9926. 
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(S,E)-5-Fluoro-3-(3′,4′,5′-trimethoxyphenyl-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one Oxime 
 
(S)-122 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.1, using (S)-5-Fluoro-3-(3′,4′,5′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclophenta[a]naphthalen-1-one, (S)-70, (0.20 g, 0.5 mmol) and hydroxylamine 
hydrochloride (76 mg, 1.1 mmol) and the product was used without further 
purification. The title compound was formed as an orange solid (173 mg, 83 %); [હ]ࡰ૛ૡ 
(c 0.1, CHCl3) +267; m.p. 127-128 °C; νmax/cm-1 3398 (s, O-H, stretch), 1591 (s, C=N, 
stretch), 1123 (s, C-O, stretch); δH (500 MHz, CDCl3) 9.05 (1H, d, J 8.5, ArH-9), 8.16 
(1H, d, J 8.5, ArH-6), 8.72 (1H, ddd, J 8.5, 7, 1, ArH-8), 7.63 (1H, ddd, J 8, 7, 1, 
ArH-7), 7.20 (1H, br. s, C-1 NOH), 6.92 (1H, d, J 10, ArH-4), 6.37 (2H, s, 2 x ArH-
2′), 4.51 (1H, dd, J 8.5, 4, CH-3), 3.87 (1H, s, CAr-4′ OCH3), 3.81 (6H, s, 2 x CAr-3′ 
OCH3), 3.73 (1H, dd, J 19, 8.5, CHH-2), 3.08 (1H, dd, J 19, 4, CHH-2); δC (125 MHz, 
CDCl3) 164.7 (C-1), 160.8 (d, 1JCF 258, CArF-5), 153.6 (2 x CAr-3′), 151.9 (d, 3JCF 9, 
(CAr), 139.6 (CAr-4′), 139.6 (CAr), 137.0 (CAr), 129.7 (CAr), 129.7 (CArH), 128.9 (CAr), 
126.6 (CAr), 126.6 (CArH), 126.2 (CArH), 126.2 (CArH), 123.7 (d, 3JCF 17, CAr), 121.3 
(d, 3JCF 6, CArH-6), 107.3 (d, 2JCF 21.5, CArH-4), 104.7 (2 x CArH-2′), 60.9 (CAr-4′ 
OCH3), 56.2 (2 x CAr-3′ OCH3), 48.1 (CH-3), 37.1 (CH2-2);  m/z (MNa+ 
C22H20FNO4Na+ requires 404.1269) found 404.1271. 
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(S,E)-3-phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one Oxime 
 
(S)-123 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.1, using (S)-3-Phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one, 
(S)-68, (0.20 g, 0.8 mmol) and hydroxylamine hydrochloride (108 mg, 1.6 mmol) and 
the product was used without further purification. The title compound was formed as 
an off-white solid (190 mg, 90 %); [હ]ࡰ૛ૡ (c 0.1, CHCl3) +372; m.p. 138-139 °C; 
νmax/cm-1 3289 (m, O-H, stretch), 2988 (w, CAr-H, stretch), 1492 (m, C=N, stretch); 
δH (400 MHz, CDCl3) 9.03 (1H, d, J 8.5, ArH-9), 7.90 (1H, d, J 8, ArH-6), 7.82 (1H, 
d, J 8.5, ArH-5), 7.66 (1H, t, J 7.5, ArH-8), 7.56 (1H, t, J 7.5, ArH-7), 7.33 (2H, t, J 
7.5, 2 x ArH-3′), 7.29-7.24 (3H, m, 2 x ArH-2′ & ArH-4′), 7.17 (1H, d, J 7.5, ArH-
4), 4.62 (1H, dd, J 8.5, 3, CH-3), 3.72 (1H, dd, J 19, 8.5, CHH-2), 3.10 (1H, dd, J 19, 
3, CHH-2); δC (125 MHz, CDCl3) 165.6 (C-1), 151.6 (CAr), 144.7 (CAr), 133.2 (CAr), 
131.7 (CArH-5), 130.5 (CAr), 128.8 (CArH), 128.7 (CAr), 128.4 (CArH), 127.8 (CArH), 
127.8 (CArH), 126.8 (CArH), 126.2 (CArH), 126.2 (CArH), 123.6 (CArH), 47.4 (CH-3), 
37.0 (CH2-2); m/z (MNa+ C19H15NONa+ requires 296.1046) found 296.1043. 
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5.3.2 Synthesis of Indan-1-one Oxime Mesylates 
The following procedure was performed in accordance with previous literature.469 To 
a solution of the appropriate indan-1-one oxime (0.3 mmol) and triethylamine (4 
mmol) in dichloromethane (10 mL) at -20 °C, was added mesyl chloride over 5 
minutes, and the reaction was stirred at -20 °C for 20 minutes. The reaction mixture 
was allowed to warm to room temperature, transferred to a separating funnel and 1M 
HCl (20 mL),was added. The organic layer was separated and further washed with 
NaHCO3 (20 mL) and brine (20 mL). The organic layer was then dried over MgSO4, 
concentrated in vacuo and used without further purificataion. Traces of MsCl were 
visible in the 1H NMR spectrum for each compound, but as this was the solvent 
employed for the Beckmann rearrangement, further purification was not necessary. 
 
 
5.3.3 Beckmann Rearrangement of Indan-1-one Mesylates 
The following procedure was performed in accordance with previous literature.469 To 
a solution of the appropriate indan-1-one oxime mesylates (0.4 mmol) in mesyl 
chloride (10 mL), was added ZrCl4 (2 mmol) at 0 °C and the reaction mixture was 
stirred for 1.5 hours. The reaction mixture was then poured into an ice-cold solution 
of NaOH (1.0 M, 20 mL), and stirred for 1 hour. The product was then extracted with 
ethyl acetate, washed with Na2CO3 (5 x 20 mL), dried over MgSO4 and concentrated 
in vacuo. The product was then purified by silica column chromatography as 
mentioned specifically. 
 
 
 
- 379 -  
(S)-6-Bromo-4-phenyl-3,4-dihydrobenz[h]isoquinolin-1(2H)-one 
 
(S)-124 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.3, using (S,E)-5-bromo-3-phenyl-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one O-methylsulfonyl oxime, (S)-116 (200 mg, 0.4 
mmol) and zirconium chloride (50 mg, 2 mmol) to give compound (S)-124 and (S)-
125 in a ratio of 48 : 52. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : ethyl acetate (2 : 1), to give a yellow 
solid (74 mg, 45 %); [હ]ࡰ૜૚ (c 0.04, CHCl3) +118.8; m.p. 221-222 °C; νmax/cm-1 3673 
(m, N-H, stretch), 2987 (m, CAr-H, stretch), 1649 (m, C=O, stretch); δH (400 MHz, 
CDCl3) 9.55 (1H, d, J 8.5, ArH-10), 8.28 (1H, d, J 8.5, ArH-7), 7.76-7.59 (2H, m, 
ArH-8 & ArH-9), 7.49 (1H, s, ArH-5), 7.37-7.28 (3H, m, 2 x ArH-3′ & ArH-4′), 7.18-
7.12 (2H, m, 2 x ArH-2′), 6.29 (1H, br. s, NH-2), 4.40-4.29 (1H, m, CH-4), 3.89 (1H, 
d, J 12.5, CHH-3), 3.68-3.60 (1H, m, CHH-3); δC (100 MHz, CDCl3) 166.0 (C-1), 
141.7 (CAr-1′), 139.6 (CAr), 132.7 (CAr), 131.7 (CAr), 129.6 (CArH), 128.9 (CArH), 
128.7 (CArH), 128.5 (CAr), 128.4 (CArH), 127.6 (CArH), 127.5 (CArH), 127.4 (CArH), 
127.3 (CArH), 124.2 (CAr), 46.3 (CH2-3), 45.4 (CH-4); m/z (MNa+ C19H1479BrNONa+ 
requires 374.0151) found 374.0153, (MNa+ C19H1481BrNONa+ requires 376.0131) 
found 376.0133. 
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(S)-4-Bromo-2-(2′-chloro-1′-phenylethyl)-1-naphthonitrile 
 
(S)-125 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.3, using (S,E)-5-bromo-3-phenyl-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one O-methylsulfonyl oxime, (S)-116 (200 mg, 0.4 
mmol) and zirconium chloride (50 mg, 2 mmol) to give compound (S)-124 and (S)-
125 in a ratio of 48 : 52. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : ethyl acetate (2 : 1), to give a yellow 
solid (77 mg, 45 %); [હ]ࡰ૛ૡ (c 0.1, CHCl3) +11.4; m.p. 89-90 °C; νmax/cm-1 3673 (m, 
N-H, stretch), 2987 (m, CAr-H, stretch), 1580 (m, C=O, stretch); δH (400 MHz, 
CDCl3) 8.22 (1H, d, J 6.5, ArH-8), 8.10 (1H, d, J 7, ArH-5), 8.05 (1H, s, ArH-3), 
7.69-7.60 (2H, m, ArH-6 & ArH-7), 7.24-7.14 (3H, m, 2 x ArH-3″ & ArH-4″), 7.13-
7.05 (2H, m, 2 x ArH-2″), 5.61 (1H, d, J 7.5, CH-1′), 3.45-3.25 (2H, m, CHH-2′ & 
CHH-2′); δC (100 MHz, CDCl3) 144.6 (CAr-1″), 135.7 (CAr), 132.6 (CAr), 131.4 (CAr), 
129.9 (CArH), 129.5 (2 x CArH-3″), 129.3 (CArH), 128.7 (2 x CArH-2″), 128.4 (CArH), 
128.0 CArH), 127.5 (CArH), 126.2 (CArH), 115.2 (CAr-1 CN), 108.3 (CAr-1), 60.3 (CH-
1′), 46.1 (CH2-2′); m/z (MNa+ C19H1279Br35ClFNNa+ requires 409.9718) found 
409.9722, (MNa+ C19H1281Br35ClFNNa+ requires 411.9695) found 411.9700. 
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(S)-6-Bromo-4-(4′-methoxyphenyl)-3,4-dihydrobenz[h]isoquinolin-1(2H)-
one 
 
(S)-126 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.3, using (S,E)-5-bromo-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one O-methylsulfonyl oxime, (S)-117 (200 mg, 0.4 
mmol) and zirconium chloride (50 mg, 2 mmol) to give compound (S)-126 and (S)-
127 in a ratio of 5 : 95. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : ethyl acetate (2 : 1), to give a yellow 
oil (8 mg, 5 %); [હ]ࡰ૜૚ (c 0.04, CHCl3) +45; νmax/cm-1 3672 (w, N-H, stretch), 2970 
(m, CAr-H, stretch), 1659 (m, C=O, stretch); δH (500 MHz, CDCl3) 9.46 (1H, d, J 8.5, 
ArH-10), 8.28 (1H, dd, J 8.5, 1, ArH-7), 7.69 (1H, ddd, J 8.5, 7, 1.5, ArH-9), 7.63 
(1H, ddd, J 8, 7, 1, ArH-8), 7.48 (1H, s, ArH-5), 7.09 (2H, d, J 8.5, 2 x ArH-2′), 6.87 
(2H, d, J 8.5, 2 x ArH-3′), 6.03 (1H, br. s, NH-2), 4.30 (1H, t, J 5.5, CH-4), 3.86 (1H, 
ddd, J 12.5, 5, 3, CHH-3), 3.80 (3H, s, CAr-4′ OCH3), 3.61 (1H, ddd, J 12.5, 6, 4.5, 
CHH-3); δC (125 MHz, CDCl3) 165.9 (C-1), 159.0 (CAr-4′), 142.2 (CAr-1′), 132.8 
(CAr), 131.8 (CAr), 131.6 (CAr), 129.6 (CArH), 129.5 (CArH), 128.7 (CArH), 128.6 
(CAr), 127.5 (CArH), 127.5 (CArH), 127.4 (CArH), 124.1 (CAr), 114.4 (2 x CArH-3′), 
55.3 (CAr-4′ OCH3), 46.5 (CH2-3), 44.7 (CH-4); m/z (MNa+ C20H1679BrNO2Na+ 
requires 404.0257) found 404.0247, (MNa+ C20H1681BrNO2Na+ requires 406.0238) 
found 406.0228. 
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(S)-4-Bromo-2-(2′-chloro-1′-(4′′-methoxyphenyl)ethyl)-1-naphthonitrile 
 
(S)-127 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.3, using (S,E)-5-bromo-3-(4′-methoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one O-methylsulfonyl oxime, (S)-117 (200 mg, 0.4 
mmol) and zirconium chloride (50 mg, 2 mmol) to give compound (S)-126 and (S)-
127 in a ratio of 5 : 95. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : ethyl acetate (2 : 1), to give a yellow 
solid (122 mg, 70 %); [હ]ࡰ૜૚ (c 0.2, CHCl3) +41.1; m.p. 60-61 °C; νmax/cm-1 2987 (m, 
CAr-H, stretch), 2213 (m, C≡N, stretch), 1302 (s, C-O, stretch); δH (400 MHz, CDCl3) 
8.30 (1H, d, J 7.5, ArH-8), 8.18 (1H, d, J 8.5, ArH-5), 8.11 (1H, s, ArH-3), 7.78-7.68 
(2H, m, ArH-6 & ArH-7), 7.08 (2H, d, J 8, 2 x ArH-2″), 6.79 (2H, d, J 8, 2 x ArH-
3″), 5.64 (1H, t, J 7.5, CH-1′), 3.58 (3H, s, CAr-4″ OCH3), 3.42 (1H, dd, J  14, 7.5, 
CHH-2′), 3.34 (1H, dd, J 14, 7, CHH-2′); δC (100 MHz, CDCl3) 158.8 (CAr-4″), 144.7 
(CAr-1″), 132.6 (CAr), 131.3 (CAr), 130.5 (CArH), 129.9 (2 x CArH-2″), 129.6 (CAr), 
129.3 (CArH), 128.4 (CArH), 128.0 CArH), 127.7 (CAr), 126.2 (CArH), 115.3 (CAr-1 
CN), 114.0 (2 x CArH-3″), 108.4 (CAr-1), 60.5 (CH-1′), 55.2 (CAr-4″ OCH3), 45.3 
(CH2-2′); m/z (MNa+ C20H1579Br35ClNONa+ requires 421.9918) found 421.9912, 
(MNa+ C20H1581Br35ClNONa+ requires 423.9897) found 423.9891. 
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(S)-4-Bromo-2-(2′-chloro-1′-(2′′,3′′,4′′-trimethoxyphenyl)ethyl)-1-
naphthonitrile 
 
(S)-128 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.3, using (S,E)-5-bromo-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one O-methylsulfonyl oxime, (S)-118 (200 mg, 0.4 
mmol) and zirconium chloride (50 mg, 2 mmol) to give compound (S)-6-Bromo-4-
(2′,3′,4′-trimethoxyphenyl)-3,4-dihydrobenz[h]isoquinolin-1(2H)-one and (S)-128 in 
a ratio of 8 : 92. The title compound was isolated by silica column chromatography, 
eluting with dichloromethane : ethyl acetate (2 : 1), to give a yellow oil (117 mg, 66 
%); [હ]ࡰ૜૚ (c 0.2, CHCl3) +9.5; νmax/cm-1 2987 (m, CAr-H, stretch), 2213 (m, C≡N, 
stretch), 1246 (s, C-O, stretch); δH (400 MHz, CDCl3) 8.29 (1H, d, J 6, ArH-8), 8.18 
(1H, d, J 8.5, ArH-5), 8.15 (1H, s, ArH-3), 7.80-7.62 (2H, m, ArH-6 & ArH-7), 6.71 
(1H, d, J 8.5, ArH-6″), 6.49 (1H, J 8.5, ArH-5″), 5.75 (1H, t, J 7.5, CH-1′), 3.93 (3H, 
s, CAr-4″ OCH3), 3.79 (3H, s, CAr-3″ OCH3), 3.77 (3H, s, CAr-2″), 3.43 (1H, dd, J 
13.5, 7.5, CHH-2′), 3.34 (1H, dd, J 14, 7.5, CHH-2′); δC (100 MHz, CDCl3) 153.4 
(CAr), 145.0 (CAr), 132.6 (CAr), 131.3 (CAr), 129.8 (CArH), 129.4 (CAr), 129.2 (CArH), 
128.7 (CArH), 128.0 CArH), 126.2 (CArH), 125.3 (CArH-6″), 121.3 (CAr), 115.2 (CAr-
1 CN), 108.5 (CAr), 106.7 (CArH-5″), 60.9 (CAr-3″ OCH3), 60.7 (CAr-2″ OCH3), 59.3 
(CH-1′), 55.9 (CAr-4″ OCH3), 40.5 (CH2-2′), (Missing 2 x CAr). 
(S)-6-Bromo-4-(3′,4′,5′-trimethoxyphenyl)-3,4-dihydrobenz[h]isoquinolin-1(2H)-one, 129 
 (S)-4-Bromo-2-(2′-chloro-1′-(3′′,4′′,5′′-trimethoxyphenyl)ethyl)-1-naphthonitrile 
130 
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(S)-6-Bromo-4-(4′-fluorophenyl)-3,4-dihydrobenz[h]isoquinolin-1(2H)-
one 
 
(S)-131 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.3, using (S,E)-5-bromo-3-(4′-fluorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one O-methylsulfonyl oxime, (S)-120 (200 mg, 0.4 
mmol) and zirconium chloride (50 mg, 2 mmol) to give compound (S)-131 and (S)-
132 in a ratio of 32 : 68. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : ethyl acetate (2 : 1), to give a yellow 
solid (46 mg, 28 %); [હ]ࡰ૜૚ (c 0.08, CHCl3) +88.1; m.p. 188-189 °C;  νmax/cm-1 3673 
(m, N-H, stretch), 2987 (m, CAr-H, stretch), 1650 (m, C=O, stretch); δH (400 MHz, 
CDCl3) 9.45 (1H, d, J 8.5, ArH-10), 8.28 (1H, d, J 8, ArH-7), 7.75-7.56 (2H, m, ArH-
8 & ArH-9), 7.46 (1H, s, ArH-5), 7.20-7.07 (2H, m, 2 x 2′), 7.01 (2H, dd, J 11.5, 5, 
2 x ArH-3′), 6.52 (1H, br. s, NH-2), 4.38-4.28 (1H, m, CH-4), 3.89 (1H, d, J 12.5, 
CHH-3), 3.67-3.53 (1H, m, CHH-3) ; δC (100 MHz, CDCl3) 166.1 (C-1), 162.2 (d, 
1JCF 246, CArF-4′), 141.6 (CAr-1′), 135.4 (CAr), 132.7 (CAr), 131.9 (CAr), 130.0 (d, 3JCF 
8, 2 x CArH-2′), 129.5 (CArH), 128.8 (CArH), 128.7 (CAr), 127.6 (CArH), 127.4 (CArH), 
124.2 (CAr), 115.9 (d, 2JCF 21, 2 x CArH-3′), 46.3 (CH2-3), 44.7 (CH-4); m/z (MNa+ 
C19H1379BrFNONa+ requires 392.0057) found 392.0057, (MNa+ C19H1381BrFNONa+ 
requires 394.0036) found 394.0037. 
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(S)-4-Bromo-2-(2′-chloro-1′-(4′′-fluorophenyl)ethyl)-1-naphthonitrile 
 
(S)-132 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.3, using (S,E)-5-bromo-3-(4′-fluorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one O-methylsulfonyl oxime, (S)-120 (200 mg, 0.4 
mmol) and zirconium chloride (50 mg, 2 mmol) to give compound (S)-131 and (S)-
132 in a ratio of 32 : 68. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : ethyl acetate (2 : 1), to give a yellow 
solid (90 mg, 52 %); [હ]ࡰ૜૚ (c 0.12, CHCl3) +9.5; m.p. 96-97 °C;  νmax/cm-1 2987 (m, 
CAr-H, stretch), 2219 (m, C≡N, stretch); δH (400 MHz, CDCl3) 8.30 (1H, d, J 8, ArH-
8), 8.18 (1H, d, J 6.5, ArH-5), 8.11 (1H, s, ArH-3), 7.77-7.71 (2H, m, ArH-6 & ArH-
7), 7.17-7.10 (2H, m, 2 x ArH-2″), 7.96 (2H, t, J 8.5, 2 x ArH-3″), 5.64 (1H, t, J 7.5, 
CH-1′), 3.44 (1H, dd, J 14, 8, CHH-2′), 3.36 (1H, dd, J 14, 7, CHH-2′; δC (100 MHz, 
CDCl3) 162.1 (d, 1JCF 246, CArF-4″), 144.4 (CAr-1″), 132.5 (CAr), 131.4 (CAr), 131.4 
(CAr), 131.1 (d, 3JCF 8, 2 x CArH-2″), 130.0 (CArH), 129.8 (CAr), 129.4 (CArH), 128.3 
(CArH), 128.0 (CArH), 126.2 (CArH), 115.6 (d, 2JCF 21.5, 2 x CAr-3″), 115.3 (CAr-1 
CN), 108.3 (CAr-1), 60.3 (CH-1′), 45.3 (CH2-2′); m/z (MNa+ C19H1379Br35ClNNa+ 
requires 391.9812) found 391.9809, (MNa+ C19H1381Br35ClNNa+ requires 393.9789) 
found 393.9788. 
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(S)-6-Bromo-4-(4′-chlorophenyl)-3,4-dihydrobenz[h]isoquinolin-1(2H)-
one 
 
(S)-133 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.3, using (S,E)-5-bromo-3-(4′-chlorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one O-methylsulfonyl oxime, (S)-121 (200 mg, 0.4 
mmol) and zirconium chloride (50 mg, 2 mmol) to give compound (S)-133 and (S)-
134 in a ratio of 39 : 61. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : ethyl acetate (2 : 1), to give an 
orange solid (55 mg, 33 %); [હ]ࡰ૜૚ (c 0.13, CHCl3) +110.7; m.p. 189-190 °C;  νmax/cm-
1 3673 (m, N-H, stretch), 2987 (m, CAr-H, stretch), 1650 (m, C=O, stretch); δH (400 
MHz, CDCl3) 9.44 (1H, d, J 8, ArH-10), 8.29 (1H, d, J 8, ArH-7), 7.76-7.56 (2H, m, 
ArH-8 & ArH-9), 7.46 (1H, s, ArH-5), 7.30 (2H, d, J 7.5, 2 x ArH-3′), 7.10 (2H, d, J 
7.5, 2 x ArH-2′), 6.49 (1H, br. s, NH-2), 4.33-4.29 (1H, m, CH-3), 3.89 (1H, d, J 12, 
CHH-3), 3.65-3.54 (1H, m, CHH-3); δC (100 MHz, CDCl3) 166.0 (C-1), 141.2 (CAr-
1′), 138.1 (CAr), 133.5 (CAr), 132.7 (CAr), 131.8 (CAr), 129.8 (CArH), 129.3 (CArH), 
129.1 (CArH), 128.8 (CArH), 128.7 (CAr), 127.6 (CArH), 127.4 CArH), 124.2 (CAr), 
46.2 (CH2-4), 44.8 (CH-3); m/z (MNa+ C19H1379Br35ClNONa+ requires 407.9761) 
found 407.9759, (MNa+ C19H1381Br35ClNONa+ requires 409.9739) found 409.9739. 
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(S)-4-Bromo-2-(2′-chloro-1′-(4′′-chlorophenyl)ethyl)-1-naphthonitrile 
 
(S)-134 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.3, using (S,E)-5-bromo-3-(4′-chlorophenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one O-methylsulfonyl oxime, (S)-121 (200 mg, 0.4 
mmol) and zirconium chloride (50 mg, 2 mmol) to give compound (S)-133 and (S)-
134 in a ratio of 39 : 61. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : ethyl acetate (2 : 1), to give a yellow 
solid (98 mg, 56 %); [હ]ࡰ૜૚ (c 0.10, CHCl3) +13.5; m.p. 129-130 °C;  νmax/cm-1 2987 
(m, CAr-H, stretch), 2218 (m, C≡N, stretch); δH (400 MHz, CDCl3) 8.31 (1H, d, J 8, 
ArH-8), 8.20 (1H, d, J 7.5, ArH-5), 8.11 (1H, s, ArH-3), 7.81-7.68 (2H, m, ArH-6 & 
ArH-7), 7.25 (2H, d, J 8, 2 x ArH-3″), 7.12 (2H, d, J 8, 2 x ArH-2″), 5.65 (1H, t, J 
7.5, CH-1′), 3.43 (1H, dd, J 15, 9, CHH-2′), 3.37 (1H, dd, J 15, 8, CHH-2′); δC (100 
MHz, CDCl3) 144.3 (CAr-1″), 134.1 (CAr), 133.4 (CAr), 132.5 (CAr), 131.5 (CAr), 130.8 
(2 x CArH-2″), 130.1 (CArH), 129.8 (CAr), 129.4 (CArH), 128.9 (2 x CArH-3″), 128.3 
(CArH), 128.1 (CArH), 126.2 (CArH), 115.3 (CAr-1 CN), 108.3 (CAr-1), 60.0 (CH-1′), 
45.3 (CH2-2′); m/z (MNa+ C19H1279Br35Cl2NNa+ requires 425.9422) found 425.9427, 
(MNa+ C19H1281Br35Cl2NNa+ requires 427.9399) found 427.9404. 
 
 
 
 
- 388 -  
(S)-6-Fluoro-4-(3′,4′,5′-trimethoxyphenyl)-3,4-
dihydrobenz[h]isoquinolin-1(2H)-one 
 
(S)-135 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.3, using (S,E)-5-fluoro-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one O-methylsulfonyl oxime, (S)-122 (200 mg, 0.4 
mmol) and zirconium chloride (50 mg, 2 mmol) to give compound (S)-135 and (S)-
136 in a ratio of 60 : 40. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : ethyl acetate (2 : 1), to give an 
orange oil (81 mg, 49 %); [હ]ࡰ૜૚ (c 0.04, CHCl3) +43.8; νmax/cm-1 3672 (N-H, stretch), 
2970 (m, CAr-H, stretch), 1659 (m, C=O, stretch), 1121 (s, C-O, stretch); δH (500 
MHz, CDCl3) 9.38 (1H, d, J 8.5, ArH-10), 8.05 (1H, d, J 8.5, ArH-7), 7.65-7.60 (1H, 
m, ArH-9), 7.54-7.50 (1H, m, ArH-8), 6.74 (1H, d, J 11, ArH-5), 6.32 (2H, s, 2 x 
ArH-2′), 6.25 (1H, br. s, NH-2), 4.23 (1H, dd, J 7, 5.5, CH-4), 3.78 (3H, s, CAr-4′ 
OCH3), 3.77-3.73 (1H, m, CHH-3), 3.70 (6H, s, 2 x CAr-3′ OCH3), 3.62-3.57 (1H, m, 
CHH-3); δC (125 MHz, CDCl3) 165.9 (C-1), 161.0 (d, 1JCF 260, CArF-6), 153.6 (2 x 
CAr-3′), 143.3 (d, 3JCF), 137.5 (CAr), 136.6 (CAr), 135.3 (CAr-4′), 133.7 (d, 3JCF 5), 
129.0 (CArH), 127.2 (CArH), 126.5 (CArH), 123.6 (d, 2JCF 15.5, CAr-6a), 120.5 (d, 3JCF 
6.5, CAr-7), 109.2 (d, 2JCF 21, CArH-5), 105.6 (2 x CArH-2′), 60.9 (CAr-4′ OCH3), 56.2 
(2 x CAr-3′ OCH3), 46.4 (CH-4), 46.3 (CH2-3); m/z (MNa+ C22H20FO4NNa+ 
requires 404.1269) found 404.1272. 
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(S)-4-Fluoro-2-(2′-chloro-1′-(3′′,4′′,5′′-trimethoxyphenyl)ethyl)-1-
naphthonitrile 
 
(S)-136 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.3, using (S,E)-5-fluoro-3-(2′,3′,4′-trimethoxyphenyl)-2,3-dihydro-1H-
cyclopenta[a]naphthalen-1-one O-methylsulfonyl oxime, (S)-122 (200 mg, 0.4 
mmol) and zirconium chloride (50 mg, 2 mmol) to give compound (S)-135 and (S)-
136 in a ratio of 60 : 40. The title compound was isolated by silica column 
chromatography, eluting with dichloromethane : ethyl acetate (2 : 1), to give a orange 
oil (54 mg, 31 %); [હ]ࡰ૜૚ (c 0.2, CHCl3) +2.8; νmax/cm-1 3067 (m, CAr-H, stretch), 
2219 (m, C≡N, stretch), 1152 (s, C-O, stretch); δH (400 MHz, CDCl3) 8.21-8.04 (2H, 
m, ArH-8 & ArH-5), 7.78-7.63 (2H, m, ArH-6 & ArH-7), 7.49 (1H, d, J 11, ArH-3), 
6.36 (2H, s, 2 x ArH-2″), 5.79-5.68 (1H, m, CH-1′), 3.77 (3H, s, CAr-4″ OCH3), 3.74 
(6H, s, 2 x CAr-3″ OCH3), 3.43 (1H, dd, J 13.5, 8, CHH-2′), 3.28 (1H, dd, J 14, 7.5, 
CHH-2′); δC (100 MHz, CDCl3) 161.7 (d, 1JCF 263, CArF-4), 153.2 (2 x CAr-3″), 146.1 
(d, 3JCF 9, CAr), 137.2 (CAr-4″), 133.7 (d, 3JCF 6, CAr), 131.3 (CAr), 130.3 (CArH), 128.4 
(CArH), 125.6 (CArH), 123.1 (d, 2JCF 18, CAr-4a), 121.3 (d, 4JCF 5, CArH-5), 115.4 
(CAr-1 CN), 108.6 (d, 2JCF 23.3, CArH-3), 106.3 (2 x CArH-2″), 104.7 (d, 4JCF 4, C-1), 
60.8 (CAr-4″ OCH3), 60.2 (CH-1′), 56.0 (2 x CAr-3″ OCH3), 46.5 (CH2-2′) ; m/z 
(MNa+ C22H1935ClFNO3Na+ requires 422.0930) found 422.0944. 
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(S)-4-phenyl-3,4-dihydrobenz[h]isoquinolin-1(2H)-one 
 
(S)-137 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.3, using (S,E)-3-phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one 
O-methylsulfonyl oxime, (S)-123 (200 mg, 0.4 mmol) and zirconium chloride (50 
mg, 2 mmol) to give compound (S)-137 and (S)-138 in a ratio of 37 : 63. The title 
compound was isolated by silica column chromatography, eluting with 
dichloromethane : ethyl acetate (2 : 1), to give a yellow oil (47 mg, 30 %); [હ]ࡰ૜૚ (c 
0.2, CHCl3) +26.3; νmax/cm-1 3673 (m, N-H, stretch), 2987 (m, CAr-H, stretch), 1649 
(s, C=O, stretch); δH (500 MHz, CDCl3) 9.48 (1H, d, J 8.5, ArH-10), 7.91 (1H, d, J 
8.5, ArH-6), 7.85 (1H, d, J 8, ArH-7), 7.66 (1H, ddd, J 8.5, 7, 1.5, ArH-9), 7.57-7.53 
(1H, m, ArH-8), 7.35-7.25 (3H, 2 x ArH-3′ & ArH-4′), 7.21-7.17 (2H, m, 2 x ArH-
2′), 7.14 (1H, d, J 8.5, ArH-5), 6.94 (1H, br. s, NH-2), 4.39 (1H, t, J 5.5, CH-4), 3.91 
(1H, ddd, J 12.5, 5, 3, CHH-3), 3.68 (1H, ddd, J 12.5, 6, 4.5, CHH-3); δC (125 MHz, 
CDCl3) 166.8 (C-1), 141.7 (CAr-1′), 140.3 (CAr), 133.2 (CAr), 132.9 (CArH), 131.5 
(CAr), 128.7 (CArH), 128.5 (CArH), 128.2 (CArH), 127.9 (CArH), 127.2 (CArH), 126.9 
CArH), 126.0 (CArH), 125.5 (CArH), 124.3 (CAr), 46.2 (CH2-3), 45.5 (CH-3); m/z 
(MNa+ C19H15NONa+ requires 296.1046) found 296.1047. 
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(S)-2-(2′-chloro-1′-phenylethyl)-1-naphthonitrile 
 
(S)-138 
 
 
The aforementioned product was synthesised using the general method outlined in 
Section 5.3.3, using (S,E)-3-phenyl-2,3-dihydro-1H-cyclopenta[a]naphthalen-1-one 
O-methylsulfonyl oxime, (S)-123 (200 mg, 0.4 mmol) and zirconium chloride (50 
mg, 2 mmol) to give compound (S)-137 and (S)-138 in a ratio of 37 : 63. The title 
compound was isolated by silica column chromatography, eluting with 
dichloromethane : ethyl acetate (2 : 1), to give a yellow oil (95 mg, 55 %); [હ]ࡰ૜૚ (c 
0.2, CHCl3) +7.5; νmax/cm-1 2987 (m, CAr-H, stretch), 2217 (m, C≡N, stretch); δH (500 
MHz, d6-DMSO) 8.39 (1H, d, J 9, ArH-8), 8.14 (1H, d, J 8, ArH-4), 8.08-8.03 (2H, 
m, ArH-5 & ArH-7), 7.84-7.79 (1H, m, ArH-6), 7.76-7.72 (1H, m, ArH-3), 7.26-7.15 
(5H, m, 2 x ArH-2″, 2 x ArH-3″ & ArH-4″), 5.77 (1H, t, J 8, CH-1′), 3.66 (1H, dd, J 
13, 6.5, CHH-2′), 3.62 (1H, dd, J 13, 7, CHH-2′); δC (125 MHz, d6-DMSO) 144.6 
(CAr-1″), 137.0 (CAr), 134.6 (CArH), 132.5 (CAr), 131.6 (CAr), 130.2 (CArH), 129.8 (2 
x CArH-3″), 129.4 (CArH), 128.8 (2 x CArH-2″), 128.8 (CArH), 127.4 (CArH), 125.1 
(CArH), 124.9 (CArH), 115.9 (CAr-1 CN), 108.1 (CAr-1), 61.5 (CH-1′), 44.0 (CH2-2′); 
m/z (MNa+ C19H1435ClNNa+ requires 314.0707) found 314.0708. 
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